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Summary 
Hypertensive disorders of pregnancy are an increasingly common disorder in 
modern society. The increasing prevalence of women with pre-eclampsia 
superimposed on a background of chronic hypertension is a significant burden in 
modern society and is profoundly detrimental to both mother and child; during 
pregnancy and beyond. Little is understood about the development of these 
multifactorial hypertensive disorders, however there is increasing evidence that 
the manifestation of hypertensive disorders during pregnancy is not solely due to 
placental-derived dysfunctions and has important maternally-driven 
components. The stroke-prone spontaneously hypertensive (SHRSP) rat is a well-
established model of human essential hypertension. SHRSP dams remain 
hypertensive throughout pregnancy and demonstrate an abnormal uterine artery 
structure and function at term.  
This project aimed to more fully characterise pregnancy in the SHRSP rat. The 
objectives were to assess maternal responses and determine how maternal 
hypertension impacts maternal and fetal well-being as well as placental 
development; to investigate the underlying genetic mechanisms behind the 
eventual abnormal pregnancy-dependent uterine artery remodelling; and, 
finally, to increase the maternal cardiovascular load in SHRSP pregnancy to 
establish a model of superimposed pre-eclampsia. In vivo and ex vivo techniques 
were used to characterise cardiovascular function in the hypertensive SHRSP and 
normotensive WKY rats during gestation, as well as assess pregnancy outcomes. 
The SHRSP dams were found to have similar cardiac function compared to WKY, 
yet there was evidence of impaired systemic vascular structure and function in 
late gestation and placental abnormalities. Nevertheless, the SHRSP maintained 
similar litter sizes to WKY and did not demonstrate any major impact on fetal 
growth. Further similarities between SHRSP and WKY pregnancy were revealed 
with the assessment of uterine artery function in early gestation. However, using 
RNA sequencing to elucidate the transcriptomic profiles of the uterine arteries, 
SHRSP were found to have strikingly different responses to pregnancy at the 
transcript expression level, compared to WKY. Finally, a model of superimposed 
pre-eclampsia was established by increasing the cardiovascular stress in the dam 
using angiotensin II infusion during pregnancy in SHRSP. This model had a 
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significantly higher systolic and diastolic blood pressure than the already 
hypertensive SHRSP. The pregnancy-dependent increase in cardiac output, 
observed in SHRSP, was negated by AngII infusion and was reduced in the highest 
treatment group. These major cardiovascular impairments were observed 
alongside increased proteinuria and reduced fetal growth; all phenotypes found 
in severely pre-eclamptic women.  
This work has provided information on systemic and uterine specific vascular 
responses to pregnancy in SHRSP and WKY rats alongside detail of underlying 
transcriptional differences. This study was the first to examine uterine artery 
gene expression changes during pregnancy. The different transcriptomic profiles 
of early pregnancy changes in the two strains make this an intriguing model to 
study maternal-driven vascular remodelling in hypertensive pregnancy. 
Furthermore, this work demonstrated that increasing the cardiovascular load 
during pregnancy in SHRSP successfully mimics superimposed pre-eclamptic 
phenotypes and could be used in the assessment of novel therapeutic strategies. 
To conclude, the SHRSP has the potential to aid our understanding of human pre-
eclamptic conditions, especially when endeavouring to determine the impact of 
maternally-driven components of hypertensive disorders of pregnancy. 
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1.1 Physiological changes during pregnancy 
Healthy human pregnancy typically lasts for 40 weeks from the last known 
menstrual period of the mother. During this relatively short time major 
physiological adaptations need to occur to support the growth of the developing 
fetus whilst maintaining the health of the mother. These physiological changes 
occur in almost all organ systems of the mother and it is important that there is 
understanding of these changes so that when complications of pregnancy arise 
they can be correctly diagnosed, managed and treated.  
1.1.1 Cardiovascular Adaptations 
Maternal cardiovascular adaptions to pregnancy have been recognised for over 
one hundred years; with maternal dilation, compensatory cardiac hypertrophy 
and changes to heart rate and rhythm all originally observed (Marshall, 1910). In 
order to establish and sustain appropriate nutrient and oxygen delivery to the 
fetus a re-direction of blood flow to the placenta is required. Successful 
maternal cardiovascular and haemodynamic adaptations are crucial for this to be 
achieved. The major changes are summarised in Table 1-1. The mechanisms 
controlling these changes are still much debated. The majority of maternal 
cardiovascular adaptations occur in the first trimester, starting as early as 5 
weeks gestation, preceding placentation (Robson et al., 1989). One of the 
earliest findings was that of increased cardiac output (CO) (Lindhard, 1915). This 
rapid increase occurs due to the pregnancy-associated increase in stroke volume 
and heart rate (Hunter and Robson, 1992). For singleton pregnancies, CO 
increases can reach as much as 50% by 16-20 weeks gestation (Hunter and 
Robson, 1992). There has been some discrepancy on the trend of CO after this 
gestational time point (possibly due to differing measurement techniques and 
positioning), however most conclude that CO reaches a plateau or has a 
continued but slowed increase until onset of labour (Robson et al., 1989, Poppas 
et al., 1997, Clapp and Capeless, 1997, Simmons et al., 2002). Blood and plasma 
volume also increase progressively over gestation and a peak, approximately 25-
50% greater than pre-pregnancy, is reached at term (Pritchard, 1965). Contrary 
to this change in blood volume and CO, the maternal systolic and diastolic blood 
pressures have been found to decease during gestation in healthy normotensive 
pregnancies (Christianson, 1976, Duvekot et al., 1993). Mean blood pressure, 
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measured using ambulatory 24-hour blood pressure monitoring, has been 
observed to be at its lowest between 16-20 weeks of gestation (approximately 
100/60 mmHg) and gradually rises to pre-pregnancy levels during the third 
trimester (Hermida and Ayala, 2002). There is evidence of hormonal control of 
these changes as they have been found to occur in the luteal phase (receptive 
period) of the menstrual cycle and post-conception (Christianson, 1976). These 
coordinated adaptations are tailored to increase the blood flow to all major 
organ systems (Chapman et al., 1998), with the placenta receiving the largest 
proportion of re-directed blood flow (~25%) (Hunter and Robson, 1992, Kliman, 
2000). This ensures the increased metabolic demands of the mother are met 
whilst supporting the developing fetus.  
The reduced vascular resistance during pregnancy, first reported as increased 
dilation in 1910 (Marshall, 1910), has been an area of frequent study (Duvekot et 
al., 1993, Poppas et al., 1997, Corsini et al., 2017, Ferrazzi et al., 2018). There 
is a reduced vascular resistance in the uteroplacental vasculature as well as 
systemically (Robson et al., 1989, Clapp and Capeless, 1997, Mandala and Osol, 
2012). This leads to a systemic decrease in vascular resistance and vasodilation; 
a driving force behind many of the observed haemodynamic changes and a 
solution to the paradox of the increased blood volume and heart rate not 
elevating maternal blood pressure. Poppas et al found that healthy pregnant 
women demonstrated increased arterial compliance, resulting in a substantial 
reduction in total peripheral resistance (TPR) (reduced by ~40% in the first 
trimester) (Poppas et al., 1997). The systemic vascular systems in pregnant 
women have also been shown to be refractory to the vasoactive peptide 
angiotensin II (AngII). AngII plays a crucial role in maintaining vascular tone 
(detailed further in section1.1.2.1). Gant et al found lower infusions of AngII 
elicited a greater vasoconstrictive response in non-pregnant women than in 
pregnant women (Gant et al., 1973). The systemic vasculature, i.e. aorta and 
mesentery, has also been shown to have decreased contractile and increased 
dilatory responses to vasoactive substances during pregnancy in animal models 
(Giardina et al., 2002, Gerber et al., 1998, Cooke and Davidge, 2003, Davidge 
and McLaughlin, 1992, Paller, 1984).  
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Table 1-1: Summary of maternal cardiovascular adaptations to healthy pregnancy 
Cardiovascular 
Parameter 
Trimester 
First Second Third 
Cardiac Output ↑↑ ↑ - or ↑ 
Stroke Volume ↑↑ ↑ - 
Heart Rate ↑ ↑ ↑ 
TPR ↓ ↓ ↓ 
Systolic BP - or ↓ - or ↓ ↑ 
Diastolic BP - or ↓ - or ↓ ↑ 
MAP - - - 
Blood volume - or ↑ ↑ - 
LVM ↑ ↑ ↑ 
The trends of different measured parameters of cardiovascular function during various stages of 
pregnancy, compared to the previous trimester (first trimester compared to pre-pregnancy levels). 
All parameters have been found to return to pre-pregnancy levels post-partum. TPR= total 
peripheral resistance, BP= blood pressure, MAP = mean arterial pressure and LVM = left 
ventricular mass (↓ decrease, ↑ increase, - plateau). (Clapp and Capeless, 1997, Hibbard et al., 
2015, Poppas et al., 1997, Thornburg et al., 2000, Thornburg et al., 2015, Sanghavi and 
Rutherford, 2014, Rovinsky and Jaffin, 1965, Simmons et al., 2002) 
 
1.1.2 Renal changes 
The kidneys are central to orchestrating the haemodynamic changes and reduced 
systemic vascular resistance associated with pregnancy, whilst also maintaining 
renal function in the pregnant woman. The cardiovascular and renal systems are 
so interlinked that changes to one will impact the other and during pregnancy is 
no exception. The main changes are increased renal vasodilation, increased 
plasma flow and increased glomerular filtration (summarised in Figure 1-1), 
which all occur in tandem to the changes observed in the cardiovascular system. 
Renal haemodynamics are influenced by a vasodilation of the renal vasculature; 
akin to the changes in systemic vasculature (Conrad, 1984, Odutayo and 
Hladunewich, 2012). There is evidence that organ-specific vasodilation occurs 
early in pregnancy due to maternal hormonal changes (Chapman et al., 1998). 
Studies examining pseudopregnancy in rodents that have induced ovulation, 
found that renal vascular vasodilation occurs in the absence of any fetoplacental 
material (Atherton et al., 1982). This suggests that there are hormonal 
influences on kidney function in early pregnancy. Of the main sex steroids that 
have been reported to increase during pregnancy (progesterone and oestrogen), 
only progesterone has been found to influence the kidney (Chesley and Tepper, 
1967). An increased renal plasma flow (RPF), by 40-50%, and glomerular 
filtration rate (GFR), of 30-40% compared to the pre-pregnancy, have been 
observed in the first trimester of human pregnancy (Davison and Dunlop, 1980, 
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Dunlop, 1981, Odutayo and Hladunewich, 2012). The increased GFR, usually 
measured in 24-hour urine samples by the clearance of creatinine, is maintained 
throughout pregnancy, whereas the increased RPF peaks and then returns 
towards pre-pregnancy levels in the third trimester (Odutayo and Hladunewich, 
2012, Dunlop, 1981). However, the GFR and RPF are consistently underestimated 
in the pregnant woman as the methods used to assess non-pregnant kidney 
function do not account for the greater ‘dead space’ volume associated with the 
increase in renal vasodilation during pregnancy (Conrad, 1984, Conrad et al., 
2015). Hydronephrosis, a swelling of the kidney, can also occur in around 90% of 
pregnancies, however, this has been associated with the increased interstitial 
and vascular volume. This process is often termed renal dilation as it is a 
physiological response to pregnancy and not pathological in this context 
(Wadasinghe et al., 2016). Ultimately the kidneys of pregnant women have been 
found increase in length and size (Odutayo and Hladunewich, 2012). Tubular 
function is also influenced by pregnancy, with regards to the altered 
reabsorption and excretion of various metabolites, summarised in Figure 1-1, 
with the aim of increasing the blood volume of pregnant women via retention of 
fluid. 
 
Figure 1-1: The pregnancy induced physiological changes of the kidney 
Summary of main anatomical, haemodynamic and functional kidney adaptations to pregnancy 
(Odutayo and Hladunewich, 2012). 
  
Anatomical Haemodynamic Tubular Function
• Length increase (~1cm)
• Weight increase
• Collecting system dilation
• Renal vasodilation
• Early and sustained GFR increase
• Increased RPF in first trimester
• Increased excretion of 
protein, glucose and uric acid
• Increased resorption of 
sodium and potassium
• Fluid retention
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1.1.2.1 The Classical Renin-Angiotensin System 
A major factor in controlling blood pressure and fluid balance in all physiological 
states is the renin angiotensin system (RAS). This system is crucial to 
cardiovascular and renal physiology during pregnancy. The RAS consists of the 
co-ordinated cascade of enzymes and peptides that ultimately produce the 
vasoactive peptide angiotensin II (AngII) that acts on receptors within the 
vasculature to modulate vascular tone (Figure 1-2) (Irani and Xia, 2011). The 
classical RAS cascade occurs in the systemic circulation, yet it is centred on the 
kidney for regulation (Sparks et al., 2014). Renin is the rate limiting enzyme of 
the RAS and is produced and released from juxtaglomerular cells in the kidney 
(Tobian et al., 1959). The release and expression of renin are controlled by the 
renal baroreceptors that sense hypotension and initiate production or inhibit 
release of renin in hypertensive states (Tobian et al., 1959). There is also a 
degree of sympathetic regulation; β1-adrenergic stimulation can initiate renin 
release, and local control; low levels of NaCl detected by the macula densa 
within the kidney can initiate renin release (Sparks et al., 2014). Circulating 
renin cleaves the peptide angiotensinogen to angiotensin I (Skeggs et al., 1956). 
Angiotensinogen is produced by many tissues, but it’s main site of synthesis is 
the liver (Matsusaka et al., 2012). The final stages of the enzyme cascade rely on 
the cleavage of angiotensin I to AngII. This is typically modulated by angiotensin 
converting enzyme (ACE) in the lungs. AngII has a main role in systemic 
vasoconstriction of the vasculature, via the AngII receptor type-1, and stimulates 
release of the anti-diuretic hormone (ADH) from the brain, to encourage a thirst 
response as well as increasing Na+ resorption, both mechanisms increase 
extracellular fluid and plasma volume. All these effects are in place to 
ultimately increase the blood pressure (Sparks et al., 2014). 
In normal pregnancy all components of the RAS have been found to increase and 
the system is activated (Langer et al., 1998). The production of angiotensinogen 
has been found to be induced by oestrogen (Immonen et al., 1983). The levels of 
this sex steroid hormone are increased during pregnancy, especially in the first 
trimester, therefore angiotensinogen gene transcription in the liver is induced 
during this period; increasing angiotensinogen in the circulation. Increased 
ovarian production of pro-renin increases plasma renin levels early in pregnancy 
(Itskovitz et al., 1987). Since the descriptions of the classical RAS, tissue specific 
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RAS have been reported, in a wide range of tissues. This allows for independent 
local regulation of organ circulations. An important extra-renal source of 
components of the RAS during pregnancy is the placenta (Herse et al., 2007). 
The placenta and decidua have been found to independently produce and 
release into circulation all major components of the RAS (Ihara et al., 1987, 
Morgan et al., 1998, Li et al., 2000). This increased production and activation 
encourages the increased blood and plasma volume observed in pregnancy, in 
order to maintain the blood pressure and organ perfusion that would fall in 
response to the systemic vasodilation and reduced vascular resistance.  
A paradox of pregnancy is that whilst the increase in RAS activity ultimately 
leads to an increase in AngII (Massani et al., 1967), there is a reduced vascular 
resistance and propagated systemic vasodilation. This is due to pregnancy being 
associated with a refractoriness to AngII, where, even though more abundant, it 
does not elicit as great a contractile response in pregnant women as in non-
pregnant women (Gant et al., 1973). AngII acts mainly through the two major 
angiotensin receptors subtypes, type-1 and type-2 (AT1R and AT2R). These have 
contradictory actions, with AT1R responsible for vasoconstriction and AT2R 
mediating vasodilation (Sparks et al., 2014). The identification of the two 
receptor subtypes occurred in the late 1980s, and it was originally suggested 
that the maintenance of cardiovascular homeostasis was predominantly 
controlled by the more abundant AT1R, with AT2R located only in fetal tissue 
(Chiu et al., 1989, Speth and Kim, 1990, Whitebread et al., 1989). However, 
there is more evidence now that the AT2R is more widely distributed throughout 
the adult vasculature and located in the ovary, adrenals and skin (Horiuchi et 
al., 1999). Specifically important for pregnancy, was the discovery of AT2R in the 
uteroplacental vasculature (Nielsen et al., 2000). With the AT1R mediating 
vasoconstriction and the AT2R promoting vasodilation, it is possible that the ratio 
of receptors is more important than their absolute presence/absence. 
 
 
 
 
Figure 1-2: The classical renin-angiotensin system 
The diagram illustrates the classical cascade of enzymes in the production of angiotensin II. Components for the classical system are found in the liver, kidney and 
lungs with the vasculature acting as the main target organ of AngII. ACE: Angiotensin converting enzyme, ADH: Anti-diuretic hormone. Diagram designed by Aria Rad 
and made available for public reproduction under the terms of the GNU Free Documentation License. 
 
 
 
 
1.1.3 Human placental development  
Human placentation is a complex process that occurs during pregnancy to create 
and maintain an organ that exists only for the period of gestation; the placenta. 
This organ’s main role is to allow the exchange of nutrients and gases between 
the fetus and the mother without the two circulations coming into direct 
contact. The placenta develops from the outer cells of the blastocyst, the 
trophoblast cells (Figure 1-3).  These cells eventually make the epithelial parts 
of the placenta (with the mesenchyme stemming from the inner cell mass). The 
placenta is composed of two main trophoblast cell types: the cytotrophoblasts 
and the syncytiotrophoblasts (Huppertz, 2008). It is the multinucleated 
syncytiotrophoblasts that begin invading the maternal uterine decidua on 
implantation, approximately 7 days post-conception. By post-conception day 15 
the cytotrophoblasts invade through the maternal decidua. The presence of 
these placental derived cells was first noted in 1870 (Friedlaender, 1870), 
however at this time they were not attributed as placental in origin. A review in 
1927 by Grosser, summarised the trophoblastic origin of these cells (Grosser, 
1927, Pijnenborg et al., 2006). This also highlighted the trophoblast-associated 
remodelling that occurs in the early stages of placentation. This remodelling 
changes the maternal spiral arteries from highly coiled, muscular high resistance 
arteries to wide vessels with low resistance in order to increase blood flow to 
the placenta (further detail in section 1.1.3.2). This ‘hijacking’ of the maternal 
blood flow is unique to the placenta and tumours (Holtan et al., 2009). The early 
placental development (prior to 12 weeks post-conception) occurs in low oxygen 
tensions, as the invading trophoblasts form trophoblastic plugs in the spiral 
arteries. This is an essential mechanism to protect placental development from 
damaging reactive oxygen species produced in oxygen rich environments 
(Pijnenborg et al., 2006). During this period the developing placenta is 
supported by uterine glands providing essential nutrition (Burton et al., 2002).  
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Figure 1-3: The first stages of implantation in the human 
(A) The human ovulation process occurs at approximately day 14 of the menstrual cycle. 
Fertilisation and then the first divisions occur in the fallopian tube before a blastocyst enters the 
uterus lumen and embeds in the decidualized endometrium approximately 6-7 days after 
fertilisation. (B) The panels show the implantation process and the beginning of the trophoblast 
invasion into the decidua and formation of lacunar (*marked with asterix), which will go on to form 
the placental villous tree. Ut: Uterine lumen, CT: Cytotrophoblast, ST: Syncytiotrophoblast, ICM: 
Inner cell mass, DE: Decidualized endometrium, SpA: Spiral artery. Ovulation cycle and uterus 
image from Servier Medical ART, adapted from (Frank, 2017). 
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1.1.3.1 Early Placental-Maternal Interactions 
The uterine lining, the endometrium, is a dynamic tissue that undergoes cyclical 
changes in post-pubescent women, known as the menstrual cycle. This key 
reproductive process prepares the uterus for reception of an embryo. The 
‘implantation window’ in humans is approximately 4 days after the release of 
the egg from the ovary. This cycle is controlled by co-ordinated fluctuations in 
hormones; progesterone, oestrogen, luteinising hormone (LH) and follicular 
stimulating hormone (FSH) (Figure 1-4). Ovulation coincides with LH, FSH and 
oestrogen peaks, at the end of the follicular phase. At this point in the cycle the 
endometrium lining the uterus decidualizes. This is a proliferative state that 
involves the enlargement and accumulation of glycogen and lipids in endometrial 
cells and the angiogenesis of the maternal spiral arteries (Kaiserman-Abramof 
and Padykula, 1989, Kliman, 2000). This decidualization prepares the uterus for 
implantation of a fertilised embryo and it is maintained throughout the luteal 
phase by the corpus luteum secreting progesterone (Kliman, 2000). In the event 
no implantation occurs, the decidualized lining is shed and the corpus luteum 
regresses, however if an embryo successfully implants the corpus luteum is 
‘rescued’ due to trophoblastic production of the hormone human chorionic 
gonadotropin (hCG) and decidualization of the uterine lining is maintained 
(Kliman, 2000). 
Implantation in humans, primates and rodents is interstitial, this is where the 
embryo fully embeds in the decidualized endometrium (Figure 1-3). By 
approximately day 8-9 post-conception lacunae appear in the 
syncytiotrophoblast, this is the formation of primary stem villus (Frank, 2017). 
Secondary villi have formed by day 16, these consist of an outer layer of 
syncytiotrophoblasts, inner cytotrophoblasts and a core of extraembryonic 
mesoderm. Tertiary stem villi are the final stage of development for the 
placenta (occurring after approximately 21 days post-conception/gestational 
week 5) and consist of a core of fetal capillaries with one layer of 
syncytiotrophoblasts between fetal and maternal blood. This creates the 
environment for exchange between mother and fetus, without the mixing of the 
two circulatory systems. 
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Figure 1-4: The human menstrual cycle 
Figure obtained from Encyclopaedia Britannica (Menstruation: human menstrual cycle [Image]. 
Encyclopaedia Britannica. Retrieved 7 April 2018, from https://academic-eb-
com.ezproxy.lib.gla.ac.uk/levels/collegiate/assembly/view/112920) 
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1.1.3.2 Uteroplacental vascular remodelling 
The human uterine circulation consists of main uterine arteries parallel to the 
left and right sides of the uterus. These arteries supply blood to the arcuate 
arteries which then branch to radial arteries which in turn flow into spiral 
arteries. These spiral arteries (SpA) are terminal vessels extending from the 
outer muscular region of the uterus, the myometrium, into the endometrium. 
This vascular system undergoes physiological remodelling during pregnancy 
which is reversed without intervention after delivery. The SpA also undergo 
minor monthly remodelling during the menstrual cycle. This angiogenesis is vital 
for the proliferation and decidualization of the endometrium (Maas et al., 2001). 
However, the major remodelling has been found to occur during pregnancy. This 
remodelling can be split into two phases, the trophoblast independent and 
trophoblast dependent remodelling (Pijnenborg et al., 2006). The aim of 
remodelling is to establish an enhanced blood supply to the placenta and the SpA 
transform from narrow, muscular, and vasoactive arteries to more flaccid, open 
vessels that are less responsive to vasoconstrictive and dilatory agents (Figure 
1-5). Maternal blood is then able to freely flow into the intervillous space thus 
allowing adequate exchange of nutrients, gases, and waste products between 
mother and fetus and vice versa, via the placenta.  
  
34 
 
 
Figure 1-5: Spiral artery structure before and during pregnancy 
Uterine arteries extend into the myometrium as radial arteries, with some branches of basal 
arteries, before becoming tightly coiled and extending into the endometrium (in the non-pregnant 
state). In pregnancy (right image) the endometrium decidualizes and spiral arteries remodel to 
allow increased blood flow to the placenta. This process is heavily influenced by the invasive 
placental trophoblasts. Diagram adapted from (Moffett-King, 2002)  
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The stages of remodelling have been elegantly reviewed by Pijnenborg et al and 
the stages are illustrated in Figure 1-6. The first trophoblast-independent stage 
is decidual-associated early vascular remodelling. This involves the vacuolation 
of endothelial cells and some swelling of the vascular muscle cells. Uterine 
natural killer (uNK) cells and other immune cells in the maternal uterus have 
been implicated in initiating these early remodelling changes and also in priming 
the uterine tissue for the second trophoblast-associated stage of remodelling 
(Chakraborty et al., 2011, Lash et al., 2010b). uNK cells account for 70% of the 
immune cell population in the uterine tissue (Robson et al., 2012). They are 
distinct from the peripheral blood populations and secret many angiogenic 
factors such as vascular endothelial growth factor (VEGF), placental growth 
factors (PlGF), angiopoietin (1 and 2) and TGF-β (Lash et al., 2010b). Secretions 
of some of these angiogenic factors from uNK cells, specifically angiopoietin 2 
and VEGF, have been found to be highest in maternal decidua from 8-10 weeks 
of pregnancy compared to later gestations (Lash et al., 2010a). This suggests 
that these factors could be initiating spiral artery remodelling prior to 
trophoblast invasion. Studying very early (pre-trophoblast invasion) remodelling 
in human decidua is a difficult concept, due to these early stages often taking 
place before the mother knows of the pregnancy. However, there is evidence 
that trophoblast independent remodelling events take place in the absence of 
placentally derived cells, as remodelling has been observed in the decidualized 
lining of the uterus when the embryo has implanted ectopically and further 
characterised in pseudopregnancies in animal models (King and Loke, 1997, 
Norambuena et al., 1984). 
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Figure 1-6: Pijnenborg's stages of trophoblast independent and dependent spiral artery 
remodelling 
The stages of spiral artery remodelling in pregnancy. Stage 1 and 2 occur independently of any 
placentally derived trophoblast involvement. Stage 3 is the first associated with invading 
extravillous trophoblasts, these quickly propagate the remodelling process and stage 5 shows the 
final spiral artery state that will remain for the duration of pregnancy. Image reproduced with 
permission from (Pijnenborg et al., 2006) 
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The trophoblast associated remodelling has been associated with the greatest 
‘physiological change’ of the SpA (Craven 1998). This remodelling occurs in 
tandem to placental villous development, and cytotrophoblast cells, that do not 
form the syncytium layer, differentiate to become extravillous trophoblasts 
(EVTs). The SpA are first influenced by the presence of interstitial EVTs that 
have invaded the decidual tissue surrounding the SpA. These cells eventually 
invade into the lower part of the myometrium in humans and rats, encouraging 
remodelling along the full length of the SpAs. EVTs produce pro-invasion factors 
such as matrix-metalloproteases (MMPs) (Bischof et al., 1995). The decidua and 
uNK cells mediate EVT invasion, balancing pro and anti-invasive factors secreted 
by the uNK cells and resistance against invasion by the thickened decidual layer 
(Lash et al., 2010a, Cohen et al., 2010). This ensures appropriate invasion for 
placental attachment and utilisation of the maternal blood supply. Excess and 
insufficient invasion are both associated with various placental pathologies 
(Pijnenborg et al., 2006). In healthy pregnancies, the EVTs cause a 
disorganisation of the vascular smooth muscle cells (VSMC) and media of the 
SpAs. This has been found to be, in part, due to EVTs secreting extracellular 
matrix degradation factors, specifically MMPs (Harris et al., 2010, Staun-Ram et 
al., 2004). The presence of endovascular EVTs are observed in the later stages of 
remodelling, and their origin is still under investigation (Pijnenborg et al., 2006). 
There is evidence that they are derived from EVTs at the terminal villi of the 
placenta and they travel through the artery lumen, or that they are derived from 
interstitial EVTs that migrate into the SpA from the surrounding decidua 
(Pijnenborg et al., 2006). Regardless, of origin these EVTs have been found to 
embed intramurally within the SpA wall. This stage of remodelling is associated 
with a complete loss of VSMCs and a replacement with a fibrinoid layer that 
interlocks the EVTs (Whitley and Cartwright, 2010). This semi-permanent 
physiological remodelling is then maintained for the duration of pregnancy in 
order to allow a constant yet steady flow of maternal blood into the intervillous 
space. This is necessary to prevent a pulsatile flow that would expose the fully 
developed placenta to periods of ischemia. It is of importance that, after 
delivery of the placenta, these remodelled arteries constrict and the 
remodelling is reversed. The vessels become narrower more structured arteries 
as in pre-pregnancy, however they never fully return to their exact pre-
pregnancy state (Khong et al., 2003). It is therefore possible that spiral arteries 
38 
 
retain some remodelling ‘memory’ and may have an improved, more immediate 
respond to remodelling signals in subsequent pregnancies. 
1.1.3.3 Maternofetal Transport 
Once the placenta is established it is the sole source of nutrient and oxygen 
provision for the fetus. The tertiary villous structure of the placenta is complete 
at approximately gestational week 5 yet there is continued branching of the 
stem villi which allows for a maximal surface area for exchange (reaching 13m2 
by term). In the last trimester, the only barrier between maternal blood and 
fetal capillaries is the single layer of syncytiotrophoblasts and the single 
endothelium of the fetal capillaries (Figure 1-7), for this reason human 
placentation is known as haemomonochorial. The syncytiotrophoblast layer 
(syncytium) is the most important barrier for nutrient/waste transport to and 
from the fetus (Sideri et al., 1984). Many molecules, such as water, oxygen and 
carbon dioxide, move to and from the placental barrier via diffusion. However, 
larger substances, such as glucose, amino acids and some ions, can only cross the 
placenta via specific transporters on the maternal facing microvillus plasma 
membrane (MVM) and the fetal facing basal membrane (FBM) (Sideri et al., 
1984). A number of different transporters exist on both membranes to control 
this movement (Desforges and Sibley, 2010). Of specific importance are the 
Na+/K+ ATPase, found on both the MVM and FBM, which sets up a concentration 
gradient of low Na+ in the syncytium and drives amino acid transport systems 
(Johansson et al., 2000). There is evidence of at least 15 amino acid transporters 
in the placenta responsible for the transport of a range of basic, neutral and 
acidic amino acids (Jansson, 2001). One of the well characterised amino acid 
transporters is the system A transporter. This transporter relies on the 
electrochemical gradient of Na+ to transport small, neutral amino acids across 
the MVM and FBM. There is evidence that as gestation progresses this transport 
rate increases, ensuring the increased demand from the growing fetus is met, 
however the mechanisms of this increased activity are still unknown (Desforges 
et al., 2009). 
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Figure 1-7: Human maternofetal barrier for placental exchange 
A cross-sectional representation of the villous structure of the human placenta composing of a core 
fetal capillary surrounded by trophoblasts. The fully formed multinucleated syncytium (ST) is the 
main barrier to movement of substances between maternal and fetal blood (arrow). Substances 
must cross the microvillus membrane and basal membrane indicated by *. CT: cytotrophoblast, EC: 
endothelial cell. Schematic created using information from (Jones and Fox, 1991). 
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1.2 Hypertension during pregnancy 
Failure to correctly adapt to the physiological challenges posed by pregnancy 
can result in serious complications. Pregnancy has been compared to a stress 
test for the cardiovascular system, as it can reveal previously unknown 
cardiovascular pathology (Sattar and Greer, 2002). Some of the most common 
pathologies of pregnancy are hypertensive disorders. Like classical hypertension 
these disorders are multi-factorial, relatively little is understood about the 
underlying causes and they can have a detrimental effect on nearly all organs in 
the body as well as influencing placental function. Hypertensive disorders of 
pregnancy can have serious detrimental effects on maternal mortality and 
morbidity as well as the wellbeing of the developing child. Hypertension that 
occurs spontaneously during pregnancy is only evident in humans, and in some 
old-world monkeys (symptoms have been described in the gorilla and 
chimpanzee), and was first described by Hippocrates in the 5th century BC. 
(Stout and Lemmon, 1969, Baird, 1981, Thornton and Onwude, 1992). However, 
these disorders can occur under many guises, and for disorders that have been 
known for millennia the treatment options are poor (the only ‘cure’ being the 
delivery of the placenta) and its causes are not fully understood. 
1.2.1 Classification of Hypertensive Disorders in Pregnancy 
Hypertensive disorders of pregnancy (HDP) can be classed into four major 
groups; gestational hypertension, pre-eclampsia, chronic hypertension and 
superimposed pre-eclampsia. All these conditions are classified by the elevation 
of blood pressure greater than 140mmHg systolic and 90mmHg diastolic (ACOG, 
2013). Gestational hypertension and pre-eclampsia are pregnancy specific, 
presenting ≥20 weeks gestation and resolving postpartum (Steegers et al., 2010). 
The arguably most severe of these conditions is pre-eclampsia, therefore this 
condition tends to be more frequently studied. A basic definition of pre-
eclampsia is the spontaneous pregnancy specific appearance of hypertension 
after 20 weeks gestation with the presence of proteinuria (>300mg/24 hours). 
Diagnosis has remained mostly unchanged for 50 years. Pre-eclampsia can range 
from mild to severe depending on the elevation of blood pressure (mild: 
≥140/90mmHg, moderate: ≥150/100mmHg and severe ≥160/110mmHg) (NICE 
Guidelines, 2010). A more severe prognosis is associated with the presentation of 
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a combination of following features: platelet count <100,000/µl; impaired liver 
function; new development of renal insufficiency; pulmonary oedema; 
headaches and/or new-onset cerebral or visual disturbances (Tranquilli et al., 
2014). Gestational hypertension presents in a similar fashion to pre-eclampsia 
without the more severe phenotypes, such as proteinuria and others outlined 
above. Hypertensive disorders of pregnancy are commonly described as resolving 
after delivery, however this is not the case. In instances of superimposed pre-
eclampsia, which is classed strictly as a hypertensive disorder of pregnancy 
(NICE Guidelines, 2010), the mother remains hypertensive post-pregnancy. There 
is also mounting evidence that some ‘pregnancy specific’ hypertensive disorders 
are diagnosed when there is a previously undetected cardiovascular impairment 
that only presents during pregnancy due to the increased cardiovascular stress. 
This can then manifest as hypertension in later life (Sattar and Greer, 2002). 
This hypothesis would highlight a women’s future risk of hypertension and/or 
cardiovascular disease development if they suffered from HDP, illustrated in 
Figure 1-8. 
 
Figure 1-8: Pregnancy as a cardiovascular 'stress-test' 
The healthy female population (blue line) have a lower risk of vascular dysfunction than those that 
develop hypertensive disorders in pregnancy (red line). Pregnancy (shaded peaks) presents a 
significant cardiovascular stress in pre-menopausal women and those women with higher 
underlying vascular risk factors develop a dysfunction during these periods, and also present 
earlier in the postmenopausal portion of life. Adapted from (Sattar and Greer, 2002).  
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1.2.1.1 Pre-eclampsia 
Pre-eclampsia is the one of the most studied HDP due having the greatest 
severity, and therefore able to be delineated from gestational hypertension by 
stringent criteria. Changes in the maternal population such as an increased 
prominence of advanced age, obesity and diabetes (which are all risk factors for 
the development of hypertension) increase the likelihood of pre-eclampsia 
development (Lawler et al., 2007). Cases of pre-eclampsia complicate between 
2-8% of pregnancies globally (Duley, 2009). However, it is hard to distinguish 
pre-eclampsia from superimposed pre-eclampsia if no information on pre-
pregnancy blood pressure is available, thus the two are often merged and 
studied together. Pre-eclampsia has been mainly thought of as a placental 
disorder, due to the large placental involvement in disease progression and the 
removal of the placenta being the only ‘cure’ for this multifactorial disorder. 
However, more evidence is emerging to suggest the maternal cardiovascular 
system dysfunction plays an important role in the disease development (Ferrazzi 
et al., 2018). Pre-eclampsia may have many subtypes and can be most easily 
classified as early or late onset (Kalafat and Thilaganathan, 2017). These 
subtypes can only be assigned at delivery, with early onset classified as delivery 
occurring prior to 34 weeks gestation and late pre-eclampsia diagnosed with 
delivery on or after 34 weeks (Valensise et al., 2008). It is early pre-eclampsia 
that is mainly attributed to placental dysfunction and is often more severe and 
associated with fetal growth restriction (FGR). Whereas late pre-eclampsia is 
believed to be more of a maternal disorder resulting in failure of the 
cardiovascular system adaptations, which may cause secondary placental 
dysfunction (Kalafat and Thilaganathan, 2017).  
1.2.1.2 Chronic Hypertension and Superimposed Pre-eclampsia 
Essential hypertension, which is hypertension without secondary causes, 
accounts for at least 90% of hypertensive cases and is strongly correlated to the 
development of cardiovascular disease (Messerli et al., 2007). Whilst 
premenopausal women have a lower incidence of hypertension than men of the 
same age, their risk of development increases exponentially after menopause 
with hypertension being more likely in women than men aged over 65 (Roger et 
al., 2012). The reasons for this are not fully understood but have been linked to 
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the cardiovascular protective roles of oestrogen and its beneficial effects on the 
RAS. These crucial hormones and systems need precise coordination during 
pregnancy to establish the appropriate cardiovascular response (section 1.1.1).  
The NICE definition of hypertension is a clinically measured blood pressure 
higher than 140/90mmHg, with an average daytime blood pressure (measured 
using several ambulatory blood pressure measurements or at home monitoring) 
of ≥135/85mmHg. This is classed as stage 1 hypertension, with the stages 
increasing with severity. Guidelines produced by the American College of 
Cardiology and American Heart Association Task Force have suggested lowering 
the blood pressure threshold to 130/80mmHg for the diagnosis of hypertension 
(Whelton et al., 2017). It is of note that the lowest threshold for blood pressure 
elevation used to diagnose many HDP is still a clinical measure of ≥140/90mmHg 
(NICE Guidelines, 2010). This limit may be too high to detect ‘pre-hypertensive’ 
women. It is likely that an abnormal blood pressure response to pregnancy 
occurs in these borderline hypertensive women due to the increased 
cardiovascular stress imposed (Sattar and Greer, 2002). Separating this group of 
women from those that suffer from other HDP would greatly benefit the study of 
the effect of chronic hypertension on pregnancy. 
At present chronic hypertension affects between 1-5% of pregnancies (Sibai, 
2002, Lawler et al., 2007, ACOG, 2013). Women with chronic hypertension 
during pregnancy are 8 times more likely to develop superimposed pre-eclampsia 
than the general population of pregnant women (Bramham et al., 2014, Lawler 
et al., 2007). This increases the risk pregnancy places upon these women, as 
well as increasing the likelihood of adverse neonatal outcomes (Bramham et al., 
2014). The prevalence of chronic hypertension in a population of US pregnancies 
was found to increase from 1.01% in 1995 to 1.76% by 2008 (Bateman et al., 
2012). This rise is likely partly attributed to the rise in age and obesity amongst 
childbearing women; as these factors are also attributed to the likelihood of 
developing hypertension (Lean et al., 2017, Guedes and Canavarro, 2014, 
Kanagalingam et al., 2005, Heslehurst et al., 2007). 
HDP are easily diagnosed if chronic hypertension has been well documented pre-
pregnancy or is present before 20 weeks gestation. However, most women of 
childbearing age are not regularly screened for hypertension and, as discussed 
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above, women who are borderline hypertensive may not be identified pre-
pregnancy. Also confounding this is that maternal blood pressure has typically 
been found to reduce during pregnancy, beginning relatively early in gestation 
(section 1.1.1). This can lead to borderline hypertensive women appearing to 
have blood pressure within the normal range when first screened during 
pregnancy, yet they could later go on to present as hypertensive and could be 
misdiagnosed with gestational hypertension or pre-eclampsia depending on 
severity.  
The pre-eclampsia foundation defines superimposed pre-eclampsia as the 
development of pre-eclampsia during a pregnancy already compromised by pre-
existing hypertension of another cause (Preeclampsia-Foundation, 2010). As the 
likelihood of pre-eclampsia development is significantly increased in 
hypertensive women, the incidences of superimposed pre-eclampsia are high 
(Lecarpentier et al., 2013, Sibai, 2002). Whilst age has been associated with 
increases in incidence of pre-eclampsia it is more difficult to dissect the 
relationship it has with superimposed pre-eclampsia. This is due to women 
identified as hypertensive pre-pregnancy (or at first antenatal appointment) are 
on average more mature (>35 years old), but it is unclear whether this is due to 
the fact an older mother is more likely to become hypertensive, thus more likely 
to develop superimposed pre-eclampsia, or that within the chronic hypertensive 
population of pregnant women age increases the risk of superimposed pre-
eclampsia (Bramham et al., 2014). Lecarpentier et al found that in a group of 
211 women with treated chronic hypertension prior to conception there was no 
age association, similar findings were previously observed by Sibai et al in a 
population (n=763) of chronically hypertensive women with and without 
treatment (Lecarpentier et al., 2013, Sibai et al., 1998). In both studies there 
were a larger proportion of older women with chronic hypertension, yet this did 
not positively correlate with development of superimposed pre-eclampsia.  
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1.2.2 Prevalence worldwide and impact 
Hypertensive disorders during pregnancy were found to be responsible for the 
second largest proportion of maternal deaths worldwide between 2003 and 2012 
(Say et al., 2014). Maternal mortality reduction was one of the Millennium 
Development Goals; to reduce maternal deaths by 75% (from the period of 1990 
to 2015). Maternal mortality has reduced globally since 1990, however only by 
45%. This was most likely achieved by better antenatal care in rural, developing 
countries as there was a documented increase in skilled health personnel 
assisting in births and an increase in antenatal visits and accessibility (The 
Millennium Development Goals Report, 2015). However, the reduction of 
maternal mortality is limited by the knowledge surrounding the conditions 
responsible for these deaths. 
Hypertension accounted for 343,000 maternal deaths worldwide in 2013 (Say et 
al., 2014). This was 14% of the pregnant population and the second largest cause 
of deaths, after haemorrhage. Interestingly, whereas haemorrhage related 
deaths were more prominent in the developing regions, hypertension related 
death prevalence was similar in both the developing and developed areas (14% 
and 12.9% respectively) (Say et al., 2014). Furthermore, it is important to note 
that in this systemic analysis of global deaths, it is not clearly explained which 
hypertensive disorders were included in this direct cause group. It is not clear 
whether this group only examined pregnancy induced hypertension (gestational 
hypertension and PE) or included chronically hypertensive disorders. It does 
state that women with co-morbidities were grouped with indirect causes of 
maternal death. This makes it difficult to dissect the true impact of 
hypertensive pregnancies. 
There are several risk factors for the development of hypertension during 
pregnancy (outlined in Table 1-2) (Tranquilli et al., 2014). Many of these risk 
factors are common to the risk factors associated with the development of 
essential hypertension, such as age, obesity, race etc. These make both 
essential and pregnancy specific hypertension difficult diseases to easily classify 
due to their multifactorial influences and presentations. A further cause for 
concern is that risk factors, such as advanced age and obesity, are becoming 
increasingly more common in women of childbearing age (Heslehurst et al., 
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2007, Roberts et al., 2011); which places these women at greater risk of 
developing pregnancy induced hypertension or developing hypertension prior to 
conceiving. 
The primary cause of deaths (both maternal and fetal/neonatal) is driven by the 
time of diagnosis and delay in initiating any of the few treatment options that 
exist. The prediction of these disorders and establishing appropriate treatments 
is key to reducing the mortality 
Table 1-2: Risk factors for the development of hypertensive pregnancy disorders 
Common Maternal Risk Factors 
▪ Nulliparity 
▪ Multiparity 
▪ Advance maternal age (older than 40 years) 
▪ Race (Caribbean and Latin heritages at highest risk) 
▪ Family history  
▪ Previous affected pregnancy 
▪ Chronic hypertension 
▪ Chronic renal disease 
▪ Obesity and high body mass index 
▪ Diabetes mellitus 
▪ Antiphospholipid syndrome 
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1.2.3 Maternal Cardiovascular Pathophysiology 
Maternal cardiovascular adaptations are crucial to successful pregnancy, as 
outlined in section 1.1.1. Any failure of these adaptations can have serious 
impact on the wellbeing of mother, pregnancy and the fetus. Hypertension 
during pregnancy is understandably linked with cardiovascular system 
dysfunction.  
HDP, pre-eclampsia especially, are referred to as endothelial disorders. This is 
evident in the increased vascular resistance of pregnant women with these 
conditions (Melchiorre et al., 2013, Valensise et al., 2008, Vasapollo et al., 2008, 
Ferrazzi et al., 2018, Stott et al., 2017). It is probable that this dysfunction 
drives the increase in blood pressure, due to the maternal cardiovascular system 
failing to adapt to the increased blood/plasma volume. This can also impact the 
cardiac output of these women. Many studies have agreed upon the increased 
total vascular resistance associated with HDP, yet there are discrepancies 
regarding the impact on CO. Several groups have found pre-term pre-eclampsia 
(i.e. diagnosis prior to 34 weeks gestation) is associated with a reduction in CO 
(Melchiorre et al., 2013, Stott et al., 2017, Valensise et al., 2008). These 
findings suggest that there is a failure of CO to increase in more severely 
affected pre-eclamptic patients. What is unclear is whether there is simply no 
increase and women retain their pre-pregnancy cardiac function or that it rises 
early but fails in later gestation. Farrazzi et al and Stott et al identified that CO 
decreases are more likely in pregnancies with poorer fetal outcomes, such as 
lower birthweights (Stott et al., 2017, Ferrazzi et al., 2018). Discrepancies in 
classification of HDP used in these studies could confound measurements and is 
an area of where a consensus would greatly benefit research.  
There is evidence that some cardiac dysfunction persists even after delivery. 
Most HDP stated as pregnancy specific resolve after the removal of the placenta, 
yet studies have found evidence that women who have suffered from pre-
eclampsia have a higher (although not hypertensive) blood pressure and 
increased vascular resistance postpartum (Valensise et al., 2008, Soma-Pillay et 
al., 2017). Some suggest these cardiovascular abnormalities still exists decades 
after the affected pregnancy (Bokslag et al., 2017). Whether the hypertensive 
pregnancy is a cause or consequence remains to be identified, yet it does add to 
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the theory of pregnancy being a cardiovascular stress test and the possibility 
that HDP could be used to indicate which women will be more at risk in later 
life.  
1.2.4 Hypertensive Pregnancies and Vascular Remodelling 
An abnormal systemic vasculature response to pregnancy is associated with HDP, 
this includes vasoconstriction and endothelial dysfunction which contribute to 
the increased TPR and hypertension (Crews et al., 2000). Insufficient spiral 
artery remodelling and improper placentation have been found to reduce 
uteroplacental blood flow. Of specific importance to the wellbeing of the 
mother and pregnancy is the uteroplacental blood flow, which is the main 
delivery route of maternal blood to the placenta. In HDP the uteroplacental 
blood flow is often reduced, indicated by an increased pulsatility index of the 
uterine artery and resistance to flow resulting in the appearance of notching on 
Doppler waveforms (Poon et al., 2010, Ferrazzi et al., 2018, Fleischer et al., 
1986). Detection of diastolic notching has proved useful as it can be found prior 
to the hypertensive phenotypes in pre-eclampsia, and thus can be used as a 
predictor of HDP, particularly early-onset pre-eclampsia (Tayyar et al., 2015, 
Poon et al., 2010). Reduced placental blood flow is thought to stem from an 
impairment in the spiral artery remodelling (Pijnenborg et al., 1991). Spiral 
arteries from pre-eclamptic patients have been found to have shallower 
remodelling (i.e. limited to decidual, not extending into the myometrium) and 
retain a contractile phenotype and do not show a pregnancy dependent increase 
in flow mediated vasodilation (Lyall et al., 2013, Brosens et al., 1972, 
Kublickiene et al., 1998, Kublickiene et al., 2000). This impairment has been 
associated with poorer trophoblast invasion in women with pre-eclampsia, 
however the mechanisms for this are still unknown (Figure 1-9). Ultimately the 
impaired remodelling creates a hypoxic uterine environment leading to placental 
damage and an increase of antiangiogenic and pro-inflammatory factors, which 
are released into the circulation leading to systemic vascular dysfunction. The 
increase in blood pressure and peripheral resistance that occur in HDP further 
propagates the restricted placental blood flow leading to worsening of the 
disorder (Brennan et al., 2014). 
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The balance of pro and antiangiogenic factors is disturbed in HDP with the 
increased release of soluble VEGF receptor-1 (s-Flt-1) which sequesters VEGF 
and PlGF and prevents their proangiogenic influences. Levels of vasodilatory 
oestrogen metabolites and the activity of the enzymes that produce them have 
also been found to be lower in pre-eclamptic women, such as catechol-O-
methyltransferase (COMT) and its product 2-methoxyoestradiol (Kanasaki et al., 
2008). Oxidative stress increases substantially in HDP due to an imbalance in 
reactive oxygen species (ROS) and anti-oxidant productions (Myatt and Cui, 
2004, Madazli et al., 2002). These are thought to be produced by the struggling 
placenta due to the increased pulsatility of the uterine artery blood flow (Hung 
et al., 2001). This subjects the placenta to periods of hypoxia followed by 
reperfusion with stimulates ROS production and also transports them 
systemically. 
 
Figure 1-9: Pregnancy induced remodelling of the spiral arteries are lessened in pre-
eclampsia 
The extent of spiral artery remodelling is less in pre-eclamptic pregnancies compared to normal 
pregnancies. The deficient remodelling results in a shallower, narrower vessel lumen. ENVT: 
endovascular trophoblast cells, EVT: extravillous trophoblasts, NK cells: natural killer cells Adapted 
from Parham 2004 (Parham, 2004) 
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1.2.5 Dysregulation of the RAS in Hypertensive Pregnancy 
Pre-eclampsia is associated with a reduction of RAS components despite an 
increased sensitivity to the main vasoactive peptide (AngII) (Herse et al., 2007, 
Shah, 2005). Historic experiments show that pregnancy increases women’s 
resistance to AngII’s pressor effects, with pregnant women requiring twice as 
much AngII as non-pregnant women to increase blood pressure (Gant et al., 
1973). However, pre-eclamptic women do not demonstrate this refractoriness 
and have increased sensitivity to AngII, which remains after parturition (Saxena 
et al., 2010). This increased response to AngII occurs even though AngII 
production has been found to be reduced in pre-eclampsia (Langer et al., 1998). 
The main AngII receptor responsible for the contractile effects of AngII (AT1R) 
has been found to have an upregulated expression in the placenta of pre-
eclamptic women (Leung et al., 2001). This could increase the pressor responses 
of AngII in the placental vasculature, regardless of reduced AngII levels, due to a 
higher abundance of AT1R. However, Knock et al found that whilst AT1R 
expression increases, the binding capacity for AngII is reduced in pre-eclampsia 
(Knock et al., 1994). Pre-eclampsia has been associated with an increase in the 
circulating autoantibody to AngII receptor 1 (AT1-AA) (Herse and LaMarca, 2013). 
AT1-AA has been found to stimulate AT1R, binding to this receptor with a higher 
affinity than AngII, thus propagating pressor responses in pre-eclampsia 
(Wallukat et al., 1999). AT1-AA are also proposed to stimulate NADPH oxidases 
and induce the generation of ROS in both maternal vasculature and placental 
trophoblasts, thereby enhancing the endothelial dysfunction and inflammatory 
responses associated with pre-eclampsia (Dechend et al., 2003). The 
dysregulation of the RAS in pre-eclampsia is complex and it is not clear whether 
it is a direct contributor to the pathophysiology or is altered in response to the 
dramatic increase in blood pressure.  
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1.2.6 Impact on Offspring’s Health  
The in-utero environment of the developing fetus is crucial not only to the 
success of pregnancy but also to the offspring’s health in adult life (Gluckman et 
al., 2008). Offspring from compromised pregnancies, such as those in 
hypertensive mothers, are more likely to have poor cardiovascular, metabolic, 
and developmental outcomes in later life (Staley et al., 2015, Gaillard et al., 
2014, Himmelmann et al., 1994). It was first realised that children of Dutch 
women exposed to a period of famine in the Netherlands in the winter of 1944-
1945 had lower birthweights than women with a normal diet (Roseboom et al., 
2006). These babies born small for gestational age or growth restricted have an 
increased risk of developing cardiovascular disease and hypertension in 
adulthood (Barker, 1991, Barker et al., 1993, Sinclair et al., 2007). The Barker 
hypothesis has highlighted the importance of these developmental origins of 
health and disease, in which it is presented that the fetal environment plays a 
key role in the development of health problems later life (Barker, 1991). It is 
now widely recognised that, alongside the adverse effects of poor maternal diet, 
maternal hypertension during pregnancy can negatively impact early-life 
development and influence fetal growth. FGR is a common occurrence alongside 
severe HDP, mainly due to a poor placental perfusion which reduces 
maternofetal transfer of nutrients and oxygen (Steel et al., 1988, Verlohren et 
al., 2010, Himmelmann et al., 1994). FGR is associated with a vast number of 
health problems for the offspring in childhood and into adult life (Crispi et al., 
2018, Hack et al., 2002). This stems from fetal programming, which takes cues 
from the in utero environment and influences from maternal and paternal 
genetics to adapt the development to suit the outside world it will be born into. 
This is a useful evolutionary trait that ensures survival if the child is born into 
the same environment it was exposed to during development. This is 
problematic, however when the poor uterine environment does not reflect the 
outside environment. Both human and animal studies have shown that offspring 
born to hypertensive mothers have a raised blood pressure in childhood, 
adolescent and into adulthood, placing them at greater risk of developing 
hypertension (Himmelmann et al., 1994, Staley et al., 2015). A dysregulation of 
RAS during pregnancy has been found to increase AngII sensitivity and 
hypertensive responses in adult offspring (Xue et al., 2017) 
52 
 
1.2.7 Current interventions 
Treatment for HDP is supportive, with the symptoms monitored and managed, 
but due to the paucity of information on the exact causes, clinical treatment 
options are lacking. The only way to stop the disorders progressing is to deliver 
the baby, which requires a balance between the risk to the mother and 
gestational age of the fetus. Premature delivery is associated with lower survival 
rates and an increased risk of many disorders of the child’s health (Iacovidou et 
al., 2010). A review of treatment options for pregnancy disorders, conducted by 
Fisk and Atun, noted that whilst there were 660 drugs under development for 
cardiovascular disease, only 17 drugs were being developed for maternal 
pregnancy disorders, the majority focusing on manipulations of labour (Fisk and 
Atun, 2008). Only 2 were specifically investigated for treatment of pre-
eclampsia and these were in early clinical trial stages (phase II) and are re-
purposed drugs, previously licensed for other conditions, thus were not 
specifically designed to treat pre-eclampsia. The current strategy of 
hypertension management reduces maternal blood pressure in severely 
hypertensive mothers, yet these women do not always reach normotension (NICE 
Guidelines, 2010). The target blood pressure for these interventions is 
140/90mmHg, which is the borderline for hypertension diagnosis and, as 
discussed previously, blood pressures between 129-139mmHg systolic and 79-
89mmHg diastolic are classed as pre-hypertensive and would not sufficiently 
remove the pregnant women from risk of HDP development.  
The main barriers to designing new interventions/treatments is that there is still 
difficulty in prediction, diagnosis, and treatment of HDP. All these disorders 
require much more in-depth study to elucidate causes, abnormalities and 
mechanisms of dysfunction. Yet, prediction of HDP is advancing with the 
utilisation of the uterine artery Doppler blood flow and the identification of 
potential biomarkers, such as sFlt-1/PlGF ratios, to detect impaired placental 
perfusion before the onset of hypertensive symptoms (Steel et al., 1988, Liu et 
al., 2013). Many of the circulating factors appear in maternal plasma prior to 
onset of any symptoms and a number of biomarkers have been identified (Liu et 
al., 2013, Kenny et al., 2014, Navaratnam et al., 2013, Myers et al., 2013). 
These studies help detect pregnancy pathologies and diagnose the conditions but 
do not tell us key information about why they are occurring. The need for more 
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reliable biomarkers of pre-eclampsia, FGR and other pregnancy complications 
have been identified by many studies and reviews previously published (Liu et 
al., 2013). 
  
54 
 
1.3 Maternal Genetics 
There is evidence of a large genetic influence in the development of HDP. 
Women with a maternal family history of pre-eclampsia are 35% more likely to 
develop pre-eclampsia themselves (Cnattingius et al., 2004). This is not a new 
concept as there are also many genetic influences for essential hypertension 
(Redman et al., 1999). 
The majority of genetic studies in human pregnancy have focused on the 
placenta. Successful placentation requires a coordinated function between the 
placental trophoblasts and the maternal immune system. Therefore, the 
placental genome, which obtains 50% of its genetic information from the father, 
is an important consideration and is crucial in understanding genetic influences 
of pregnancy disorder. Whilst the placenta plays a pivotal role in these 
conditions, the maternal genomic contribution should not be overlooked. It is 
the maternal response to pregnancy that ultimately controls placentation and 
the ability of the maternal cardiovascular system to adapt appropriately.  
1.3.1 Transcriptomics 
Prediction of pre-eclampsia has been a driving force in the use of ‘omic’ 
technologies in pregnancy research. ‘Omic’ technologies comprise of genomics; 
examining the genome, transcriptomics; the study of transcribed genes (mRNA), 
proteomics; large scale study of proteins, and metabolomics; study of 
metabolite production. Proteomics and metabolomics are leading the way for 
‘omics’ in pregnancy research and they are instrumental in detecting potential 
biomarkers, which can be used in the prediction of HDP (Kenny et al., 2014, 
Navaratnam et al., 2013). This type of information is essential; however, in 
order to fully understand the molecular mechanisms that underlie specific 
conditions, it is important to look prior to translation and protein metabolism, to 
the dynamic gene expression changes that are occurring in response to 
placentation and pregnancy. The transcriptomic profiling of various tissues is a 
valid method for determining the control of protein production, as well as 
control of gene expression. 
Transcriptomics is the study of the RNA transcripts produced by the genome. 
This method of examination allows the identification of differentially expressed 
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genes in different tissues and cell types, under specific conditions and/or at 
various time points. Thus providing comparisons that can help delineate 
differences in the genetic regulations and responses to pregnancy adaptations. 
Transcriptome profiling can provide dynamic information on the uterine 
environment, such as inflammation, oxidative stress and the maternal immune 
regulation (Cox et al., 2015) 
1.3.2 Microarray and RNA-Sequencing Technologies 
The methods utilised to provide a transcriptome profile of tissue/cells are high-
throughput sequencing technologies, such as microarrays and RNA-sequencing. 
The majority of transcriptome studies focusing on pregnancy and its disorders 
have utilised microarray technology (Enquobahrie et al., 2008, Akehurst et al., 
2015, De Felice et al., 2015, Sitras et al., 2015, Zhao et al., 2014, Lian et al., 
2010, Cox et al., 2015). These studies allow for a vast number of gene 
expressions to be assessed at the same time and have revealed large numbers of 
gene changes; however, they do not cover the entire genome (Cox et al., 2015, 
Chandran et al., 2016). Microarray studies have revealed many genes that are 
differentially expressed in the placenta of normal and hypertensive pregnancies 
(Kleinrouweler et al., 2013). However,  the systematic review by Kleinrouweler 
et al found inconsistencies with the differential expression of reported genes 
(Kleinrouweler et al., 2013). Microarrays produce information about expression 
of specific genes due to defined probes on the arrays themselves, meaning 
different study designs will lead to investigations examining different sets of 
specified genes and thus not reaching consensus easily. Alternatively, studies 
using similar arrays of gene probes may artificially inflate the significance of 
certain gene changes. The more recent next generation sequencing technique of 
high-throughput RNA sequencing (RNA-Seq) allows for the profiling of all 
transcribed RNAs across an entire genome, and may be more appropriate in 
examining gene changes in pregnancy (Wang et al., 2009). This technology 
provides information on gene expression that is not limited to the known 
genomic sequence (Wang et al., 2009). RNA-Seq also highlights all RNA 
populations in a cellular/molecular system (Table 1-3); including long non-coding 
RNAs (lncRNA), which are becoming known to have a more prominent role in 
many cellular functions and diseases, having been found to be associated with 
the regulation of gene expression (He et al., 2013, Wang and Chang, 2011). RNA-
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Seq is being utilised in pregnancy research, mainly in examination of the 
placental transcriptome (Shankar et al., 2012, Kaartokallio et al., 2015). The 
first of the large-scale studies identified 53 differentially expressed genes 
between ‘normal’ and pre-eclamptic placenta (Kaartokallio et al., 2015). RNA-
Seq has also been utilised to examine the different transcriptome signatures of 
single cell types in the human placenta (Nelson et al., 2016, Tan et al., 2016). A 
study specifically focused on examining the transcriptome profile of the 
maternofetal interface using single cell RNA-seq provided information on the 
transcriptome signatures of individual cell populations that stem from the 
placenta and influence maternal decidua (Nelson et al., 2016). However, the 
nature of this analysis meant that maternal responses were only assessed in 
relation to shallow trophoblast invasion and no vasculature was examined. Whilst 
this does provide in-depth detail of gene regulation of specific functional 
biological pathways of the placental and decidual cell types alone, it does not 
detail how one influences the other.  
Table 1-3: Most common transcript biotypes detected in RNA-Seq studies and the known 
number annotated in human, rat and mouse 
Transcript Biotype Human Mouse Rat 
Protein coding 20,376 22,630 22,250 
Non-coding 22,305 15,537 8,934 
     Small non-coding 5,363 5,531 5,122 
     Long non-coding 14,720 9,443 3,288 
     Misc. non-coding 2,222 536 524 
Pseudogenes 14,692 12,522 1,668 
All transcripts 203,903 135,276 41,078 
 
Only a small number of studies have examined gene expression in maternal 
tissue and the majority have isolated the transcript signatures of term 
pregnancies when a myometrial biopsy is taken during caesarean sections. Kim 
et al examined the transcriptome landscape of the placenta which included 
identifying the gene signature of the maternal tissue (the decidua) using RNA 
sequencing (Kim et al., 2012). This revealed that there is a vast difference in the 
transcriptome profile between the maternal decidua and the placenta as well as 
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between different tissues in the body. However, genes involved in vascular 
remodelling and development were identified (from Gene Ontology terms) in the 
chorion of the placenta (where placental angiogenesis occurs), yet were not 
identified in the decidua suggesting the presence of the spiral arteries in the 
decidua were not reflected in the gene data. (Kim et al., 2012). This may be due 
to decidual samples being macroscopically dissected from term placentas, and 
therefore would only be very superficial placental bed samples. This could 
suggest that the method of maternal decidua tissue collection is not appropriate 
for sampling the changes in the maternal uteroplacental vasculature. A flaw in 
these human studies is that they only isolate tissue and cells at term. This is 
understandable due to the inaccessibility of early gestation tissue; however, the 
gestational time point will most likely heavily influence the transcriptome 
profile of both the placenta, decidua and spiral arteries due to the relatively 
short timescale of placental development compared to other organs. 
Furthermore, studies in term placental tissue have highlighted that the placenta 
has diversity in gene expression profiles that differ from other tissues. Therefore 
in this short-lived organ the gene expression and RNA processing changes may 
have a profound impact on function relatively quickly (Kim et al., 2012). The 
sampling of tissues from different gestational ages is difficult in humans due to 
ethical considerations of collecting early pregnancy tissue. Non-pregnant 
maternal tissue can only be collected from hysterectomies, yet this presents 
challenges with age matching samples and introduces increased variability as the 
hysterectomy may have been required due to another condition, such as cancer, 
which would impact the RNA profile of the tissue significantly. There has been 
some investigation into early pregnancy gene expression differences using human 
trophoblast cell lines (Highet et al., 2016). Highet et al attempted to investigate 
placental angiogenesis using the HTR8/SVneo trophoblast cell line which mimics 
blood vessel development. This focused on trophoblast invasion gene expression, 
and used a directed microarray so was comparatively limited. The microarray 
method is also more biased than RNA-Seq as the expression of genes are 
examined are targeted and planned, instead of examining the entire 
transcriptome. Furthermore, the approach using an in vitro mimic of blood 
vessel formation cannot detail the maternal uterine and spiral artery response to 
placentation. The transcription level knowledge in this area is lacking as no 
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studies have specifically examined maternal uteroplacental vasculature or the 
transcription-controlled responses of the spiral arteries to placentation.   
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1.4 Animal models of pregnancy 
Animal models are crucial in fully understanding pregnancy and pregnancy 
disorders. Utilising appropriate animal models avoids placing human mothers and 
fetuses at risk. Most information of placental physiology in humans has been 
obtained at delivery; which only provides information on the fully formed 
placenta, or from elective abortions; which are infrequently used due to the 
ethical considerations and at this stage it cannot be determined whether the 
pregnancy was to go on to develop problems (Guttmacher et al., 2014). 
Furthermore, most pregnancy focused studies cannot accurately measure 
changes to the cardiovascular and renal systems in humans due to the most 
reliable measurements needing invasive procedures. The hazards associated with 
invasive measures of uterine blood flow and placental function in vivo also 
highlight the need to study these systems in animal models to gain better insight 
into the human condition. 
Pregnancy and placental research have developed exponentially with the 
utilisation of experimental animal models and without these models a full 
understanding the physiological changes in vivo would be near impossible. 
However, care must be taken when choosing to study human pregnancy 
conditions in an animal model as placentation differs hugely across species and 
with a wide variety of placental structures making comparisons difficult. One 
group of mammals, however, are most appropriate for human research; those 
with haemochorial placentas. Haemochorial placentation occurs in humans and 
in higher order primates, guinea-pigs, rats and mice. This type of placentation 
allows maternal blood to come into direct contact with fetal cells (the chorion) 
allowing rapid transfer of gases, solutes and nutrients.  
Animal models are a good substitute when investigating these maternal 
responses to placentation and pregnancy, especially at the early time points. 
Rodent placentation and humans have striking similarities and findings from 
these animals can guide knowledge on human pregnancies. Both humans and 
rodents have similar placentation with rats mimicking the deep trophoblast 
invasion that has been observed in humans (Wooding and Burton, 2008). These 
similarities allow us to carefully extrapolate the basic mechanisms of early 
pregnancy. The transcriptome of the rat placenta at term has been investigated 
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and compared with human pregnancy pathologies such as maternal obesity, 
gestational hypertension and placental ischemia and has also proven invaluable 
in understanding the normal physiological mechanisms of placentation and 
pregnancy induced gene expression changes (Shankar et al., 2012, Vaswani et 
al., 2015, George et al., 2014). Yet, no animal model is perfect in recapitulating 
human HDP. This is due to pregnancy-induced hypertension being specific to 
humans and some old-world monkeys (Thornton and Onwude, 1992). However, 
there is a wealth of possibility to study various phenotypes and impacts of HDP 
with the best course being the utilisation of a wide range of animal models. 
 
1.4.1 Pregnancy in Rodents  
The animals used in the study of pregnancy and placentation vary from routine 
laboratory animals, such as rabbits, rats and mice, to the more exotic, such as 
guinea pigs, chinchillas and baboons (Mikkelsen et al., 2017, Grigsby, 2016). 
Whilst all the afore mentioned animals have similar placentation to humans; rats 
and mice have proved the most appropriate animals to use due to their ease of 
use and maintenance (McCarthy et al., 2011, Dilworth and Sibley, 2013). Rat 
gestation differs greatly from human in that it occurs over 21-22 days, compared 
to the human 40 week gestation period. Implantation of multiple offspring in 
rodents occurs between 4 and 5 days postcoitous and decidualization differs 
from humans as it is stimulated by the implanting blastocyst and is not a cyclical 
process. However, there are major similarities between human and rat 
placentation, including the invasion of trophoblast cells into the maternal 
decidua and into the proximal region of the myometrium. The maternal 
uteroplacental vasculature of women and rats has a similar structure regardless 
of the uterine structural differences (Figure 1-10), as both have main uterine 
arteries that branches into arcuate, radial and finally spiral arteries. The spiral 
artery remodelling and changes observed to maternal uteroplacental circulation 
are also similar between rat and humans (Osol and Moore, 2014). Table 1-4 
shows the similarities and differences between these animals and human 
placentation. 
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Figure 1-10: Comparison of the human and rodent uterine vasculature 
The human (A) and rodent (B) uterus with blood supplied from main uterine arteries branching into 
uterine tissue culminating in spiral arteries. This image was reproduced with permission from (Osol 
and Moore, 2014)  
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Table 1-4: Comparison between key placentation events in the human, rat and mouse 
Human Rat Mouse 
- Discoid and haemomonochorial 
placental structure 
- Villous structure 
- Remodelling of spiral arteries linked 
to trophoblast invasion 
- Deep trophoblast invasion through 
decidua and proximal part of 
myometrium 
- Discoid and haemotrichorial 
placental structure 
- Labyrinthine structure 
- Remodelling of spiral arteries 
linked to trophoblast invasion 
- Deep trophoblast invasion through 
decidua and proximal part of 
myometrium 
- Discoid and haemotrichorial 
placental structure 
- Labyrinthine structure 
- Remodelling of spiral arteries 
linked to trophoblast invasion 
- Shallow trophoblast invasion 
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1.4.1.1 Rodent Placentation 
Many reviews of in vivo pregnancy and placental research group rats and mice 
together under rodents or use evidence from one animal to establish a 
conclusion about the other (Soares et al., 2012). There are notable differences 
in mouse vs. rat vs. human gestation. Rats have a much shorter gestation time 
and a greater number of offspring compared to humans. Yet the placenta, even 
though it develops at a much more rapid pace in rats than in humans, has many 
similarities between the two. Analogous trophoblast cell types have been found 
with the human extra-villous trophoblasts showing similarities to invasive 
trophoblasts in rats. These invasive trophoblasts have been proposed to arise 
from the junctional placental zone (most proximal to the maternal decidua) and 
have been found to invade deep into the decidualized endometrium and into the 
myometrial portions of spiral arteries (Ain et al., 2003). This process is most 
similar to the deep trophoblast invasion observed in human placentation than in 
mice where trophoblast invasion is shallower (Ain et al., 2003, Verlohren et al., 
2008). Furthermore, rats have a similar maternal vascular response to 
placentation as the uterine arteries undergo a similar remodelling process as in 
humans (Osol and Cipolla, 1993).  
Both human and rat placenta are haemochorial, which means that the 
trophoblast cells of the placenta are in direct contact with maternal blood 
(Figure 1-11). Transport across the placenta in rats and humans is also analogous 
with the same transporters for specific amino acids (e.g. taurine and system A) 
being utilised for placental transport in both species (Glazier et al., 1996). The 
two placenta types do differ in that rats have haemotrichorial placentas (three 
trophoblast layers) whilst humans have haemomonochorial placentas (one layer). 
Therefore rat placentas, like in mice, have three trophoblast cell-layers as a 
barrier between fetal blood and maternal blood (Figure 1-11C), whereas humans 
only have one full layer, the cytotrophoblasts fuse to form the 
syncytiotrophoblast layer (Figure 1-11D) (Huppertz, 2008, Dilworth and Sibley, 
2013). Figure 1-11 illustrates that whilst the gross placental structures of the 
two species seem very different, the cytoarchitecture is similar. Rat trophoblast 
layer I consists of very sparse mononuclear trophoblasts that do not create a 
sufficient permeability barrier, this proposes that the syncytial layer II is the 
first barrier to nutrient exchange, suggesting that it has the most functional 
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similarity to the human syncytiotrophoblast layer. The maternal facing 
syncytiotrophoblast (microvillus membrane (MVM)) of the human placenta is 
analogous to the maternal facing membrane of trophoblast layer II in rats. The 
human MVM and the apical trophoblast layer II of rat have both been found to 
utilise the same calcium transporters of the transient receptor potential gene 
family and both have been found to have the enzyme alkaline phosphatase 
localised to this area (Dilworth et al., 2010). The human syncytiotrophoblast 
basal membrane and possibly also the cytotrophoblast layer have been suggested 
to be analogous to the fetal facing side of rat trophoblast layer III, however, due 
to their fetal facing location it is very difficult to obtain samples and perform 
reliable experiments that can conclude any similarities/differences (Dilworth 
and Sibley, 2013).  
 
Figure 1-11: Comparison of the rat and human placental cellular structure and villous 
compositions 
The structure of (A) the rat labyrinthine placenta and (B) the human villous placenta. Placental 
tissue is depicted in purple/green and fetal tissue is pink. Maternal blood (MB) is in red. (A) The rat 
placenta is composed of a junctional (Jx) zone near on the maternal side which consists of giant 
trophoblast cells (GT) and spongiotrophoblasts (SpT). (B) The human placenta consists of 
placental villi in direct contact with maternal blood in the intervillous space. The villi have clusters of 
column cytotrophoblast cells (CCT) which anchor the placenta to maternal decidua, also present 
are extravillous trophoblasts (EVT) which invade and remodel maternal spiral arteries (not shown).  
(C-D) Are cross-sectional diagrams of the maternofetal exchange area. * Barriers to maternofetal 
transport. Adapted from (Rossant and Cross, 2001). 
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1.4.1.2 Rodent Models of Pre-eclampsia 
Animal models are of paramount importance to pregnancy research as they can 
be used to investigate the underlying causes of abnormality and the fetal 
outcome. They are essential in understanding the molecular basis of pre-
eclampsia which is crucial for developing the current understanding of this 
pregnancy disorder. A good animal model requires a multitude of factors to 
resemble the multi-phenotypic nature of the human condition, such as 
developing hypertension and proteinuria specific to pregnancy, but also having a 
disproportionate balance of angiogenic factors and displaying endothelial 
dysfunction as well as abnormal uterine artery remodelling (McCarthy et al., 
2011). Despite pre-eclampsia being unique to humans and some higher order 
primates, there are a number of available animal models that can be used to 
study specific phenotypes of pregnancy induced hypertension and pre-eclamptic 
like symptoms with a varying degree of usefulness (McCarthy et al., 2011). The 
outline of some of the most used rodent models below is not exhaustive and 
many strategies of imposing HDP in rodents can be used in combination 
(Arguelles et al., 2017, Murphy et al., 2012, Shirasuna et al., 2015). 
1.4.1.3 The Reduced Uteroplacental Perfusion Model 
A reduced uteroplacental blood flow has been implicated in the pathogenesis of 
some HDP, especially pre-eclampsia (Pijnenborg et al., 1991, Brosens et al., 
1972). A model of studying early term pre-eclampsia is the reduced uterine 
perfusion pressure (RUPP) model. This model involves surgically restricting the 
aorta (above the iliac bifurcation) and ovarian arteries mid-way through 
gestation (GD14.5) to reduce blood flow to the uterus. This method induces 
hypertension during pregnancy and reduces uteroplacental blood flow by 
approximately 40% (Granger et al., 2006). The most common and well 
characterised of the RUPP models is the RUPP rat. Characterised by Granger et 
al this model of reduced uteroplacental perfusion mimics symptoms of early 
stage severe pre-eclampsia (Crews et al., 2000, Alexander et al., 2001, Granger 
et al., 2006). These include an increased blood pressure (around 30mmHg higher 
than normal pregnancy levels), an increased peripheral resistance, decreased 
cardiac output, decreased renal plasma flow and kidney function, proteinuria, 
systemic endothelial dysfunction and fetal growth restriction (Granger et al., 
2006, Brennan et al., 2016, Walsh et al., 2009). Whilst not spontaneous, the 
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symptoms were found to be pregnancy specific as reducing perfusion to the 
uterus in non-pregnant rats did not elicit a blood pressure response (Alexander 
et al., 2001). Interestingly, the RUPP model does show a resolution of blood 
pressure back to normotensive levels after delivery yet retains some systemic 
vascular dysfunction, observed in mesenteric and thoracic arteries 3 months 
postpartum (Brennan et al., 2016). This is a useful caveat of this model due to 
the mounting evidence supporting the theory that women with a past pre-
eclamptic pregnancy are more at risk to cardiovascular disease in later life 
(Sattar and Greer, 2002). 
The advantages of this model as a model of pre-eclampsia are clear, in that it 
matches the major symptoms and stimulates placental ischemia. However, one 
major disadvantage of the RUPP rat model is the large number of animals 
required due to exclusion of dams with total loss of pregnancy. All previous 
studies using this method have stated that dams with no viable pups were 
excluded, and of those that reported the number of excluded animals, up to 37% 
removed from the studies (Brennan et al., 2016). 
1.4.1.4 Nutritional and Pharmacological Models  
Both maternal and paternal nutrition prior to and during pregnancy can impact 
fetal development (Roseboom et al., 2006, Barker, 1991, Watkins et al., 2017). 
The majority of diet manipulation is used more to investigate the impact of 
obesity on pregnancy, or nutritional influence on the development and health 
quality of the offspring, with hypertension being studied in subsequent 
generations and not the mothers (Fraser et al., 2010, Gaillard et al., 2014, 
Richter et al., 2009). 
HDP can be mimicked pharmacologically using infusions of substances known to 
cause systemic vascular dysfunction by promoting inflammation and endothelial 
damage, such as sFlt-1, TNF-α, interleukin-11, L-NAME and AngII. All these 
substances have the ability to ultimately increase uteroplacental vascular tone, 
thus mimicking the reduced placental perfusion (Murphy et al., 2012, Bobek et 
al., 2015, Zhou et al., 2007, Winship and Dimitriadis, 2018, Soobryan et al., 
2017). All these models described can provide an insight into a variety of factors 
that arise as a consequence of pre-eclampsia (i.e. fetal growth restriction and 
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other conditions of fetal distress). However, they are simulating hypertension by 
means of applying the stressors that are caused by pre-eclampsia and other HDP, 
therefore may not be very useful in determining underlying predispositions or 
causal mechanisms of development. 
1.4.1.5 Renin-Angiotensin Manipulation Models 
Healthy pregnancies in both humans and rodents have increased RAS activity and 
RAS component expression within the placenta (Vaswani et al., 2015). A 
dysregulation of the RAS has long been associated with development of HDP 
(Herse et al., 2007). Alterations of the RAS in rodents have been utilised to 
create hypertensive models for decades and have been used by several groups to 
mimic HDP (Xue et al., 2017, Hering et al., 2010, Brewer et al., 2013, Kawada et 
al., 2002). The chief focus has been on the assessment of hypertension 
development in adult offspring exposed to AngII in utero, with maternal 
maladaptation being presented only as evidence of HDP symptom development. 
For example, Xue et al utilised AngII infusion to mimic hypertensive pregnancy 
to investigate the impact on offspring brain development and pre-disposition to 
hypertension in adult life (Xue et al., 2017).  
Pre-eclampsia has been associated with an increased AngII sensitivity proposed 
to be due to increased activation of the AT1R via the angiotensin II type I 
receptor. The AT1R receptor autoantibody (AT1-AA) has been found to have 
higher affinity for this receptor than AngII and is increased in pre-eclampsia 
(Leung et al., 2001). Rat models have been developed that exploit this 
knowledge by infusing otherwise healthy rat pregnancies with AT1-AA (Herse and 
LaMarca, 2013, Wallukat et al., 1999, Zhou et al., 2008). These models found 
that increasing AT1AA in serum the pregnant rodents produced pre-eclamptic 
phenotypes such as elevated blood pressure, evidence of proteinuria, increased 
mediators of endothelial dysfunction (e.g. sFlt-1, soluble endoglin) and impaired 
renal function. 
Another method of manipulation of the RAS comes from transgenic crosses which 
artificially elevate the concentrations of placental specific AngII. Female mice 
with the human angiotensinogen gene developed pregnancy specific 
hypertension when mated with males carrying the human renin gene (Takimoto 
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et al., 1996). This highlights the importance of AngII production in regulating 
maternal hypertension during pregnancy, and the important role the placenta 
plays in pregnancy specific hypertension. Many more studies have utilised this 
transgenic cross in both rats and mice (Hering et al., 2010, Bohlender et al., 
2000, Denney et al., 2017). Due to the consensus that there is a sudden yet 
sustained increase in blood pressure from mid-gestation which returned to pre-
pregnancy levels after delivery, this model is highly appropriate for studying 
outcomes of gestational hypertension, however its usefulness is limited in 
uncovering underlying mechanisms. The model mirrors symptoms of human pre-
eclampsia with significantly increased blood pressure, increased proteinuria, 
evidence of kidney damage and a reduction in fetal weight. This model may be 
particularly useful for examining the offspring from these transgenic crosses, as 
these have been found to have vascular and cardiac dysfunctions later in life, 
however this may be confounded by the fact that the offspring themselves will 
possess both human renin and angiotensinogen (Bohlender et al., 2000). 
1.4.1.6 Genetic Models  
The term HDP encompasses many conditions, each one multifactorial, which 
makes it impossible to perfectly reproduce a model of the entire disorder. 
Instead, one of the more successful approaches is to focus on a specific cause of 
a specific phenotype and create genetic manipulations that mimic this. 
Endothelial dysfunction is a common manifestation of many HDP (Crews et al., 
2000). As such the genetic knockout of endothelial NO synthase (eNOS-/-) has 
shown promise in investigations of HDP due to its impaired uterine artery 
function (Kulandavelu et al., 2013, Kusinski et al., 2012, Hefler et al., 2001). 
However, not all studies have agreed on the profile of maternal blood pressure 
in the eNOS-/- model. Shesely et al found that whilst eNOS-/- mice had pre-
pregnancy hypertension, these dams were not hypertensive during pregnancy; 
possibly due to the pregnancy associated BP reduction (Shesely et al., 2001). 
However, Hefler et al did not observe pregnancy dependent reduction in 
maternal BP in the eNOS-/- model and furthermore found a significant increase 
in maternal blood pressure in the 2nd and 3rd ‘trimesters’ compared to wild type 
animals. However this significant difference could be attributed to the 
pregnancy dependent decrease in BP of wild type animals (Hefler et al., 2001). 
The confusion surrounding the maternal BP profile of the eNOS-/- model may 
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place it as a more appropriate model to examine fetal growth restriction, caused 
by poor placental perfusion rather than HDP (Kusinski et al., 2012). 
A deficiency in catechol-O-methyltransferase (COMT-/-) has also proved useful in 
replicating underlying causes of pre-eclampsia. COMT-/- mice are characterised 
by pregnancy hypertension and proteinuria (McCarthy et al., 2011, Kusinski et 
al., 2012, Kanasaki et al., 2008). The deficiency in COMT means that 2-
methoxyestraadiol, a metabolite of oestrogen and prominent vasodilator, is not 
produced leading to antiangiogenic effects and increased Hif-1α and sFlt-1 levels 
(Kanasaki et al., 2008). These models also demonstrate abnormal uterine and 
umbilical Doppler waveforms with diastolic notching, indicative of impaired 
uteroplacental blood flow and placental hypoxia and commonly used as a 
diagnostic tool for pre-eclampsia (Stanley et al., 2012, Kanasaki et al., 2008, 
Fleischer et al., 1986). Indeed, the uterine arteries of these mice have been 
found to have a more propagated contractile response to vasoconstrictive agents 
(Stanley et al., 2012).  
The borderline hypertensive mouse (BPH/5) is an inbred mouse strain that 
spontaneously develops hypertension and proteinuria during late gestation 
(Davisson et al., 2002). The BPH/5 mice are hypertensive prior to pregnancy 
with a blood pressure approximately 20mmHg higher than C57 reference strains, 
yet pregnancy worsens this hypertension, and by late gestation the blood 
pressure is approximately 1.5x times higher than the reference strain (Davisson 
et al., 2002). It has also been noted that this model has evidence of kidney 
damage, proteinuria, systemic endothelial dysfunction and increased decidual 
inflammation (Davisson et al., 2002, Heyward et al., 2017). This model is an 
interesting model as it is more likely than specific knockouts to have more 
relevance to the human multifactorial condition and can also be used to 
investigate the effects of pre-hypertension on pregnancy and effects on offspring 
development and health. However, the mouse placentation process is lacking in 
similarity to the human placenta when compared to the rat. 
  
70 
 
1.5 The Stroke-Prone Spontaneously Hypertensive Rat  
The stroke-prone spontaneously hypertensive (SHRSP) rat is a genetically inbred 
hypertensive model, which has been used in the study of human essential 
hypertension and stroke for decades. Despite the breeding of this strain since 
the 1960s, very few studies have examined the SHRSP pregnancy and its use as a 
model of HDP has not been fully assessed. 
1.5.1 SHRSP characteristics and history 
SHRSP rat origins stem from the University of Kyoto where the selective breeding 
of Wistar Kyoto (WKY) rats with slightly elevated blood pressure produced the 
spontaneously hypertensive rat (SHR) in 1963 (Okamoto and Aoki, 1963). The SHR 
strain was subjected to further selective inbreeding to produce the SHRSP rat in 
1974 (Yamori and Okamoto, 1974), which has been further inbred in many 
institutions (including the University of Glasgow) (Figure 1-12). The male SHRSP 
develops hypertension at approximately 8 weeks of age (Ueda et al., 1979). It 
has the highest blood pressure of these spontaneously hypertensive rat strains; 
>220mmHg (Yamori and Horie, 1977). In comparison the SHR blood pressure 
maximum is approximately 200mmHg. The SHRSP is also 70% more likely to 
suffer a stroke than the SHR strain, with incidence of stroke in SHRSP on high 
salt diets being 100%. This, therefore, is a model of a more extreme 
hypertensive condition associated with increased endothelial dysfunction and 
left ventricular hypertrophy as the animal ages (Harvey et al., 2017, Jesmin et 
al., 2005). It is these multiple pathologies that make it an incredibly relevant 
model for human cardiovascular disorders. The genome of both the SHRSP and 
normotensive WKY has been sequenced, for both the original strains and the 
colonies maintained at the University of Glasgow (Atanur et al., 2013), making 
this model even more suited to studying the genetic influences of hypertension 
(Delles et al., 2008). 
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Figure 1-12: Genealogy of the Stroke-Prone Spontaneously Hypertensive Rat 
Selective breeding of hypertensive WKY rats lead to the first generation of SHR rats in Kyoto, 
Japan (P). Subsequent generations (F) where in bred in many institutes and locations, eventually 
leading to the current strains available, detailed at the base of the diagram. NIH: National Institute 
of Health 
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1.5.2 Uses in Cardiovascular Disease and hypertension 
The SHRSP rat has been key in the discoveries of the genetic basis of 
hypertension, specifically the revelation of specific quantitative trait loci 
involved in blood pressure regulation (Hilbert et al., 1991, Jacob et al., 1991). 
The hypertension in this model is multifactorial and, like the human condition, is 
worsened by elevated dietary salt and reduced potassium, which can lead to 
damage to the cardiovascular system; resulting in ischemic stroke, cardiac 
hypertrophy and renal disease (Di Castro et al., 2013, Takeda et al., 2001).  
There is evidence of the SHRSP model having a dysregulated RAS. SHRSP have 
been found to have higher plasma renin activity and AngII levels as well as an 
increased renal sensitivity to AngII (Takemori et al., 2005, Berecek et al., 1980). 
With the RAS being intimately associated with blood pressure regulation, these 
dysregulations are important in the study of hypertensive disorders and 
treatment options. SHRSP rats have also been found to have high vascular 
oxidative stress, mediated by a dysregulation of the Nrf2-antioxidant system 
promoting a shift towards pro-oxidants and thus increasing endothelial 
dysfunction and vascular damage (Lopes et al., 2015). Evidence of vascular 
dysfunction is further supported by the findings of Kerr et al who found an 
increase in superoxide produced by NADPH oxidases in the vascular smooth 
muscle cells of SHRSP, and proposed this could account for the decreased nitric 
oxide availability observed in SHRSP rats (Kerr et al., 1999). However, this study 
also found a dissimilarity between male and female SHRSP, with female SHRSP 
having a lower aortic endothelial nitric oxide synthase (eNOS) expression than 
their male counterparts yet still generating increased superoxide levels than 
WKY females (Kerr et al., 1999).  
The majority of studies examining cardiovascular disease, stroke and 
hypertension using the SHRSP rats have focused on the males. This is generally 
due to the males having higher blood pressure and associated end-organ 
damage, and it reduces experimental variability introduced by the hormone 
cycling specific to females. (Davidson et al., 1995, Clark et al., 1996). However, 
due to the preference of male use in pre-clinical research, knowledge of 
vascular disease in females is lacking (Anthony and Berg, 2002). This gender 
73 
 
disparity is important as it is only the female that must physiologically respond 
to pregnancy. 
1.5.3 SHRSP Maternal Pregnancy Characterisation 
The hypertensive pregnancy of the SHRSP rat was first examined and published 
in the late 1970s and early 1980s (Yamada et al., 1981, McCarty and Kopin, 
1978). These early studies examined SHRSP blood pressure over gestation, 
finding dams remained hypertensive throughout pregnancy, yet were limited in 
their examinations of maternal and fetal impairments associated with HDP. More 
detailed pregnancy outcome characterisations of the SHR revealed that this 
model has hypertensive pregnancies, with blood pressure lowering towards 
delivery, associated with less maternal weight gain, an increased fetal loss and 
some histological evidence of placental haemorrhage (Lorenz et al., 1984, Scott 
et al., 1985, Lewis et al., 1997, Peracoli et al., 2001). There is some 
contradiction as to whether this hypertension impacts fetal weight with some 
finding a reduced weight compared to WKY and others no difference (Lewis et 
al., 1997, Scott, 1986, Peracoli et al., 2001). Fewer studies have been conducted 
specifically on the SHRSP than have been carried out on the SHR, with only 18 
recorded publications found between 1979 and 2018 (search conducted May 
2018). From the small numbers examining SHRSP pregnancy in comparison to 
normotensive WKYs, it was revealed that SHRSP pregnancies are hypertensive 
throughout, with a dip in blood pressure towards delivery (Gompf et al., 2002, 
Small et al., 2016, Barrientos et al., 2017). These studies further suggested that 
SHRSP fetal development may be impacted by this hypertension, due to reduced 
fetal weights, a smaller number of pups per litter and increased fetal loss (Fuchi 
et al., 1995a, Small et al., 2016, Barrientos et al., 2017). Placental 
abnormalities have been documented in SHRSP pregnancy. These include a 
reduced transport capacity (inferred from lower placental Na+/K+ ATPase 
activity), structural abnormalities (with a loss of glycogen cells in the placental 
junctional zone and reduced labyrinth vascularity) and a reduced endovascular 
trophoblast invasion into the spiral arteries (Fuchi et al., 1995a, Barrientos et 
al., 2017, Ferrazzi et al., 2018). Two studies have examined maternal vascular 
function in pregnant SHRSP (Gompf et al., 2002, Small et al., 2016). Gompf et 
al, focused on maternal aortic function and found increased vasodilatory 
responses in pregnant compared to non-pregnant vessels from both normotensive 
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WKY and hypertensive SHRSP (Gompf et al., 2002). SHRSP aortas from pregnant 
dams demonstrated a propagated relaxation response to stimulated NO release 
and increased eNOS expression compared to pregnant WKY (Gompf et al., 2002). 
A different vascular bed was examined by Small et al, this revealed that SHRSP 
uterine arteries have an impaired vasodilatory ability and enhanced contractile 
response (Small et al., 2016) (Figure 1-13). This was evident in virgin WKY and 
SHRSP comparisons, and whilst the pregnant SHRSP uterine arteries did become 
more responsive to vasodilatory agents it was still reduced compared to 
normotensive WKY dams. Also evident were structural variations in the pregnant 
arteries compared to normotensive WKY rats, with SHRSP arteries having smaller 
diameters both pre-pregnancy and at term. This study is suggestive that the 
SHRSP have an impairment in uterine artery remodelling during pregnancy and 
that the response is not due to a systemic hypertension, as antihypertensive 
treatment with Nifedipine failed to improve the structural and functional effects 
on the uterine artery. The impaired uteroplacental blood flow in the SHRSP 
could therefore be impacting the placental function and offspring outcome. Yet 
it is unclear why the SHRSP have these impairments and how the maternal 
cardiovascular impairment may play a role in their development.  
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Figure 1-13: Diameters and functional responses of uterine arteries from pregnant WKY and 
SHRSP dams  
The external and internal diameters (A-B) and functional responses to noradrenaline (C) and 
carbachol (D) of uterine arteries from pregnant (GD18.5) WKY, SHRSP and SHRSP treated with 
Nifedipine. SHRSP dams with and without Nifedipine treatment demonstrated reduced uterine 
artery diameter and impaired constriction and dilation; ** p<0.01 vs. WKY. Data analysed by 
comparing area under the curve values using one way ANOVA and Tukey’s post-hoc test. 
Published in Small et al., 2016 
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1.6 Hypothesis and Aims 
The maternal SHRSP vasculature fails to adapt normally to the demands of 
pregnancy. In an exacerbated hypertensive pregnancy, SHRSP rats demonstrate 
pathophysiologies associated with human superimposed pre-eclampsia and the 
poorer pregnancy outcomes associated with hypertensive pregnancies. 
 To fully assess maternal response to pregnancy in SHRSP dams by 
examining the cardiovascular and renal systems and haemodynamic 
changes through gestation. 
 Examine placentation and fetal outcome in SHRSP pregnancies. 
 Gain insight into underlying genetic differences between uterine arteries 
of SHRSP and WKY dams to examine how the uterine artery transcriptome 
changes in response to pregnancy. 
 Create a model of hypertensive pregnancy with increased cardiovascular 
load to impose excess maternal stress and mimic superimposed pre-
eclampsia. 
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Chapter 2 General Materials and Methods 
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This section describes the standard laboratory practice and common methods. 
More specific methods are outlined in each chapter. 
2.1 General Laboratory Practice 
All procedures were carried out in a laboratory setting following general 
laboratory health and safety guidelines. A laboratory coat and non-latex powder 
free gloves were worn at all times during procedures. Hazardous reagents were 
handled as per manufactures safety datasheets and disposed of as described in 
the Control of Substances Hazardous to Health regulations. 
Laboratory equipment was ensured to be in working order and cleaned prior to 
and after use. All glassware and re-usable plastic were cleaned by soaking in 
Decon 75 detergent (Decon Laboratories Ltd, Sussex, UK) and rinsed with 
distilled water and dried at 37°C. Other plastics used were sterile and 
disposable. These included microcentrifuge tubes of varying sizes (Greiner Bio-
One, Gloucestershire, UK), 15ml and 50ml Corning® centrifuge tubes (VWR, 
Leicestershire, UK), 5ml and 20ml Sterilin™ containers (VWR, Leicestershire, UK) 
and Corning® cell culture flasks and plates (VWR, Leicestershire, UK). 
Calibrated Gilson pipettes were used when necessary with sterile, appropriately 
sized pipette tips (Greiner Bio-One, Gloucestershire, UK), ranging from 0.1µl to 
1000µl. For volumes of liquid between 1ml and 25ml Stripette® serological 
pipettes were used with an electronic pipette filler (ThermoFisher Scientific, 
Paisley, UK), for volumes larger than 25ml clean measuring cylinders were used. 
Regents were weighed on either a Mettler Toledo PB1501 balance (sensitive to 
0.1g) or a Sartorius Extend balance (sensitive to 0.0001g). The measurement and 
adjustment of pH was conducted using a Jenway 3510 pH meter calibrated 
before each use following manufactures protocol. 
Centrifugation of sample volumes less than 2ml was conducted using a desktop 
Eppendorf 5145 R microcentrifuge at 4-20°C. Larger volumes and 96 and 384 
well plates were centrifuged using a Mega star 3.0R centrifuge (VWR, 
Leicestershire, UK). 
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All experiments involving ribonucleic acid (RNA) extraction required a 
ribonuclease (RNase) free environment, thus all micro centrifuge tubes and 
pipette tips used were RNase-free (Mettler-Toledo Rainin, California, USA) and 
sterile nuclease-free water (Qiagen, Manchester, UK) was used. 
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2.2 General Laboratory Techniques 
2.2.1 Nucleic Acid Extraction 
All RNA extraction was performed on animal tissue snap-frozen at time of 
sacrifice using Qiagen miRNeasy Mini Kit (Qiagen; Manchester, UK). RWT and RPE 
buffers were prepared prior to use by addition of 100% ethanol as per 
manufacturer’s instructions.  
Tissue was disrupted and homogenised in 700µl QIAzol Lysis Reagent using either 
Polytron™ PT 2100 homogenizer with 3mm rotor dispersion aggregate or bead-
milling in TissueLyser at 25Hz for 30 seconds repeated twice, placing samples on 
ice between lysis periods. Bead-milling was performed for uterine tissue due to 
the small amounts; all other tissue was lysed using Polytron homogenization. 
Tissue lysates were either stored at -80°C or RNA extracted immediately. 
Homogenates were brought to room temperature for 5 minutes prior to starting 
extraction protocol.  
Homogenates were shaken with 140µl chloroform and centrifuged at 12,000xg 
for 15 minutes at 4°C. The upper aqueous phase containing the RNA was 
transferred to separate tube and mixed with 1.5x volume of 100% ethanol 
(aqueous phase was approximately 400µl therefore 600µl ethanol was used). 
700µl of the sample was placed onto RNeasy Mini spin column and centrifuged at 
8000xg for 15 seconds at room temperature; this was repeated for the remaining 
300µl of sample. DNA digest was performed at this stage for uterine artery 
samples  only; samples were centrifuged with 350µl RWT buffer (8000xg for 15 
seconds) and an on column DNA digest was performed using 80µl of DNase I stock 
solution diluted 1:7 with RDD buffer incubated for 15 minutes at room 
temperature. Samples were then centrifuged again with 350µl RWT buffer 
(8000xg for 15 seconds). All other samples did not require this step and 700µl 
RWT buffer was added and samples centrifuged at 8000xg for 15 seconds. 
Samples were then centrifuged with 500µl RPE buffer at 8000xg for 15 seconds, 
then again with 500µl RPE buffer at 8000xg for 2 minutes. Membranes were 
further dried by spinning columns at 13,000xg for 1 minute. RNA was eluted from 
membrane using 30µl RNase-free water and centrifuging at 8000xg for 1 minute.  
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RNA concentration and purity was determined using Nanodrop spectrophometer 
(ThermoFisher Scientific, Paisley, UK). Absorbance was read at 260nm (A260) to 
detect nucleic acids, at 280nm (A280) which identifies protein contaminants, and 
at 230nm to detect any organic or solvent contamination from the extraction 
process. A260/A280 ratios of between 1.9 and 2.1 signified appropriate sample 
purity and samples were stored at -80°C until needed. 
2.2.1.1 Agilent Bioanalysis 
Total RNA was sent for Agilent Bioanalysis for concentration and quality 
measurements. Select samples of RNA were analysed using a eukaryote total RNA 
picochip assay (Agilent Technologies, Cheshire, UK) on the Agilent Bioanalyser 
2100. This analysis was run by Glasgow Polyomics at the University of Glasgow. 
The analysis included separation of the samples using electrophoresis to 
establish the presence of the 18S and 28S ribosomal RNA (rRNA) species within 
the samples. Electrograms were produced using this information and enabled the 
quantification of 18S and 28S rRNA and thus the ratio between the two to be 
determined; this produces the RNA integrity number (RIN). All RNA with a RIN 
greater than 5 was accepted. 
2.2.2 Reverse Transcriptase Polymerase Chain Reaction (PCR) 
Complementary DNA (cDNA) was prepared using an input of between 400ng-
1000ng RNA using the Multiscribe Reverse Transcription kit (ThermoFisher 
Scientific, Paisley, UK). 
The RT-PCR was conducted in a 96-well plate where the final concentrations per 
well were: 1x reverse transcription buffer, 5.5mM MgCl2, 0.5mM of each dNTP, 
2.5µM random hexamers, 0.4U/µl RNase inhibitor and 1.25U/µl Multiscribe. A 
total volume of 20µl in each well was achieved using RNase free sterile water. 
Each plate contained a non-template control that had no RNA sample and 
instead had 7.7ul RNase free water. Plates were covered with adhesive PCR 
plate seal (ThermoFisher Scientific, Paisley, UK) and centrifuged at 8,000xg for 
30 seconds to ensure appropriate mixing of reaction components. The PCR was 
run on a 96-well Dyad DiscipleTM thermal cycler (MJ Research, Massachusetts, 
USA) with the following temperature cycles: Anneal primers at 25°C for 10 
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minutes, transcription and extension at 48°C for 30 minutes, heat denature 
enzyme at 95°C for 5 minutes. Samples were then cooled to 4°C and diluted to 
an approximate final concentration of 5ng/µl cDNA. Samples were stored at -
20°C until use. 
2.2.3 Quantitative Real Time PCR (qRT-PCR) 
2.2.3.1 SYBR Green qRT-PCR  
Custom PCR primers (Eurofins Genomics, Ebersberg, Germany) were utilised to 
determine mRNA expression of specific genes (Table 2-1) using SYBR® Green 
dye. This method relies on the fluorescent SYBR® green dye binding to all 
double stranded DNA, so as the target is amplified during PCR more dye is 
incorporated in the double stranded PCR product and fluorescence intensity 
increases proportional to the amount of product. All primers were designed to 
span exon-exon boundaries were possible and were reconstituted in RNase free 
water to make 10µM stock concentrations.  
Samples were set up in a MicroAmp™ Optical 384-Well Reaction Plate 
(ThermoFisher Scientific, Paisley, UK)  with 2.5µl cDNA (produced as in section 
2.2.2, a final amount of 12.5ng cDNA per well) and 1x Power SYBR® Green 
Master Mix (ThermoFisher Scientific, Paisley, UK), 500nM forward primer, 500nM 
reverse primer made up to final volume of 12.5µl with RNase free water, all 
samples were performed in triplicate with separate samples run with Gapdh 
primers as a stable housekeeper for gene expression level comparison. Each 
plate also contained two triplicates of non-template controls in which the cDNA 
was replaced with the either the non-template control from section 2.2.2 or 
2.5µl additional RNase free water. Plates were centrifuged at 8,000xg for 30 
seconds to ensure appropriate mixing of reaction components and all volume is 
in the bottom of each well. Quantitative Real Time PCR (qRT-PCR) was run on 
7900HT Fast Detection System (Applied Biosystems, California, USA). Samples 
were subject to a hold phase of 50°C for 2 minutes then 95°C for 10 minutes to 
activate the Taq polymerase enzyme before undergoing 40 cycles with the 
following conditions: 95°C for 15 seconds followed by 60°C for 60 seconds for 
denaturation, primer annealing and product extension. A final dissociation step 
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was performed to produce a melt curve analysis in order to assess that the 
product produced was singular and specific. 
 
Table 2-1: Primers for use in SYPR® Green qRT-PCR 
Gene Forward Primer Reverse Primer 
Gapdh GACATGCCGCCTGGAGAAAC AGCCCAGGATGCCCTTTAGT 
Desmin GGGACATCCGTGCTCAGTAT AGAGCATCAATCTCGCAGGT 
Prl8a4 (Prolactin) GCATGTATGGTGGAAGAGGGT GCAATCTTTTCCAGTTATGAGACA 
Vegfr2 AAGCAAATGCTCAGCAGGAT GAGGTAGGCAGGGAGAGTCC 
Nox2 AACGTGGAGTGGTGTGTGAA TTTGGTGGAGGATGTGATGA 
p22 phox TTGTTGCAGGAGTGCTCATC CAGGGACAGCAGTAAGTGGA 
Primer sequences are in the 5’ to 3’ direction and were ordered from Eurofins Genomics 
(Ebersberg, Germany).   
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2.2.3.2 Taqman® Gene Expression Assay 
The Taqman® assay used a fluorogenic probe, labelled with FAMTM or VICTM dye, 
specific for the target gene and unlabelled target specific primers (detailed in 
Table 2-2). This assay allows for the probe to incorporate in the double strand 
DNA during the PCR. It is then cleaved in the next cycle and the dye is separated 
from a non-fluorescent quencher. The intensity of fluorescence increases 
proportional to the amount of PCR product produced.  
Assays were prepared in a MicroAmp™ Optical 384-Well Reaction Plate 
(ThermoFisher Scientific, Paisley, UK) with 2µl cDNA (produced in section 2.2.2 
with a final amount of 10ng cDNA per well). Assays utilised a duplex reaction, 
using a FAMTM labelled probe for the gene of interest and a VICTM labelled 
housekeeper probe (0.25µl of each probe was added to the wells). The final 
volume was made up 1x Taqman® Universal Master Mix II to give a total volume 
of 5µl per well. Each assay plate also contained non-template controls in which 
the cDNA was replaced with the non-template control from section 2.2.2 or 2µl 
additional RNase free water. All samples and controls were run in triplicate. 
Plates were sealed with self-adhesive Advanced Polyolefin StarSeal (STARLAB, 
Milton Keynes, UK) and centrifuged at 8,000xg for 30 seconds to ensure reaction 
components were mixed and in the base each well. The qRT-PCR reactions were 
conducted using a QuantStudio 12K Flex Real-Time PCR System (ThermoFisher 
Scientific, Paisley, UK). The cycling conditions were the same as in section 
2.2.3.1, however there was no requirement for producing a melt curve as the 
Taqman® assays use probes that are more specific in amplifying only the target 
product than standard primers. 
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Table 2-2: Rat specific Taqman® probe details 
Gene name 
Gene 
Symbol 
Assay ID 
Fluorescent 
label 
Angiotensin I converting enzyme 2 Ace2 Rn01416293_m1 FAM-MBG 
α-adrenergic receptor 2C Adra2c Rn00593341_s1 FAM-MBG 
Angiotensin II receptor, type 1a Agtr1a Rn02758772_s1 FAM-MBG 
Angiotensin II Receptor , type 2 Agtr2 Rn00560677_s1 FAM-MBG 
Corin Corin Rn00711040_m1 FAM-MBG 
P22phox Cyba Rn00577357_m1 FAM-MBG 
Gp91-phox Cybb Rn00576710_m1 FAM-MBG 
Ficolin B Fcnb Rn00586231_m1 FAM-MBG 
Hypoxia-inducible factor 1-α Hif1α Rn01472831_m1 FAM-MBG 
Inositol Trisphosphate Receptor Type 1 Itpr1 Rn01425738_m1 FAM-MBG 
Matrix metalloproteinase-1 Mmp1 Rn01486634_m1 FAM-MBG 
Matrix metalloproteinase-2 Mmp2 Rn01538170_m1 FAM-MBG 
Matrix metalloproteinase-8 Mmp8 Rn00573646_m1 FAM-MBG 
Matrix metalloproteinase-9 Mmp9 Rn00579162_m1 FAM-MBG 
Phospholipase A2 Pla2g2a Rn00580999_m1 FAM-MBG 
Super oxide dismutase 1 Sod1 Rn00566938_m1 FAM-MBG 
Tissue inhibitor of metalloproteinases Timp1 Rn01430873_g1 FAM-MBG 
Vascular cell adhesion molecule 1 Vcam1 Rn00563627_m1 FAM-MBG 
Vascular endothelial growth factor-α Vegfα Rn01511602_m1 FAM-MBG 
Β actin Β actin Rn00667869_m1 VIC-MBG 
β-2-Microglobulin β2m Rn00560865_m1 VIC-MBG 
Where suffix of assay ID is _m1 the probe spans exon junctions, therefore specific form mRNA. If 
suffix is _s1 (primers and probes are within single exon) or _g1 (primers and/or probe may span 
single exon) these probes can detect genomic DNA, however as a DNA digest was performed this 
should not have influenced the expression results. 
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2.2.4 Biochemical Urine Analysis 
Urine was collected at different gestational time points (as described in section 
2.3.5). Urine samples were thawed and prepared by briefly centrifuging at low 
speed (<500xg) for 1 minute at 4°C to remove any debris that remained from 
collection; 200µl of uncontaminated urine were used for biochemical analysis. 
The concentration of albumin and creatinine in each sample was determined 
using the Roche Cobas C311 Analyser. The assays used were the Albumin, Gen.2 
Tina-Quant assay and the Creatinine Jaffe Gen.2 assay, both designed for the 
photometric detection of the respective protein in urine and used in with Total 
Protein Urine/CSF assay control kit (all from Roche, Mannheim, Germany). The 
concentrations were then expressed as a ratio of albumin to creatinine as 
creatinine is a constant and should not have been altered by gestation, strain or 
treatment. 
2.2.5 Tissue Processing and Sectioning 
Tissue was fixed in either 10% neutral buffered formalin or a formaldehyde free 
zinc-based fixative [100mM Tris, 3.16mM Ca(CH3OO)2, 27.25mM Zn(CH3COO)2, 
36.68mM ZnCl2; pH6.8] for 12-24 hours. Tissue was washed three times in PBS to 
remove all traces of fixative before being stored in 70% ethanol at 4°C. Tissues 
were dehydrated and placed into paraffin wax at 60°C in a Citadel 1000 
processor (Thermo Scientific, Loughborough, UK) which exposed the tissues to a 
timed sequence of alcohol and xylene at different concentrations (outlined in 
Table 2-3). Tissues were then embedded in warmed paraffin wax (≤60°C) and 
cooled. Tissue blocks were kept at 4°C overnight before being sectioned using 
Leica RM2235 Microtome (Leica Biosystems, Milton Keynes, UK). 5µm sections 
were cut and placed on 40°C water to soften the wax before being transferred 
to a silane treated microscope slide and baked to dry the section in 50°C oven 
overnight. For placental tissue, fixed using zinc based fixative; sections were cut 
until the maternal channel was observed. This is indicative of the middle of the 
placenta and ensures all layers will be visible and all placentas sectioned in 
relatively the same areas. Between 8 and 10 serial 5µm sections were then cut 
and numbered before being placed on slides as stated above. Prior to staining all 
sections were dewaxed and rehydrated at room temperature by placing slides in 
Histo-Clear (Fisher Scientific, Loughborough, UK) (a safer substitute for xylene) 
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twice then a gradient of ethanol: 100%, 90%, 70% and placing the slides in 
deionised H2O for 5 minute periods each. All staining procedures were conducted 
at room temperature unless otherwise stated. After staining was complete 
sections were dehydrated by going up through the ethanol gradient; 70%, 90%, 
100%, and cleared in Histo-Clear twice for 5 minute periods each. Coverslips 
were mounted over the sections using DPX mounting medium. 
Table 2-3: Conditions used to process formalin fixed tissues  
Solution Incubation time  
70% Ethanol 15 minutes 
85% Ethanol 15 minutes 
90% Ethanol 25 minutes 
95% Ethanol 25 minutes 
100% Ethanol 15 minutes 
100% Ethanol 15 minutes 
100% Ethanol 15 minutes 
Xylene 30 minutes 
Xylene 30 minutes 
Paraffin Wax 30 minutes 
Paraffin Wax 30 minutes 
Details of different solutions and timings that formalin fixed tissue samples were exposed to during 
processing for embedding into paraffin wax to be used for histology and immunohistochemistry. 
 
2.2.6 Histology 
2.2.6.1 Haematoxylin and Eosin Staining 
Haematoxylin and eosin staining was used as to assess basic tissue morphology. 
Tissue sections were placed in Harris haematoxylin for 2 minutes and then 
transferred to tepid running tap water to produce the blue nuclei stain. The 
sections were dipped in 70% ethanol then counterstained with Eosin Y for 1 
minute to differentiate the cytoplasm (pink) and dipped several times into 
deionised H2O for 10 seconds. Sections were dehydrated, cleared and mounted 
as in section 2.2.5. 
2.2.6.2 Periodic Acid Schiff Staining 
Periodic Acid Schiff (PAS) staining was used to detected polysaccharides, thus 
determining glycogen containing cells. All reagents were brought to room 
temperature before use. Sections were incubated in 0.5% periodic acid (w/v in 
deionised (d)H2O) for 5 minutes; excess stain was removed by washing 3 times in 
dH2O for a total of 10 minutes. Sections were then incubated in the dark with 
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Schiff reagent (Sigma, Dorset, UK) for 15 minutes at room temperature before 
being washed again in running tap H2O. Sections were counterstained using 
Harris haematoxylin for 2 minutes. The excess stain was removed with running 
tap H2O for 5 minutes and sections were dehydrated, cleared and mounted as in 
section 2.2.5. 
2.2.6.3 Picrosirius Red Staining 
After dewaxing and rehydrating sections slides were transferred to Weigert’s 
haematoxylin; freshly made following manufacturer’s instructions (Sigma, 
Dorset, UK) for 10 minutes. Excess stain was then washed in running tap H2O for 
10 minutes. 0.1% picrosirius red solution was made using 0.1% w/v Sirius red F3B 
(Sigma, Dorset, UK) in dH2O. Sections were incubated in 0.1% picrosirius red 
solution for 90 minutes protected from light. The excess picrosirius red stain was 
washed off the sections using acidified dH2O (0.01N HCl) for 5 minutes, repeated 
twice, and any excess moisture was removed before sections were dehydrated, 
cleared and mounted as stated in section 2.2.5. 
2.2.7 Immunohistochemistry 
Immunohistochemistry was used to assess placental sections for the presence of 
cytokeratin; a trophoblast cell marker, and α-actin; a vascular smooth muscle 
cell marker. Two serial sections cut from placentas fixed in the zinc-based 
fixative were used, one for trophoblast analysis and the other for α-actin. 
Sections were de-waxed and rehydrated as outlined in section 2.2.5. Sections 
were circled with an ImmEdgeTM Hydrophobic Barrier PAP Pen (Vector 
Laboratories Ltd, Peterborough, UK) to provide a water repellent barrier to keep 
the sections covered with the antibody solutions and prevent sections drying 
out. 
2.2.7.1 Trophoblast Cell Stain 
Alkaline phosphatase activity in the sections was quenched using incubation in 
0.2M hydrochloric acid for 10 minutes. No antigen retrieval step was required 
due to the zinc-based fixative not masking the epitope of the antigen targeted 
by the cytokeratin antibody. Sections were then washed 3 times in 0.01M Tris-
buffered saline (TBS) [20mM Tris, 150mM NaCl; pH7.6] for 5 minutes each time 
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with gentle agitation using a Rotatest plate shaker (LUCKHAM R100, at medium 
speed). Tissue sections were then incubated with a blocking solution of TBS with 
2% bovine serum albumin (BSA), 1% non-fat dried milk and 0.1% Tween®-80 for 
15 minutes at room temperature. This prevented non-specific immunoglobulin 
binding by blocking irrelevant binding sites and saturating these with irrelevant 
proteins in the BSA and milk. Tween®-80 is a non-ionic detergent that was added 
to reduce surface tension and allow the solution to spread over entire section. 
Tween®-80 was chosen over Tween®-20 as it is a stabilizing agent for proteins.  
The primary mouse monoclonal antibody for cytokeratin clone MNF116 (M0821; 
DAKO, Glostrup, Denmark) was diluted 1:100 with TBS to give an approximate 
final immunoglobulin concentration of 0.6mg/L. The primary antibody was 
incubated on sections in a humidified chamber overnight at 4°C. All traces of 
the primary antibody were then removed by washing 3 times in TBS as previously 
described. The primary antibody was detected using with unconjugated goat 
anti-mouse immunoglobulins (Vector Laboratories Ltd, Peterborough, UK) diluted 
1:50 in TBS and incubated on sections for 30 minutes at room temperature. The 
wash steps were repeated as previously stated. A tertiary step was needed to 
detect the unconjugated goat anti-mouse antibody; this allowed a greater signal 
amplification that would not have been achievable if a conjugated secondary 
antibody was used. A mouse monoclonal alkaline phosphatase anti-alkaline 
phosphatase (APAAP) complex (Bio-Rad, Oxford, UK) was diluted 1:100 in TBS 
and applied to the sections for 30 minutes. The sections were washed 3 times in 
TBS as previously. Sections were incubated in nitroblue tetrazolium / 5-bromo-4-
chloro-3-indoyl phosphate (NBT/BCIP) (Roche, Mannheim, Germany) for 10 
minutes to detect the alkaline phosphatase activity. The NBT/BCIP was prepared 
by dissolving one tablet in 10ml dH2O and used immediately whilst protecting 
from light. This chromogen develops a purple/black colour that was visualised as 
positive primary antibody conjugation to cytokeratin. Sections were then rinsed 
with dH2O for 5 minutes, 3 times, before being counterstained using a Periodic 
Acid Schiff stain (as detailed in section 2.2.6.2). Sections were not dehydrate 
and cleared using alcohol and Histo-Clear as NBT is soluble in solvents. For this 
reason, coverslips were mounted on the sections using a VectaMount aqueous-
based mounting medium (Vector Laboratories Ltd, Peterborough, UK). 
90 
 
2.2.7.2 Vascular Smooth Muscle Cell Stain 
Endogenous peroxidase activity was blocked by incubating the sections in 3% 
hydrogen peroxide in methanol for 30 minutes. No antigen retrieval step is 
required as stated in section 2.2.7.1. Sections were then washed 3 times in TBS 
as previously stated. The placental sections were blocked as in section 2.2.7.1. 
The primary mouse monoclonal anti-α actin antibody (clone 1A4; DAKO, 
Glostrup, Denmark) was diluted 1:200 in TBS, giving an approximate 
immunoglobulin concentration of 0.5µg/ml. Primary antibody was incubated at 
4°C overnight. 
Peroxidase conjugated goat anti-mouse immunoglobulins (Vector Laboratories 
Ltd, Peterborough, UK) were used as the direct detection antibody. This was 
diluted 1:100 and incubated on the sections for 30 minutes at room 
temperature. Sections were then washed 3 times in TBS as previously stated. 
The secondary antibody was detected using hydrogen peroxide solution and 
colour was developed using diaminobenzene (DAB) (DAB Peroxidase (HRP) 
Substrate Kit; Vector Laboratories Ltd, Peterborough, UK). A stock solution 
containing DAB and hydrogen peroxide was made following the manufacturer’s 
instructions; 2 drops of buffer stock solution, plus 4 drops of DAB and 2 drops of 
hydrogen peroxide were added to 5mls dH2O. This solution as incubated on the 
sections for 2 minutes before being rinsed in dH2O for 5 minutes. The sections 
were then counterstained with Harris’s Haematoxylin for 30 seconds and the 
blue counterstain colour developed in running, tepid tap H2O. Sections were 
then dehydrated, cleared and mounted in DPX as stated in section 2.2.6. 
2.2.8 Image Analysis 
All slides were blinded before imaging. Sections were imaged on a Zeiss AX10 
polarized light Microscope (Carl Zeiss Ltd, Cambridge, UK) and where necessary 
stitched together using Microsoft Image Composite editing software. Analysis was 
conducted using Image J software for stain intensity measurements using an 
observer blinded to section identity. The image type was converted into a 
red:blue:green stack image and viewed using the appropriate channel for each 
particular stain. Threshold was set to its maximum to get the number of all 
pixels within the image before the threshold was adjusted to identify only the 
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positively stained pixels. This would give area values for the positively stained 
pixels which could then be expressed as a percentage of the whole tissue. 
  
92 
 
2.3 In Vivo Procedures 
The stroke-prone spontaneously hypertensive (SHRSP) and Wistar Kyoto (WKY) 
rats used were from inbred colonies that have been maintained in house at the 
University of Glasgow since 1991 by brother x sister mating. All rats were housed 
in controlled 12 hour light/dark conditions with a constant temperature (21±3°C) 
with ad libitum access to water and standard diet (rat and mouse No.1 
maintenance diet, Special Diet Services). All animal procedures were approved 
by the Home Office according to the Animals (Scientific Procedures) Act 1986 
(Project License 60/9021). 
2.3.1 Time Mating  
Virgin 12-week-old ± 4 days female rats were placed in time mating cages with 
males of the same strain for up to 4 days. Presence of a copulation plug on cage 
floor was evidence of successful mating and denoted as gestational day (GD) 0.5. 
2.3.2 Anaesthetic Procedure 
Rats were anaesthetised where necessary using an induction box filled with 5% 
isoflurane in 1.5L/min medical oxygen. Once anaesthetised, the rats where 
placed either in the supine or prone position with their nose and mouth fully 
inserted and secured in an anaesthetic mask. Isoflurane levels were adjusted 
depending on procedure. All rats were checked to be fully under anaesthesia 
before beginning any procedure. 
2.3.3 Radiotelemetry 
Radiotelemetry enables continuous live haemodynamic measurements using 
implantable transmitters and the Dataquest ART Telemetry System (Data 
Sciences International, Minneapolis, USA). Probes can measure systolic and 
diastolic blood pressure alongside heart rate and activity of a conscious animal. 
Probes were sterilised using 24 hour incubation in Actril® cold sterilant (VWR, 
Lutterworth, UK) at room temperature and the calibration was checked to be 
within ±3mmHg of factory calibration settings prior to use. 
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Surgery was conducted under sterile conditions with the operating table covered 
with sterile surgical cover and surgical gowns and gloves were worn at all times. 
All instruments were autoclaved prior to use. 10-week-old female rats were 
anaesthetised as in section 2.3.1 and maintained at 3% isoflurane in 1.5L/min 
medical oxygen in the supine position. Hair was removed from the abdomen and 
swabbed with povidone-iodine solution (Betadine®). A scalpel was used to 
perform a midline laparotomy through the abdominal wall. The peritoneal cavity 
was cleared to visualise the abdominal aorta and iliac bifurcation. Connective 
tissue and fat was cleared using cotton swabs and three MERSILK® Ethicon suture 
ties (NU-CARE, Bedfordshire, UK) were placed around the arteries (position 
indicated in Figure 2-1) to temporarily occlude blood flow. A 22-guage needle 
was bent to an approximate 45° angle and used to create an opening in the 
aorta. The catheter of a sterilised telemetry probe was inserted up towards the 
renal arteries and secured with tissue adhesive. The probe was secured in the 
abdominal wall using ETHILON® Ethicon nylon sutures (NU-CARE, Bedfordshire, 
UK) and the rat was sutured up using VICRYL® Ethicon sutures (NU-CARE, 
Bedfordshire, UK). Rats were given 5mg/kg Rymadil analgesic subcutaneously 
and recovered from surgery on surgical Vetbed bedding in 37°C incubator. After 
a one week recovery period, probes were switched on and data was collected 
using Dataquest ART system.  
 
Figure 2-1: Illustration of ligation points for radiotelemetry probe implantation. 
Illustration shows the structure of arteries proximal to the abdominal aorta. Prior to probe 
implantation blood supply was restricted using suture ties (black arrows). An incision was made 
above the iliac bifurcation (red oval) and the catheter of the probe inserted along length of 
abdominal aorta. Probe was secured so that the open end of the catheter was just below the renal 
artery branches. Illustration creased using Servier Medical ART. 
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2.3.4 Tail Cuff Plethysmography 
Blood pressure was measured on conscious rats at pre-pregnancy, GD6.5, GD14.5 
and GD17.5 time points using tail cuff plethysmography. All measurements were 
made in the morning between 08:00 and 10:00 hours, to minimise diurnal 
variation. Rats were acclimatised to the procedure prior to pregnancy. Rats were 
placed in pre-warmed incubation boxes with heat lamps at 30-32°C for 5-10 
minutes to allow dilation of the arteries in the tail so that measurements of 
blood pressure could be made. After warming, rats were gently restrained in a 
warm, dry towel and placed on a heated platform so that only the tail was 
exposed. A blood pressure occlusion cuff was placed at the base of the tail 
followed by a piezoceramic pressure transducer cuff. The pressure transducer 
relies on volume pressure recording (VPR) sensor technology which measures 
blood pressure based on volume changes. The occlusion cuff was inflated in 
controlled 1mmHg steps to 250mmHg and then deflated and the blood pressure 
was recorded using equipment designed and built in collaboration with the 
Electronics/Medical Devices Unit (NHS Greater Glasgow & Clyde) (Evans et al., 
1994). The inflation/deflation cycle was repeated 5 consecutive times and an 
average was taken for each animal to obtain mean systolic blood pressure.  
2.3.5 Metabolic Cage Urine Sampling 
Rats were placed individually in metabolic cages pre-pregnancy for an 
acclimatization period of 2 hours before being placed in cages for 24 hours at a 
pre-pregnancy, GD6.5, GD14.5 and GD17.5 time points. Rats had access to 200ml 
water and standard rat chow ad libitum. Final water volume remaining and 
volume spilt was recorded at the end of the 24-hour period. Urine and faecal 
matter were separated and urine volume was recorded before being aliquoted in 
2ml tubes and stored at -80°C. 
2.3.6 Tail Vein Blood Sampling 
Blood samples were collected pre-pregnancy and at GD6.5 and GD12.5 or 
GD14.5. Rats were anaesthetised as in section 2.3.1 and maintained at 2% 
isoflurane in 1.5L/min medical oxygen in a prone position. One of three veins 
(two lateral and one dorsal) in the tail were located and punctured using sterile 
scalpel. Gentle pressure was applied and approximately 1ml of blood was 
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collected in heparinised tubes. Plasma was isolated by centrifugation of the 
blood at 1200xg for 20 minutes at 4°C. Plasma was aliquoted and stored at -
80°C.  
2.3.7 Transthoracic Echocardiography  
Echocardiography were performed at pre-pregnancy, GD6.5, GD12.5 or GD14.5 
and GD18.5 time points using an Acuson Sequoia c512 ultrasound system with a 
linear array transducer at a frequency of 15MHz. Rats were anaesthetised as in 
section 2.3.1 and hair removed from chest and abdomen using electric shaver. 
Rats were placed in the supine position, with a slight rotation towards their 
right-hand side, and maintained at 1.5% isoflurane in 1.5L/min medical oxygen.  
Pre-warmed (room temperature) ultrasound gel was applied to the transducer 
and skin. The heart was imaged along the long-axis (Figure 2-2) and M-mode 
measurements recorded for 6-7 cardiac cycles. This was repeated 3 times.   
Analysis of the echocardiograph images was conducted using Image J software. 
Distance between waveform peaks and troughs were measured as shown in 
Figure 2-2.  These measures were inputted into formulae to calculate the stroke 
volume (SV) and cardiac output (CO), ejection fraction (EF), fractional 
shortening (FS) and left ventricular mass. The calculation formulae were: 
Stroke volume (ml) = 𝐸𝐷𝑉 𝐸𝑆𝑉⁄  
Cardiac output (ml/min) = 𝑆𝑉 × 𝐻𝑅 
Ejection Fraction (%) = (𝑆𝑉 𝐸𝐷𝑉𝑜𝑙⁄ ) × 100 
Fractional shortening (%) = (𝐸𝐷𝐷 − 𝐸𝑆𝐷 𝐸𝐷𝐷⁄ ) × 100 
Left ventricular mass (g) = (0.8 ×  𝐴𝑆𝐸𝑐𝑢𝑏𝑒) + 0.6 1000⁄   
Where ASEcube = 1.04 × (𝐼𝑉𝑆𝑇𝑑 + 𝐿𝑉𝐼𝐷𝑑 + 𝑃𝑊𝑇𝑑)3 − 𝐿𝑉𝐼𝐷𝑑3 
 LVIDd = average EDD*10 
IVSTd = average AWTd*10 
APWTd = average PWTd*10 
EDVol = 1.047 × 𝐿𝑉𝐼𝐷𝑑3 
 ESV = 1.047 × (𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐸𝐷𝐷𝑠)3 
 HR = Taken from conscious animals on radiotelemetry (beats/min) 
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Figure 2-2: Representative echocardiography image 
The heart echocardiography was performed on the long axis which can visualise the left atrium 
(LA) and left ventricle (LV) as C-shape shown in A, measurements are made along the dotted line. 
The waveforms in B visualise anterior wall thickness (AWT), posterior wall thickness (PWT); in 
systole (s) and diastole (d), end diastolic diameter (EDD) and end systolic diameter (ESD). 
 
2.3.8 Uterine Artery Ultrasound Doppler 
Uterine artery Dopplers were conducted at the same time as the 
echocardiography and the rats were prepared for the procedure as in section 
2.3.7. The uterine artery was located lateral to the uterus using colour Doppler 
in P-mode. Once located the transducer was placed parallel to the uterine artery 
and pulse wave Doppler was recorded for at least 6 cardiac cycles. This was then 
repeated for the uterine artery on the opposite uterine horn. Peak systolic 
velocity (PSV) and end diastolic velocity (EDV) of the uterine arteries were 
measured from the 6 consecutive cardiac cycles and used to calculate resistance 
index (RI) (RI = [PSV-EDV]/PSV) and S/D ratio (PSV/EDV). As gestation progressed 
detect fetal heart beat was able to be detected. This was done by moving the 
transducer over the dam’s abdomen until a fetus was visualised and the Doppler 
recording, as outlined above, was repeated for the fetal cardiac cycle. This 
measure was used to confirm the pregnancy was maintaining viable fetuses. 
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2.4 Sacrifice Procedure 
Rats were anaesthetised as in section 2.3.1 and euthanized by exsanguination 
under sustained anaesthetic of 5% isoflurane in 1.5L/min medical oxygen at 
either GD6.5, GD14.5, GD18.5 or GD20.5 or non-pregnant age matched controls 
where appropriate. Exsanguination was performed by making a midline incision 
and opening the thoracic cavity by blunt dissection of the diaphragm and cutting 
along either side of the rib cage. Once the heart was exposed the aorta was 
severed and the heart removed. The rats were ensured to be dead before 
continuing with harvesting tissues. 
2.4.1 Cardiac Puncture Blood Sampling 
Blood sampling via cardiac puncture was performed just prior to exsanguination. 
Rats were maintained at 5% isoflurane in 1.5L/min medical oxygen. The heart 
was exposed as in section 2.4. A 21-gauge needle attached to a 5ml syringe was 
inserted into the left ventricle and 4-5mls of blood was slowly removed. This was 
collected in heparin and/or EDTA coated BD Vacutainer® tubes and kept on ice 
to allow plasma isolation; as detailed in section 2.3.6. Heparin tubes were used 
as standard; these tubes inhibit thrombin formation and allow for plasma 
separation. However, EDTA tubes prevent clotting by calcium chelation and 
allow the separation of plasma whilst conserving peptide structures; making this 
appropriate for measurement of angiotensin II levels.  
2.4.2 Maternal Tissue Collection 
Maternal heart, liver and kidneys were dissected and cleaned. The hearts were 
gently blotted on absorbent paper towel to remove any blood and renal fascia 
was removed from the kidneys. Whole organ weights were recorded (Appendix 
section 8.1). The atria and right ventricle were then removed from the whole 
heart and the left ventricle was weighed before being halved transversely. The 
lower apex was placed in 10% neutral buffered formalin; for histological 
assessment (section 2.2.5), and the upper portion snap frozen in liquid nitrogen 
for RNA extraction (section 2.2.1). The right kidney was cut in half perpendicular 
to the long axis; one half was fixed in 10% neutral buffered formalin for 
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histological assessment (section 2.2.5) and the other snap frozen in liquid 
nitrogen for RNA extraction (section 2.2.1) 
The intestines were collected in their entirety and placed into chilled Ca2+ free 
physiological salt solution (PSS) [120mM NaCl, 4.7mM KCl, 1.2mM MgSO4, 25mM 
NaHCO3, 1.2mM KH2PO4, 10mM glucose, 0.023mM EDTA] and kept on ice for 
preservation until the dissection of the mesenteric arteries (section 2.4.3). A 
hysterectomy was performed and the whole gravid uterus weighed and placed in 
chilled Ca2+ free PSS to humanely euthanize the fetuses by cooling. The uterine 
artery and vein were dissected from the main uterine horn and placed on ice in 
chilled Ca2+ free PSS as to be preserved for later dissection (section 2.4.3). The 
numbers of implantations were recorded as was the location of fetuses and 
resorptions. 
2.4.3 Artery dissection 
Uterine and mesenteric arteries were dissected for ex vivo analysis. The main 
uterine artery (illustrated in Figure 2-3) was microscopically dissected in Ca2+ 
free PSS in a clean sylgard-coated plate. The surrounding adipose tissue was 
carefully removed to reveal the artery and vein before the vein was removed 
away. Small branches were kept on the dissected artery to be tied off if 
necessary when used for myography (section 2.5).  
For mesenteric artery dissection, the intestines were pinned out on a clean 
sylgard plate in Ca2+ free PSS so that the mesentery was gently spread out and 
the 1st order mesenteric artery was visualised. This was orientated so that the 
artery was on top of the vein. The arterial tree was followed down to the 3rd 
order mesenteric arteries, which were then microscopically dissected. The 
connective and adipose tissue was dissected and discarded before the vein was 
removed. Arteries for myography were placed in Ca2+ free PSS overnight at 4°C 
before use, others were snap frozen in liquid nitrogen for extraction of RNA 
(section 2.5). 
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Figure 2-3: Illustration of the pregnant rat uterus with vascular structure. 
The diagram highlights the bifurcation of a rodent uterine horn and the arrangement of major 
arteries that supply the fetoplacental units. The portion of the main uterine artery that was used for 
myography is indicated in the black box, the portion on the opposite horn was also taken. Image 
was created on Microsoft PowerPoint. 
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2.4.4 Fetoplacental tissue 
At either GD14.5, GD18.5 or GD20.5 each fetoplacental unit was carefully 
dissected in phosphate buffered saline (PBS) [137mM NaCl, 2.7mM KCl, 4.3mM 
Na2HPO4, 1.47mM KH2PO4; pH7.4], separating the placenta and fetus and 
removing amniotic fluid and fetal membranes. Fetal and placental tissue was 
gently blotted on absorbent paper to remove excess fluid and weights were 
recorded. Two placentas (not weighed) were dissected so that they were still 
attached to the maternal mesometrial triangle and cut as shown in Figure 2-4, 
one placenta was placed into standard 10% neutral buffered formalin fixative 
and the other into a formaldehyde free zinc-based fixative (detailed in section 
2.2.5) for 24 hours at room temperature. The zinc-based fixative was chosen due 
to better antigen presentation and increased sensitivity to specific antibodies. 
Three separate placentas were then dissected into the different tissue layers, 
mesometrial/decidua, junctional zone, labyrinth zone and chorionic plate 
(Figure 2-4) and snap frozen in liquid nitrogen. Fetal crown:rump length, head 
circumference and abdominal circumference were measured using a length of 
VICRYL® suture soaked in PBS (Figure 2-5) (Kusinski et al., 2012). 
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Figure 2-4: Diagrammatic representation of the rat placenta 
The diagram shows a lateral and aerial view of the rodent placenta after dissection from the fetus. 
The left image shows the different layers; maternal = mesometrial triangle with decidua; placental = 
junctional and labyrinth zones; and fetal = chorionic plate. This is the view of the placenta that is 
achieved when sectioning for histology and also shows the bidirectional blood flow between mother 
and placenta and between fetus and placenta. The right-side image shows the aerial view of the 
placenta and the dashed lines indicating the cuts made to take the central placenta portion for 
fixation 
 
 
Figure 2-5: Representation of measurements for fetal proportion 
Morphometry of the fetus was measured using a softened suture placed at different points on the 
fetus and measured in mm using a ruler. The head circumference was measured above the eyes 
and ears. Crown-rump length was measured from the top of the head (at the intersection with the 
head circumference) to the base of the tail, following the curvature of the spine. Abdominal 
circumference was taken around the abdomen of the fetus at the umbilical cord insertion site. 
Image depicts a GD20.5 WKY fetus. 
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2.4.5 Fetal Growth Trajectory and Weight Distribution 
Fetal growth trajectories were determined by plotting the average fetal weight 
obtained at GD14.5, GD18.5 and GD20.5. The rate was determined by calculating 
the gradient of this line. 
For fetal weight distributions, the individual fetal weights at GD18.5 were 
pooled for all fetuses of that strain and/or treatment group. These numbers 
were used to construct a histogram of the distribution of fetal weights using 
frequency distribution bin centres at 0.05g. Non-linear regressions were then 
performed using a Gaussian distribution. This presented the fetal weight 
distribution as a percentage of the total population. Clinically, fetal growth 
restriction can be determined by calculating the lowest 5th percentile for 
predicted fetal weight; and if the fetus falls within this then is diagnosed with 
growth restriction. Using the fetal weight distributions, the lowest 5th centile 
can be determined for WKY or vehicle control groups and the percentage of 
fetuses that fall below this in other strains/treatment groups can be calculated. 
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2.5 Uterine and Mesenteric Artery Myography 
2.5.1 Wire Myography 
Two vessel segments (approximately 2cm in length) from the central portion of 
each dissected artery (as described in section 2.4.3) were mounted on 40µm 
wire on a multi wire myograph system (620M, Danish Myo Technology, Aarhus, 
Denmark) in PSS containing Ca+2 [120mM NaCl, 4.7mM KCl, 1.2mM MgSO4, 25mM 
NaHCO3, 1.2mM KH2PO4, 10mM glucose,2.5mM CaCl2]. LabChart software 
(ADInstruments, Oxford, UK) was used to record and analyse vessel tension 
response. Vessels were then equilibrated to 37°C and gassed with 95% O2 and 5% 
CO2 for 20 minutes before normalisation using DMT normalisation procedure. 
This involves distending the vessel in a stepwise manner to determine the 
optimal tension at which the vessel segment has maximal active force 
production and sensitivity to agonists. The transmural pressure for mesenteric 
and uterine arteries was the internal circumference at 100mmHg = 13.3KPa 
multiplied by a factor of 0.9 (IC1). Normalised vessels were left again to 
equilibrate for 60 minutes to reach a stable baseline tension before being 
subject to a ‘wake-up’ procedure with the addition of 5ml high potassium PSS 
(KPSS) [120mM KCl, 1.2mM MgSO4, 25mM NaHCO3, 1.2mM KH2PO4, 10mM glucose, 
2.5mM CaCl2] to the bath for 5 minutes. KPSS was removed and vessels were 
‘washed’ with the addition of 5ml PSS, this was repeated 3 times and left for 8-
10 minutes to return to baseline before beginning the experiment. 
The vessels contractile response was assessed by adding noradrenaline to the 
bath in 2 minute increments to give final concentrations of 1x10-9M, 1x10-8M, 
1x10-7M, 1x10-6M, 1x10-5M, and 3x10-5M. The previously described wash step and 
return to baseline was repeated before pre-constricting vessels with 2x10-5M 
noradrenaline. After 2-5 minutes (once the vessel reached a steady tension) 
vessels were subjected to varying doses of carbachol, the synthetic analogue of 
acetylcholine, in 2-minute increments at the following final concentrations: 
1x10-8M, 1x10-7M, 1x10-6M, 1x10-5M, and 3x10-5M. Vessels were washed as before 
and a relaxation response was then repeated using sodium nitroprusside, a nitric 
oxide donator, at the following final concentrations: 1x10-9M, 1x10-8M, 1x10-7M, 
1x10-6M, 1x10-5M, and 3x10-5M. Finally, vessels were washed again and 5ml KPSS 
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replaced the PSS in the bath to ensure vessels still exhibited a contractile 
response that signified they were alive. 
Data analysis was conducted using LabChart Reader (ADInstruments, Oxford, 
UK). Mean baseline tension prior to each dose response curve, maximal 
contractile responses and mean relaxation responses were measured for each 
agonist concentration. The following equations were used to determine 
constriction response to noradrenaline: 
Normalised diameter (µm) = 
Internal circumference (IC1)
𝜋
 
Wall tension (mN/mm) = 
𝐹𝑜𝑟𝑐𝑒 𝑐ℎ𝑎𝑛𝑔𝑒 (𝑚𝑁)
2 𝑥 𝑣𝑒𝑠𝑠𝑒𝑙 𝑙𝑒𝑛𝑔𝑡ℎ (𝑚𝑚)
 
Active Effective Pressure (KPa) = 
𝑊𝑎𝑙𝑙 𝑡𝑒𝑛𝑠𝑖𝑜𝑛 (𝑚𝑁 𝑚𝑚⁄ )
(𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟µ𝑚 2⁄ )𝑥 100
 
Vasodilation response was expressed as a percentage of noradrenaline 
constriction, where 100% was fully constricted. Each dose response curve was 
also used to determine the half maximal effective concentration (EC50). The 
active effective pressure curves for constriction response were normalised and 
the relaxation responses were inverted to produce a sigmoidal curve ranging 
from 0 (100% constriction) to 100 (0% constriction), all response curves were 
then transformed so that X=log(X) and a non-linear regression analysis 
conducted. The EC50 values were then subject to further statistical analysis. 
2.5.2 Pressure Myography 
One vessel segment which had no or minimal branches was placed into a 
chamber containing Ca2+ free PSS at 37°C aerated with 95% O2, 5% CO2 in the 
DMT pressure myograph system 110PXL (Danish Myo Technology, Aarhus, 
Denmark). The open ends of the vessel were mounted onto two glass cannulas 
and secured using nylon sutures, any branches were tied-off to ensure the flow 
system was closed. The chamber was mounted onto the pressure interface which 
contained a reservoir of Ca2+ free PSS at 37°C. All bubbles were removed from 
the system before opening the valves to the glass cannulas and perfusing the 
vessel with Ca2+ free PSS at 10mmHg. The vessel was checked for any holes or 
leaks in the system before being ‘normalised’ to 70mmHg for 1 hour. The vessel 
was exposed to incremental increases in a range of physiological pressures for 5 
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minute periods each, these pressures where 10mmHg, 20mmHg, 40mmHg, 
60mmHg, 80mmHg, 100mmHg, 110mmHg and 120mmHg. The vessel was filmed 
and the external and internal diameter were continually recorded throughout 
the experiment using MyoView software (Danish Myo Technology, Aarhus, 
Denmark). At the end of the experiment pressure was maintained whilst the 
heating was turned off and Ca2+ free PSS was replaced with 10% neutral buffered 
formalin. This was then left to fix the vessel at 120mmHg for 30 minutes at room 
temperature. Once complete the vessel was carefully removed and placed in 
fresh 10% neutral buffered formalin overnight before being processed for 
histology as in section 2.2.6. Measurements for internal (Di) and external (De) 
diameter were derived from MyoView software using LabChart Reader 
(ADInstruments, Oxford, UK), these measures were then used to calculate the 
wall thickness (De - Di 2⁄ ), cross-sectional area ( π 4(De2 - Di 2)⁄ ), circumferential 
wall strain (Di - Di@10mmHg Di@10mmHg⁄ ) and the wall stress 
(1332 x pressure x Di 2 x wall thickness⁄ ), where 1mmHg = 1332 dynes/cm2. 
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2.6 Vascular Smooth Muscle Cell Culture 
2.6.1 Primary cell isolation 
Uterine arteries were dissected as in section 2.4.3 from three non-pregnant rats 
or three pregnant dams between GD5.5 and GD8.5. These arteries were 
collected in chilled F-12 Ham media [1mM L-glutamine, 14mM sodium 
bicarbonate, 1mM sodium pyruvate] (N6658, Sigma, Dorset, UK) supplemented 
with 100IU/ml penicillin, 100µg/ml streptomycin, 2mM L-glutamine (all from 
GibcoTM ThermoFisher Scientific, Paisley, UK) and kept at 4°C for a maximum of 
1 hour. The two uterine arteries (from both sides of the uterine horn) from the 3 
rats were halved so that the isolation began with 12 artery segments. The 
segments were digested in the above F12 media supplemented with 2mg/ml 
bovine serum albumin (A7906, Sigma, Dorset, UK), 250 units/ml collagenase 
type-I (LS004196, Lorne Laboratories, Berkshire, UK) 0.5 units/ml elastase 
(E7885, Sigma, Dorset, UK) and 0.4mg/ml soybean trypsin inhibitor (T9003, 
Sigma, Dorset, UK); pre-heated to 37°C for 5 minutes prior to use, to ensure 
enzymes were active. Two artery segments were placed in 1ml of warmed 
digestion media and incubated with gentle agitation at 37°C using a Biometra 
OV2 mini hybridisation oven (Thistle Scientific, Glasgow, UK) for approximately 
40 minutes. The incubation was stopped when the vessels were softened and had 
a ‘fluffy’ appearance. The vessels were then homogenised using needles of 
increasing gauges; 18G, 19G and 23G respectively. The vessels and digestion 
media were passed through each needles 5 times with the same syringe being 
used throughout. The homogenised vessels were then centrifuged at 1200xg for 3 
minutes at room temperature before being resuspended in 500µl of complete 
F12 media [100IU/ml penicillin, 100µg/ml streptomycin, 2mM L-glutamine] with 
10% fetal bovine serum. This results in a total of 3ml primary cell resuspension 
which was placed in a T25 flask and topped with 1ml complete F12 media. After 
cells had adhered to the plastic (after 48 hours) the media was changed to 
complete Dulbecco’s Modified Eagle’s medium (DMEM) with GlutamaxTM 
supplement [4mM L-glutaime, 5.5mM D-glucose, 1mM sodium pyruvate, 44mM 
sodium bicarbonate] (GibcoTM ThermoFisher Scientific, Paisley, UK) 
supplemented with 100IU/ml penicillin, 100µg/ml streptomycin, 2mM L-
glutamine and completed with 10% fetal bovine serum (FBS) (GibcoTM 
ThermoFisher Scientific, Paisley, UK). 
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2.6.2 Maintenance of primary cell line 
Cells were checked daily and media was changed every 48-72 hours. Cells were 
passaged at 80% confluency. To passage the cells the complete media was 
removed and the flasks washed with sterile PBS. An amount of 1x trypsin-EDTA 
that sufficiently covered the entire base of the flask was added (approximately 
1ml for T25, 3ml for T75). This was incubated for between 2-5 minutes and the 
flask was gently tapped against a solid surface every couple of minutes until the 
cells detached from the base and were floating freely in the trypsin solution. 
The trypsin was then inactivated by the addition of 3x volume of complete 
DMEM. The complete DMEM was able to stop the trypsinization as the FBS 
contains protease inhibitors. The media was pipetted against the base of the 
flask to ensure all cells were suspended in solution before being transferred to a 
sterile universal and centrifuged at 1500rpm for 5 minutes. The pellet was then 
resuspended in 1ml of complete DMEM. For the first passage (P1) the cells were 
seeded onto two T25 flasks by adding 500µl of cell suspension to 4ml complete 
DMEM in each flask. Once these two flasks reached confluency they were 
trypsinized and resuspended as previously described and then combined and 
seeded onto a T75 flask. From P2 onwards cells were split 1:2 when necessary. 
Cells were frozen between P2 and P4 during the exponential growth phase. Cells 
were trypsinized as previously described and resuspended in 1ml complete DMEM 
supplemented with 10% sterile dimethyl sulfoxide (DMSO); a cryoprotective 
agent that maintains the cellular osmotic balance. This suspension was placed in 
a cryovial (Alpha-laboratories, Hampshire, UK) which was in turn placed in a 
room temperature Mr. Frosty™ Freezing Container (ThermoFisher Scientific, 
Paisley, UK) filled with isopropanol which was then placed in a -80°C freezer. 
This ensured slow, uniform cooling of the cells (approximately 1°C per minute) 
and reduced intracellular ice crystal formation. After 24 hours the cells were 
removed from the Mr. Frosty™ Freezing Container and stored at -80°C.  
Cells were thawed when required. This was done by removing cells from the 
freezer and placing them immediately into water at 37°C to warm the cells 
rapidly. The cryovial was removed from the water bath when only a small ice 
crystal was left in the cell suspension. 1ml of pre-warmed complete DMEM was 
gently added to the cryovial and then 1ml was removed and added to 10ml pre-
warmed complete DMEM in a universal this was repeated 3-5 times and then the 
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entire contents of the cryovial was transferred to the universal. The cell 
suspension was centrifuged at room temperature 1500rpm for 5 minutes and the 
pellet resuspended and plated as above into a T25 flask. 
2.6.3 Cell Viability 
Cell viability was checked when cells were defrosted and at every passage 
thereafter. This was done using Trypan blue cell exclusion. Cells were revived 
and maintained once thawed as described in section 2.6.2. To determine the 
viability of the cells, 10µl of cell suspension was added to 10µl 0.4% solution of 
trypan blue (Sigma, Dorset, UK) to create a 1:1 dilution. The two were gently 
mixed and ~10µl was loaded onto a haemocytometer. All cells in the four outer 
grids were counted and an average was multiplied by 104 and corrected for any 
dilution factor to give the total number of cells. The counting was then repeated 
only for cells that had a blue colour. This was the number of dead cells that had 
taken up Trypan Blue. Viability was calculated as a percentage by dividing the 
live count by the dead count. Viability in cells between P2 and P5 ranged from 
90% to 50%. Cells with viability lower than 50% were not used. 
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2.7 Statistical Analysis 
Coding was used to blind observers to different strain or treatment groups during 
data acquisition wherever possible. Blinding remained for any relevant 
assessments and decoded prior to statistical analysis. Animals were assigned to 
different treatment or gestational groups randomly and the ARRIVE (Animal 
Research: Reporting of In Vivo Experiments) guidelines were followed for all in 
vivo studies. Results are presented as a mean ± standard error of the mean (SEM) 
unless stated otherwise. The telemetry data obtained from the Dataquest system 
included hourly, daily and weekly averages. The best representation of the data 
was determined to be a presentation of the 12-hour averages of each measured 
parameter. These values were analysed using area under the curve (AUC) at 
specified pregnancy time points and compared using one-way ANOVA with Sidak 
post-hoc tests. Data that represented any rate of change were analysed using 
regression analysis; these gradients were then compared to a null hypothesis 
mean of 0 using a one-sample t-test to determine gestational dependent change. 
The cycle threshold values of gene expression data obtained from qPCR were 
normalised to the relevant housekeeper to obtain a delta cycle threshold (ΔCT; 
Ct value of the housekeeper gene subtracted from the Ct value of gene of 
interest). These ΔCT values were used for statistical analysis using the 
appropriate test for comparison. The mean ΔCT for each sample group where 
then expressed relative to the mean ΔCT of the control group (either WKY or the 
vehicle control) to give a ΔΔCT value. This was finally expressed as 2-ΔΔCT, which 
accounted for primer efficiency and expressed the change in gene expression as 
a relative quantity in relation to 1. The error was calculated as a relative 
quantity minimum and maximum value for each group (minimum= 2-(ΔΔCT+ SEM) – 1; 
maximum= 2-(ΔΔCT- SEM) – 1). Statistical analysis and graphical representation was 
completed using Prism 6.0 GraphPad software. Statistical significance was 
accepted if a p-value was less than 0.05 and confidence intervals of 95% were 
used. Further information on the specific statistical tests used are detailed in 
the results chapters. 
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Chapter 3 Characterisation of SHRSP Pregnancy 
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3.1 Introduction 
Uncomplicated pregnancy requires major adaptations of the cardiovascular, 
renal and metabolic systems. It is associated with an increased cardiovascular 
burden that is intensified in hypertensive pregnancy complications such as pre-
eclampsia. The WHO found that hypertensive complications during pregnancy 
account for 14% of direct maternal deaths worldwide (Say et al., 2014). This 
systematic review of global maternal deaths classed gestational hypertension as 
a direct cause of death; however it grouped pre-existing conditions, such as 
chronic hypertension and cardiovascular disease, separately as indirect causes 
(Say et al., 2014). This makes it unclear how many maternal deaths were due to 
hypertensive complication present during pregnancy, but it is probable that it is 
much greater than the stated 14%. In the developed world the proportion of 
maternal deaths directly attributed to gestational hypertension was 12.9% 
between 2003 and 2009 (Say et al., 2014). This is a complication that is 
becoming increasingly more prominent in the developed world, as mothers are 
having children later in life and are more likely to have pre-existing medical 
conditions; such as obesity, diabetes and pre-existing hypertension (ACOG, 2013, 
Antza et al., 2017, Sibai, 2002).  
Modelling gestational hypertensive disorders has always been problematic due to 
the more severe pre-eclamptic conditions specifically occurring in humans and 
higher order primates (Steegers et al., 2010). Many pharmacological and surgical 
manipulations of animal models have been developed to explore the pathological 
consequences of gestational hypertension (Podjarny et al., 2004, McCarthy et 
al., 2011). The main drawback of these models is that they require an 
intervention or manipulation. Genetic modifications of mice and rats have been 
utilised in an attempt to replicate underlying molecular causes of gestational 
hypertensive disorders such as pre-eclampsia. The endothelial nitric oxide 
synthase knockout mouse (eNOS-/-) has been found to mimic the abnormal 
uterine artery function associated with some cases of pre-eclampsia and the 
catechol-O-methyl transferase knockout (COMT-/-) has demonstrated a pregnancy 
hypertensive phenotype and proteinuria; which are the major symptoms of pre-
eclampsia (McCarthy et al., 2011, Kusinski et al., 2012, Kanasaki et al., 2008). 
Transgenic models have also been developed in order to mimic human pre-
eclampsia more closely, as these models are often able to mimic the placental 
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dysfunction associated with pre-eclampsia (Takimoto et al., 1996). A transgenic 
rat model used by Bohlender et al imposed pre-eclamptic like symptoms in rats 
by increasing placental specific angiotensin II production (Bohlender et al., 
2000). One caveat to these models is that they are not spontaneous, as in the 
human condition. A borderline hypertensive inbred mouse strain (BPH/5) has 
been identified as a spontaneous model of pre-eclamptic like phenotypes, with 
the borderline hypertensive blood pressure of these pregnant mice rising to 
hypertensive levels in the last week of pregnancy (Davisson et al., 2002). 
However, as this is a mouse model, it is limited when drawing comparisons 
between human uteroplacental vascular remodelling and placentation. The 
placenta plays a key role, alongside the maternal cardiovascular system, in the 
development of gestational hypertension and its impact on the fetus. Out of the 
commonly used laboratory rodents, rats are more akin to humans in their 
placentation and cardiovascular adaptations to pregnancy and thus may be more 
suitable than mice (McCarthy et al., 2011). 
The spontaneously hypertensive rat (SHR) has been acknowledged as a potential 
model of hypertensive pregnancy and deficient maternal cardiovascular 
adaptations during pregnancy. The SHR was found to demonstrate fetal growth 
restriction, however only limited study was given to the underlying molecular 
mechanisms (Peracoli et al., 2001). Chu et al investigated the vascular reactivity 
in pregnancy but focused on systemic circulation and did not investigate 
uteroplacental circulation, which is of crucial importance in the detection of 
pre-eclampsia and the development of placental under perfusion which in turn 
can cause and/or aggravate gestational hypertensive disorders (Peracoli et al., 
2001, Chu and Beilin, 1993). More recently, pregnancy in the stroke-prone SHR 
(SHRSP) has undergone preliminary investigations and could provide a more 
appropriate spontaneous hypertensive model (Barrientos et al., 2017, Small et 
al., 2016, Mary et al., 2017). 
The uteroplacental blood flow and uterine artery vascular reactivity of the 
SHRSP rat has been found to be impaired during pregnancy (Small et al., 2016). 
This was found to be independent of the chronic hypertension exhibited by these 
rats pre-pregnancy, as defects were still observed when blood pressure was 
lowered using antihypertensive treatment from 7 weeks of age (Small et al., 
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2016). This suggests that there is a major maternal influence in the development 
of impaired uteroplacental blood flow in the SHRSP. Yet pregnancy in these 
animals has not been fully characterised and understanding the physiological 
response to the hypertensive pregnancy exhibited by these rats will allow a more 
in depth understanding of the pathophysiological mechanisms of gestational 
hypertension. 
3.2 Hypothesis and Aims 
3.2.1 Hypothesis 
SHRSP have an inappropriate maternal response to pregnancy, with impaired 
placentation and detrimental impact on the development of the fetus, when 
compared to pregnancy in the normotensive WKY.  
3.2.2 Aims  
 To profile the maternal response to pregnancy and examine 
cardiovascular and renal adaptations in SHRSP and WKY dams. 
 To evaluate SHRSP and WKY fetal number and growth throughout 
gestation. 
 To examine the structure, function and development of the SHRSP and 
WKY placenta. 
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3.3 Materials and Methods 
Animals were housed and mated as described in general methods (Chapter 2). 
Urines were collected pre-pregnancy and during the first and second week of 
pregnancy using metabolic cages as outlined in section 2.3.5 and the albumin 
and creatinine ratio determined as in section 2.2.4. Maternal weights were 
recorded weekly to determine weight gain over gestation. At sacrifice the 
maternal weight was subtracted from that of the gravid uterus to obtain a 
measure of gravid-independent weight gain. Echocardiography was conducted as 
described in section 2.3.7. Maternal tissue and fetoplacental units were obtained 
at gestational ages GD12.5, GD14.5, GD18.5 and GD20.5, and the weights 
recorded, as described in general methods section 2.4. These time points 
allowed the full assessment of pregnancy in SHRSP and WKY rats. Litter number 
was recorded for each dam, furthermore the number of offspring born to WKY 
and SHRSP breeding females had been recorded for >10 years. These values were 
collected and analysed. In rodents the formation of the chorioallantoic placenta 
occurs between GD8.5 and 10.5 with placental cell lineage determined by 
GD12.5. At GD14.5 the chorioallantoic placenta is fully formed and the fetal and 
placental tissues can be accurately dissected. By GD18.5 the placental 
trophoblasts have reached maximal invasion and GD20.5 allows for an accurate 
measurement of fetal weight prior to birth. Placentas were dissected and fixed 
or frozen for histological, immunohistochemical or gene expression analysis, as 
outlined in section 2.4.4.  
3.3.1 Vesicle Preparation 
Transport across the placenta is adaptive and strives to meet the demands of the 
fetus. Obtaining an estimate of placental transport is a good measure of 
placental function, which can be detrimentally affected in hypertensive 
pregnancies. The main barrier to maternofetal transport is the maternal facing 
plasma membrane of the syncytiotrophoblast layer II of the placenta (Figure 
3-1). This can be isolated from rodent placentas using Mg2+ precipitation and 
ultracentrifugation. This layer can then be manipulated to form membrane 
vesicles that can be utilised to estimate maternofetal transport of particular 
amino acids across the placenta. 
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Figure 3-1: Representation of the area of nutrient and gas exchange between mother and 
fetus in the rodent haemotrichorial placenta 
The rodent placenta has 3 syncytiotrophoblast layers (I, II and III). The 1st main barrier to 
maternofetal transport is the plasma membrane of syncytial layer II (highlighted in dark blue). This 
can be isolated and purified for ex vivo examination. MB = maternal blood; FC = fetal capillary. 
 
GD18.5 placenta were dissected and weighed as described in general methods 
before being placed into a ~8ml of ice cold mannitol buffer solution [30mM 
mannitol, 1mM MgCl2, 10mM HEPES-Tris, pH 7.4] in a Sterilin® container on ice. 
All placentas were then weighed together and total placental weight was used to 
calculate the volume of ice cold mannitol buffer solution required for 
homogenisation. Homogenisation required a volume of mannitol buffer 4 times 
that of the placental weight (w/v). The placentas were homogenised using a 
Polytron™ PT 2100 homogenizer with 3mm rotor dispersion aggregate (blade 
attachment was cleaned with 3% hydrogen peroxide for 30 minutes and rinsed 
with 70% ethanol, dH2O then mannitol buffer prior to use). Homogenisation was 
conducted on ice in 30 second bursts and lasted between 2 and 4 minutes until a 
smooth homogenate was obtained. The homogenate containing all placental 
membranes was then placed into a glass beaker with magnetic stirrer and kept 
at approximately 4ºC by surrounding beaker with ice. Homogenates were stirred 
slowly and 10µl was removed for later purity analysis. 12mM MgCl2 was added to 
the homogenate and stirring was continued for 10 minutes. Mg2+ was used to 
precipitate unwanted membrane fractions as the apical plasma membrane of the 
syncytiotrophoblast layer has a net anionic charge therefore it cross-links with 
the Mg2+ and other non-apical membranes aggregate in order to balance the 
Maternal
Fetal
116 
 
 
charge, thus precipitating from solution. Unwanted and unhomogenised tissue 
was removed by centrifugation at 2300xg for 15 minutes at 4°C. The supernatant 
was transferred to pre-weighed ultracentrifugation tubes (Beckman Coulter, 
High Wycombe, UK). Tubes were filled to the top with fresh mannitol buffer if 
required to prevent collapse during centrifugation. The tubes were then placed 
in a pre-cooled (4°C) OptimaTM L-80 XP ultracentrifuge (Beckman Coulter, High 
Wycombe, UK) and spun at 23,500xg for 40 minutes, using a SW32-Ti rotor. This 
stage allowed the purified plasma membrane fraction of syncytiotrophoblast 
layer II to pellet. The supernatant was discarded and the tube re-weighed. The 
weight of the pellet was calculated and re-suspended in 2.8x intravesicular 
buffer (IVB) [290mM sucrose, 5mM Tris-base, 5mM HEPES: pH 7.4]. The 
suspension was then exposed to shear stress by passing through a 25 gauge 
needle 15 times in order to form the vesicles, due to the hydrophobic membrane 
segments joining to protect hydrophobic regions. 10µl of the vesicle suspension 
was placed on ice to later evaluate vesicle purity. Vesicles were finally placed 
into 500µl aliquots and snap-frozen in liquid nitrogen. 
3.3.2 Vesicle Quality and Purity 
3.3.2.1 BCA Protein Assay 
The total protein concentration of the original placental homogenate and the 
prepared vesicles were determined using a Pierce™ BCA protein assay 
(ThermoFisher Scientific, Paisley, UK). The standards used were Pierce™ pre-
diluted bovine serum albumin standards (ThermoFisher Scientific, Paisley, UK), 
the concentrations were 125µg/ml, 250µg/ml, 500µg/ml, 750µg/ml, 1000µg/ml, 
1500µg/ml, 2000µg/ml. The working reagent was prepared immediately prior to 
use and consisted of 50 parts Reagent A and 1 part Reagent B. Placental 
homogenate samples were diluted 1:20 and vesicle suspensions were diluted 
1:50 before use to place them in an optimal range for later calculations. The 
reactions were conducted in a 96-well flat-bottomed clear microplate. Each well 
had a sample/standard to working reagent ratio of 1:8; with 25µl of sample or 
standard and 200µl of working reagent. The solutions were mixed and the plate 
protected from light and incubated at 37°C for 30 minutes. Once the plate had 
cooled to room temperature the absorbance was measured on SpectraMax M2 
microplate reader (Molecular Devices, Berkshire, UK) at 562nm. A standard curve 
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was constructed from the known standard concentrations and the concentrations 
of homogenate and vesicle were extrapolated.   
3.3.2.2 Alkaline Phosphatase Activity Assay 
Alkaline phosphatase activity was measured to ensure the maternal facing 
plasma membrane of syncytiotrophoblast layer II was isolated and correctly 
orientated with the maternal facing alkaline phosphatase on the external 
surface of the vesicle (Kusinski et al., 2010). Samples of the homogenate were 
diluted 1:20 and vesicles were diluted 1:100. The assay relied on alkaline 
phosphatase converting p-nitrophenylphosphate (Sigma, Dorset, UK) to 
paranitrophenol which produces a yellow colour that can be quantified. The 
reaction was carried out in 250µl of DEA buffer [1M Diethanolamine, 0.5mM 
MgCl2: pH 9.8] with 5µl of homogenate or vesicle sample. The reaction was 
initiated with the addition of 25µl of p-nitrophenylphosphate substrate stock 
(3.75µg/µl) made fresh in DEA buffer. The absorbance was read at a wavelength 
of 410nm at 5 seconds after addition and again after 2 minutes 5 seconds. The 
change in absorbance gives the indication of alkaline phosphatase activity over 2 
minutes. The activity value was then divided by the total protein concentration 
of the sample to give an approximation of purity. The purity values for 
homogenates and vesicles were used to determine the enrichment factor. 
Enrichment factor = vesicle purity/homogenate purity 
3.3.2.3 Assessment of Nanoparticle Size 
A NanoSight LM10 (Malvern, Worcestershire, UK) was used to further assure 
spherical vesicles had been obtained. A heterogeneous population of vesicles 
was expected in regard to size due to the method used to vesiculate which 
involved forcing membranes to re-join using passage through a needle. One 
vesicle preparation from WKY and one from SHRSP were assessed. Vesicles were 
diluted 1:100 in IVB and approximately 500µl vesicle suspension was injected 
onto stage. After focusing the microscope, a 60 second video was recorded and 
analysed using Nanoparticle Tracking Analysis v2.3 software to track particle 
number and size. 
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3.3.3 14C-MeAIB Transport Assay 
This assay utilises a radiolabelled synthetic analogue of System A amino acids; 
14C-methylaminoisobutyric acid (14C-MeAIB). This substance can be transported 
into vesicles by system A (SysA) amino acid transporters and its accumulation 
within vesicles measured due to the isotope presence. Each sample of vesicles 
were diluted to 7mg/ml in IVB and brought to room temperature before use. The 
principle of this assay relies on the Na+ dependent activity of the SysA 
transporter. Vesicles are incubated with 0.33mM 14C-MeAIB in an extracellular 
vesicle buffers (EVB) that contains Na+ [145mM NaCl, 5mM Tris-base, 5mM 
HEPES; pH 7.4 (Na+ EVB)] or [145mM KCl, 5mM Tris-base, 5mM HEPES; pH 7.4+ 
[(K+ EVB)]. This allows Na+ dependent transport to be estimated as well as 
indication of passive transport or leak of tracer into the vesicles. 20µl of vesicle 
sample was pipetted into round-bottomed plastic UltraclearTM tubes (Beckman 
Coulter, High Wycombe, UK) and 20µl of appropriate EVB was pipetted directly 
into this suspension at time 0. Reactions were carried out at room temperature. 
Thorough mixing was achieved by pipetting and gentle vortexing. Reactions were 
stopped with the addition of 2ml cold (4°C) ‘stop’ solution [130mM NaCl, 10mM 
Na2HPO4, 4.2mM KCl, 1.2mM MgSO4, 0.75mM CaCl2; pH 7.4] at 15 seconds, 30 
seconds, 45 seconds and 60 seconds. The entire tube content was dispensed onto 
0.45µm pore cellulose filter paper (pre-soaked in ‘stop’ solution) and washed 
with 2x5ml ‘stop’ solution whilst being subject to vacuum filtration on a 12-cup 
vacuum filtration manifold (Model 1225, Millipore®, Hertfordshire, UK). The 
filter paper was then removed from manifold and placed in labelled scintillation 
vials. Vesicle uptakes were run in duplicate for each sample, each EVB and each 
time point. A ‘no protein control’ was included for each EVB where vesicles are 
replaced with 20µl of IVB only. Two positive controls for total isotope count 
were also included for each EVB, where 5µl EVB was added to a pre-soaked filter 
and placed directly into a scintillation vial. The filter membranes were dissolved 
and vesicles lysed with the addition of 2ml of 2-ethoxyethanol. Four scintillation 
vials which only contained 2ml of 2-ethoxyethanol were also included as a 
negative control (blanks). Finally, 10ml of scintillation fluid (Perkin Elmer, 
Buckinghamshire, UK) was added and the disintegrations per minute (DPM) of 14C 
alpha emission was read on a Packard Tri-carb 2100TR Liquid Scintillation 
Analyser.  
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The average DPM of the blanks was subtracted from each sample and positive 
control to correct for background radiation. Net DPM was calculated by further 
subtraction of the ‘no protein control’ from the samples. Uptake rate was 
corrected for protein content and expressed as pmol/µg. Finally, Na+ dependent 
uptake was calculated. 
3.3.4 Trophoblast Invasion and Spiral Artery Assessment  
Serial sections of the placenta were prepared and subjected to 
immunohistochemical processing to highlight trophoblast (cytokeratin 7) 
presence and smooth muscle actin (outlined in Chapter 2). 
Assessment of trophoblast invasion was restricted to the maternal mesometrial 
triangle tissue and this was separated into three zones (Figure 3-2). The number 
of positive pixels for the whole area and each individual zone was recorded. This 
was then presented as a proportion of positive staining in the whole tissue and a 
percentage of positive pixels restricted to each zone.  
Three to four spiral arteries were identified in each mesometrial zone by a 
blinded observer. The same arteries were located on placentas stained for 
cytokeratin 7 and for SMA.  Trophoblast association within the vessel 
(endovascular) and/or nearby the vessel; within the field of view, approximately 
200-400µm from the vessel in all directions (interstitial) was noted as a yes 
(scored numerically as 1) or no (scored numerically as 0). The average for each 
zone was determined and expressed as a percentage of trophoblast association. 
The assessment of spiral artery remodelling was conducted using a scoring 
system for the presence/absence of SMA staining within vessels walls as well as 
the degree of rounding/separation of vascular smooth muscle cells (Table 3-1).  
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Figure 3-2: A representative placental section highlighting trophoblast presence in the 
mesometrial triangle. 
Placental sections with the maternal mesometrial triangle attached were stained with cytokeratin 7. 
The dark purple staining indicates positive trophoblasts and these can be recorded in the placenta 
(which is composed mainly of trophoblasts) and the maternal tissue proximal to placental 
implantation (the mesometrial triangle). The zonal separation performed on analysis is indicated by 
the dashed lines and labels 1-3. 
 
 
Table 3-1: Spiral artery smooth muscle actin staining assessment scores 
Score 
Percentage of VSMC demonstrating 
rounding/separation 
1 No visible SMA stain, complete loss of VSMC 
2 >50% 
3 25%-50% 
4 10-25% 
5 <10% 
The scoring method for assessing the amount of vascular smooth muscle cell (VSMC) 
dedifferentiation using the degree of rounding and separation observed adapted from the VSMC 
disruption  assessment used by Lash et al  (Lash et al., 2016). 
  
Zone 1
Zone 2
Zone 3 Mesometrial 
triangle
Placenta
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3.3.5 Statistical Analysis 
All data are presented as mean ±standard error (SEM) unless otherwise stated. 
Where appropriate normality was assessed using a Gaussian distribution. Where 
only two comparisons between SHRSP and WKY were required an unpaired 
student’s t-test was conducted. In data presenting a rate of change over 
different pregnancy time points from the same animals a regression analysis was 
conducted for each strain between gestations and then compared using an 
unpaired student’s t-test. Measurements with 3 or more groups and two 
influencing factors made from the same animal or placenta over the course of 
gestation/within different zones of the same tissue were subject to a repeated 
measure two-way ANOVA. Other data which compared 3 or more groups and had 
two influencing factors utilised an ordinary two-way ANOVA. Both were subject 
to a Sidak post-hoc test for additional comparison between set groups. 
Statistical analysis for the gene expression data compared the ΔCT values 
between WKY and SHRSP using an unpaired student’s t-testing in each layer 
separately, then a repeated measures one-way ANOVA was used to examine 
changes across the layers for each strain separately. A p value<0.05 was 
determined as significant. 
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3.4 Results 
3.4.1 Maternal Pregnancy Profile 
Maternal body and tissue weights were recorded between 4 and 0 days pre-
pregnancy (the non-pregnant (NP) weight) and at gestational day (GD) 6.5, 14.5, 
18.5 and 20.5 time points. These weights are summarised in Table 3-2. 
3.4.1.1 Weight Change throughout Gestation 
Maternal weight gain was assessed by examining absolute weights and the rate 
of weight gain (Figure 3-3A). WKY had significantly larger weights than the 
SHRSP both pre-pregnancy and at each gestational time point. The overall rate 
of weight gain in WKY dams was also significantly greater than SHRSP (4.4±0.23 
versus 3.0±0.28; p<0.01) (Figure 3-3A). The maternal weight gain was further 
investigated by removing the variable weight of the gravid uterus, thus 
producing information on pregnancy maternal induced weight gain, independent 
of number/size of fetal and placental units: the gravid-independent weight gain 
(Figure 3-3B). WKY had a significantly larger gravid-independent weight increase 
compared to SHRSP (26.5±2.02g versus 14.8±2.66; p<0.01) (Figure 3-3B). 
3.4.1.2 Maternal tissue weights  
Maternal hearts were dissected to obtain the mass of the left ventricle (LV) and 
both the left and right kidneys were weighed at sacrifice; these weights were 
then adjusted for tibia length. SHRSP normalised LV mass was found to be 
significantly greater than WKY at both NP (1.9±0.27 versus 1.6±0.18; p<0.001) 
and GD18.5 (1.8±0.17 versus 1.5±0.17; p<0.05) time points (Figure 3-4A). 
Pregnancy did not significantly affect the LV mass in either strain. The 
normalised kidney mass of NP SHRSP dams was significantly greater than that of 
NP WKY (4.3±0.31 versus 3.6±0.30; p<0.001). There was no difference between 
the two strains at GD18.5 (Figure 3-4B). 
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Table 3-2: Maternal body and whole organ weights throughout gestation 
 
The maternal body weights, whole organ weights and tibia length were recorded pre-pregnancy 
and at different gestational time points. Significant differences were assessed using a two-way 
ANOVA with Sidak post-hoc comparison vs NP (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) and 
vs WKY (†p<0.05, ††p<0.01, †††p<0.001, ††††p<0.0001). Data presented as mean ± SEM. 
Gestation Body (g) Heart (g) Liver (g) Tibia (mm)
W
K
Y
NP 179.23 ± 4.7(n=15)
0.64 ± 0.01
(n=13)
7.50 ± 0.42
(n=4)
29.70 ± 0.78
(n=10)
GD6.5 205.63 ± 3.1(n=22)
0.69 ± 0.02
(n=8)
8.93 ± 0.32
(n=5)
31.83 ± 0.95
(n=6)
GD14.5 220.37 ± 7.7 (n=3)
0.73 ± 0.03
(n=3)
11.93 ± 0.56
(n=3)
32.00 ± 3.00
(n=3)
GD18.5 249.74 ± 3.6 (n=16)
0.72 ± 0.02
(n=8)
11.24 ± 0.53
(n=3)
32.75 ± 0.59
(n=8)
GD20.5 268.83 ± 8.1(n=4)
0.72 ± 0.05
(n=4)
12.53 ± 0.67
(n=4)
32.00 ± 0.41
(n=4)
S
H
R
S
P
NP 169.23 ± 2.3(n=15)
0.69 ± 0.02
(n=14)
7.14 ± 0.13
(n=5)
27.56 ± 0.91
(n=9)
GD6.5 184.73 ± 2.4(n=20)
0.73 ± 0.02
(n=8)
8.30 ± 0.47
(n=3)
31.63 ± 0.78
(n=8)
GD14.5 210.43 ± 4.0(n=4)
0.80 ± 0.01
(n=5)
9.45 ± 0.10
(n=5)
30.00 ± 1.03
(n=3)
GD18.5 216.02 ± 4.9(n=14)
0.79 ± 0.01
(n=6)
10.64 ± 0.36
(n=4)
32.00 ± 1.30
(n=5)
GD20.5 231.50 ± 6.2(n=5)
0.85 ± 0.01
(n=5)
10.45 ± 0.36
(n=5)
31.25 ± 0.75
(n=5)
***
†††
***
††
***
**
†††
***
***
***
***
**
***
***
†
***
***
***
***
***
†††
*
**
**
***
†
†
*
***
††
*
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Figure 3-3: Maternal weight change over gestation in WKY and SHRSP 
(A) The rate of total weight gain over gestation; NP was non-pregnant weights recorded between 4 
and 0 days pre-pregnancy, the weights were then recorded on GD6.5, 14.5 and 18.5. Statistical 
significance between WKY and SHRSP was determined using unpaired students t-test (†p<0.05, 
†††p<0.001 and ††††p<0.0001), the overall weight gain rate was calculated using regression analysis 
for each dam and the gradients were then compared using unpaired students t-test (**p<0.01); 
n=5-6 dams. (B) The total amount of weight gained that was independent of the mass of the gravid 
uterus was calculated by subtracting the weight of the gravid uterine horn at sacrifice from the 
GD18.5 weight of the dam. The change from GD6.5 weights was then calculated to give a gravid 
independent weight increase over pregnancy. Statistical significance was determined using an 
unpaired students t-test (**p<0.01); n=5-6 dams. 
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Figure 3-4: Left ventricle and total kidney mass normalised to tibia length prior to and 
during pregnancy in WKY and SHRSP 
(A) Left ventricle mass (LVM) and (B) kidney mass was recorded at sacrifice in separate age-
matched animals at a pre-pregnancy (NP) and at GD18.5 time point and normalised to tibia length. 
Statistical significance was determined using one-way ANOVA with Sidak post-test to examine 
differences between NP and GD18.5 in both strains as well as comparisons between WKY and 
SHRSP (*p<0.05, ***p<0.001); n=9-11.  
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3.4.1.3 Cardiac Function 
Echocardiography was used to assess cardiac function over gestation. 
Measurements of the anterior and posterior wall thickness during diastole and 
systole as well as the end diastolic and systolic diameter were used to calculate 
stroke volume (SV), cardiac output (CO), ejection fraction (EF) and fractional 
shortening (FS). SV was significantly increased in WKY between NP and GD18.5 
(0.22±0.03ml versus 0.36±0.05; p<0.01). This was not observed in SHRSP. The SV 
of GD18.5 WKY was also significantly greater than that of GD18.5 SHRSP dams 
(0.36±0.05 versus 0.24±0.02; p<0.05) (Figure 3-5A). The CO response to 
pregnancy in WKY and SHRSP showed a significant increase from NP to GD18.5 
(WKY: 80.5±5.44ml/min versus 125.3±12.28ml/min; p<0.05 and SHRSP: 
51.7±4.09ml/min versus 87.4±6.33ml/min; p<0.05). The CO was also significantly 
increased in GD18.5 WKY dams compared to SHRSP (p<0.05) (Figure 3-5B). There 
were no significant differences observed in the FS or EF over the 18.5 days 
gestation, and no strain differences were found at any gestational stage (Figure 
3-5C-D) 
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Figure 3-5: Cardiac function calculated from echocardiographs recorded over gestation in 
WKY and SHRSP. 
The stroke volume (A), cardiac output (B), fractional shortening (C) and ejection fraction (D) of the 
heart were calculated from echocardiograph images taken one week prior to pregnancy (NP) and 
at each subsequent week of pregnancy (GD6.5, GD12.5 and GD18.5). Statistical significance was 
determined using a two-way ANOVA with Sidak post-hoc test to examine differences between 
strain at each gestation (+p<0.05, ++p<0.05) and change over gestation from NP to GD18.5 
(*p<0.05, **p<0.01); n=3-6.  
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3.4.1.4 Urinary Analysis 
Pregnancy did not significantly increase the water intake (Figure 3-6A) or urine 
output (Figure 3-6B) in either strain. Furthermore, there were no significant 
differences in the volume of water intake between WKY and SHRSP at any of the 
measured gestational time points (Figure 3-6A). Both strains appeared to have 
an increased urine output in the first two weeks of gestation. However, urine 
output was significantly lower in SHRSP compared to WKY during the last week 
of pregnancy (Figure 3-6B).  
The albumin and creatinine concentrations were measured from 24-hour urine 
samples collected at time points one week prior to pregnancy (NP), during 
gestational week 1 (GD5.5-7.5) and during gestational week 2 (GD12.5-15.5). No 
significant differences were found in the albumin:creatinine ratios of WKY and 
SHRSP dams at any of the time points (Figure 3-6C). 
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Figure 3-6: Maternal urinary profile over gestation in WKY and SHRSP 
The water intake (A) and urine output (B) were recorded pre-pregnancy (NP) and during the 1st 
week (GW1: between GD5.5-7.5), the 2nd week (GW2: between GD12.5-15.5) and 3rd week (GW3 
between GD16.5-18.5) of gestation. (C) The albumin and creatinine were measured from 24-hour 
urine samples collected pre-pregnancy (NP) and at gestational week 1 (GW1) and gestational 
week 2 (GW2). The albumin:creatinine ratio of these samples was then calculated. Data analysed 
using unpaired two-way ANOVA, with Bonferroni post-hoc tests to compare strains at the different 
time points; **p<0.01. Linear regression analysis was used for each strain to assess change over 
gestation using the gradient; n=3-4. 
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3.4.2 Offspring Outcome 
3.4.2.1 Live litter size 
The breeding database for SHRSP and WKY colonies maintained at the University 
of Glasgow was examined, allowing for the analysis of the number of pups born 
to each dam through brother x sister mating between 2009 to 2017. The average 
number of pups born to each primiparous dam was examined over this time 
period and each litter average presented in Figure 3-7A. The average number of 
pups born varied each year between 2009 and 2017, however there were no 
significant differences between WKY and SHRSP Figure 3-7B. The number of pups 
born to WKY mothers ranged from 2-14 and the range for SHRSP was 2-16 pups 
per litter. The only significant difference found was that fewer pups were born 
per litter to WKY dams in 2015 compared to 2017 (6±1.3 versus 11±0.7; p<0.05). 
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Figure 3-7: The number of WKY and SHRSP pups per litter born between 2009 and 2017 
All live pups born to primiparous WKY and SHRSP mothers were recorded between 2009 and 
2017. (A) The number of live pups born per litter in WKY and SHRSP; analysed using unpaired 
students t-test. (B) The number of average number of pups born per litter each year from 2009 to 
2017 for WKY and SHRSP; analysed using two-way ANOVA to compare strain difference and 
change over time (*p<0.05); WKY n=89 litters, SHRSP n=154 litters 
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3.4.2.2 GD18.5 Fetal Parameters 
Representative images of the gravid WKY and SHRSP uterus are shown in Figure 
3-8, along with images of individual fetoplacental units, the fetus and placenta.  
The whole uterus was inspected and the number of fully formed fetuses was 
recorded, along with the number of any fetal resorptions. There were no 
significant differences in the frequency of resorptions found (Table 3-3). 
There were no differences in the number of pups recorded per litter at GD18.5 
(Figure 3-9). The average fetal weight for each litter was not significantly 
different between WKY and SHRSP (Figure 3-10A). In order to better assess fetal 
growth, a fetal weight distribution curve was generated by creating a histogram 
of all individual fetal weights and performing a non-linear fit of these 
histograms. This produced a curve for both WKY and SHRSP fetal weight 
proportions within their respective populations (Figure 3-10B). The 5th centile 
was then calculated for the WKY fetal population, as fetal weights below this 
are regarded clinically as growth restricted in humans. This was found to be 
<0.86g, and 5.6% of SHRSP fetuses were under this weight. Further fetal 
measurements were conducted to assess for any growth restriction (Figure 3-11). 
There was no evidence of head sparing as the head:body weight ratio 
(determined by weighing fetal heads separately from the whole body) and head 
circumference were not significantly different between strain (Figure 3-11A-B). 
There was also no difference in the length of the fetus (Figure 3-11C). However, 
SHRSP fetal abdominal circumference was found to be significantly smaller than 
WKY (22.7±0.3mm versus 24.1±0.6mm; p<0.05) (Figure 3-11D). 
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Figure 3-8: Representative images of uteroplacental units of WKY and SHRSP at GD18.5 
(A) The whole gravid uterus for WKY and SHRSP, showing both horns of the fully pregnant rat 
uterus at GD18.5. (B) An individual fetoplacental unit still contained within the fetal membranes 
surrounded by amniotic fluid. (C) The fetus attached to its respective placenta via the umbilical 
cord. (D) The placenta dissected from membranes, fetus and umbilical cord left image is showing 
the chorionic plate surface (fetal side) and right image is showing the decidual layer (maternal side) 
for both WKY and SHRSP. 
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Table 3-3: Resorption statistics for WKY and SHRSP pregnancies 
Resorption information WKY SHRSP 
Total number of pregnancies 29 23 
Number exhibiting 1 or more resorptions 15 8 
Ratio of resorptions to number of implant sites 0.042 0.054 
% resorptions normalised to total litter size 12.21 15.51 
The total number of pregnancies and the number of these effected by resorptions are stated. The 
ratio of number of resorptions identified was not significantly different in WKY and SHRSP; 
similarly, there was no difference in the percentage of resorptions within a litter. 
 
 
Figure 3-9: Number of fetuses per litter at GD18.5 for WKY and SHRSP dams 
The number of pups per litter were counted at GD18.5 sacrifice. Statistical analysis was conducted 
using unpaired student’s t-test; n=23-30 litters. 
 
 
Figure 3-10: GD18.5 fetal weights and size parameters for WKY and SHRSP. 
Each fetal weight was recorded individually at GD18.5. (A) A litter average for the fetal weight was 
plotted for WKY and SHRSP; n=20-23 litters, analysed using unpaired student’s t-test. (B) Shows 
the fetal weight distributions, calculated from WKY and SHRSP individual fetal weights from all 
litters. The distribution curve indicates the range of weights of the population of WKY and SHRSP 
fetuses. The dotted line indicates the lowest 5th percentile for WKY fetal weights; WKY, n=228 
(from 23 litters) and SHRSP n=205 (from 20 litters). 
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Figure 3-11: Fetal size parameters measured at GD18.5 for WKY and SHRSP 
(A) Measurements of fetal size proportions were made by calculating the ratio of head weight to 
total body weight. Anthropometric measurements were performed using a cotton thread to measure 
(B) the head circumference; the circumference of the head above the ears and eyes, (C) the 
crown-rump length; the distance between the top of the head (intersection with the head 
circumference measure) and the base of the tail, following the curve of the fetal spine and (D) the 
abdominal circumference; the circumference around the fetal abdomen at the site of umbilical cord 
insertion. Statistical significance was determined using unpaired student’s t-test (*p<0.05); n=13 for 
head:body weight ratio and n=4-8 for anthropometric measurements. 
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Figure 3-12: Images of gestational day 14.5 and 20.5 fetus and placenta from WKY and SHRSP 
Representative images of GD14.5 and GD20.5 fetus and placenta are shown with fetal images on the left and placenta on the right. At GD14.5 the fetus is still in early 
stages of development and is smaller than the placenta. GD20.5 is approximately 2-3 days before birth for WKY and SHRSP dams, at this stage the fetal development 
is near completion and its size has increased exponentially. 
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3.4.2.3 Fetal growth trajectory 
Fetal weights were also investigated at GD14.5 and GD20.5. Figure 3-12 shows 
representative images of the fetus and placenta at these gestational stages. The 
rate of fetal growth between GD14.5 to GD18.5 significantly increased in both 
WKY and SHRSP (WKY: 0.097±0.003g versus 0.960±0.089g; p<0.0001 and SHRSP: 
0.093±0.005g versus 0.973±0.044g; p<0.0001) and then again from GD18.5 to 
GD20.5 (WKY: 0.960±0.089g versus 2.75±0.07; p<0.0001 and SHRSP: 
0.973±0.044g versus 2.62±0.04g; p<0.0001). The rate of growth significantly 
increased between GD18.5 and GD20.5 compared to GD14.5-GD18.5 in both WKY 
and SHRSP (WKY: 1.01±0.13 versus 0.16±0.04; p<0.01, and SHRSP: 0.83±0.02 
versus 0.22±0.02; p<0.001) (Figure 3-13A). The late gestational stage of fetuses 
collected at GD20.5 allowed for gendering the litter and male and female 
weights were separated for analysis. There were no significant differences in 
fetal weights between WKY and SHRSP for both gender, and males and females 
were not significantly different from one another within each strain (Figure 
3-13B). 
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Figure 3-13: Fetal growth trajectory and the gender separated weights at GD20.5 
(A) The fetal weights were recorded from separate pregnancies at GD14.5 (n=3-4 litters), GD18.5 
(n=7-8 litters) and GD20.5 (n=4 litters). Statistical significance was determined by using a two-way 
ANOVA to examine differences between WKY and SHRSP at each time point as well as changes 
over gestation (****p<0.0001 vs GD14.5 WKY, ††††p<0.0001 vs SHRSP GD14.5). (B) Due to the 
advanced developmental stage of GD20.5 fetuses gender was able to be determined, thus each 
litter average was split into the male and female fetal weights. Analysed using one-way ANOVA.   
M a le F e m a le
0
1 .0
1 .5
2 .0
2 .5
3 .0
3 .5
W K Y
S H R S P
G
D
2
0
.5
 F
e
ta
l 
w
e
ig
h
t
(L
it
te
r
 A
v
e
r
a
g
e
s
 (
g
))
1 4 .5 1 6 .5 1 8 .5 2 0 .5
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
3 .0
3 .5
G e s ta tio n a l d a y
F
e
ta
l 
w
e
ig
h
t
(l
it
te
r
 a
v
e
r
a
g
e
s
 (
g
))
W K Y
S H R S P
A
B
0 2 0 4 0 6 0 8 0
0
1 0
2 0
3 0
4 0
5 0
W K Y  N a
+
S H R S P  N a
+
W K Y  K
+
S H R S P  K
+
T im e
1
4
C
-M
e
A
IB
 u
p
ta
k
e
(p
m
o
l/
m
g
 p
r
o
te
in
)
****
****
****
****
0 2 0 4 0 6 0 8 0
0
1 0
2 0
3 0
4 0
5 0
W K Y  N a
+
S H R S P  N a
+
W K Y  K
+
S H R S P  K
+
T im e
1
4
C
-M
e
A
IB
 u
p
ta
k
e
(p
m
o
l/
m
g
 p
r
o
te
in
)
****
****
****
****††††
††††
139 
 
 
3.4.3 Placental Outcome 
Placentas were weighed and collected at GD14.5, 18.5 and 20.5 to examine 
placental characteristics of the SHRSP and WKY. 
3.4.3.1 Placental growth trajectory, size and gross morphology 
Placental weights at GD18.5 were not found to be significantly different 
between strains (Figure 3-14A). There was also no evidence of placental 
insufficiency relative to fetal size as the fetal:placental ratios were not 
significantly different between the two strains (Figure 3-14B). 
Placental growth between GD14.5 and GD18.5 and GD20.5 was similar in WKY 
and SHRSP (Figure 3-15). Both strains demonstrated a significant increase in 
placental weight between GD14.5 and GD18.5 (WKY: 0.08±0.009g versus 
0.23±0.004g; p<0.0001, and SHRSP: 0.07±0.009g versus 0.23±0.005g; p<0.0001) 
as well as a significant increase in weight between GD18.5 and GD20.5 (WKY: 
0.23±0.004g versus 0.27±0.006g; p<0.01, and SHRSP: 0.23±0.005g versus 
0.27±0.009g; p<0.001). The rate of increase was significantly greater between 
GD14.5 and 18.5 than between GD18.5 and GD20.5 in SHRSP (gradient of 
0.04±0.002 versus 0.02±0.007; p<0.05).  
Placentas were sectioned for histology and stained with PAS stain. This allowed 
for the visualisation of the placental layers (the junctional and labyrinth zones) 
as well as the maternal mesometrial triangle; which is the location of the 
decidua and myometrium (Figure 3-16A). The quantification of placental layer 
size was conducted by analysing the total pixel area of the junctional and the 
labyrinth zones. The proportional size of each layer was then determined along 
with the junctional:labyrinth ratio (Figure 3-16 B-C). WKY placentas were 
composed of 70±1.6% labyrinth zone to 30±1.5% junctional zone whereas the 
SHRSP had a slightly larger labyrinth proportion (77±1.4%) with a smaller 
junctional zone (23±1.4%). Both these layers were significantly different in 
proportions compared between strains (p<0.01) (Figure 3-16B). This is reflected 
in the significantly greater junctional:labyrinth ratios observed in WKY compared 
to SHRSP (0.44±0.03 versus 0.31±0.02; p<0.01) (Figure 3-16C). 
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Figure 3-14: Placental weights and the fetal:placental weight ratios at GD18.5 
(A) Placental weights recorded at GD18.5 for WKY and SHRSP, presented as litter averages. (B) 
The fetal weight to placental weight ratios expressed as averages for each litter to indicate any 
placental insufficiency. Assessed using unpaired student’s t-test; n=21-23 litters. 
 
 
 
 
 
Figure 3-15: Placental growth trajectory across gestation in WKY and SHRSP 
The placental weights were recorded from separate pregnancies at GD14.5 (n=3-4 litters), GD18.5 
(n=7-8 litters) and GD20.5 (n=4 litters). Statistical significance was determined by using a two-way 
ANOVA to examine differences between WKY and SHRSP at each time point as well as changes 
over gestation (****p<0.0001 vs GD14.5 WKY, ††††p<0.0001 vs SHRSP GD14.5; *p<0.05 vs WKY 
GD18.5, ††p<0.01 vs SHRSP GD18.5).  
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Figure 3-16: Histological analysis of placental size using layer proportions 
(A) A representative image of the rodent placenta highlighting the different maternal, placental and 
fetal zones. Mes= maternal mesometrial triangle; Jx = placental junctional zone; Lab = placental 
labyrinth zone and CP= fetal chorionic plate. (B) The proportional size of the two placental zones 
(Jx and Lab) were determined using pixel number. Significant differences in layer proportion 
between WKY (n=9) and SHRSP (n=7) were determined using unpaired student’s t-test (**p<0.01). 
(C) The proportional size was also expressed as a ratio between total pixel area of the junctional 
zone and total pixel area of the labyrinth zone (Jx:Lab ratio), statistical significance was determined 
using unpaired student’s t-test (**p<0.05); n=16-17. 
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3.4.3.2 Placental glycogen cell content 
Placenta from WKY demonstrated significantly more PAS positive staining in the 
junctional zone of the placenta than SHRSP at GD14.5 (41.4±4.8% versus 
16.6±2.5%; p<0.01) (Figure 3-17A). There were no significant differences 
observed in PAS staining between strains at GD20.5. WKY placentas 
demonstrated a significant loss of PAS positive staining between GD14.5 and 
GD20.5 (41.4±4.8% versus 15.74±3.2%; p<0.001), whereas the SHRSP showed no 
significant change over gestation. Representative images of WKY and SHRSP 
placenta from GD14.5 and 20.5 are demonstrated in Figure 3-17B-E. 
3.4.3.3 Placental collagen content 
Placental collagen content was visualised using picrosirius red staining. This 
demonstrated significantly less collagen staining in the maternal mesometrial 
triangle of the SHRSP compared to WKY (46.0±5.2% versus 73.7±3.5%; p<0.0001) 
(Figure 3-18A-C). However this observation was changed in the labyrinth zones, 
with the percentage of positive staining found to be significantly increased in 
the SHRSP compared to WKY placenta (29.0±2.5% versus 8.8±1.0%; p<0.0001) 
(Figure 3-18A). 
3.4.3.4 Trophoblast invasion and Spiral Artery Remodelling 
Trophoblast invasion into the mesometrial triangle was evaluated using 
immunohistochemistry, representative placental images of WKY and SHRSP are 
shown in Figure 3-19A-B. WKY were found to have a significantly higher 
proportion of cytokeratin 7 positive staining in the maternal mesometrial 
triangle than SHRSP (2.2±0.3% versus 0.68±0.1%; p<0.01) (Figure 3-19C). This 
invasion was then assessed according to depth of invasion through the three 
mesometrial zones. Whilst there were no significant differences between the 
percentage of positive staining between WKY and SHRSP in either zone, 
significantly less cytokeratin staining was observed in SHRSP zone 3 compared to 
zone 1(most proximal to the placenta) (10.9±2.1% versus 55.8±1.9%; p<0.05) 
(Figure 3-19D).  
Spiral artery remodelling was assessed using a scoring system for 
dedifferentiation and loss of smooth muscle actin (SMA) staining around spiral 
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arteries in the 3 mesometrial zones (1= no SMA staining; 5 = >50% of the artery 
surrounded by SMA, with no rounding/separation of VSMC).  There were no 
differences in the scores between WKY and SHRSP within any of the 3 zones 
(Figure 3-20A). Zone 1 had a significantly lower SMA score than zone 3 for WKY 
(1.7±0.1 versus 3.7±0.4; p<0.01); and a significantly lower score compared to 
zones 2 and 3 in SHRSP (1.5±0.2 versus 3.6±0.4; p<0.01 and 4.2±0.5; p<0.001). 
Representations of the SMA staining within each mesometrial zone is illustrated 
for WKY and SHRSP in Figure 3-20B. The presence of trophoblasts within 
(endovascular) and proximal to (interstitial) the spiral arteries was also assessed. 
These were assigned a presence (1) or absence (0) score and a percentage was 
calculated from all the arteries assessed in that zone of that mesometrial 
triangle. Both WKY and SHRSP had a significantly higher percentage of 
endovascular trophoblasts identified as present in spiral arteries in zone 1 
compared to zone 2 (WKY; 80±13.3% versus 33.3±18.3%; p<0.05 and SHRSP; 
91.7±8.3% versus 33.3±19.3%; p<0.05) (Figure 3-20C). There were no significant 
differences between the strains in either zone. There were no significant 
differences in interstitial trophoblast presence between the zones or between 
the strains (Figure 3-20D). The spiral arteries identified in zone 3 had no 
trophoblast association. Representative images of the trophoblast association 
with spiral arteries in each zone are presented in Figure 3-20E.  
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Figure 3-17: PAS stained placenta from GD14.5 and GD20.5 from WKY and SHRSP 
(A) The percentage of positive PAS staining in the junctional zone of WKY and SHRSP placenta at 
GD14.5 (n=3-4) and GD20.5 (n=5-8) was quantified by a blinded observer using Image J. 
Statistical comparisons between WKY and SHRSP at each gestation and the difference between 
gestations of each strain was assessed using a two-way ANOVA with a Sidak post-hoc test 
(*p<0.05, **p<0.01, ***p<0.001). Representative images of the whole placenta at GD14.5 (B-WKY; 
C-SHRSP), and GD20.5 (D-WKY; E-SHRSP) stained using PAS, highlighting the positive magenta 
staining in the junctional zone. 
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Figure 3-18: Collagen staining of the GD18.5 placenta from WKY and SHRSP 
(A) The percentage of picrosirius red staining was quantified in the different maternal, placental and 
fetal zones (Mes= maternal mesometrial triangle; Jx = placental junctional zone; Lab = placental 
labyrinth zone and CP= fetal chorionic plate) and expressed as a percentage relative to the total 
size of that area revealed significant. Statistical comparisons between WKY (n=8) and SHRSP 
(n=7) in each zone was assessed using a two-way ANOVA with a Sidak post-hoc test 
(****p<0.0001). The collagen stained red, representative images of the whole placenta for (B) WKY 
and (C) SHRSP.  
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Figure 3-19: Assessment of trophoblast invasion in WKY and SHRSP 
Representative images of trophoblast cytokeratin 7 staining in the mesometrial triangle of (A) WKY 
and (B) SHRSP. (C) The percentage of positive staining within the entire mesometrial triangle was 
quantified by a blinded observer using Image J software. Statistical significance was determined by 
using an unpaired student’s t-test (**p<0.01). (D) Further quantification was obtained by expressing 
the total positive staining as a percentage in the different zones within the mesometrial triangle, 
with zone 1 being most proximal to the placenta and zone 3 most distal. Analysed using two-way 
ANOVA with Tukey post-hoc test; *p<0.05 Zone 1 vs Zone 3; n=4-5.  
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Figure 3-20: Spiral artery remodelling assessment and scoring in WKY and SHRSP 
Between 3-4 spiral arteries were identified in each zone of the mesometrial triangle. (A) Vascular smooth muscle cell dedifferentiation was scored between 1 (no visible 
smooth muscle actin (SMA) staining and 5 (presence of SMA with <10% of rounding/separation of the VSMC in the vessel wall) by one observed blinded to strain and 
zone location. (B) Representative images of the spiral arteries of WKY and SHRSP in the 3 different zones. (C-D) The presence of endovascular and interstitial 
trophoblasts in and around the spiral arteries was recorded. The presence or absence was then calculated to reveal a percentage association of endovascular and 
interstitial trophoblasts within the spiral arteries in zone 1 and zone 2. Arteries in zone 3 had no endovascular or interstitial trophoblast association. (E) Representative 
images of endovascular and interstitial trophoblast association in zone 1 and 2 of the WKY and SHRSP mesometrial triangle. Statistical significance was determined 
using a two-way ANOVA with Tukey post-hoc test; n=15-20 arteries per zone, N=5 placentas. 
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3.4.3.5 Placental Gene Expression 
Placental RNA was extracted from the maternal, placental and fetal layers 
(mesometrial triangle, junctional and labyrinth zones and the chorionic plate; 
illustrated in Figure 3-16) in order to examine relative gene expression within 
the placenta.  
Layer dissection accuracy was deemed appropriate due to the relative 
expression of desmin, prolactin and vascular endothelial growth factor receptor 
(Vegfr). Desmin expression, which is an intermediate filament protein expressed 
by decidualized cells, was significantly greater in the maternal mesometrial 
triangle and junctional zone compared to in the labyrinth and chorionic plate in 
both WKY and SHRSP (Figure 3-21A). Prolactin expression is located to 
trophoblast cells in the junctional zone and was found to have a significantly 
higher expression in the junctional zone compared to all other layers in both 
strains (Figure 3-21B). Vegfr expression localises to highly vascularised zones and 
expression was found to be significantly higher in the labyrinth and decidua 
zones compared to chorionic plate in both strains, with the junctional zone in 
WKY also having a significantly higher expression (Figure 3-21C). 
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Figure 3-21: Placental layer enrichment validated by specific gene expressions in the 
different placental zones. 
Gene expression within the Mes= maternal mesometrial triangle; Jx = placental junctional zone; 
Lab = placental labyrinth zone and CP= fetal chorionic plate were investigated to determine if 
accurate dissection of the placenta had taken place. Expression was normalised to Gapdh and is 
presented relative to the Mes. (A) Desmin expression highlights decidualized cells, (B) prolactin 
(Prl8a4) expression indicative of trophoblast giant cells and (C) vascular endothelial growth factor 
receptor (Vegfr2) expression indicating highly vascularised zones. Variation of expression was 
examined using the ΔCT values and tested for statistical significance using a one-way ANOVA with 
a Tukey post-hoc test; vs Mes: †p<0.05, †††p<0.001, ††††p<0.0001; vs Jx: αp<0.05, ααp<0.01, 
αααp<0.001, ααααp<0.0001; vs Lab φφp<0.01, φφφp<0.001, φφφφp<0.0001. n=5. Values above each bar 
indicate unadjusted cycle threshold values. 
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3.4.3.6 Gene expression of markers of oxidative stress and hypoxia 
The gene expression profile across the maternal, placental and fetal layers was 
examined and then the layers were individually compared between WKY and 
SHRSP.  
3.4.3.6.1 Comparison of placental layers 
Sod1 expression in WKY was found to be significantly higher in the chorionic 
plate (CP) compared to the mesometrial triangle (2.1±0.16 ΔCT versus 3.0±0.21 
ΔCT; p<0.05), there were no significant changes between the layers in SHRSP 
(Figure 3-22A). Gpx1 expression was significantly higher in the mesometrial 
triangle compared to other layers in WKY (1.6±0.11 ΔCT versus 3.7±0.34 ΔCT 
(Jx); p<0.0001 and 3.9±0.15 ΔCT (Lab); p<0.0001 and 2.9±0.15 ΔCT (CP); p<0.01) 
and in SHRSP (1.7±0.07 ΔCT versus 3.5±0.25 ΔCT (Jx); p<0.0001 and 4.7±0.16 
ΔCT (Lab); p<0.0001 and 2.6±0.26 ΔCT (CP); p<0.05). The expression in the fetal 
CP was also greater than the labyrinth zone in both strains (p<0.05) and 
significantly greater than the junctional zone in SHRSP only (p<0.01) (Figure 
3-22B). In WKY the Hif1α expression was greater in the junctional zone 
compared to mesometrial triangle (6.6±0.11 ΔCT versus 7.3±0.15 ΔCT; p<0.01) 
and the labyrinth zone (6.6±0.11 ΔCT versus 7.1±0.07 ΔCT; p<0.05). In SHRSP 
this trend was altered as the mesometrial zone had the lowest expression 
compared to all other layers (7.5±0.10 ΔCT vs 6.4±0.12 ΔCT (Jx); p<0.0001, 
6.6±0.07 ΔCT (Lab); p<0.0001 and 6.8±0.13 ΔCT (CP); p<0.05) (Figure 3-22C). 
Vegf expression in WKY was reduced in the junctional zone, compared to the 
mesometrial triangle and labyrinth zones (7.8±0.26 ΔCT versus 5.3±0.15 ΔCT 
(Mes); p<0.0001 and 5.8±0.11 ΔCT (Lab); p<0.0001. An increased labyrinth zone 
expression was also observed compared to fetal CP (5.8±0.11 ΔCT versus 
7.2±0.10 ΔCT; p<0.01). In SHRSP placentas the expression trends were similar to 
WKY in that Vegf expression was significantly reduced in the junctional zone, 
compared to the mesometrial triangle and labyrinth zones (7.6±0.17 ΔCT versus 
5.4±0.26 ΔCT (Mes); p<0.0001 and 6.2±0.12 ΔCT (Lab); p<0.001), however this 
strain also demonstrated reduced expression in the labyrinth and CP zones 
compared to the mesometrial triangle (5.4±0.26 ΔCT (Mes) versus 6.2±0.12 ΔCT 
(Lab); p<0.05 and versus 7.0±0.15 ΔCT (CP); p<0.001) (Figure 3-22D). 
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3.4.3.6.2 Comparison between strains 
SHRSP had a significantly greater Sod1 expression in the mesometrial triangle 
(2.1±0.13 ΔCT versus 3.0±0.21 ΔCT; p<0.01), junctional zone (1.62±0.12 ΔCT 
versus 2.8±0.17 ΔCT; p<0.01) and labyrinth zone (1.8±0.18 ΔCT versus 3.4±0.21 
ΔCT; p<0.01) compared to WKY (Figure 3-22A). Hif1α expression was also 
increased in the SHRSP labyrinth layer compared to WKY (6.6±0.07 ΔCT versus 
7.0±0.07 ΔCT; p<0.01) (Figure 3-22 C). Gpx1 and Vegf expression were both 
significantly reduced in SHRSP labyrinth zones compared to WKY (Gpx1: 4.7±0.16 
ΔCT versus 3.9±0.15 ΔCT; p<0.01 and Vegf: .6.2±0.14 ΔCT versus 5.8±0.11 ΔCT; 
p<0.05) (Figure 3-22B and D). 
 
Figure 3-22: Placental gene expression of markers of oxidative stress and hypoxia 
Expression of (A) superoxide dismutase 1 (Sod1), (B) glutathione peroxidase 1 (Gpx1), (C) 
Hypoxia-inducible factor 1α (Hif1α) and (D) vascular endothelial growth factor (Vegf) were 
normalised to β actin and presented relative to the mesometrial triangle portion of the WKY 
placenta. Statistical analysis was conducted on the ΔCT values for each layer (WKY n=4, SHRSP 
n=4) using an unpaired student’s t-test to compare WKY and SHRSP within each individual layer 
(*p<0.05, **p<0.01) and a one-way ANOVA with Tukey’s post-hoc test was then used to assess the 
change in expression across the layers within each strain, highlighted blue for WKY comparisons 
and red for SHRSP comparisons (vs Mes: †p<0.05, ††p<0.01 †††p<0.001, ††††p<0.0001; vs Jx: 
αp<0.05, ααp<0.01, αααp<0.001, ααααp<0.0001; vs Lab φp<0.05, φφp<0.01). Values above each bar 
indicate unadjusted cycle threshold values. 
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3.4.3.7 Gene expression of markers of extracellular matrix degradation 
3.4.3.7.1 Comparison of placental layers 
Mmp1 expression in WKY placenta demonstrated a significantly higher expression 
in the mesometrial triangle and junctional zone compared to the labyrinth zone 
(3.9±0.46 ΔCT (Mes) and 4.3±0.31 ΔCT (Jx) versus 8.7±0.43 ΔCT (Lab); p<0.0001 
and p<0.01). This same trend was observed in SHRSP placental layers (2.3±0.32 
ΔCT (Mes) and 2.8±0.45 ΔCT (Jx) versus 6.3±0.55 ΔCT (Lab); p<0.01 and p<0.01). 
This strain also demonstrated a significantly reduced CP expression compared to 
the mesometrial triangle and Jx zone (7.9±0.25 ΔCT (CP) versus 2.3±0.32 ΔCT 
(Mes); p<0.01, and 2.8±0.45 ΔCT (Jx); p<0.01) (Figure 3-23A). Mmp8 expression 
was found to be significantly reduced in the CP layer compared to the junctional 
zone in WKY (Figure 3-23B). No other layer differences were determined in WKY 
or SHRSP, however the expression levels detected were low (cycle threshold 
values >32). Mmp9 was most highly expressed in the Jx zone of the placenta in 
WKY compared to the mesometrial triangle and CP (8.2±0.30 ΔCT versus 
10.2±0.20 ΔCT (Mes); p<0.01 or versus 12.6±0.62 ΔCT (CP); p<0.05). This pattern 
of expression was different in SHRSP, with the CP having a significantly lower 
expression than both the mesometrial triangle (12.5±0.31 ΔCT versus 7.8±0.28 
ΔCT; p<0.01) and the Jx zone (versus 8.6±0.27 ΔCT; p<0.01) (Figure 3-23C). 
Timp1 had an expression was higher in the mesometrial triangle compared to all 
other layers in WKY (6.4±0.16 ΔCT versus 9.8±0.26 ΔCT (Jx); p<0.0001 and 
10.1±0.08 ΔCT (Lab); p<0.0001 and 9.6±0.68 ΔCT (CP); p<0.0001) and in SHRSP 
(6.2±0.13 ΔCT versus 8.8±0.32 ΔCT (Jx); p<0.0001 and 10.3±0.09 ΔCT (Lab); 
p<0.0001 and 9.2±0.27 ΔCT (CP); p<0.0001). SHRSP also demonstrated a 
significant increase in JX zone expression compared to Lab (p<0.001) and CP 
(p<0.05). 
3.4.3.7.2 Comparison between strains 
Mmp1 expression was found to be significantly higher in SHRSP compared to WKY 
in the mesometrial triangle (2.3±0.32 ΔCT versus 3.9±0.46 ΔCT; p<0.05), Jx zone 
(2.8±0.45 ΔCT versus 4.3±0.31 ΔCT; p<0.05) and Lab zone (6.3±0.55 ΔCT versus 
8.7±0.43 ΔCT; p<0.05). Mmp9 also demonstrated a significant increase in the 
SHRSP mesometrial triangle compared to WKY (7.8±0.28 ΔCT versus 8.2±0.30 
ΔCT; p<0.05). Conversely Mmp8 expression was decreased in this layer in SHRSP 
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compared to WKY (16.1±0.34 ΔCT versus 15.0±0.17 ΔCT; p<0.05). The expression 
of Timp1, a regulator of Mmps, was increased significantly in the Jx zone of 
SHRSP compared to WKY (8.8± 0.32 ΔCT versus 9.8±0.26 ΔCT: p<0.05), no 
differences were observed in the other zones. 
 
Figure 3-23: Placental gene expression of markers of extracellular matrix degradation 
Expression of matrix metalloproteases 1 ((A) Mmp1), 8 ((B) Mmp8) and 9 ((C) Mmp9) as well as 
the tissue inhibitor of metalloproteinases 1 ((D) Timp1) were normalised to β actin and presented 
relative to the mesometrial triangle portion of the WKY placenta. Statistical analysis was conducted 
on the ΔCT values for each layer (WKY n=4, SHRSP n=4) using an unpaired student’s t-test to 
compare WKY and SHRSP within each individual layer (*p<0.05, ***p<0.001) and a one-way 
ANOVA with Tukey’s post-hoc test was then used to assess the change in expression across the 
layers within each strain, highlighted blue for WKY comparisons and red for SHRSP comparisons 
(vs Mes: ††p<0.01, ††††p<0.0001; vs Jx: αp<0.05, ααp<0.01, αααp<0.001; vs Lab φp<0.05). Values 
above each bar indicate unadjusted cycle threshold values. 
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3.4.3.8 Gene expression of components of the placental renin-angiotensin 
system 
Gene expression of several components of the renin angiotensin system were 
examined including the two main AngII receptors (AngII receptor type 1 (Agtr1) 
and type 2 (Agtr2)) and the angiotensin converting enzyme (Ace2). 
3.4.3.8.1 Comparison of placental layers 
In WKY the expression of Agtr1 was lowest in the junctional zone of the placenta 
compared to the mesometrial triangle (16.1±0.97 ΔCT versus 12.5±0.76 ΔCT; 
p<0.05) and the labyrinth zone (versus 11.8±0.77 ΔCT; p<0.05). In SHRSP the 
junctional zone also had the lowest expression compared to Mes (15.5±0.33 ΔCT 
versus 13.7±0.49 ΔCT; p<0.01), Lab (versus 11.7±0.29 ΔCT; p<0.0001) and CP 
(versus 12.6±0.45 ΔCT; p<0.0001) (Figure 3-24A). This strain also demonstrated a 
significant reduction in mesometrial Agtr1 expression compared to Lab 
(13.7±0.49 ΔCT versus 11.7±0.29 ΔCT; p<0.01). Agtr2 expression was 
significantly higher in the labyrinth zone compared to the mesometrial triangle 
in WKY (13.2±0.32 ΔCT versus 14.6±0.42 ΔCT; p<0.05) (Figure 3-24B). No 
significant changes in layer expression of Agtr2 were found in SHRSP. The 
expression of Ace2 was significantly higher in the labyrinth zone and CP 
compared to both Mes and Jx zones in WKY (9.1±0.26 ΔCT (Lab) and 10.8±0.37 
ΔCT (CP) versus 17.3±0.71 ΔCT (Mes); p<0.0001 and p<0.0001 or versus 15.7±0.57 
ΔCT (Jx); p<0.0001 and p<0.0001) and in SHRSP (10.1±0.21 ΔCT (Lab) and 
10.8±0.08 ΔCT (CP) versus 17.4±0.51 ΔCT (Mes); p<0.0001 and p<0.0001 or versus 
14.6±0.62 ΔCT (Jx); p<0.0001 and p<0.0001) (Figure 3-24C). SHRSP also had a 
significantly higher junctional zone expression compared to the mesometrial 
triangle (p<0.001). It is also of importance to note that the expression levels of 
Ace2 in the mesometrial triangles were almost at undetectable levels (>35 cycle 
threshold).  
3.4.3.8.2 Comparison between strains 
Expression differences between WKY and SHRSP were found for both AngII 
receptors and Ace2 (Figure 3-24A-C). There was a significantly reduced Agtr1 
expression in the SHRSP mesometrial triangle compared to WKY (13.7±0.49 ΔCT 
versus 12.5±0.76 ΔCT; p<0.05) and an increased SHRSP expression in the 
junctional zone (15.5±0.33 ΔCT versus 16.1±0.97 ΔCT; p<0.05). The labyrinth 
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zone of SHRSP placenta was found to have a significantly lower expression of 
Agtr2 (14.5±0.19 ΔCT versus 13.2±0.32 ΔCT; p<0.01) and Ace2 (10.1±0.21 ΔCT 
versus 9.1±0.26 ΔCT; p<0.05) compared to WKY. 
 
 
 
Figure 3-24: Placental renin-angiotensin system gene expression in the WKY and SHRSP 
Expression of components of the renin-angiotensin system examined were (A) angiotensin 
receptor type 1 (Agtr1a), (B) angiotensin receptor type 2 (Agtr2) and (C) angiotensin converting 
enzyme (Ace2). Expression was normalised to β actin and presented relative to the mesometrial 
triangle portion of the WKY placenta. Statistical analysis was conducted on the ΔCT values for 
each layer (WKY n=4, SHRSP n=4) using an unpaired student’s t-test to compare WKY and 
SHRSP within each individual layer (*p<0.05, **p<0.01) and a one-way ANOVA with Tukey’s post-
hoc test was then used to assess the change in expression across the layers within each strain, 
highlighted blue for WKY comparisons and red for SHRSP comparisons (vs Mes: †p<0.05, ††p<0.01 
†††p<0.001, ††††p<0.0001; vs Jx: αp<0.05, ααααp<0.0001). Values above each bar indicate 
unadjusted cycle threshold values 
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3.4.3.9 Estimation of placental function using C14-MeAIB transport assay  
Maternal facing syncytiotrophoblast membrane vesicles were created from 
placental tissue to estimate the rate of transport of a synthetic System A 
analogue (MeAIB) ex vivo. Vesicle purity and correct membrane orientation was 
assessed using the alkaline phosphatase activity corrected for the protein 
concentration for the vesicle and its respective homogenate. An enrichment 
score was calculated based on the ratio of vesicle purity:homogenate purity. The 
protein concentrations of vesicles from WKY and SHRSP were not significantly 
different (Table 3-4). The vesicle alkaline phosphatase activity was higher than 
that of the homogenate in both WKY and SHRSP and therefore the enrichment 
scores were not significantly different between strains (Table 3-4).  Vesicle 
quality and size was then assessed using nanoparticle tracking software on a 
NanoSight. Figure 3-25A-B shows representative traces of particle size estimation 
for WKY and SHRSP. Figure 3-25C illustrates the vesicle shapes and sizes from a 
still image representing the NanoSight recordings. This method of vesicle 
preparation cannot produce a heterogeneous particle size and the two strains 
did not have identical particle sizes when a small volume was measured using a 
NanoSight (approximately 500µl) (Table 3-5). However, the particle sizes did not 
differ greatly and the heterogeneous size would not affect the uptake 
experiments conducted as the vesicle preparation was mixed before use thus 
ensuring an even distribution of vesicles (Glazier et al., 1990). 
The rate of transport of the radioisotope labelledC14-MeAIB was determined in 
vesicles produced from WKY and SHRSP placenta over a period of 60 seconds. 
The movement of C14-MeAIB into the vesicles was found to be via Na+ dependent 
active transport, as the transport rate was higher in the presence of Na+ than in 
the presence of K+ at 30 seconds (22.7±0.77pmol/mg versus 8.5±4.28pmol/mg; 
p<0.01), 45 seconds (29.0±1.93pmol/mg versus 16.0±2.99pmol/mg; p<0.01) and 
60 seconds (41.1±2.62pmol/mg versus 17.1±3.70pmol/mg; p<0.0001) in WKY. In 
SHRSP the transport was higher in the presence of Na+ than K+ at 30 seconds 
(17.3±1.69pmol/mg versus 5.0±1.94pmol/mg; p<0.05), 45 seconds 
(23.4±2.14pmol/mg versus 9.7±1.57pmol/mg; p<0.01) and 60 seconds 
(30.4±3.66pmol/mg versus 13.7±2.91pmol/mg; p<0.0001) (Figure 3-26A). The 
Na+ dependent transport at 60 seconds was significantly greater that the 
transport at 15 seconds in both WKY (41.1±2.62pmol/mg versus 
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12.8±0.95pmol/mg; p<0.01) and SHRSP (30.4±3.66pmol/mg versus 
9.4±2.22pmol/mg; p<0.01) vesicles (Figure 3-26B), however there were no 
significant differences in the overall rate of transport between strain (Figure 
3-26C).  
 
158 
 
 
Table 3-4: Vesicle quality and purity check 
 
WKY (n=4) SHRSP (n=6) WKY vs SHRSP 
Homogenate Vesicles Homogenate Vesicle Homogenate Vesicle 
Protein concentration (µg) 4.36 ±0.04 0.91 ±0.12 4.03 ±0.23 1.02 ±0.14 NS NS 
Alkaline phosphatase activity 
(product per µg protein min
-1
) 
0.03 ±0.003 0.17 ±0.016 0.03 ±0.003 0.25 ±0.009 NS P<0.01 
Enrichment score  6.48 ±0.44  7.84 ±0.56  NS 
The protein concentration and alkaline phosphatase activity of homogenates and vesicles were used to calculate the enrichment score for each sample (n=4-6). 
Protein was calculated using a BCA protein assay and corrected for volume used to measure alkaline phosphatase activity. Statistical analysis conducted using 
unpaired student’s t-test, sample size shown on table. Alkaline phosphatase activity of the vesicles and un-vesiculated homogenate was used to produce an 
enrichment score for the vesicles produced from WKY (n=4) and SHRSP (n=6) (more detail in section 3.3.2). An acceptable enrichment score that indicated good 
quality vesicles was between 6 and 10 (Glazier et al., 1990). 
 
Table 3-5: Placental syncytiotrophoblast membrane vesicle properties 
 WKY SHRSP 
Particle concentration 2.62x10
8
 particles / ml 2.17x10
8
 particles / ml 
Particle size (nm) 72 ± 5.61 131 ± 24.96 
An estimation of particle concentration and size was determined for one vesicle preparation from each strain using nanoparticle tracking on a NanoSight. 
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Figure 3-25: Nanoparticle size information for WKY and SHRSP vesicles from NanoSight 
The NanoSight nanoparticle tracking software produced a distribution for particle size (A-B) (C) 
Representative images of the vesicles in solution show a mixed size population, black dots indicate 
one vesicle. 
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Figure 3-26: Placental C14MeAIB transport assay in WKY and SHRSP placental membrane 
vesicles 
(A) The absolute rates of transport in the presence of Na+ and the absence of Na+ (presence of K+). 
Statistical significance was determined using a two-way ANOVA with Tukey’s post-hoc test to 
examine the differences between Na+ dependent and independent (K+) transport at each time 
point; in WKY **p<0.01, ****p<0.0001; in SHRSP †p<0.05, †p<0.01, ††††p<0.0001. (B) The overall 
change in Na+ dependent transport from 15 seconds to 60 seconds. Analysed using unpaired 
student’s t-test; **p<0.01. (C) The Na+ dependent rate adjusted for any Na+ independent uptake. 
Analysed using regression analysis of line gradient, compared using an unpaired student’s t-test; 
n=4. 
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3.5 Discussion 
Hypertensive pregnancies not only impact fetal development and offspring 
health but have serious implications for the mother, both during the pregnancy 
and beyond. Having an appropriate animal model to assess maternal 
antihypertensive treatment options would be hugely beneficial. This chapter has 
provided information on the physiological response to pregnancy in WKY and 
SHRSP rats. The chronically hypertensive SHRSP produced apparently healthy 
offspring which can reach adulthood. However, these hypertensive dams did not 
have the same physiological response observed in normotensive WKY. 
Specifically, they demonstrated differences in pregnancy weight gain, cardiac 
profile and placental structure. 
Profiling the maternal response to pregnancy is crucially important for assessing 
any pathology. The SHRSP demonstrated weight gain; however, this was at a 
slower rate than WKY. The weight gain was assessed as a change from non-
pregnant as this corrected for the smaller starting weights of SHRSP. The 
subtraction of fetal and placental mass from maternal weight revealed that 
maternal specific weight gain was reduced in SHRSP compared to WKY. Healthy 
pregnancy is associated with an increased energy demand, and the nutritional 
flow to the fetus is sustained by the mothers fat stores, diet and changes to the 
metabolism (Thornburg et al., 2015). In previous studies male SHRSP have been 
found to have a reduced glucose uptake in skeletal and adipose tissues (James et 
al., 2001, Hajri et al., 2001), and therefore if the impaired weight gain during 
SHRSP pregnancy is a failure to increase adipose tissue energy stores this could 
impact the metabolic rate and impact the flow of nutrients to the fetus (Hajri et 
al., 2001, James et al., 2001). However, as focus was only given to weight gain 
this is just speculation, as a thorough evaluation of the muscle mass, metabolic 
rate and adiposity of the dams would be needed to determine if SHRSP impose a 
nutrient restriction of their offspring. 
Major maternal cardiovascular adaptations to pregnancy are required to re-
direct blood flow to the placenta to ensure the developing fetus receives 
appropriate nutrients (Wang, 2010). The physiological changes in the maternal 
cardiovascular system have been known for the past half century (Thornburg et 
al., 2015). These include a necessary increase in cardiac output by up to 50% for 
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singleton pregnancies (Hall et al., 2011). Both WKY and SHRSP exhibited an 
increased cardiac output, of up to 65%. However, the cardiac output of SHRSP 
was significantly smaller than WKY at the end of pregnancy. This could be 
accounted for due to a marginally lower pre-pregnancy cardiac output than 
WKY. Utilising echocardiography allows for the measurements of cardiac 
parameters throughout pregnancy in the same individual, unfortunately in this 
study, due to timing conflicts and imaging issues, not all the measurements for 
cardiac output, stroke volume, ejection fraction and fractional shortening were 
made for each animal at each gestational time point. The SHRSP further 
demonstrated potential cardiovascular impairment due to an increased LV mass 
both pre-pregnancy and at term. LV hypertrophy is associated with hypertension 
and is a risk factor for developing cardiovascular disease (Dominiczak et al., 
1997, Koren et al., 1991). LV hypertrophy is well established in both male and 
female SHRSP rats and this adaptation to raised blood pressure becomes 
pathological in older animals (Dominiczak et al., 1997, Graham et al., 2004). 
However, during pregnancy the SHRSP demonstrated a normal ejection fraction 
and fractional shortening, which indicates that the hearts were functioning 
normally. The increased LV mass observed could be suggestive that SHRSP are 
not responding to the stress of pregnancy as efficiently as WKY and they are 
possibly at more risk of damage from the increased cardiovascular load. Women 
that develop hypertensive complications of pregnancy such as pre-eclampsia 
have also been found to exhibit some LV hypertrophic remodelling (Melchiorre et 
al., 2013). 
Other phenotypes of pre-eclampsia were investigated in this characterisation of 
SHRSP pregnancy. Proteinuria, used as a marker of kidney damage in 
hypertension and pre-eclampsia, was not identified in either the normotensive 
or hypertensive rat strains during pregnancy. Studies in 20-week-old salt-
challenged male SHRSP have shown the presence of proteinuria and abnormal 
renal morphology in an advanced hypertensive state, suggesting insults to the 
cardiovascular and renal systems can elicit pathological changes in the kidney 
(Koh-Tan et al., 2017). However, as no such alterations were observed in the 
pregnant SHRSP this suggests that the chronic hypertension plus pregnant state 
do not impact the kidney function. This study was limited in only investigating 
one protein (albumin) and not examining other excreted products, such as salts, 
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and furthermore was only collected for 24 hours. A more detailed urinary 
analysis and water intake/excretion profiles may have been possible by 
extending collection times to 48 hours. Even in the absence of evidence of 
proteinuria, sub-clinical damage cannot be ruled out without further 
investigations. For example glomerular filtration rate and histological 
examination of glomeruli structure would be most beneficial to provide more 
detailed information on the pregnant SHRSP kidney function (Lopes van Balen et 
al., 2018, Cunningham et al., 2016). 
Fetal growth restriction (FGR) has long been associated with hypertensive 
pregnancies, especially those resulting from pre-existing maternal chronic 
hypertension (Srinivas et al., 2009, Lees and Ferrazzi, 2017). In this study, fetal 
growth was examined by means of absolute weights, weight centiles and fetal 
anthropological measurements. There was no evidence of growth restriction in 
SHRSP when using the proportional growth distribution curves. These curves are 
constructed to estimate whether the baby will be small for gestational age (<10th 
percentile) or classed as growth restricted (<5th percentile) (2013, Gordijn et al., 
2016). Clinically, these have been shown to accurately highlight babies that are 
at risk of complications associated with FGR; whilst also accounting for the 
individual mother’s size (Iliodromiti et al., 2017). SHRSP did not have more 
fetuses under the 5th centile than WKY. The fetal weights used to construct 
these distributions were obtained at GD18.5, which is approximately 4-5 days 
before parturition. This may be too early in fetal development in the rat to 
accurately determine FGR. However, fetal weights of groups examined at 
GD20.5 remained similar between the two strains. GD18.5 was used for the 
majority of studies as it is before the exponential fetal growth stage and thus 
minimises size variation due to minor time differences. The variation could arise 
from using copulation plugs to confirm pregnancy; when these plugs were found 
pregnancy was confirmed. However, checks were usually made at the start and 
end of each day therefore the number of hours before confirmation could 
fluctuate depending on actual time of mating. Other studies have used the 
presence of sperm from vaginal smears to confirm copulation, however these are 
still open to variation depending on when and how often the smears are 
conducted.  
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This study is the first to demonstrate no SHRSP fetal weight reductions compared 
to WKY. Only two other groups have examined and reported on the fetal weights 
of SHRSP versus WKY (Fuchi et al., 1995a, Barrientos et al., 2017). Barrientos et 
al determined growth restriction due to fetal weight and length reductions in 
SHRSP compared to WKY at GD18.5 and GD20.5 (Barrientos et al., 2017). What is 
interesting about their study is that the values for GD18.5 fetal weight for SHRSP 
and WKY (SHRSP: 0.55±0.001g, WKY: 0.70±0.01g) were much lower than the 
average fetal weight at this gestation found using the Glasgow strains (SHRSP: 
1.06±0.04g WKY: 1.18±0.05g). The reason for these differences are not obvious, 
but could possibly be accounted for by the fact that SHRSP and WKY used in the 
Barrientos study were purchased from a commercially available source, whereas 
the Glasgow strains have been maintained as separate colonies since December 
1991, therefore have been geographically isolated from other strains for nearly 
27 years (Dominiczak et al., 1993). Fortunately, the time spent breeding these 
strains in house over this period has allowed for litter numbers from both to be 
recorded for over three decades. The changes over the past decade were 
evaluated and no difference found between the two strains. Many other studies 
in SHR and SHRSP report that the hypertensive strains have fewer pups per litter 
(Barrientos et al., 2017, Peracoli et al., 2001, Bassan et al., 2005), this was not 
the case in this study, and could be due to a much greater sample size being 
available, and therefore the SHRSP litters were evaluated over a much longer 
time period than previous studies, thus minimalizing variation often associated 
with short study timescales. The only significant difference observed between 
the fetuses from SHRSP and WKY dams in this study was that SHRSP 
demonstrated a reduced abdominal circumference. As these measurements of 
size are conducted physically with cotton thread it is open to some error. 
Measurements collected were only from a small number of litters due to the 
technique being employed late in the study, this reduces the power to 
determine whether significant differences truly exist.  
An assessment of offspring outcome would further aid the fetal measures 
obtained in this study. Whilst no growth restriction was determined, the impact 
hypertension has on the offspring development after birth is still to be 
investigated in SHRSP rats. This is an important area as the development and 
origins of health and disease have long been known to be linked with the in 
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utero environment (Barker, 1991, Barker et al., 1993). Bassan et al found that 
SHR offspring, which are exposed to maternal hypertension in utero, have 
neurodevelopmental issues, specifically delayed neonatal reflexes (Bassan et al., 
2005). Others have stated an association with pre-eclampsia and the 
development of stroke and hypertension and an increased risk of cardiovascular 
disease in humans (Davis et al., 2015). 
A healthy and correctly functioning placenta is crucial to fetal survival and 
wellbeing. For this reason, the placental characteristics were examined in SHRSP 
and WKY. Appropriate placental growth was observed in both strains. Placental 
growth needs to occur rapidly prior to the rapid weight gain of the fetus as it is 
the organ that sustains the fetus. Placental weights can be used alongside the 
fetal weights to highlight any insufficiencies (Hayward et al., 2016). As no FGR 
was observed the ratio of fetal placental weights was not expected to change, 
and no differences were found. However, previous studies have suggested that 
SHRSP placenta have a reduced blood flow, reduced Na+/K+ ATPase activity and 
impaired trophoblast invasion (Small et al., 2016, Barrientos et al., 2017, Fuchi 
et al., 1995a). On examination of the morphology of SHRSP placenta differences 
were observed to that of WKY. The proportional sizes varied between WKY and 
SHRSP and there was a lower glycogen staining in the junctional zone. This 
placental zone is mainly composed of spongiotrophoblasts and trophoblastic 
glycogen cells (Malassiné et al., 2003). The full functions of the junctional zone 
are not fully understood; however, there is evidence to suggest it has an 
endocrine function and acts as a site of energy reserves for the placenta (Ain et 
al., 2003, Coan et al., 2006, Gebbe et al., 1972). The glycogen cell number is 
known to reduce as gestation progresses in rodents (Coan et al., 2006). 
However, SHRSP junctional zones exhibited a reduction in glycogen content at 
GD14.5 compared to WKY, which remained low at a later gestational stage. This 
suggests that the SHRSP placenta fails to develop glycogen stores, which in WKY, 
appear to be used up later in pregnancy when fetal growth is increasing rapidly. 
The lack of these stores in the SHRSP could implicate a placental dysfunction. As 
there were no placental or fetal size differences between strains it would 
suggest that the placenta of SHRSP could be maintaining appropriate nutrient 
delivery to the fetus yet cannot rely on placental energy stores as it has no 
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reserves, thus may be over-working to acquire both nutrients for itself and its 
fetus. 
SHRSP trophoblast presence in the mesometrial triangle was found to be reduced 
in this study, which is in concurrence with Barrientos et al (Barrientos et al., 
2017). However, as this is not a direct measure of invasion, further assessment 
was made using the zonal separation methods utilised by other groups 
(Barrientos et al., 2017, Geusens et al., 2008). This revealed that a greater 
proportion of SHRSP trophoblasts are located more proximal to the placenta 
(zone 1) than distal (zone 3), indicating a possible impairment of trophoblast 
invasion. Uterine spiral arteries branch from radial uterine arteries in the 
myometrium and extend into the decidualized uterus towards the placenta, 
remodelling of these terminal arteries is essential for normal pregnancy 
development (Pijnenborg et al., 2006). The spiral arteries transition to wide, 
low-resistance vessels accommodating an increase in placental specific blood 
flow (approximately 80% of the uterine perfusion is diverted to the placenta). 
Trophoblast involvement has long been established with this remodelling as the 
vessels lose their vascular smooth muscle definition and these cells are replaced 
with fibrinoid and trophoblast cells (Pijnenborg et al., 2006). In hypertensive 
complications of pregnancy, the remodelling occurs to a lesser extent, resulting 
from an impaired trophoblast invasion (Pijnenborg et al., 1991, Lyall et al., 
2013). Investigations in this chapter revealed SHRSP spiral arteries in zones 2 and 
3 of the mesometrial triangle had greater muscular definition than those that 
were fully remodelled in zone 1. This assessment may be improved by isolating 
trophoblasts and examining their invasive properties in vitro (Bevilacqua et al., 
2014). However, as the majority of trophoblast invasion in rodents occurs 
between GD15 and peaks at GD18 (Ain et al., 2003), the time point chosen for 
this histological assessment was appropriate.  
Further histological and gene expression assessment revealed that SHRSP 
placenta had less collagen staining and increased expression of Mmp1 
(collagenase) and Mmp9 (gelatinase) in the maternal decidual tissue. This is 
paradoxical to other studies which have found hypertensive pregnancies have a 
reduced expression and activity of Mmps (Li et al., 2014, Dias-Junior et al., 
2017). These studies focused mainly on Mmp2 and Mmp9 and their role in early 
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spiral artery vascular remodelling. Mmps are implicated in many stages of 
reproduction including the oestrus and menstrual cycles and pregnancy; 
specifically, trophoblast invasion, spiral artery remodelling and labour (Bischof 
et al., 1995, Geng et al., 2016, Harris et al., 2010). The ubiquitous functions and 
locations of many different Mmp could go some way to explaining the variations 
observed with different hypertensive models of pregnancy (Wang and Khalil, 
2018). Furthermore, the SHRSP placentas in the present study were observed to 
have poorer structural stability when dissecting the layers compared to WKY. 
The structural integrity of the SHRSP and the structural collagen properties 
require further evaluation in order to establish any firm conclusions. 
Hypoxia is crucial to early placental development and trophoblast differentiation 
which occurs in low oxygen tensions. Hif1α is a transcription factor, key in 
regulating gene expression in hypoxic conditions and its presence is necessary to 
sustain a pregnancy (Wakeland et al., 2017). A loss of Hif1α function has been 
shown to have embryonic lethality at mid-gestation and seriously impacts the 
vascularization of placenta and fetus (Ryan et al., 1998, Iyer et al., 1998). A 
hypoxic placental environment in the later stages of gestation can lead to 
oxidative stress and placental damage (Burton and Jauniaux, 2011). This has 
been associated with placental impairment leading to fetal development issues 
and encourages the development and progression of gestational hypertensive 
disorders (Aljunaidy et al., 2017, Myatt, 2006). An increased expression of Hif1α 
at these stages is suggestive of a poor placental situation as it indicates a 
hypoxic environment at a time when the placenta should be oxygen rich (Soares 
et al., 2017). SHRSP demonstrated an increased placental Hif1α expression at 
GD18.5. The expression of Sod1 was also found to increase in the placenta and 
mesometrial triangle of the SHRSP. Sod1 is an antioxidant enzyme that protects 
against oxidative stress by reducing the bioavailability of superoxide (Fukai and 
Ushio-Fukai, 2011). It has been located within human and rodent placentas and 
is crucial in oxidative stress balance (Jones et al., 2010, Jauniaux et al., 2000). 
The increase in hypoxia suggested by Hif1α could be interpreted as creating an 
environment that encourages reactive oxygen species production, and thus 
increasing damaging oxidative stresses. Yet the parallel increase in Sod1 
expression implies that SHRSP placenta is attempting to maintain the balance of 
pro and anti-oxidants. However, this is a simplistic view as there are many more 
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factors that influence oxidative stress balance; such as other antioxidant 
enzymes. Glutathione peroxidase (Gpx1) is one of these enzymes (Conrad et al., 
2007). Expression of Gpx1 was investigated in the SHRSP placenta and found to 
have an opposite expression pattern to Sod1, with a decreased placental 
expression observed. This would skew the balance in favour of pro-oxidative 
species, leading to increased reactive oxygen species and possible placental 
damage. Further evaluation of oxidative stress state, by examining oxygen 
radicals, hydrogen peroxide and lipid peroxidation levels, would be beneficial to 
understanding placental function and damage. 
Components of the renin-angiotensin system (RAS) were found to be 
dysregulated in the SHRSP placenta. The placenta has the largest extra-renal 
RAS, and its components and receptors have been located within rodent 
placenta throughout gestation (Vaswani et al., 2015, Paul et al., 2006, Williams 
et al., 2010). The RAS is crucial to maintaining the homeostasis of maternal 
cardiovascular and renal systems during pregnancy (Irani and Xia, 2011, Nielsen 
et al., 2000). AngII receptor type-2 (AT2R) and angiotensin converting enzyme 2 
(Ace2) both have protective roles in the vasculature. AT2R activation via AngII 
typically results in vasodilation, whilst Ace2 promotes the conversion of AngII to 
Ang1-7 which activates AT2R and Mas receptors which further promotes 
vasodilation (Irani and Xia, 2011, McKinney et al., 2014). The expressions of both 
AT2R (Agtr2) and Ace2 were reduced in the highly vascularised placental 
labyrinth zone in SHRSP. This is the location for the exchange of maternal 
nutrients and oxygen and a reduction in these ‘protective’ components would 
suggest an impaired blood flow and therefore loss of function. This study also 
found that SHRSP had a reduced expression of AngII receptor type-1 (AT1R) in the 
maternal mesometrial tissue. This receptor has a counter-regulatory mechanism 
to AT2R and is responsible for the vasoconstrictive response to AngII (McKinney et 
al., 2014). An increase in AT1R expression and activity has been described by 
some to be observed in pre-eclampsia (Herse et al., 2007). The reduction in 
expression in the hypertensive pregnancy of SHRSP is therefore contrary to that 
particular study, as a lower receptor expression would suggest lower AngII 
receptor mediated vasoconstriction (Takeda-Matsubara et al., 2004, Mishra et 
al., 2011). However, as the two main AngII receptors have contradictory 
responses when stimulated by AngII, the final response depends heavily on the 
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balance of expression of different receptors (McKinney et al., 2014). SHRSP also 
demonstrated an increase in AT1R expression in the junctional zone of the 
placenta. In human placental tissue AT1R has been located to the 
syncytiotrophoblasts and villous cytotrophoblast early in gestation and it has 
been found to be altered depending on the gestational stage in rodents (Tower 
et al., 2010, Vaswani et al., 2015). The rodent junctional zone in not highly 
vascularised and therefore suggests that the roles of the AngII receptors are 
varied and may have different functions in different placental compartments as 
gestation progresses. Cuffe et al found that placental AT1R expression increases 
in hypoxic pregnancies, which could partly explain the increase observed in this 
study (Cuffe et al., 2014). Furthermore, an imbalance of AngII receptors (a 
proportional increase in AT1R activation) has been found to reduce the placental 
transport of system A amino acids (Shibata et al., 2006). This study was limited 
in that only the gene expression of RAS components were investigated, and no 
assessment of receptor activation or function was conducted. This investigation 
would be key in dissecting the importance of the patterns of gene expression in 
the different placental layers. 
Preliminary investigations into the functional transport capacity of the WKY and 
SHRSP placenta via system A (SysA) amino acid transporter were examined in 
this study at the GD18.5 time point. This is when the placenta are at their 
functional peak (Malassiné et al., 2003). There was evidence that the SysA 
transporter is present on the maternal facing membranes of syncytiotrophoblasts 
in SHRSP and WKY placenta and that this transporter is functional. This is the 
first study to show this in SHRSP and WKY. The vesicle uptake experiments were 
limited due to small numbers of biological replicates, this occurred due to the 
need for protocol optimisation prior to carrying out the full experiment. This 
data was suggestive of SHRSP exhibiting a lower transport capacity; however, 
the small sample size and variability in Na+ dependent transport rate between 
animals would require further investigation to determine whether significance 
exists between strains. SysA transport was assessed due to being intimately 
involved in the development of FGR and placental transport in hypertensive 
pregnancies has been found to be reduced (Glazier et al., 1996, Glazier et al., 
1997, Mahendran et al., 1993). SHRSP placenta have previously been found to 
have a reduced Na+/K+ ATPase activity which was thought to contribute to the 
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growth retardation observed in this strain (Fuchi et al., 1995a). More precise 
measures of placental transport can be conducted in vivo. These include the 
unidirectional maternofetal transfer of a radiolabelled amino acid across the 
placenta by introducing this amino acid to maternal systemic circulation and 
measuring its abundance in the fetus (Lean et al., 2017). Performing these 
studies would give a better overview of placental transport systems and delivery 
of nutrients to the fetus in SHRSP and WKY.  
Impairments within the maternal cardiovascular system and the placenta are 
increasingly recognised as important partners in the development of pre-
eclampsia. It is therefore becoming crucial to recognise the maternal influence 
of these gestational hypertensive disorders. The development of a model which 
has a significant maternal influence will be vital to the further study of 
gestational hypertension. Non-pregnant SHRSP rats are excellent, well 
established cardiovascular risk models and this study has provided some 
evidence that the normotensive and hypertensive strains respond to pregnancy 
differently. The chronically hypertensive SHRSP showed minor impairments in 
maternal cardiovascular adaptations to pregnancy as well as placental 
abnormalities; however, this occurred with no alterations of litter size or major 
impact on fetal growth. Chapter 6 describes how the SHRSP model responds to a 
cardiovascular challenge by means of AngII administration during pregnancy and 
how this increased cardiovascular load can mimic superimposed pre-eclampsia. 
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Chapter 4 Vascular changes in SHRSP 
pregnancy 
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4.1 Introduction 
The haemodynamic and cardiovascular changes, described in Chapter 1, are 
pregnancy-specific adaptations that ensure the re-direction of blood flow to the 
placenta. Uterine blood flow is approximately 10 times greater by the end of the 
first trimester in healthy human singleton pregnancies and continues to increase 
throughout gestation, reaching levels of between 500-800ml/min (Hale et al., 
2009, Wang, 2010, Browne et al., 2015, Osol and Mandala, 2009). This is vital to 
the wellbeing of the pregnancy. The increase in cardiac output (CO), described 
in section 1.1.1, increases the capacity for blood flow and a decrease in total 
peripheral vascular resistance occurs in tandem to the CO changes to ensure 
there is no increase in blood pressure in healthy normotensive pregnancies 
(Robson et al., 1989). This reduced systemic vascular resistance ensures that 
there is no opposition to uterine blood flow and the uterine index is increased, 
suggesting a larger proportion of CO is directed to the placenta during 
pregnancy, which is crucial for achieving appropriate fetal growth (Hale et al., 
2009, Mahendru et al., 2017). The reduction in systemic vascular resistance has 
been found to occur as early as 6 weeks gestation, which suggests that 
alterations to blood flow are not solely due to local changes driven by the 
placenta but are influenced by systemic hormonal changes (Chapman et al., 
1998). Prior to 10-12 weeks gestation relatively little endocrine control is 
derived from the placenta and adaptations to accommodate pregnancy are 
under maternal control (Gellersen et al., 2007, Tal et al., 2000). The main 
uterine artery in rodents has been shown to increase in diameter and begin the 
remodelling process in pseudopregnancy, giving evidence towards a maternal 
control of early uterine artery remodelling (van der Heijden et al., 2005b, Osol 
and Mandala, 2009, Paller et al., 1989). 
A central component to the development of gestational hypertensive disorders, 
such as pre-eclampsia, is a reduction in uteroplacental perfusion (Bosio et al., 
1999, Goulopoulou, 2017).  However, the vascular pathology in these conditions 
is still not fully understood. Placental under perfusion may result from systemic 
and uteroplacental vascular dysfunction, and a dysfunctional placenta can result 
in increased production of antiangiogenic and inflammatory factors which are 
released into systemic circulation propagating endothelial dysfunction and 
vascular impairment (summarised in Figure 4-1) (Ali and Khalil, 2015, 
173 
 
 
Goulopoulou, 2017). It is still not fully understood which is the cause and which 
the consequence.  
 
 
 
Figure 4-1: Illustration of the influences increased vascular resistance and placental under 
perfusion have on each other 
The cause/consequence relationship of the under perfused placenta exacerbating the systemic 
vascular dysfunction and encouraging a hypertensive response, adapted from review by 
Goulopoulou et al (Goulopoulou, 2017). 
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Whilst examining the uterine artery response is vitally important to reveal local 
controls and dysregulations, the systemic responses should not be overlooked. 
Systemic vascular dysfunction plays a significant role in the development of 
hypertensive disorders of pregnancy (Rang et al., 2008, Ramirez et al., 2011). 
Total peripheral resistance has been found to increase in pre-eclampsia and 
early studies by Gant et al highlighted systemic vascular dysfunction associated 
with hypertensive disorders of pregnancy and their increased vasoconstrictive 
response to AngII (Bosio et al., 1999, Visser and Wallenburg, 1991, Gant et al., 
1973).  The myogenic control of resistance arteries is vitally important in 
maintaining blood pressure (Kublickiene et al., 1998, Ramirez et al., 2011). The 
medial layer of these small arteries (composed mainly of vascular smooth muscle 
cells (VSMC) and elastin fibres) contracts or relaxes in response to increases or 
decreases in blood flow/volume in order to maintain blood pressure (Touyz, 
2014). During normal pregnancy the response of the VSMC are altered as the 
blood volume increases with no increased contractile response and therefore no 
change in blood pressure (Kublickiene et al., 1997). In fact, the arteries become 
more vasodilatory and less responsive to vasoconstrictive substances 
(Kublickiene et al., 1997). However, the reverse has been observed in situations 
of reduced uterine perfusion in the rat (Ramirez et al., 2011), and in human 
hypertensive pregnancy (Kublickiene et al., 1997, Kublickiene et al., 1998). 
The previous chapter highlighted the importance of maternal influences of 
gestational hypertension and provided evidence that the cardiovascular 
adaptations to pregnancy in chronically hypertensive SHRSP rat are impaired; 
which is also observed in gestational hypertensive disorders (Robson et al., 1989, 
Stott et al., 2017, Visser and Wallenburg, 1991). The changes in uteroplacental 
blood flow of SHRSP pregnancy were examined by Small et al using uterine 
artery Doppler at gestational day (GD6.5, 12.5 and 18.5) (Small et al., 2016). 
This study found SHRSP pregnancy to be associated with restricted blood flow 
within the uterine artery and abnormal vascular function at GD18.5 compared to 
WKY. This finding was due to SHRSP retaining their pre-pregnant uterine artery 
vascular function and no blood flow changes where apparent across gestation 
(Small et al., 2016). This study also concluded that virgin SHRSP uterine arteries 
have a more vasoconstrictive phenotype than WKY (Small et al., 2016). This 
raises the question of whether SHRSP uterine arteries are impaired pre-
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pregnancy and thus ignore cues to reduce their resistance and encourage an 
increased blood flow during pregnancy, as is observed in the normotensive WKY. 
Few investigations have examined systemic vasculature and no studies have 
examined early vascular changes during pregnancy in SHRSP. This chapter was 
designed to study the responses of systemic vasculature to pregnancy in SHRSP 
and WKY and to characterise in depth the maternal control of early uterine 
artery remodelling. 
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4.2 Hypothesis and Aims 
4.2.1 Hypothesis 
The absence of a pregnancy-dependent increase in uteroplacental blood flow in 
SHRSP is due to a lack of response of systemic and uterine vascular systems to 
pregnancy. 
4.2.2 Aims  
 Evaluate the functional and mechanical properties of mesenteric arteries 
over the course of gestation in SHRSP and WKY 
 Assess early (GD6.5) uterine specific vascular remodelling associated with 
the first 6 days of gestation in SHRSP and WKY 
 Determine the influence that maternal plasma from early (GD6.5) and 
late (GD18.5) gestation has on non-pregnant uterine artery function 
 Examine properties of uterine artery vascular smooth muscle cells from 
virgin and GD6.5 SHRSP and WKY 
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4.3 Materials and Methods 
Details of mesenteric and uterine artery dissection are outlined in the general 
materials and methods section 2.4.3. Functional studies were conducted using 
wire myography, detailed in section 2.5.1, and passive mechanical wall 
properties were assessed using pressure myography, detailed in section 2.5.2.  
4.3.1 Uterine Artery Plasma Incubation 
To examine the maternal endocrine control on uterine artery function, non-
pregnant arteries were incubated with maternal plasmas of different 
strain/pregnancy stage prior to performing wire myography. Uterine arteries 
from 13-14 week old virgin WKY and SHRSP rats were equally sectioned (Figure 
4-2). Each artery section was exposed to a different plasma condition (Non-
pregnant (NP) WKY, NP SHRSP and either GD6.5 WKY, GD6.5 SHRSP or GD18.5 
WKY, GD18.5 SHRSP) by placing the artery into PSS containing 3% v/v plasma at 
4°C for ~18 hours. Plasma was isolated from blood taken via cardiac puncture in 
non-pregnant and GD6.5 or GD18.5 pregnant WKY and SHRSP dams as outlined in 
sections 2.4.1. Wire myography was performed as detailed in section 2.5.1, for 
each plasma condition in duplicate. Preliminary dose response experiments 
revealed that these uterine arteries reached 80% of maximal contraction with 
1x10-5M noradrenaline; therefore this was the preconstriction dose used. 
 
Figure 4-2: Non-pregnant uterus highlighting uterine artery dissection 
The main uterine artery was dissected from surrounding tissue and the vein. The yellow highlighted 
regions were used for functional assessment and were sectioned at the sites marked with red 
crosses. This produced four sections of the uterine artery from one animal. Each section was 
placed in different plasma conditions. Image adapted from (Osol and Moore, 2014) with 
permission. 
Abdominal Aorta
Ovary
Uterine horn
Main uterine artery
Radial artery
Arcuate artery
Common iliac artery
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4.3.2 Vascular smooth muscle cell 
Vascular smooth muscle cells (VSMC) were isolated and cultured as described in 
section 2.6. 
4.3.2.1 Migration Scratch Assay 
VSMC were used between passage (P)3 and P5 (after P5 cell growth slowed, 
viability was reduced to <50% and the time taken to reach confluency in a T75 
was greater than 1 week). For each cell type (NP WKY, GD6.5 WKY, NP SHRSP 
and GD6.5 SHRSP) 6 wells were plated in complete DMEM for one scratch assay 
experiment at a cell density of 1x105 cells per well. Once a confluent monolayer 
of cells was established (between 24 and 36 hours after plating) the media was 
removed and wells washed briefly with sterile 1x PBS. The cells were then 
incubated with DMEM containing 0.5% FBS for 48 hours at 37°C. This ensured all 
cells were at the same stage of the cell cycle and reduced the proliferation 
ability of VSMCs. At time zero (T0) the cell monolayers were scratched using a 
P200 pipette tip, guided by a ruler. The media in all wells was replaced with 
DMEM containing 10% FBS and gently swirled to smooth scratch edges. All media 
was then removed. Wells rinsed with 1x PBS as previously stated and DMEM 
containing either 0.5% FBS (acting as a negative control) or 10% FBS (to stimulate 
cell migration) was added. Each condition was conducted in triplicate. Three 
images from each well were taken of the scratch at 10x magnification using an 
EVOS microscope, set for phase observation 4/10PH, at T0, T1 (6 hours), T2 (12 
hours) and T3 (24 hours). Plates were returned to a 37°C incubator with 5% 
oxygen in between time points. Markings on the base of the wells ensured 
scratch was central and images were taken in the same locations. 
Images were analysed by measuring the width of the scratch by drawing 15-20 
straight lines from one edge to the other (Figure 4-3) using Image J software. An 
average for each image at each time point was calculated. The T1, T2 and T3 
averages were subtracted from their T0 average and expressed as a percentage. 
Further to this the 0.5% FBS controls were subtracted from the 10% FBS to give a 
FBS dependent migration value for each time point. 
179 
 
 
 
Figure 4-3: Representative image of scratch assay analysis 
Each image was overlaid with a grid to ensure measurements across wound were linear. 15-20 
measurements were made between marked lines for each image to give representation of width 
across the well. 
4.3.3 Statistical Analysis 
The area under the curve (AUC) and the half maximal response (EC50) was 
calculated for all untreated mesenteric and uterine artery myography dose 
response curves and these were then compared using one-way ANOVA with Sidak 
post-hoc test. Maximal KPSS responses were compared using one-way ANOVA and 
Sidak post-hoc test. Uterine arteries incubated with 3% plasma were analysed in 
the same manner, with the AUC and EC50 values calculated, however a repeated-
measures one-way ANOVA with Sidak post-hoc testing was used for the 
comparisons due to each vessel having 4 segments with different plasma 
incubations. The pressure myography curves could not be analysed in the same 
way as the dose response curve, so a two-way repeated measures ANOVA was 
used to assess the changes at each pressure between the groups using a Sidak 
post-hoc test. Finally the percentage migration at 24 hours was compared across 
strain, pregnancy and FBS condition using a two-way ANOVA. Further analysis of 
the rate of migration was assessed using linear regressions compared using one-
way ANOVA with Sidak post-hoc test. 
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4.4 Results 
4.4.1 Systemic Vascular Function and Mechanical Properties 
4.4.1.1 Mesenteric Artery Function across Gestation  
Ex vivo mesenteric artery function was determined in virgin WKY and SHRSP and 
at early (GD6.5) and late pregnancy (GD18.5) time points. Segment lengths used 
were not significantly different between strains or gestational age (summarised 
in Table 4-1), therefore reducing variation between active effective pressure 
calculations. No significant relaxation or constriction responses were observed 
between NP and GD6.5 in either strain (Figure 4-4A-G). There were also no 
significant functional changes between strains at NP or GD6.5 time points (Figure 
4-4A-G).  Mesenteric arteries from WKY dams did exhibit a significantly 
increased vasodilation response to carbachol in late pregnancy (GD18.5) 
(220±25.8 AUC versus 388±34.7 AUC; p<0.01) (Figure 4-4A-B). An overall trend 
towards increased sodium nitroprusside mediated dilation was observed in WKY 
GD18.5 arteries compared to NP, with the GD18.5 arteries demonstrating a 
reduced half maximal response, nearing significance, compared to NP (1.55±0.6 
x10-7 M versus 3.01±1.1 x10-5 M; p<0.05) (Figure 4-4C-D). The GD18.5 WKY 
mesenteric arteries also exhibited a significantly increased vasodilatory response 
to carbachol compared to GD18.5 SHRSP (220±25.8 AUC versus 389±26.8 AUC; 
p<0.01) (Figure 4-4A). No significant differences were observed between NP and 
GD18.5 SHRSP mesenteric arteries relaxation responses (Figure 4-4A-D). Neither 
strain nor pregnancy affected the contractile response of mesenteric arteries; 
there were no significant differences in the contractile responses to 
noradrenaline or maximal contractions to KPSS (Figure 4-4E-G).  
Table 4-1: Length (mm) of segments of mesenteric artery used for wire myography 
 
 
Non 
Pregnant 
GD6.5 GD18.5 
WKY 1.95±0.04 1.96±0.03 1.87±0.04 
SHRSP 1.90±0.02 1.90±0.06 1.90±0.02 
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Figure 4-4: Mesenteric Artery Function Throughout Gestation 
The functional responses of mesenteric arteries from non-pregnant (NP) (n=5), GD6.5 (n=6) and 
GD18.5 (n=3-4) pregnant WKY and SHRSP assessed using wire myography. The relaxation 
response to carbachol (A-B) and sodium nitroprusside (C-D) are presented as a percentage of 
constriction to 2x10-5M noradrenaline and the half maximal responses (EC50). The contractile 
response to noradrenaline expressed as an (E) active effective pressure and (F) the half maximal 
responses (EC50) for each curve. Statistical significance determined by comparing area under the 
curve and EC50 values using one-way ANOVA with Sidak post-hoc test. (G) The maximal response 
to KCl (in KPSS); analysed using one-way ANOVA with Sidak post-hoc test. Data presented as 
mean±SEM.  
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4.4.1.2 Mesenteric Artery Passive Wall Properties across Gestation  
The internal and external diameter of mesenteric arteries were measured using 
pressure myography and the cross-sectional area, wall thickness, wall stress and 
the stress/strain relationship were calculated. Pregnancy had no significant 
influence on the overall change in WKY or SHRSP mesenteric artery diameter; 
however SHRSP GD18.5 arteries demonstrated a significant increase in internal 
diameter at 110mmHg compared to NP arteries (305±15.2µm versus 241±17.8µm; 
p<0.05) (Figure 4-5A-B). The mesenteric arteries from both strains showed a 
significant reduction in cross-sectional area in GD18.5 arteries compared to NP 
arteries at pressures greater than 40mmHg (e.g. WKY: 49861±6672µm2 versus 
68092±9946µm2; p<0.05 at 110mmHg. SHRSP: 29589±5148µm2 versus 
53714±2532µm2; p<0.05 at 110mmHg) (Figure 4-5C). Mesenteric arteries from 
SHRSP GD18.5 dams had a significantly reduced wall thickness compared to NP 
SHRSP for the entire pressure curve (28.1±4.4µm versus 57.7±3.8µm; p<0.001 at 
110mmHg) (Figure 4-5D). There were no significant differences between NP and 
GD6.5 mesenteric arteries of either strain in any of the measured/calculated 
structural parameters (Figure 4-5A-F). Both WKY and SHRSP GD18.5 mesenteric 
arteries demonstrated an increased wall stress, with SHRSP GD18.5 arteries 
being significantly greater than NP at pressures above 60mmHg (0.98±0.14x106 
dynes/cm2 versus 0.32±0.04x106 dynes/cm2; p<0.0001 at 110mmHg) and WKY 
GD18.5 arteries demonstrating a significantly increased wall stress, compared to 
NP WKY arteries at pressures above 100mmHg (0.80±0.19x106 dynes/cm2 versus 
0.47±0.09x106 dynes/cm2; p<0.01 at 110mmHg) (Figure 4-5E). The mesenteric 
vascular stiffness (as measured by the stress/strain relationship) was not 
changed over pregnancy (Figure 4-5F). 
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Figure 4-5: Mesenteric Artery Mechanical Wall Properties throughout Gestation 
Non-pregnant (NP) and pregnant GD6.5 and GD18.5 mesenteric artery external (A) and internal 
(B) diameter were measured over a range of physiological pressures using pressure myography. 
The vessel cross-sectional area (C), wall thickness (D) and wall stress (E) were calculated. The 
relationship between wall stress and strain was also plotted (F). Data presented as mean ±SEM 
(n=4-6); statistical significance was determined using a repeated measures two-way ANOVA with 
Sidak post-hoc test comparing change from NP in both strains; #p<0.05, ##p<0.01 NP vs GD18 
WKY, †p<0.05, ††p<0.01, †††p<0.001, ††††p<0.0001 NP vs GD18.5 SHRSP; and change between 
strains; *p<0.05, **p<0.01, ***p<0.001  GD18  WKY vs GD18 SHRSP. 
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4.4.2 Uterine Specific Vascular Structure and Function 
4.4.2.1 Uterine Artery Function at Gestational Day 6.5 
Uterine artery function in SHRSP and WKY was examined at GD6.5, an early 
gestational time point in rats. No significant differences were found in any of 
the uterine artery responses to carbachol (Figure 4-6A-B), SNP (Figure 4-6C-D) or 
noradrenaline (Figure 4-6E-F). There was also no significant changes observed in 
the maximal constriction responses in either comparisons across pregnancy or 
between WKY and SHRSP (Figure 4-6G). 
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Figure 4-6: The Impact of Early Pregnancy (GD6.5) on Uterine Artery Function 
Functional response of non-pregnant (NP) and GD6.5 uterine arteries from WKY and SHRSP 
dams. The relaxation response to carbachol (A-B) and sodium nitroprusside (C-D) are presented 
as a percentage of constriction to 2x10-5M noradrenaline and the half maximal responses (EC50). 
The contractile response to noradrenaline (E-F) expressed as an active effective pressure and the 
half maximal responses (EC50) for each curve. Statistical significance determined by comparing 
area under the curve and EC50 values using one-way ANOVA with Sidak post-hoc test; NP n=4-7, 
GD6.5 n=6-7 (G) The maximal response to KCl (in KPSS); analysed using one-way ANOVA with 
Sidak post-hoc test.  
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4.4.2.2 Uterine Artery Passive Wall Properties at Gestational Day 6.5  
NP WKY uterine arteries had a significantly larger internal and external diameter 
than NP SHRSP at pressures greater than 40mmHg (e.g. internal: 390±10.4µm 
versus 324±16.7µm at 110mmHg; p<0.01 and external: 464±8.7µm versus 
416±10.7µm at 110mmHg; p<0.01) (Figure 4-7A-B). There was no significant 
difference in the diameter changes between NP and GD6.5 uterine arteries. Only 
the SHRSP arteries demonstrated a significant pregnancy-dependent difference 
in cross-sectional area, and only at 80mmHg (NP: 5.15±0.4x104 µm2 versus 
GD6.5: 7.09±0.8x104 µm2; p<0.05) (Figure 4-7C). Wall thickness was increased in 
the WKY GD6.5 arteries only at 10mmHg (62.3±4.9µm versus 44.1±4.2µm at 
110mmHg; p<0.01), no other significant differences were observed. GD6.5 
uterine arteries from WKY dams demonstrated a significantly reduced wall stress 
at 110mmHg compared to NP (0.61±0.11x106 dynes/cm2 versus 0.86±0.09x106 
dynes/cm2; p<0.01). Furthermore, WKY vessels were found to have a 
significantly increased wall stress at 110mmHg compared to SHRSP NP 
(0.86±0.09x106 dynes/cm2 versus 0.58±0.10x106 dynes/cm2; p<0.05) and GD6.5 
(0.61±0.11x106 dynes/cm2 versus 0.40±0.05x106 dynes/cm2; p<0.05) vessels. 
(Figure 4-7E). Distensibility of the NP arteries was similar in both strains and was 
not altered by pregnancy in WKY. (Figure 4-7F) 
  
187 
 
 
 
Figure 4-7: The Impact of Early Pregnancy (GD6.5) on Uterine Artery Passive Mechanical 
Wall Properties 
Pressure myography was used to measure the external (A) and internal (B) diameter of WKY and 
SHRSP uterine arteries from non-pregnant (NP) (n=10-11) and GD6.5 pregnant (n=6) dams. 
Cross-sectional area (C), wall thickness (D) and wall stress (E) were calculated along with plotting 
the wall stress/strain relationship (F). (A-E) Data are presented as means ±SEM. Statistical 
significance was determined using a repeated measures two-way ANOVA with Sidak post-hoc test 
comparing change between NP and GD6.5 in both strains; #p<0.05, ##p<0.01 WKY and †p<0.05 
SHRSP; and change between strains; *p<0.05, **p<0.01, ***p<0.001 NP WKY vs NP SHRSP and 
φp<0.05 GD6.5 WKY vs GD6.5 SHRSP. 
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4.4.2.3 Early Pregnancy (GD6.5) Plasma Impact on WKY Uterine Artery 
Function 
Uterine arteries from non-pregnant WKY were exposed to 3% NP plasma or 3% 
GD6.5 plasma from either WKY or SHRSP for ~18 hours at 4°C. The function of 
these vessels was assessed using wire myography. No significant differences were 
found in the vessels in response to vasodilators (carbachol and SNP (Figure 4-8A-
B) or the vasoconstrictor noradrenaline (Figure 4-8C). Incubation with WKY 
GD6.5 plasma significantly reduced the maximal constriction response to KPSS 
compared to NP WKY plasma (27±5.3KPa versus 44±6.5KPa; p<0.05) (Figure 
4-8D). No significant differences were observed with GD6.5 SHRSP plasma. 
 
Figure 4-8: Functional responses of WKY uterine arteries incubated with GD6.5 plasma 
Wire myography was used to assess function of non-pregnant uterine artery from virgin WKYs after 
incubation with 3% plasma from NP and GD6.5 WKY and SHRSP dams. The relaxation response 
to (A) carbachol and (B) sodium nitroprusside as a percentage of constriction to 1x10-5M 
noradrenaline. (C) The contractile response to noradrenaline. Data analysed by comparing the 
area under the curve and EC50 values for each curve using a repeated measure one-way ANOVA 
with Sidak post-hoc test. (D) The maximal response to KPSS; analysed using repeated measure 
one-way ANOVA with Sidak post-hoc test; *p<0.05; n=3. 
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4.4.2.4 Early Pregnancy (GD6.5) Plasma Impact on SHRSP Uterine Artery 
Function 
Uterine arteries from non-pregnant SHRSP were exposed to 3% NP plasma or 3% 
GD6.5 plasma from either WKY or SHRSP for ~18 hours at 4°C. The function of 
these vessels was assessed using wire myography. No significant differences were 
found in the vessels in response to vasodilators (carbachol and SNP) (Figure 4-9A-
B) or the vasoconstrictor noradrenaline (Figure 4-9C). Incubation with plasma 
also had no significant effects on maximal constriction response to KPSS (Figure 
4-9D).  
 
Figure 4-9: Functional responses of SHRSP uterine arteries incubated with GD6.5 plasma 
Non-pregnant SHRSP uterine artery function was assessed using wire myography after incubation 
with non-pregnant (NP) or GD6.5 plasma from WKY and SHRSP. (A) The endothelium 
independent vasodilation to carbachol expressed as a percentage of 10-5M noradrenaline 
constriction. (B) The endothelium independent relaxation response to sodium nitroprusside 
expressed as a percentage of 10-5M noradrenaline constriction. (C) The contractile response to 
noradrenaline. Data analysed by comparing the area under the curve and EC50 values for each 
curve using a repeated measure one-way ANOVA with Sidak post-hoc test. (D) The maximal 
response to KPSS; analysed using repeated measure one-way ANOVA with Sidak post-hoc test; 
*p<0.05; n=5. 
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4.4.2.5 Late Pregnancy (GD18.5) Plasma Impact on WKY Uterine Artery 
Function 
The function of non-pregnant WKY uterine arteries was assessed after incubation 
with 3% NP plasma or 3% GD18.5 plasma from either WKY or SHRSP for ~18 hours 
at 4°C. Plasma incubation did not significantly change the response to carbachol 
(Figure 4-10A) or SNP (Figure 4-10B). Incubation with NP or GD18.5 plasma had 
no significant impact on the response to noradrenaline or on maximal 
constriction response to KPSS (Figure 4-10C-D). 
 
Figure 4-10: Functional responses of WKY uterine arteries incubated with GD18.5 plasma 
Non-pregnant WKY uterine arteries were incubated with non-pregnant (NP) and GD18.5 pregnant 
plasma from WKY and SHRSP dams. Functional response to carbachol (A) and sodium 
nitroprusside (B) determined endothelium dependent and independent vasodilation as a 
percentage of constriction to 10-5M noradrenaline. (C) The contractile response determined by a 
dose response to noradrenaline. Data analysed by comparing the area under the curve and EC50 
values for each curve using a repeated measure one-way ANOVA with Sidak post-hoc test. (D) 
The maximal response to KPSS; analysed using repeated measure one-way ANOVA with Sidak 
post-hoc test; *p<0.05; n=4-5 
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4.4.2.6 Late Pregnancy (GD18.5) Plasma Impact on SHRSP Uterine Artery 
Function 
Non-pregnant SHRSP uterine arteries incubated with NP and GD18.5 plasma 
demonstrated no significant functional changes in vasodilation (Figure 4-11A-B) 
or constriction (Figure 4-11C-D) responses. 
 
Figure 4-11: Functional responses of SHRSP uterine arteries incubated with GD18.5 plasma 
Non-pregnant SHRSP uterine arteries were incubated with non-pregnant (NP) and GD18.5 
pregnant plasma from WKY and SHRSP dams. Functional response to carbachol (A) and sodium 
nitroprusside (B) determined endothelium dependent and independent vasodilation as a 
percentage of constriction to 10-5M noradrenaline. (C) The contractile response determined by a 
dose response to noradrenaline. Data analysed by comparing the area under the curve and EC50 
values for each curve using a repeated measure one-way ANOVA with Sidak post-hoc test. (D) 
The maximal response to KPSS; analysed using repeated measure one-way ANOVA with Sidak 
post-hoc test; *p<0.05; n=3. 
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4.4.3 Uterine Artery Vascular Smooth Muscle Cell Migration  
Vascular smooth muscle cells (VSMC) were isolated from uterine arteries at non-
pregnant and GD6.5 time points. VSMC migration rates were estimated using a 
wound closure assay (Figure 4-12A). No significant differences in migration 
capability were found in VSMCs exposed to 0.5% FBS (Figure 4-12B). GD6.5 VSMCs 
stimulated with 10% FBS showed significantly more migration compared to their 
0.5% FBS control for both WKY and SHRSP (WKY: 44.6±11.5 versus 17.2±5.3; 
p<0.05, SHRSP: 58.7±14.1 versus 24.1±3.1; p<0.05) (Figure 4-12B). GD6.5 SHRSP 
VSMCs exposed to 10% FBS also demonstrated an increased migration compared 
to NP SHRSP cells (58.7±14.1 versus 19.7±3.9; p<0.05) (Figure 4-12B). FBS-
dependent migration was not significantly different between strain at any time 
point (Figure 4-12C).  
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Figure 4-12: Migration of uterine artery vascular smooth muscle cells from WKY and SHRSP 
VSMCs were isolated from uterine arteries from non-pregnant (NP) and GD6.5 pregnant WKY and 
SHRSP dams. Migration was measured over 24 hours in the presence (10%) and absence of FBS 
(0.5%) after 48 hour serum starvation. (A) Representative images of NP and GD6.5 WKY and 
SHRSP uterine artery VSMC wound closure at 0 hours (T0) and after 24 hours (T3) in 0.5% and 
10% FBS. Original scratch outlined at T0 and superimposed on T3, with dotted lines highlighting 
the migration of cells into the wound. (B) Migration at 24 hours was measured and expressed as a 
percentage; statistically analysed using repeated-measure two-way ANOVA with Sidak post-hoc 
test; *p<0.05 versus NP; #p<0.05 versus 0.5% FBS. (C) The change in migration between 0.5% 
FBS and 10% FBS (FBS dependent) over the three time points (6 hour, 12 hour and 24 hour); rate 
of change analysed using linear regression compared using repeated measures two-way ANOVA 
with Sidak post-hoc test. Data expressed as mean ±SEM; n=3. 
10% FBS0.5% FBS
W
K
Y
 G
D
6
.5
SH
R
SP
 G
D
6
.5
W
K
Y
 N
P
SH
R
SP
 N
P
M
ig
r
a
ti
o
n
 (
%
)
0 .5 %  F B S 1 0 %  F B S
0
2 0
4 0
6 0
8 0
1 0 0 N P  W K Y
G D 6 .5  W K Y
G D 6 .5  S H R S P
N P  S H R S P
M
ig
r
a
ti
o
n
 (
%
)
0 .5 %  F B S 1 0 %  F B S
0
2 0
4 0
6 0
8 0
1 0 0
*
#
#
0 3 6 9 1 2 1 5 1 8 2 1 2 4
0
1 0
2 0
3 0
4 0
5 0
W K Y  N P
S H R S P  N P
T im e  (h o u rs )
F
B
S
 d
e
p
e
n
d
e
n
t 
m
ig
r
a
ti
o
n
 (
%
)
W K Y  G D 6 .5
S H R S P  G D 6 .5
A
B C
T0 T3
T0 T3
T0 T3
T0 T3
T0 T3
T0 T3
T0 T3
T0 T3
200µl
194 
 
 
4.5 Discussion 
This chapter provides evidence that the systemic mesenteric resistance arteries 
of WKY rats become more responsive to vasorelaxation as pregnancy progresses 
and that SHRSP vessels have a functional impairment in this regard. The 
increased relaxation response in WKY rats is in parallel with the observations of 
GD18.5 uterine arteries from these strains (Small et al., 2016). The SHRSP 
mesenteric arteries demonstrated significantly reduced wall thickness and 
smaller cross-sectional area in response to pregnancy. Whilst WKY mesenteric 
arteries were found to have a significantly reduced cross-sectional area, with 
only minimal change to the wall thickness. These GD18.5 WKY arteries also 
exhibited a larger diameter compared to SHRSP. GD18.5 arteries in both strains 
demonstrated higher wall strain than their non-pregnant counterparts, indicative 
of an increased ability to stretch in response to the greatest strain. These 
findings suggest that pregnancy influences WKY and SHRSP mesenteric artery 
mechanical properties in a similar manner. Artery diameter changes are crucial 
in increasing or decreasing vascular resistance (Touyz, 2014). Pre-eclamptic 
women have an increased systemic vascular resistance compared to 
normotensive pregnancies (Bosio et al., 1999, Stott et al., 2017). This may be an 
artefact of hypertensive women retaining their pre-pregnancy vascular function. 
The significantly reduced wall thickness of the mesenteric artery observed in 
pregnant SHRSP dams suggests a hypotrophic remodelling. Previous studies have 
found that resistance arteries in male spontaneously hypertensive rat models 
typically demonstrate eutrophic remodelling in response to hypertension, 
resulting in reduced lumen diameter in the absence of wall thickness changes 
(Arribas et al., 1997, Intengan et al., 1999). This was observed in the non-
pregnant SHRSP compared to non-pregnant WKY in this chapter, suggesting 
hypertensive remodelling is the same in females as in males. However, it is 
unclear why pregnancy in the SHRSP appears to reduce wall thickness and medial 
cross-sectional area of the mesenteric arteries. Whilst hypertension is generally 
associated with a narrowing of resistance vessels and increased peripheral 
vascular resistance, the opposite is the case for healthy pregnancy (Touyz, 2014, 
Mandala and Osol, 2012). Neither of these conditions are usually associated with 
the outward hypotrophic remodelling observed in SHRSP. This remodelling type 
has been observed in arteries from SHR rats where hypertension has been 
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ameliorated with the use of calcium channel blocker Felodipine (Ledingham and 
Laverty, 2001). The findings from this chapter reveal that mesenteric arteries 
from WKY dams undergo a pregnancy-dependent increase in responsiveness to 
vasodilation, thus providing a mechanism for the reduced vascular resistance 
associated with pregnancy. This functional response was not observed in SHRSP 
mesenteric arteries. Whilst both WKY and SHRSP demonstrated some narrowing 
of the mesenteric artery, it was more pronounced in the SHRSP. This may 
suggest that the significant reduction in wall thickness in mesenteric arteries 
from SHRSP could be an attempt by the vessels to reduce vascular resistance in 
order to accommodate the increased blood flow during gestation. A more in-
depth investigation of the mesenteric structural and mechanical properties 
would need to be conducted in order to fully answer this.  
Pregnancy-dependent systemic vascular structural and functional changes have 
not been fully evaluated in humans, due to tissue inaccessibility and the 
associated risks. One study is utilising mathematical modelling of the 
cardiovascular adaptations to pregnancy and can be manipulated to highlight 
changes in hypertensive disorders (Corsini et al., 2017). However, this still 
requires reference and for this reason, appropriate animal models are 
invaluable. Investigating total peripheral vascular resistance in vivo was not 
conducted in SHRSP or WKY pregnancy and would be a beneficial addition to this 
study. 
Alongside the assessment of mesenteric artery changes over pregnancy, the 
uterine arteries were investigated early in gestation, specifically before any 
major placental influenced remodelling. Previously GD18.5 uterine arteries from 
normotensive WKY have been found to respond to pregnancy by becoming less 
constrictive with more pronounced vasodilatory responses. However this has not 
been observed in the SHRSP (Small et al., 2016). Early gestational changes of the 
rat uterine artery investigated in this chapter are more likely to be controlled by 
hormonal influences as the placenta is not fully established until GD12-15, with 
trophoblast invasion peaking around GD18.5 (Caluwaerts et al., 2005, Soares et 
al., 2012).  Early pregnancy (GD6.5) uterine arteries demonstrated no significant 
differences in the functional response to vasodilation or vasoconstriction when 
compared to non-pregnant uterine arteries in either SHRSP or WKY.  
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Trends towards hypertrophic remodelling were observed in WKY GD6.5 uterine 
artery structure, with a trend towards an increased wall thickness and reduced 
internal diameter. This is contradictory to the changes observed at GD18.5 
(Small et al., 2016). Previous studies in rats have found the lumen diameter has 
a 60% increase by late pregnancy compared to non-pregnant (Osol and Mandala, 
2009, Osol and Cipolla, 1993, Small et al., 2016). The early wall thickness 
changes observed in this study may be associated with VSMC axial hypertrophy or 
hyperplasia (Osol and Mandala, 2009, Cipolla and Osol, 1994). Uterine vascular 
remodelling occurs throughout the menstrual cycle, as well as during pregnancy, 
suggesting some degree of hormonal control (Brosens et al., 2009). Progesterone 
and oestrogen, the classical reproductive hormones, have the ability to alter 
vascular function and influence angiogenesis (Chandran et al., 2016, Orshal and 
Khalil, 2004). Oestrogen peaks prior to ovulation during the menstrual cycle of 
non-pregnant women (Orshal and Khalil, 2004). It has been found to exert non-
genomic changes to vascular smooth muscle to encourage vasodilation (Orshal 
and Khalil, 2004).  During pregnancy progesterone is produced first by the corpus 
luteum and then production is taken over by the established placenta (Davis and 
Rueda, 2002).  Progesterone has a different role to oestrogen in regards to 
vascular function. It has been found to inhibit VSMCs contractility and impact 
cellular proliferation, which could lead to the initiation of vascular remodelling 
in the uterine arteries (Barbagallo et al., 2001, Tal et al., 2000, Lee et al., 
1997). Yet, as these two hormones are not the only endocrine factors influencing 
this gestational stage, further assessment of hormonal changes in the first week 
of SHRSP and WKY gestation would need to be conducted. It would be interesting 
to investigate the remodelling and mechanical wall properties in 
pseudopregnancy in SHRSP and WKY, as this could delineate maternal control of 
vascular remodelling in the absence of any fetal and placental influences. 
Non-pregnant uterine arteries where incubated with maternal plasma to 
examine whether circulating factors from pregnancy could directly influence 
vascular function ex vivo. Non-pregnant WKY arteries exposed to WKY GD6.5 
plasma had a significantly lower contractile response to high-potassium 
depolarization than their non-pregnant plasma counterpart. The plasma 
components involved in the regulation of vascular smooth muscle contractility 
also have the ability to influence other vasodilatory and contractile components 
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of the systemic circulation, such as circulating hormones and endothelium 
derived vasodilatory substances (Jackson, 2000). As already stated, early 
pregnancy is associated with multiple alterations in hormone production 
compared to the non-pregnant state, which could alter the ability of VSMC to 
constrict on depolarisation (Tal et al., 2000). However, due to the variability in 
maximum contractile response and complex interplay of different local and 
systemic factors, this would require a more thorough mechanistic evaluation to 
determine any physiological relevance. Neither GD6.5 nor GD18.5 plasma had 
any significant impact on the endothelium dependent (carbachol- acetylcholine 
mimic) or independent (SNP- nitric oxide (NO) donor) vasodilatory responses of 
the non-pregnant uterine arteries from either strain. NO has a crucial yet 
contradictory relationship in mediating vascular changes in pregnancy and 
hypertensive pregnancies (outlined in review by Saldek et al (Sladek et al., 
1997)). NO biosynthesis increases in the circulatory system during normotensive 
pregnancy to maintain a reduced vascular resistance in the gravid state (Xu et 
al., 1996, Conrad et al., 1993).  Many studies have shown an inhibition or lack of 
nitric oxide synthase enzymes produce symptoms of gestational hypertensive 
disorders, highlighting its essential role in maintaining appropriate vascular tone 
during healthy pregnancy (Kulandavelu et al., 2006, van der Heijden et al., 
2005a, Kulandavelu et al., 2013, Molnár et al., 1994, Baylis et al., 1992, Barron 
et al., 2010). Interestingly no significant changes were observed in any 
vasodilatory or vasoconstrictive functions in WKY and SHRSP non-pregnant 
arteries incubated with GD18.5 plasma from either strain. The non-pregnant 
SHRSP arteries had no functional responses to pregnant plasma at any 
gestational stage; which could be interpreted as SHRSP maternal plasma lacking 
factors that propagate a pre-eclamptic like phenotype (Goulopoulou, 2017). 
However, as these incubation studies were performed on non-pregnant UA which 
are already less responsive than during pregnancy, it may not be possible to 
discern these defects. Further limitations of this study, was that plasma 
concentration was diluted in physiological saline to 3%. This was chosen due to 
previous studies examining the effect of high and low density lipoproteins on 
WKY and SHRSP vessel function, however for the purpose of examining all 
circulatory factors in this study that concentration may have been too low and 
should have been raised to a more physiological level. Furthermore, it may have 
been wiser to perfuse these artery explants rather than incubate with plasma 
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factors, to ensure a more physiological environment with the plasma in contact 
with the inside endothelium lining of the arteries. 
Pregnancy-dependent vascular remodelling has been associated with a change in 
VSMCs from quiescent to more migratory and proliferative (Cipolla and Osol, 
1994). Moreover, the major circumferential remodelling changes of the uterine 
artery during pregnancy have been attributed to changes in VSMC mass and 
length (Cipolla and Osol, 1994, Mandala and Osol, 2012). In the present study, 
both WKY and SHRSP demonstrated increased migration in VSMCs isolated from 
pregnant uterine arteries, with early pregnant SHRSP VSMCs demonstrating 
significantly more migration than non-pregnant. In both WKY and SHRSP, the 
migration of GD6.5 uterine artery VSMCs was significantly increased upon FBS-
stimulation compared to the same VSMCs in the absence of 0.5% FBS, this was 
not observed in the VCMCs from non-pregnant uterine arteries. This is suggestive 
that the VSMC of GD6.5 uterine arteries have a more migratory/proliferative 
phenotype than those from a non-pregnant state. These altered cellular 
properties of the uterine arteries in WKY and SHRSP dams suggest that these 
vessels are preparing for remodelling events, even at early gestational stages. 
However, as the proliferation of these cells was not directly evaluated in this 
study, a more thorough investigation into the characteristics of VSMCs from 
uterine arteries at early and late pregnancy time points would be beneficial. 
Similarly, to give a more all-encompassing evaluation of the cellular composition 
of these arteries other cell types could be isolated. For example the functional 
responses observed in GD18.5 arteries are endothelium dependent (Small et al., 
2016). Thus, relaxation responses could be influenced by endothelial cell derived 
factors which could be investigated in vitro using primary uterine artery 
endothelial cells. 
The main limitation that must be considered for the studies presented in this 
chapter is the small sample size used (often n=3) which will greatly impact any 
statistically significant interpretations. In particular, the measurements of 
vascular function and passive mechanical properties were measured using 
myography which has the possibility to introduce large variation to a study, 
which could have been overcome with a greater number of biological replicates. 
However, this chapter has provided evidence that remodelling occurs in the 
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systemic vasculature during pregnancy, and that SHRSP dams have impaired 
systemic vascular responses. This may impact the re-direction of blood flow to 
the uteroplacental unit that is required for a favourable pregnancy outcome. 
Also revealed in this chapter, was that during early gestation uterine arteries 
from WKY and SHRSP dams demonstrate no functional or structural differences. 
This is in contrast to the changes observed in WKY late pregnancy where uterine 
arteries show remodelling associated with increased responsiveness to 
vasodilators and reduced sensitivity to contractile agents, whereas the SHRSP 
uterine arteries show similarity between early and late pregnancy, both lacking 
functional or structural changes (Small et al., 2016).  This highlights the need to 
further investigate the underlying molecular factors which contribute to the 
eventual failure to remodel in the uterine arteries of SHRSP dams. Molecular 
investigations into the transcriptome profile of the uterine arteries was 
conducted by RNA-Seq analysis, the results of which are described in Chapter 5.
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Chapter 5 Transcriptome profiling of early 
pregnancy uterine arteries 
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5.1 Introduction 
Transcriptome profiling of maternal, placental and fetal tissues during 
pregnancy can provide dynamic information on the uterine environment. 
Advancement in high throughput sequencing technologies, such as microarrays 
and RNA sequencing (RNA-Seq), can reveal details about the changes to the 
transcriptome of specific tissues at different time points and in various 
pregnancy pathophysiologies (Wang et al., 2009). Transcriptomic studies have 
already revealed a vast number of genes to be implicated in the development of 
pregnancy complications such as pre-eclampsia, fetal growth restriction and 
gestational diabetes (Enquobahrie et al., 2008, Kaartokallio et al., 2015). These 
genes have been found to be involved in crucial biological pathways that play 
key roles in pregnancy development, such as inflammation, oxidative stress and 
the maternal immune regulation (Walker et al., 2015, Burton and Jauniaux, 
2011, Brewer et al., 2013). Pregnancy is a relatively short physiological change, 
occurring over a 40 week period in humans, which requires rapid and dynamic 
changes in gene expression and RNA processing (Robertson et al., 1975). Any 
deviations from the norm will have profound impact on maternal adaptations, 
placental function and fetal outcome. Due to this, a genomic approach is too 
static. Studying changes at the transcript level is more appropriate as it reveals 
a snapshot of the genes being actively transcribed at different time points (Kim 
et al., 2012). 
Only 596 studies have studied transcriptomic changes in pregnancy using 
microarray or RNA sequencing (RNA-Seq) technologies; based on ArrayExpress 
search conducted April 2018 (Filtered for ‘RNA Assay’ experiment type; search 
terms: ("pregnancy"[MeSH Terms] OR "pregnancy"[All Fields]) OR 
("gravidity"[MeSH Terms] OR "gravidity"[All Fields] OR "pregnant"[All Fields]). 
Most of these studies employed microarray technologies (536), with only 60 
utilising RNA-Seq.  Many studies have focused on changes in placental tissue or 
cells (Enquobahrie et al., 2008, Kaartokallio et al., 2015, Sood et al., 2006, Kim 
et al., 2012, Shankar et al., 2012). Whilst this can give an indication of any 
dysregulation of gene expression in pregnancy complications, it doesn’t inform 
on maternal gene responses to pregnancy or lack thereof. Only 20 of the 60 RNA-
Seq specific studies focused on the maternal gene expression during pregnancy. 
With the focus of these studies examining trophoblast interactions with decidual 
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cells or with human aortic vascular smooth muscle cells in vitro (Bird et al., 
1998, Cale et al., 1997, Fukushima et al., 2008, Gifford et al., 2003, Gong et al., 
2014, Harris et al., 2010, Hess et al., 2007, Houser et al., 2011, Jokhi et al., 
1994, Nelson et al., 2016, Wallace et al., 2013, Wang et al., 2012, Weston et al., 
2002, Weston et al., 2003). Some have examined the total transcriptome profile 
of complete myometrial/decidual tissue biopsies, giving some indication of 
maternal changes (Autio-Harmainen et al., 1992, Chen et al., 2000, Gibb and 
Sun, 1996, Herse et al., 2012, Kitaya et al., 2007, Peng et al., 2015, Penna et 
al., 2010, Rider et al., 2000, Wu et al., 2000, Founds et al., 2013, Lian et al., 
2010).  However, no studies have specifically investigated the gene expression 
profile of isolated whole vessels in the maternal uterine vasculature during 
pregnancy. 
During pregnancy, the maternal uteroplacental vasculature undergoes essential 
remodelling (Pijnenborg et al., 2006). This adaptation relies on mechanisms that 
are not fully understood and even less is known about the gene expression 
changes required for successful remodelling. RNA-Seq has major advantages over 
other gene expression assays as it can fully examine the RNA profile including 
non-coding RNA (for example miRNA, lncRNA and snRNA) from relatively small 
amounts of starting material, it is not limited to a specified catalogue of RNA 
(therefore avoids biases of examining only expected changes) and has a much 
more dynamic range of quantifying gene expression (from detecting small fold 
changes up to >8000 fold changes) (Wang et al., 2009). This approach can reveal 
key transcriptional regulations that the underlying molecular development of 
both physiological and pathophysiological processes. 
Impaired uteroplacental remodelling and the associated reduced uteroplacental 
haemodynamics have a well-established influence on the development of pre-
eclampsia and fetal growth restriction in humans (Brosens et al., 1972, 
Robertson et al., 1975). Impaired trophoblast invasion has been suggested to be 
the main contributor to impaired vascular remodelling (Geusens et al., 2010, 
Lyall et al., 2013), however little is understood about the maternal vasculatures 
response to these cells, and even less is known about how the maternal 
uteroplacental circulation is regulated prior to the invasion of trophoblasts 
(Jauniaux et al., 2000). The lack of investigation into maternal uterine artery 
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gene expression profiles during pregnancy could be due to the inaccessibility of 
maternal tissue during pregnancy. Many samples are collected at delivery, yet at 
this time point is too late to observe active remodelling changes (Robson et al., 
2002, Lash et al., 2016). Maternal tissue can also be obtained from early 
pregnancy terminations however these samples are difficult to obtain due to 
ethical considerations and the sample size is often very small (Robson et al., 
2012, Pitman et al., 2013). It is for these reasons that animal models must be 
utilised in the study of early vascular remodelling in pregnancy.  
The genome of both the SHRSP and WKY strains, bred in-house at the University 
of Glasgow, have been sequenced and therefore RNA-Seq references for 
alignment are available. The SHRSP rat has a deficiency in uterine artery 
remodelling, demonstrated by an impaired uteroplacental blood flow at GD18.5 
(Barrientos et al., 2017, Small et al., 2016). To examine the maternal vascular 
response to pregnancy, vessels must be examined prior to any fetal influence 
from the trophoblast invasion. Implantation in the rat occurs between 
gestational day (GD) 5.5 and 6.5, with trophoblast invasion beginning at mid-
gestation (between GD14.5 and GD15.5), reaching a peak at approximately 
GD18.5 (Vercruysse et al., 2006, Phillips and Poyser, 1981, Ain et al., 2003). The 
SHRSP did not show any structural or functional alterations by GD6.5 of 
pregnancy (Chapter 4) and produced similar numbers of offspring (of similar 
weight) as the WKY rats (Chapter 3), yet SHRSP has previously demonstrated an 
impaired uteroplacental blood flow at GD18.5 (Small et al., 2016). Therefore, it 
is of paramount importance to uncover any pregnancy dependent transcriptomic 
alterations to ascertain physiological responses; as well as investigating the 
maternal vascular responses to pregnancy in a model of chronic hypertension.  
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5.2 Hypothesis and Aims 
5.2.1 Hypothesis 
Differences in the transcriptome of SHRSP and WKY rats are responsible for 
altered uterine artery gene expression in the SHRSP which affects its ability to 
remodel in response to pregnancy. 
5.2.2 Aims 
 To determine early (GD6.5) pregnancy dependent expression changes of 
protein-coding genes at the transcript level of uterine arteries from SHRSP 
and WKY. 
 Predict the influences any gene changes have on vessel function between 
non-pregnant and pregnant uterine arteries. 
 Validate differentially expressed genes in key pathways. 
 Identify lncRNA expression changes in the uterine artery between strains 
and across early pregnancy.   
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5.3 Materials and Methods 
Uterine arteries from virgin 13-week-old and GD6.5 pregnant age-matched WKY 
and SHRSP were dissected as in the general materials and methods (section 
2.4.3). These arteries were stored at -80°C until tissue was homogenised and 
RNA was extracted and the quality checked using the Agilent Bioanalyzer as 
described in the general materials and methods (section 2.2.1).  
5.3.1 RNA Sequencing  
RNA sequencing (RNA-Seq) was conducted by Glasgow Polyomics. A minimum of 
400ng total RNA was processed using the Illumina TruSeq Stranded Total RNA 
with Ribo-Zero Gold kit, following the manufacturer’s guidelines. The gene and 
transcript expression profiling were conducted using the NextSeq500® Illumina 
sequencing system, with paired-end sequencing at a depth of 50 million reads 
per sample. Adapter and quality trimming of the reads was preformed using 
CutAdapt and Sickle software packages.  FastQC was used to ensure sequence 
quality was suitable throughout processing. Reads were then mapped using the 
Ensembl Rnor_6 reference genome and tested for differential expression using 
DESeq2 software package (Bioconductor 3.6). Base mean of gene and transcript 
expressions across all groups were determined. Comparisons were made between 
the strains and pregnant state for transcript level analysis, illustrated in Figure 
5-1and Figure 5-2. 
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Figure 5-1: Schematic illustration of the RNA sequencing process 
Total RNA is extracted from tissue and undergoes ribosomal depletion and the preparation of a 
cDNA library using paired end sequencing. The library is then sequenced and mapping programs 
are used to align the reads with a reference genome. This can determine transcript biotype and 
chromosomal location. The reads are then quantified to give the number of fragments per kilobase 
of transcript per million mapped reads (FPKM). These values can determine fold change when 
compared between two samples. miRNA = microRNA, snRNA = small nuclear RNA, lncRNA = long 
non-coding RNA. 
 
 
Figure 5-2: Multiple comparison groups for DESeq2 analysis of reads 
RNA samples from uterine arteries were compared between strain both at the non-pregnant (NP) 
and gestational day (GD)6.5 pregnant (P) stage, as well as between NP and P for WKY and 
SHRSP. Arrows indicate comparisons, n=3 for each group. 
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5.3.2 Data Handling and Analysis 
Lists of differentially expressed transcripts were examined by biotype and the 
false discovery rate (which determines the significance of expression changes) 
was restricted to (padj)<0.05. This revealed less than 1000 changes so no further 
restrictions were applied for analysis. Differential transcript expression was 
examined using a comparison between WKY NPvsP and SHRSP NPvsP and a 
comparison between NP WKYvsSHRSP and P WKYvsSHRSP (Figure 5-2). This 
examined the different number of significantly differentially expressed 
transcripts between the comparison groups and those that overlapped. 
Expression increased or decreased relative to the second group; for example, if 
comparison was A vs B expression differences are expressed relative to B, i.e. a 
negative fold change would be a decrease in A relative to B. 
Heatmaps were created for quality control assessment of the expression 
datasets. The 50 most significant differentially expressed genes in each 
comparison group were chosen, giving a total of 148 genes due to some overlap 
between groups. The individual intensities for each uterine artery sample of 
these genes were then entered into Heatmapper web software, and a heatmap 
created (Babicki et al., 2016). Centroid linkage hierarchical clustering was 
performed for the transcripts and samples to assess the similarity between 
different samples of the same group. Similar expression intensities are expected 
between uterine arteries from the same pregnancy/strain group as these should 
have similar RNA profiles. Any differences would suggest variation in sample 
preparation.  
Ingenuity® Pathway Analysis (IPA: Qiagen) was used to functionally correlate 
transcript expression profiles and produce biological relevance pathway changes 
to protein coding gene expression. The differentially expressed transcripts were 
filtered with padj<0.05 and to confirm quantifiable expression the fragments per 
kilobase of transcript per million mapped reads (FPKM) criteria was >1.0. An 
expression analysis was conducted for each dataset to highlight key disease and 
function pathway involvement. This was further investigated using a core 
comparison analysis of the datasets to identify differences in canonical pathways 
and assign activation z-scores for each comparison group. The z-score is a 
predictor of activation state of transcriptional regulators, inferred from 
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observed gene expression. Its numerical value is determined as a statistical 
measure of the similarity/differences between expected relationships (from 
literature) and the observed gene expression (input from RNA-Seq study). A 
negative z-score suggests inhibition of that pathway or function, whereas a 
positive value suggests activation. 
5.3.3 Validation of key genes using Taqman q-RT PCR  
Taqman® q-RT PCR was performed as previously described in the general 
materials and methods (section 2.2.3.2) using the primers illustrated in Table 
2-2. 
5.3.4 Investigations of detected lncRNA 
All significantly differentially expressed lncRNAs were identified using Ensembl. 
This also provided location information for each lncRNA. There is evidence to 
suggest that lncRNAs can influence expression of adjacent genes, therefore the 
proximity of these RNAs to protein coding genes was assessed (Wang and Chang, 
2011). The number of protein coding genes that were within 5 million base pairs 
of the lncRNA was noted (Ballantyne et al., 2016), with any that were also found 
to be significantly differentially expressed examined in more detail, with 
location and forward/reverse strand direction recorded.  
One lncRNA from each comparison group was chosen for further validation, along 
with others of interest signified by their proximity to differentially expressed 
protein coding genes, in total 6 lncRNA were further examined. Standard PCR 
was used to amplify the transcripts from cDNA, produced from RT-PCR described 
in the general materials and methods (section 2.2.2). Primers were designed to 
span exon-exon boundaries where possible (Table 5-1). PCR was conducted in a 
96-well plate where the final concentrations per well were: 1x ThermoPol® 
reaction buffer (New England Biolabs, Hitchen, UK), 0.5mM of each dNTP, 0.5mM 
of forward primer, 0.5mM of reverse primer and 0.625 U/µl Taq polymerase. A 
total volume of 20µl in each well was achieved using RNase free sterile water. 
1µl of cDNA template (prepared as in general materials and methods section 
2.2.2) was added. The PCR was run on a 96-well Dyad DiscipleTM thermal cycler 
(MJ Research, Massachusetts, USA) with the following temperature cycles: an 
initial denaturation step of 94°C for 5 minutes then a cycle of denaturing at 
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94°C for 30 seconds, annealing at 58°C for 30 seconds and extension at 68°C for 
1.5 minutes; for 35 cycles, with a final elongation step of 5 minutes at 68°C. 
Loading buffer (New England Biolabs, Hitchen, UK) was added to the PCR 
product (1:6 dilution) and the products were run on a 1.5% agarose gel 
containing 0.66% ethidium bromide. A 100bp DNA ladder (Promega, 
Southampton, UK) was run alongside the samples. Gels were run for 40 minutes 
at 90V and imaged on Gel Doc™ XR+ System and presence/absence of bands of 
correct size were noted. The expression of any lncRNA that produced positive 
bands of the correct fragment size was examined using SYBR Green qRT-PCR, as 
described in general materials and methods section 2.2.3.1, using the primers in 
Table 5-1. 
Table 5-1: Primer sequences for six differentially expressed lncRNA 
lncRNA 
Forward Primer 
3’ -> 5’ 
Reverse Primer 
3’ -> 5’ 
Fragment 
size 
AABR07051787.1 TGTCTATGAGCTGCCGGTC GGATCTCAAGCACTTGCTTG 222bp 
AABR07069473.1 CGAAGGCGGCTTGGATTTAG ATGTCTTGCTCTGGAGGAGC 370bp 
AABR07055801.1 CGGCTGTGAAGCTAGCAGT TCTCCCTGGGTAAGTCCTG 106bp 
AABR07069816.1 ATCCTCTGTGATGTCACCAG TGTTGATTACCACAGGGCCA 255bp 
AABR07008309.1 CTGGAAGAAGCAGAGAGTAG AAGATGTCCCTTCTGAACGG 140bp 
Rn50_X_0663.2*  AATGCCGTGGACTGCACAATG ATGTGCTCCGAAGGTCAGACA 197bp 
* lncRNA Rn50_X_0663.2 had only one exon, so primers do not span exon-exon boundary.  
 
5.3.5 Intracellular Calcium Release in Uterine Artery VSMCs 
Vascular smooth muscle cells (VSMC) were isolated and cultured as described in 
general materials and methods section 2.6. Cells were used between passage 4 
and 6 and were not used later than this due to a change in growth. After 
reaching confluency in a T75 flask the cells were removed from the flask and 
counted as previously described (section 2.6.3). Cells were seeded onto a 12 
well plate at a density of 1x106 cells per well in complete DMEM media. Each cell 
type was seeded into 3 wells to provide technical replicates. The cells were then 
allowed to reach 80% confluency (between 28 and 72 hours). Cells were then 
starved of serum, by replacing complete media with DMEM containing 0.5% FBS 
for 72 hours) to ensure the cells all began at the same growth cycle stage and 
that there was no FBS in the media during the experiment as this can alter the 
calcium release observed.  
210 
 
 
The calcium release was measured using the fluorescent calcium indicator, Cal-
520® AM (ab171868, Abcam, Cambridge, UK). This calcium sensitive dye works by 
being pre-loaded into cells and its lipophilic blocking groups are cleaved once 
inside the cell, causing it to remain intracellularly. When calcium is release the 
Cal-520 fluorescence greatly increases and produces detectable signals that can 
be recorded. Cells were briefly rinsed with 0.5% (v/v) FBS DMEM medium 
containing HEPES [100IU/ml penicillin, 100µg/ml streptomycin, 2mM L-
glutamine, 5.5mM D-glucose, 1mM sodium pyruvate, 25mM HEPES] (22320 Gibco, 
ThermoFisher Scientific, Paisley, UK) and 400µl of HEPES-DMEM media containing 
2µM Cal-520 AM was added to the cells. The cells were protected from light to 
prevent bleaching and incubated at 37°C for 75 minutes. After incubation Cal-
520/HEPES media was removed and cells were washed once with 1ml of Ca2+ 
free HEPES solution [20mM HEPES, 130mM NaCl, 5mM KCl, 1mM MgCl2, 10mM 
glucose, 0.1mM EDTA; pH7.4] and then 800µl of Ca2+ free HEPES solution was 
added and the cells were incubated at room temperature for 30 minutes, 
protected from light.  
Visualisation of the calcium release was conducted using live cell microscopy 
(Ziess Axio Observer Z1, Carl Zeiss Ltd, Cambridge, UK). The cells were placed 
on a heated mount at 37°C and a field of vision was found with focusing 
adjustments conducted using bright field microscopy settings. Once the cells 
were located the microscope was switched to detection of fluorescent 
wavelengths of Ex/Em 490/525nm. Baseline fluorescence was recorded for 2 
minutes before 100µl 1mM angiotensin II was added to the first well and timed 
for 2 minutes. At the 4-minute mark 100µl 1mM ionomycin was added and the 
resulting fluorescent change recorded for 2 minutes. This process was repeated 
for all technical replicates and cell types. 
The mean intensity for the field of vision was recorded every 1.2 seconds using 
Zen software. The average baseline value (between 0 and 2 minutes) was 
subtracted from all subsequent intensity measurements and this was used to 
construct a trace of intracellular Ca2+ release caused by AngII and ionomycin. 
The difference between baseline and peak AngII stimulated and baseline and 
peak ionomycin stimulated Ca2+ release was calculated.  
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5.4 Results 
5.4.1 RNA Quality Control Prior to RNA Sequencing 
Prior to conducting the RNA Sequencing the total RNA purity and integrity was 
assessed using an Agilent Bioanalyzer. The gel-like image produced by the 
Bioanalyzer shows distinct bands for 18S and 28S. This suggests the RNA is of an 
acceptable quality as degradation would have resulted in fragmentation, 
producing many more bands. An electropherogram profile of the RNA in each 
sample was also produced. An example is shown in Figure 5-3 that shows distinct 
peaks in fluorescence at approximately 2000 to 4000 nucleotides in size, which is 
indicative of 18S and 28S RNA respectively. The fluorescent peaks of these RNAs 
were used to determine the RNA integrity number for each sample, presented in 
Table 5-2. Eight of the 11 samples tested had a RIN higher than 7 and all were 
above the accepted RIN of 5, which is indicative of some degradation but is 
trivial when using ribosomal depletion library preparation for RNA sequencing.  
All samples demonstrated peaks between 50 and 200nts which suggests small 
RNA fragments have been retained during extraction, these could include miRNA 
however these would have been lost during library preparation for RNA 
sequencing as this RNA-Seq was not designed to include detection of these RNAs.  
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Figure 5-3: Example of Agilent Bioanalyzer 2100 results. 
A RNA picochip assay of non-pregnant (NP) and GD6.5 pregnant WKY (A numbers) and SHRSP 
(C numbers) uterine arteries allowed assessment of RNA quality and integrity. (A) The analysis 
produced a gel-like image which highlights 28S at ~4000 nucleotides (nts) and 18S at ~2000nts, 
some degraded and small RNA is indicated by the band at ~100nts. (B) The electropherogram for 
sample A6743 GD6 shows that the 28S and 18S RNA have a distinct large fluorescent peak in the 
appropriate locations. Another peak apparent between 50-200nts is indicative of smaller RNA 
fragments (such as long non-coding) and is also evident of partial degradation. The peak at 25nt 
represents the DNA marker. 
 
Table 5-2: Agilent Bioanalyzer determined RNA Integrity Number (RIN) for each sample  
 WKY SHRSP 
 Non-pregnant Pregnant (GD6) Non-pregnant Pregnant (GD6) 
ID A45 A44 A46 A51 A43 A50 C65 C74 C68 C56 C58 C59 
RIN 6.8 5.8 6.5 7.9 7.7 --- 7.8 5.5 7.1 7.9 7.8 7.5 
Sample A50 did not undergo Agilent Bioanalysis as the pico-chip RNA assay had a limit of 11 
samples (plus one ladder control). Animal ID’s are presented for reference; A = WKY and C = 
SHRSP. 
  
B
A
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5.4.2 RNA Quality Control Post-RNA Sequencing 
A principal component analysis plot was constructed to visualise the variation 
between individual samples and groups in the experiment. All gene expression 
interpretations were made from these comparison groups (n=3). Figure 5-4 shows 
that the transcript reads for each sample are clearly segregated across 
pregnancy (PC1=30% variance) and across strain (PC2=18% variance). As the 
variation across pregnancy is the largest, this suggests that pregnancy has more 
of an impact on transcript expression in the uterine arteries than differences 
between strains.  
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Figure 5-4: Principal component analysis of each individual uterine artery transcript 
expression 
This plot shows that the transcript expressions of each sample cluster between strain and 
pregnancy. Principal component 1 was attributed to pregnancy and demonstrated the largest 
variance (30%). Principal component 2 was the strain variance between WKY and SHRSP, 
accounting for 18% variance.  
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5.4.3 Summary of Differentially Expressed Transcripts  
Mean Average (MA) plots were constructed to show global distribution of 
expressed transcripts (Figure 5-5). It distributes each transcript based on the 
log-fold change (y-axis) and the normalised mean expression (x-axis). Each 
transcript is represented on the plot, with red dots indicating significantly 
differentially expressed transcripts that have a padj<0.05. The MA plots for each 
of the four comparison groups indicates that each have a sizeable portion of 
significant differentially expressed genes.  
The number of significantly differentially expressed (DE) transcripts for each 
comparison group is stated in Table 5-3. This highlights the comparison of non-
pregnant vs. pregnant vessels in WKY and SHRSP. There were found to be a 
greater number of DE transcripts in the SHRSP group compared to WKY, with the 
majority being upregulated in the pregnant uterine artery. Common DE 
transcripts were viewed by comparing the transcript ID’s from the original WKY 
and SHRSP comparisons of non-pregnant vs pregnant using online software Venny 
(http://bioinfogp.cnb.csic.es/tools/venny) (Figure 5-6). This showed that there 
were 32 common upregulated transcripts and 115 common downregulated 
transcripts in response to pregnancy in both strains.  
Table 5-3 also shows the number of DE transcripts between WKY and SHRSP 
uterine arteries in the non-pregnant and pregnant state, as well as a comparison 
of these two groups. This shows common DE transcripts which suggests the 
transcriptional expression of these transcripts are unaffected by pregnant state. 
A heatmap was constructed using the individual means of the 50 most significant 
DE transcripts (padj<0.05) from each of the comparison groups (148 DE 
transcripts in total) to determine the reliability of the differential expression 
between samples (Figure 5-7). These transcripts were chosen to give a 
representation of transcriptional changes in each individual sample. Hierarchical 
clustering was applied, which grouped the individual samples according to 
pregnancy then according to strain. This suggests that there are robust 
transcriptional differences between non-pregnant and GD6.5 pregnant uterine 
artery and that these are of a reliable uniformity within each sample group. 
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Figure 5-5: Mean-Average (MA) plots for each comparison group. 
An MA plot was constructed for each comparison group in order to visualise the transcriptomic 
expression differences. Each transcript is represented by one dot and the plots illustrate the 
distribution of the fold change verses mean expression intensity. (A-B) Changes induced by 
pregnancy. (C-D) Changes induced by strain. Significant (<0.05 padj) differentially expressed 
genes are indicated by red dots. 
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SHRSP
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Non-Pregnant
WKY vs SHRSP
Pregnant
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Figure 5-6: Venn diagrams illustrating the number of differentially expressed gene transcripts that are common or distinctive to pregnancy and strain. 
The significantly DE transcripts from each of the 4 comparison groups (WKY NP vs P; SHRSP NP vs P; Non-pregnant WKY vs SHRSP and Pregnant WKY vs SHRSP) 
were compared to reveal similarities and differences in significant transcript expression number over pregnancy and strain. The numbers used in the Venn diagrams 
were determined using http://bioinfogp.cnb.csic.es/tools/venny/ 
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Table 5-3: Number of significantly upregulated and downregulated gene transcripts in each group and the number that are common between WKY and 
SHRSP or between non-pregnant and pregnant 
 Non-Pregnant vs Pregnant WKY vs SHRSP 
WKY  SHRSP  Common Non-Pregnant Pregnant Common 
Upregulated  177 166 32 245 135 55 
Downregulated 358 630 115 232 76 52 
Total 535 796 147 477 211 107 
The DE transcripts between the original four comparison groups were limited to padj<0.05 to give the total number of significantly DE genes and the number of 
common genes determined from Figure 5-6. This was further split into the number of upregulated (higher in 1st group; i.e. in non-pregnant or WKY) and downregulated 
(lower in 1st group) genes in each group.  
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Figure 5-7: Heatmap of the individual intensity of the most significant differentially gene 
transcripts 
The heatmap demonstrates the individual intensities of the top 50 most significant DE genes 
(padj<0.05) from each comparison group. Hierarchical centroid linkage clustering was applied for 
each individual uterine artery (labelled with animal ID at base). Row z-score indicates the intensity 
change of samples for that particular gene transcript. The dendrogram at the top shows gene 
expression clusters within strains and groups non-pregnant and pregnant separately within that 
cluster. Heatmap was generated using http://www.heatmapper.ca/  
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5.4.4 Pregnancy Associated Genes 
Due to the vast data sets generated in the RNA-Seq experiment, the remainder 
of this chapter focuses on the comparison between non-pregnant and pregnant 
uterine artery transcript expression differences of WKY and SHRSP separately. 
These comparisons had the largest number of DE transcripts in both strains and 
would allow for the investigation of changes across pregnancy. The 147 DE genes 
that were revealed to be pregnancy dependent in section 5.4.3 were uploaded 
to IPA® to investigate their predicted involvement in biological functions. Figure 
5-8 shows the most likely biological functions predicted to be influenced by this 
subset of DE genes. The most significant are cellular movement and cell growth 
& proliferation.  
IPA® assigned activation z-scores to each comparison group for different 
canonical pathways based on the pattern of gene expression changes across 
pregnancy. These were then compared using a core comparison analysis. Figure 
5-9 shows the heatmap of the comparison between WKY and SHRSP. A more 
negative z-score suggests that the genes in that pathway are downregulated in 
respect to the non-pregnant state.  
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Figure 5-8: Important biological functions altered due to pregnancy determined by IPA® 
The 147 DE genes found to be common to pregnancy in WKY and SHRSP were predicted to have 
the most significant influences on these biological functions. The bars represent the likely hood of 
these genes influencing this function (-log(p-value); the longer bars represent lower p-values and 
therefore more statistically likely. 
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Figure 5-9: Canonical pathway prediction for WKY and SHRSP non-pregnant vs pregnant 
The canonical pathway activation was predicted by the gene expression profiles in IPA. An 
activation z-score was assigned (blue = increase relative to non-pregnant; orange = decrease 
relative to non-pregnant) to each pathway and group and the list is presented with the biggest 
differences between the two comparison groups. NP = non-pregnant; P = pregnant. 
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5.4.5 Differences in Strain Response to Pregnancy 
The following sections focus on some differences identified between WKY and 
SHRSP uterine artery’s response to pregnancy. This was led by differences 
observed in the canonical pathway z-scores and core comparisons as well as by 
known factors that would influence vessel function, such as calcium signalling 
and mitochondrial function. 
5.4.6 Production of Reactive Oxygen Species by NADPH Oxidase 
The z-score for the production of reactive oxygen species (ROS) via NADPH 
Oxidase was -2.13 for the NPvP SHRSP group and 1 for NPvsP WKY. This 
interpretation suggests that the SHRSP uterine arteries ROS expression is 
increased during pregnancy and the WKY remains unchanged. The genes 
responsible for subunits of NADPH oxidase 2 were found to have a reduced 
expression in non-pregnant uterine arteries compared to pregnant in the SHRSP 
group only (Figure 5-10). This suggests that the SHRSP uterine arteries may have 
an increased Nox2 expression in the first 6 days of pregnancy, which is not the 
case in WKY. Table 5-4 demonstrates the fold change values and significance 
(padj) of key gene changes involved.  
The expressions of Cyba (p22-phox) and Cybb (Gp91) in the uterine arteries of 
non-pregnant and GD6.5 pregnant rats were validated firstly by using qRT-PCR. 
There was a significant increase in the expression of Cyba in GD6.5 pregnant 
uterine arteries compared to non-pregnant in SHRSP, whereas there was no 
difference in expression in WKY vessels (Figure 5-11A). There was no significant 
difference in Cybb gene expression in WKY or SHRSP, however the SHRSP showed 
a trend towards an increased expression with a 3-fold increase (Figure 5-11B). 
The expression of these two genes was also compared from uterine arteries of 
GD18.5 pregnant dams. These showed no significant difference between strains 
(Figure 5-11C-D). These vessels were not compared to the non-pregnant vessels 
from the same strain as the B2m housekeeper expression was found to reduce by 
GD18.5. 
Functional validation of changes in Nox2 expression was conducted using IHC. 
Staining for Nox2 revealed no differences in the protein levels of Nox2 in uterine 
arteries from NP, GD6.5 and GD18.5 WKY and SHRSP (Figure 5-12).  
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Figure 5-10: The network of genes involved with the production of ROS via NADPH oxidase 
The pathway of ROS production was highlighted by IPA and further investigation revealed gene 
expression changes in the NADPH oxidase subunits in SHRSP only. WKY expression levels 
remained the same in pregnancy as in non-pregnant (grey), where-as 3 subunits had an increased 
expression (green) and two had conflicting expression (green/red) in pregnant compared to non-
pregnant vessels. 
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Table 5-4: Genes involved in ROS production via NADPH Oxidase 
 
Gene Symbol 
WKY  
NP vs P 
SHRSP 
NP vs P 
Gene Name Rat Human padj FC padj FC 
NADPH oxidase 2       
Cytochrome b-245 α chain Cyba p22-phox  0.7491 -1.10 0.0105 -1.62 
Cytochrome b-245 β chain Cybb Gp91 0.3246 -1.39 0.0154 -1.85 
Neutrophil cytosolic factor 2 Ncf2*P p67-phox 0.7745 -1.17 0.0562 -2.03 
Neutrophil cytosolic factor 4 Ncf4 p40-phox 0.1582 -1.53 0.0003 -2.21 
Phosphatidylinositol 3 kinase complex       
Fibroblast growth factor receptor 3 Fgfr3* FGFR3 0.3786  1.31 0.0426  1.64 
Phosphatidylinositol-bisphosphate 3-kinase catalytic subunit γ Pik3cg PIK3CG 0.6709 -1.10 0.0036 -1.52 
Protein phosphatase 1/2A complex       
Protein phosphatase, Mg2+/Mn2+ dependent 1L Ppm1l PPM1L 0.9566  1.02 0.0467  1.36 
Protein phosphatase 1 regulatory inhibitor subunit 14B Ppp1r14b PPP1R14B 0.1956 -1.31 0.0001 -1.76 
Protein phosphatase 1 regulatory subunit 3C Ppp1r3c PPP1R3C 0.1623  1.50 0.0213  1.73 
The NADPH oxidase subunit genes and the associated complexes had a significantly altered expression in SHRSP (padj <0.05; shown in bold). The same genes did 
not reach significance in WKY. * indicates 2 or more transcript variants for that gene. Ncf2 P is a non-coding processed transcript in rat.
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Figure 5-11: Validation of Cyba and Cybb expression in uterine arteries using qRT-PCT 
(A) Cyba expression was found to be increased in GD6.5 SHRSP uterine arteries compared to 
non-pregnant (n=4-5). (B) No significant changes in Cybb expression where observed in either 
strain (n=4-5). Comparisons at GD18.5 found no differences between WKY and SHRSP for (C) 
Cyba or (D) Cybb (n=3-4). Numbers above bars represent average cycle threshold (CT) values. 
Data expressed as relative quantity (RQ) to B2m housekeeper, and relative to WKY NP or WKY 
GD18.5. Analysed using one-way ANOVA (A-B) or student’s t-test (C-D); *p<0.05. 
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Figure 5-12: Quantification of Nox2 and Immunohistochemical location in uterine arteries  
Uterine arteries fixed at 120mmHg were stained for Nox2. (A) Staining was quantified as a 
percentage of the total vessel area. No statistical analysis could be established due to low n 
numbers. WKY: non-pregnant (NP) n= 2, GD6.5 n=1, GD18.5 n=4; SHRSP: NP n=2, GD6.5 n=4, 
GD18.5 n=2. (B) Representative images of the Nox2 staining.  
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5.4.7 Calcium Signalling Differences 
Pathway analysis on IPA revealed pregnancy dependent changes in the α 
adrenergic signalling pathway was not the same between WKY and SHRSP (Figure 
5-9), with WKY having an expression pattern that suggested reduction in Ca2+ 
signalling in the pregnant vessels (Figure 5-13). The expressions of inositol-
trisphosphate receptor (Ip3r), phospholipase C (Plc) and Ca2+/calmodulin 
dependent protein kinase (Camk2) gene transcripts in non-pregnant vessels from 
WKY were significantly greater than that of the pregnant vessels of the same 
strain, and calmodulin 1 (Calm1) was observed to have an increased expression 
during pregnancy (Table 5-5). The same pattern of differential expression is not 
observed in SHRSP vessels. In this strain, there are no significant differences in 
Ip3r or Calm1, which suggest the release and sequestering of Ca2+ is not altered 
during pregnancy by this mechanism. However, there are reductions in the 
expression of Camk2 and myosin light chain kinase (Mylk) in pregnant SHRSP 
uterine arteries.  
Taqman® qRT-PCR was conducted to validate the expression of Calm1, Ip3r and 
Mylk, to determine consistency with the RNA-Seq analysis. The RNA-Seq analysis 
identified that Calm1 expression increased in WKY GD6.5 compared to NP 
uterine arteries, with no changes in the SHRSP comparison group. However, qRT-
PCR revealed no significant differences between the GD6.5 and NP WKY vessels, 
and uterine arteries from GD6.5 SHRSP compared to NP SHRSP were found to 
have a significantly increased Calm1 expression (Figure 5-14). The expression of 
inositol trisphosphate receptor type 1 (Itpr1), was significantly greater in SHRSP 
compared to WKY at GD6.5 (Figure 5-14), however there was no apparent 
change in expression over the course of pregnancy in either strain, which 
somewhat contradicts the RNA-Seq results. Mylk expression, was found to be 
reduced in SHRSP GD6.5 uterine arteries compared to NP in the RNA-Seq 
dataset, but was not significantly different between any of the groups when 
using qRT-PCR (Figure 5-14). The qRT-PCR results suggest that Ip3r may be more 
highly expressed in SHRSP compared to WKY, which would increase Ca2+ release 
in the hypertensive strain potentially leading to detrimental effects due to the 
potential for increased VSMC contraction.  
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Further investigation of the intracellular Ca2+ signalling was conducted by 
visualising intracellular Ca2+ release using fluorescent Cal-520. The pre-loaded 
cells fluoresced when exposed to agonists of calcium release. Figure 5-15 shows 
the fluorescent intensity of VSMC from WKY non-pregnant and GD6.5 pregnant 
uterine arteries. The first peak was the angiotensin II stimulated Ca2+ release. 
This shows that the non-pregnant VSMCs responded more to AngII than the 
pregnant cells. Both cell types responded with similar intensities to ionomycin. 
When the maximal delta peak for AngII intensity was calculated for each 
replicate, there was found to be a significantly higher response in the non-
pregnant cells compared to the pregnant, this significant difference was not 
observed in response to ionomycin. These results are technical replicates from 
one cell isolation for non-pregnant and pregnant WKY VSMCs. Due to technical 
issues with preparation of VSMC from SHRSP uterine arteries it was not possible 
to complete the Ca2+release experiments for this strain. 
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Figure 5-13: Components of intracellular calcium release in vascular smooth muscle cells 
Gene interaction network created from IPA shows that there is differential expression of genes 
involved in Ca2+ release during pregnancy in both strains; however different gene changes are 
occurring in the two strains. Red = reduced expression and green = increased expression in the 
pregnant (P) uterine artery relative to non-pregnant (NP) 
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Table 5-5: The significantly differentially expressed genes involved in calcium release and regulation 
 
Gene 
Symbol 
Ensembl Transcript ID 
NP vs P 
Genes involved in Ca2+ release in WKY padj FC 
Calmodulin 1 Calm1 ENSRNOT00000022603 0.013873 -1.46 
Calcium/calmodulin dependent protein kinase II delta Camk2d*+ 
ENSRNOT00000016026 0.016504  1.93 
ENSRNOT00000015564 0.020787  1.81 
Inositol 1,4,5-trisphosphate receptor type 1 Itpr1* ENSRNOT00000082723 0.007585  2.54 
Inositol 1,4,5-trisphosphate receptor type 2 Itpr2 ENSRNOT00000040645 0.034061  1.32 
Phospholipase C gamma 2 Plcg2 ENSRNOT00000090165 0.001353  1.50 
    
 
Gene 
Symbol 
Ensembl Transcript ID 
NP vs P 
Genes involved in Ca2+ release in SHRSP padj FC 
Calcium/calmodulin dependent protein kinase II delta Camk2d* ENSRNOT00000016026 0.009844  1.93 
Myosin light chain 6 Myl6* ENSRNOT00000082518 0.000923  1.48 
Myosin light chain kinase Mylk* ENSRNOT00000067060 0.041940  1.44 
Phospholipase C like 2 Plcl2 ENSRNOT00000018146 0.049080 -1.32 
The false discovery rate (padj) and fold change (FC) of significant (padj <0.05) DE gene transcripts in WKY and SHRSP intracellular calcium release. * indicates 2 or 
more transcript variants for that gene. + 2 or more transcripts of the gene were found to be significantly differentially expressed. 
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Figure 5-14: Expression of genes involved in calcium signalling cascade measured using 
qRT-PCR 
(A-B) Calm1, (C-D) Itpr1 and (E-F) Mylk expression was analysed using qRT-PCR in non-pregnant 
(NP) (n=3), GD6.5 (n=4) and GD18.5 (n=3) pregnant uterine arteries.  (A) Expression of Calm1 
was increased in SHRSP pregnancy, but not significantly in WKY pregnancy or between strains. 
(B) There were also no differences between strains at GD18.5. (C) Expression of Itpr1 was not 
significantly changed over pregnancy in both strains yet was significantly higher in GD6.5 SHRSP 
vs GD6.5 WKY. (D) There was no significant change in expression at GD18.5. (E-F) Mylk 
expression was not found to be significantly changed in either a strain or pregnancy manner. 
Numbers above bars represent average cycle threshold (CT) values. Data normalised to B2m 
housekeeper, and expressed as relative quantity (RQ) to WKY NP or WKY GD18.5. Analysed one-
way ANOVA with Bonferroni post-hoc test when comparing NP vs GD6 in WKY and SHRSP, or 
with student’s t-test when analysing GD18; *p<0.05. 
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Figure 5-15: Calcium release measured by Cal-520 fluorescent intensity in WKY uterine 
artery vascular smooth muscle cells 
(A) Calcium release was measured over 6 minutes. A fluorescence baseline was established 
between 0-2 minutes and subtracted from the trace. AngII addition occurred at 2 minutes and a re-
establishment of baseline was reached before ionomycin was added at 4 minutes. The dip 
observed in baseline throughout the experiment was due to bleaching of the fluorophore. (B) Non-
pregnant (NP) VSMCs produce greater fluorescent intensity in response to AngII than GD6.5 
pregnant VSMCs. (C) No differences were observed in the responses to ionomycin between NP 
and GD6.5 VSMCs. Analysed using student’s t-test; *p<0.05; n=3.  
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5.4.8 Inflammatory Response to Pregnancy 
WKY and SHRSP displayed differential gene expression profiles that suggested an 
increased inflammatory response to pregnancy in the uterine arteries in the first 
6 days of gestation. However, the genes influencing this change were varied 
between strains (Figure 5-16 and Figure 5-17). A total of 40 genes contribute to 
the predicted increased inflammatory response in WKY, these are illustrated in 
Figure 5-16 and Table 5-6. There were more than double the number of 
contributing genes in the SHRSP uterine arteries; a total of 88 genes contributed 
to the increased inflammatory response, shown in Figure 5-17 and Table 5-7. 
SHRSP and WKY had 19 contributing genes that overlapped (Table 5-8) showing 
the same directionality and similar fold changes. One gene of particular interest 
was phospholipase A2 (Pla2g2a) as it had the highest fold change of all the 
inflammatory-associated genes in both WKY and SHRSP. The expression of this 
gene was validated using qRT-PCR (Figure 5-18A), which confirmed that 
expression increased significantly in the pregnant vessels from both WKY and 
SHRSP. Additionally, there was a significant increase in Pla2g2a expression in 
uterine arteries from non-pregnant SHRSP compared to non-pregnant WKY. 
Another gene involved in the inflammatory response to pregnancy in both strains 
was ficolin A, this gene was not found to be present in non-pregnant vessels 
from both strains (CT value for WKY averaged 38.0, undetermined in SHRSP) but 
was present in GD6.5 vessels (Figure 5-18B). The RNA-Seq analysis identified a 
fold change of -1.87 for WKY and -1.82 for SHRSP, suggesting an increase in 
expression, however due to the low expression in NP uterine arteries 
(determined by a high CT or undetectable PCR product using qRT-PCR), it may 
be possible that ficolin expression is switched on in the uterine artery during 
pregnancy. 
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Figure 5-16: Genes predicted to influence inflammatory response during pregnancy in WKY 
uterine arteries  
The WKY uterine artery gene expression profile had a predicted enhancement of the inflammatory 
response in GD6.5 pregnant (P) uterine arteries compared to non-pregnant (NP). A total of 40 
genes contributed to this prediction. The 19 genes common to WKY and SHRSP pathways are 
shown as lower semi-circle. These genes had the same differential expression direction (i.e. 
increased or decreased in both WKY and SHRSP). An increased measurement (red) indicates that 
gene was more highly expressed in the non-pregnant (NP) uterine artery, and thus reduced over 
pregnancy and vice versa for a decreased measurement (green).  
 
WKY
NP vs P
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Figure 5-17: Genes predicted to influence inflammatory response during pregnancy in 
SHRSP uterine arteries 
The SHRSP uterine artery gene expression profile had a predicted enhancement of the 
inflammatory response in GD6.5 pregnant (P) uterine arteries compared to non-pregnant (NP). A 
total of 88 genes contributed to this prediction. The 19 genes common to WKY and SHRSP 
pathways are shown as lower semi-circle. These genes had the same differential expression 
direction (i.e. increased or decreased in both WKY and SHRSP). An increased measurement (red) 
indicates that gene was more highly expressed in the non-pregnant (NP) uterine artery, and thus 
reduced over pregnancy and vice versa for a decreased measurement (green)
SHRSP
NP vs P
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Table 5-6: Differential expression of inflammatory genes specific to WKY pregnancy 
WKY Specific Inflammatory genes 
Gene 
Symbol 
Ensembl 
Transcript ID 
(ENSRNO) 
WKY 
NP vs P 
padj FC 
Adhesion G protein-coupled receptor E5 Adgre5 T00000006152 0.003724 1.43 
Peroxiredoxin 5  Prdx5 T00000028687 0.041195 -1.57 
C-X-C motif chemokine ligand 13 Cxcl13 T00000039383 0.000200 -3.22 
Solute carrier family 1 member 5 Slc1a5* T00000021455 0.002071 -2.06 
Peroxisome proliferator-activated receptor gamma Pparg* T00000012137 0.001617 -2.86 
Heat shock protein family D member 1  Hspd1 T00000066589 0.033457 -1.58 
Integrin subunit alpha 9  Itga9 T00000015113 0.030174 1.34 
RT1 class Ia, locus A1 Rt1-a1* T00000078972 0.020952 -2.24 
Arachidonate 15-lipoxygenase  Alox15 T00000026038 0.011840 -2.36 
Hydroxycarboxylic acid receptor 2  Hcar2 T00000032249 0.034305 -2.20 
Lipase A, lysosomal acid type Lipa* T00000025845 0.007890 1.96 
ISG15 ubiquitin-like modifier Isg15 T00000039263 0.012420 -2.31 
Adenosine A1 receptor  Adora1* T00000004602 0.030174 -2.23 
Fatty acid binding protein 4 Fabp4* T00000014701 0.001000 -2.79 
Adiponectin, C1Q and collagen domain containing Adipoq*a 
T00000002492 0.000586 -3.10 
T00000089988 0.016504 -1.73 
Free fatty acid receptor 4  Ffar4 T00000034563 0.036322 -2.18 
Ephrin B1 Efnb1 T00000009635 0.045673 -1.61 
ADP-ribosyltransferase 3 Art3* T00000052035 0.038451 -1.85 
Phospholipase C, gamma 2 Plcg2 T00000090165 0.001353 1.50 
ATP binding cassette subfamily D member 2 Abcd2 T00000021064 0.026721 -2.08 
S100 calcium binding protein B S100b T00000001743 0.004339 -2.28 
The fold change (FC) and significance of this change (padj) of all 21 significant (padj <0.05) DE gene 
transcripts that are specific to WKY uterine arteries during the first 6 days of pregnancy. * indicates 
2 or more transcript variants for that gene; a All transcripts of that gene were found to have a 
significantly altered expression. 
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Table 5-7: SHRSP differentially expressed genes influencing the inflammatory response to 
pregnancy 
SHRSP Specific Inflammatory genes 
Gene 
Symbol 
Ensembl 
Transcript ID 
ENSRNOT00 
SHRSP 
NP vs P 
padj FC 
Spi-1 proto-oncogene Spi1 000016306 0.000051 -1.77 
Pentraxin 3 Ptx3 000016541 0.000059 -3.13 
Leukocyte immunoglobulin like receptor B4 Lilrb4* 000077186 0.000067 -3.02 
Transglutaminase 2 Tgm2 000018328 0.000139 1.64 
HCK proto-oncogene, Src family tyrosine kinase Hck 000012432 0.000155 -2.01 
Integrin subunit alpha D Itgad 000026748 0.000178 -1.89 
Sphingosine-1-phosphate receptor 3 S1pr3* 000019473 0.000190 1.76 
Lysozyme 2 Lyz2 000007747 0.000309 -2.38 
Phospholipase A2 group VII Pla2g7 000038222 0.000441 -2.67 
RB transcriptional corepressor like 1 Rbl1 000064824 0.000863 -2.20 
Tyro protein tyrosine kinase binding protein Tyrobp 000028284 0.000920 -2.34 
Rac family small GTPase 2 Rac2 000009994 0.001000 -1.64 
Leukocyte immunoglobulin like receptor B3 Lilrb3 000077327 0.001503 -2.08 
Complement C3a receptor 1 C3ar1 000012216 0.001602 -2.20 
Fc fragment of IgE receptor Ig Fcer1g 000029179 0.001955 -2.12 
BCL2-related protein A1 Bcl2a1 000039850 0.001965 -2.22 
Coronin 1A Coro1a 000026496 0.002225 -1.98 
Myeloid differentiation primary response 88 Myd88 000018341 0.002251 -1.51 
CD74 molecule Cd74* 000025344 0.002819 -1.69 
Arachidonate 5-lipoxygenase Alox5* 000017633 0.002857 -1.86 
Galectin 3 Lgals3* 000014216 0.003148 -1.99 
Gremlin 1 Grem1 000037895 0.003525 -2.52 
NCK associated protein 1 like Nckap1l* 000088956 0.003525 -1.77 
Phosphatidylinositol-4,5-bisphosphate 3-kinase γ Pik3cg 000012487 0.003553 -1.52 
Complement C5a receptor 1 C5ar1 000073034 0.004601 -1.86 
Allograft inflammatory factor 1 Aif1* 000001135 0.004957 -2.26 
Colony stimulating factor 1 receptor Csf1r*+ 
000079360 0.005573 -1.82 
000049357 0.039505 -1.61 
LYN proto-oncogene, Src family tyrosine kinase Lyn 000011130 0.005573 -1.71 
Thymosin, beta 10-like Ptmb10 000022846 0.005725 -1.70 
Capping actin protein, gelsolin like Capg 000018562 0.006066 -1.57 
Lymphocyte cytosolic protein 1 Lcp1* 000014502 0.007300 -1.91 
C-X-C motif chemokine ligand 14 Cxcl14 000016009 0.008176 -2.41 
TNF alpha induced protein 8 like 2 Tnfaip8l2 000028642 0.010489 -1.77 
Cytochrome b-245 alpha chain Cyba 000017564 0.010523 -1.62 
Complement C1q binding protein C1qbp 000037517 0.010964 -1.47 
Vav guanine nucleotide exchange factor 1 Vav1 000073294 0.012376 -1.68 
phospholipase A2 Pla2g2d 000022579 0.013372 -1.84 
SAM and SH3 domain containing 3 Sash3 000006035 0.013372 -1.70 
Fc fragment of IgG receptor IIb Fcgr2b* 000035400 0.013517 -1.98 
Cytochrome b-245 beta chain Cybb 000038994 0.015395 -1.85 
Interferon alpha and beta receptor subunit 1 Ifnar1* 000029985 0.015877 -1.32 
CD33 molecule Cd33 000047473 0.017657 -1.97 
Serine protease inhibitor LOC299282* 000014073 0.019724 -2.21 
239 
 
 
Cathepsin B Ctsb 000014177 0.019965 -1.66 
Phosphoinositide-3-kinase adaptor protein 1 Pik3ap1* 000017938 0.020698 -1.61 
BH3 interacting domain death agonist Bid 000016776 0.021381 -1.41 
Integrin subunit beta 2 Itgb2 000001639 0.021507 -1.47 
Chitinase 3 like 1 Chi3l1 000078599 0.022693 -1.97 
Myosin IF Myo1f 000011513 0.022829 -1.50 
Fc fragment of IgG receptor Ia Fcgr1a* 000028780 0.024666 -1.92 
TNF receptor superfamily member 1B Tnfrsf1b 000022478 0.025100 -1.49 
B-cell linker Blnk 000019014 0.026700 -1.88 
Ceramide synthase 6 Cers6 000058763 0.033069 -1.52 
NLR family, pyrin domain containing 3 Nlrp3* 000004280 0.033258 -1.71 
Toll-like receptor 7 Tlr7 000005620 0.033979 -1.90 
Protein tyrosine phosphatase, non-receptor type 6 Ptpn6* 000082739 0.034012 -1.87 
Chemokine (C-C motif) receptor 5 Ccr5* 000082774 0.034842 -1.76 
Lymphocyte-specific protein 1 Lsp1 000054864 0.035562 -1.37 
Heparanase Hpse 000002983 0.039026 -1.83 
Toll-like receptor 2 Tlr2 000013025 0.039978 -1.97 
Arachidonate 5-lipoxygenase activating protein Alox5ap 000001207 0.040572 -1.91 
Gelsolin Gsn* 000025857 0.040572 1.56 
Integrin subunit alpha L Itgal 000024404 0.041281 -1.58 
Myosin light chain kinase Mylk* 000067060 0.041940 1.44 
TNF superfamily member 13 Tnfsf13* 000056903 0.042795 -1.69 
E2F transcription factor 2 E2f2 000072618 0.043386 -1.61 
Hyaluronoglucosaminidase 1 Hyal1 000021408 0.044235 1.54 
C-C motif chemokine receptor 1 Ccr1 000008772 0.045020 -1.92 
Prostaglandin-endoperoxide synthase 2 Ptgs2 000003567 0.046684 -1.87 
 
The fold change (FC) and false discovery rate (padj) of all 69 significant (padj <0.05) DE gene 
transcripts that are specific to SHRSP uterine arteries during the first 6 days of pregnancy. 
*indicates 2 or more transcript variants for that gene. + 2 or more transcripts of that gene were 
found to be significantly differentially expressed in one or both comparison group
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Table 5-8: Common inflammatory response genes that were differentially expressed in response to pregnancy 
Common Inflammatory genes 
Gene 
Symbol 
Ensembl 
Transcript ID 
(ENSRNO) 
WKY 
NP vs P 
SHRSP 
NP vs P 
padj FC padj FC 
Phospholipase A2 Pla2g2a T00000022827 1.28x10-20 -7.17 7.11x10-11 -4.29 
Heme oxygenase 1 Hmox1 T00000019192 0.021005 -1.85 1.36x10-8 -3.22 
Actin Filament Associated Protein 1 Like 2 Afap1l2* T00000073346 2.74x10-07  1.47 8.43x10-8  1.47 
Insulin-like growth factor 1 Igf1*+ 
T00000085680 0.021526 -2.22 0.413053 -1.45 
T00000038780 1.43x10-04 -2.18 7.52x10-6 -2.32 
Secreted frizzled-related protein 1 Sfrp1 T00000024128 6.20x10-04 -2.01 1.96x10-5 -2.19 
PDZ binding kinase Pbk T00000064306 0.039028 -2.17 3.14x10-4 -3.02 
TNF alpha induced protein 6 Tnfaip6 T00000070792 0.044179 -2.12 3.16x10-4 -2.98 
Oxidized low density lipoprotein (lectin-like) receptor 1 Olr1 T00000086390 0.008740 -2.51 0.000995 -2.79 
Lumican Lum T00000006109 0.018769 -2.04 0.003533 -2.20 
CD163 molecule Cd163*+ 
T00000084588 0.009832 -1.80 5.51x10-4 -1.98 
T00000068407 0.325710 -1.44 0.008154 -2.08 
Perilipin 2 Plin2 T00000009749 0.031875 -1.60 0.018484 -1.61 
Proenkephalin Penk* T00000011892 0.031493 -2.10 0.019099 -2.12 
Ficolin A Fcna T00000023022 0.020869 -1.87 0.021104 -1.82 
Coagulation factor II (thrombin) receptor F2r T00000074626 0.006113 -1.60 0.022944 -1.47 
Netrin 1 Ntn1 T00000005255 0.024627  1.41 0.023718  1.39 
Complement C6 C6 T00000033112 5.97x10-4 -2.90 0.026000 -2.09 
Annexin A2 Anxa2 T00000038677 0.035889 -1.65 0.030282 -1.64 
Matrix metalloproteinase-28 Mmp28 T00000083214 0.023786  1.77 0.034051  1.68 
Cd63 molecule Cd63* T00000010180 0.009568 -1.67 0.043524 -1.51 
The fold change (FC) and false discovery rate (padj) of 21 significant (padj <0.05) DE gene transcripts that are common to both WKY and SHRSP uterine arteries 
during the first 6 days of pregnancy. *indicates 2 or more transcript variants for that gene, +indicates 2 transcripts of that gene were found to be significantly 
differentially expressed in one comparison group; non-significant changes written in italics.
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Figure 5-18: Gene expression quantification of phospholipase A2 and ficolin A in WKY and 
SHRSP 
(A) Phospholipase A2 (Pla2g2a) expression was found to increase in GD6.5 uterine arteries 
relative to non-pregnant (NP) in both WKY and SHRSP. The relative quantity was also greater in 
NP SHRSP compared to NP WKY. Analysed using one-ANOVA of the dCT values; **p<0.01, 
***p<0.001, ****p<0.0001; n=5-6. (B) Ficolin A (Fcna) expression was only detected in GD6.5 
uterine arteries and was significantly higher in SHRSP (n=5) relative to WKY (n=4). Analysed using 
student’s t-test of the dCT values; **p<0.01. Numbers above bars indicate the average cycle 
threshold (CT) values. Data normalised to B2m expression and presented as a relative quantity 
(RQ) to WKY NP (A) or WKY GD6.5 (B). 
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5.4.9 Mitochondrial Function Differences 
Pregnancy induced mitochondrial changes were predicted by IPA® to occur only 
in the WKY group due to the differential expression of the genes stated in Table 
5-9. SHRSP did not show any significant differences between non-pregnant and 
pregnant arteries (Figure 5-19). The genes listed in Table 5-9 are predicted to 
increase mitochondrial function in WKY GD6.5 pregnant vessels (Figure 5-19) 
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Figure 5-19: Differential expression of mitochondrial genes in response to pregnancy in 
WKY and SHRSP 
IPA identified changes in mitochondrial function due to the differential expression of genes in 
complex I, IV and V and in γ secretase in WKY. These genes had an increased expression in 
GD6.5 pregnant (P) compared to non-pregnant (NP) and are highlighted in green and bold. No 
gene changes were found in SHRSP. 
 
WKY
NP vs P
SHRSP
NP vs P
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Table 5-9: The differentially expressed genes involved in mitochondrial function changes due to pregnancy 
Gene name 
Gene 
Symbol 
Ensembl 
Transcript ID 
WKY 
NP vs P 
SHRSP 
NP vs P 
padj FC padj FC 
γ secretase       
Aph-1 homolog A, γ-secretase subunit Aph1a* ENSRNOT00000056289 0.034281 -1.42 0.148424 -1.30 
Complex I       
Nadh:ubiquinone oxidoreductase subunit A3 Ndufa3 ENSRNOT00000091288 0.033190 -1.75 0.521554 -1.26 
Nadh:ubiquinone oxidoreductase subunit V3 Ndufv3* ENSRNOT00000086272 0.007563 -2.13 0.750155 -1.15 
Nadh:ubiquinone oxidoreductase core subunit S2 Ndufs2 ENSRNOT00000058423 0.049292 -1.42 0.863587 -1.05 
Nadh:ubiquinone oxidoreductase subunit A13 Ndufa13 ENSRNOT00000027980 0.024985 -1.38 0.557827 -1.12 
Complex IV       
Cytochrome c oxidase subunit 5A Cox5a ENSRNOT00000025525 0.030155 -1.74 0.434517 -1.30 
Cytochrome c oxidase subunit 8A Cox8a ENSRNOT00000028754 0.028464 -1.54 0.836964 -1.07 
Complex V       
F0 complex       
ATP synthase, H+ transporting, mitochondrial f0 complex subunit C3 (subunit 9) Atp5g3 ENSRNOT00000058234 0.023756 -1.80 0.581195 -1.23 
ATP synthase, H+ transporting, mitochondrial f0 complex subunit F2 Atp5j2 ENSRNOT00000033537 0.006157 -1.70 0.654905 -1.14 
F1 complex       
ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide Atp5b ENSRNOT00000003965 0.012193 -1.50 0.849460 -1.05 
The fold change (FC) and false discovery rate (padj) of mitochondrial genes that were significantly differentially expressed in WKY non-pregnant (NP) vs pregnant (P) 
and the FC and padj or the same genes from SHRSP NP vs P. Significance is defined as padj <0.05. *genes which have multiple transcripts.
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5.4.10 Long non-coding RNAs 
A major advantage to using RNA-Seq to investigate the transcriptome profile of 
uterine arteries is that it can detect non-coding transcripts such as long-non-
coding RNA (lncRNA). Of the 1966 lncRNAs that were detected in this study, 19 
were found to be significantly differentially expressed in one or more of the 
comparison groups (Table 5-10). These 19 lncRNAs were assessed for proximity 
to significantly DE protein coding genes, 13 were found to be within 5 million 
base pairs of significantly DE protein coding genes (Table 5-11). At least one 
lncRNA was chosen from each comparison group, with a fold change >-2 or <2, to 
be validated by end-point PCR (Table 5-12). LncRNA 1, 2, 3 and 6 all produce a 
positive product (visualised on an agarose gel, indicated by band at the 
appropriate location for the size of the product (Figure 5-20)), indicating that 
these lncRNAs are transcribed and spliced. These four lncRNA were quantified 
using SYBR Green qRT-PCR. lncRNA 1 and 2 produced more than one melt-curve 
peak indicating there is more than one product and therefore could not be 
accurately quantified (Figure 5-21). However, lncRNA 3 and 6 both produced one 
product (Figure 5-22). The expression of lncRNA 3 was found to be reduced in 
vessels from GD6.5 SHRSP compared to non-pregnant which confirmed findings 
from the RNA-Seq analysis; however, there was no significant difference 
between the two strains (Figure 5-23). LncRNA 6 showed no significant changes 
in expression in either of the four comparison groups (Figure 5-23). These 
lncRNAs were investigated further at a later stage of pregnancy (GD18.5) and 
lncRNA 3 was found to have a significantly higher expression in WKY compared to 
SHRSP; no significant changes were observed in lncRNA 6 (Figure 5-24). 
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Table 5-10: Significantly differentially expressed lncRNA in the four comparison groups 
Comparison 
Group 
lncRNA Ensembl ID padj 
Fold 
change 
WKY NP vs P 
AABR07069816.1 ENSRNOT00000086487 0.020451 -2.23 
AABR07069840.1 ENSRNOT00000090495 0.028785 -1.91 
SHRSP NP vs P 
AABR07008309.1 ENSRNOT00000083729 0.003342 -2.10 
AABR07072528.2 ENSRNOT00000090119 0.013971 1.38 
Rn50_X_0663.2 ENSRNOT00000076358 0.014578 -2.05 
AABR07006038.2 ENSRNOT00000088263 0.018484 1.31 
AABR07035065.1 ENSRNOT00000086043 0.024834 1.59 
AABR07019088.1 ENSRNOT00000084024 0.028182 1.20 
NP 
WKY vs SHRSP 
AABR07051787.1 ENSRNOT00000084727 1.05x10-16 -3.91 
AABR07001634.1 ENSRNOT00000078019 2.77 x10-11 -2.68 
AABR07030366.1 ENSRNOT00000088573 0.000107 2.50 
Rn50_X_0663.3 ENSRNOT00000041963 0.000689 -2.92 
AABR07030091.1 ENSRNOT00000088428 0.009267 -2.14 
LOC100909586 ENSRNOT00000086712 0.026629 -1.74 
AABR07048342.1 ENSRNOT00000083131 0.031622 -1.94 
AABR07069473.1 ENSRNOT00000087743 0.032714 -2.20 
AABR07043772.1 ENSRNOT00000077876 0.040692 -1.57 
AABR07041724.2 ENSRNOT00000080023 0.044570 -1.66 
P 
WKY vs SHRSP 
AABR07051787.1 ENSRNOT00000084727 1.47E-20 -4.08 
AABR07001634.1 ENSRNOT00000078019 2.47E-09 -2.38 
AABR07030366.1 ENSRNOT00000088573 0.000846 2.26 
AABR07055801.1 ENSRNOT00000079790 0.037022 2.10 
Significantly DE lncRNAs were observed in all comparison groups. Significance was defined as 
padj <0.05. LncRNA presented in bold highlights duplicates that were differentially expressed in 
more than one comparison group. LncRNA in bold indicated significant differential expression in 
more than one group. NP = non-pregnant, P = pregnant. 
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Table 5-11: LncRNAs proximal to significantly differentially expressed protein coding genes 
Group lncRNA Direction 
Fold 
change 
padj 
# proximal 
pc genes 
# significant 
DE pc genes 
PC gene 
names 
Transcript ID Direction 
Fold 
change 
padj 
WKY 
NP vs P 
AABR07069816.1 R -2.23 0.020451 117 2 
Vwa5a ENSRNOT00000015986 F -2.19 0.001353 
Hepacam ENSRNOT00000012248 F 1.90 0.029884 
AABR07069840.1 R -1.91 0.028785 129 2 
Vwa5a ENSRNOT00000015986 F -2.19 0.001353 
Hepacam ENSRNOT00000012248 F 1.90 0.029884 
SHRSP 
NP vs P 
AABR07008309.1 F -2.10 0.003342 41 1 C6 ENSRNOT00000033112 F -2.09 0.026000 
AABR07006038.2 R 1.31 0.018484 191 7 
Ifitm1 ENSRNOT00000005645 F -3.20 5.88x10-7 
Igf2 ENSRNOT00000073850 R 1.92 8.62x10-6 
Ap2a2 ENSRNOT00000064254 F -1.48 0.002450 
Mir675 ENSRNOT00000062103 R -2.19 0.009040 
Mob2 ENSRNOT00000027195 R 1.53 0.030760 
Lsp1 ENSRNOT00000054864 F -1.37 0.035560 
Igf2 ENSRNOT00000080246 R 2.05 0.043060 
AABR07035065.1 F 1.59 0.024834 67 4 
Map2k7 ENSRNOT00000084460 R 1.84 0.001090 
Rfc3 ENSRNOT00000001444 F -2.06 0.007220 
Rxfp2 ENSRNOT00000001197 R 1.64 0.015660 
Stxbp2 ENSRNOT00000001322 F -1.64 0.035880 
NP WKY 
vs 
SHRSP 
Rn50_X_0663.3 R -2.92 0.000689 104 3 
Mrpl4 ENSRNOT00000049706 F 1.81 6.49x10-5 
Cnn1 ENSRNOT00000029577 F -1.71 0.001027 
Ldlr ENSRNOT00000013496 F -1.82 0.002510 
AABR07069473.1 F -2.20 0.032714 92 2 
Aldoc ENSRNOT00000015535 F -2.00 0.000299 
Vtn ENSRNOT00000039954 F -2.14 0.002527 
AABR07030091.1 R -2.14 0.009267 101 2 
Samd14 ENSRNOT00000005519 F 2.96 0.000596 
Abcc3 ENSRNOT00000079711 R 1.96 0.021220 
LOC100909586 F -1.74 0.026629 57 3 
Vcl ENSRNOT00000015179 R -1.58 0.001553 
Plau ENSRNOT00000014273 R -1.68 0.024306 
Kcnk5 ENSRNOT00000075153 F 1.63 0.041872 
AABR07041724.2 R -1.66 0.04457 115 2 Plekhg4 ENSRNOT00000022439 F 2.50 0.007947 
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Ces2g ENSRNOT00000048385 F -1.63 0.017913 
AABR07043772.1 F -1.57 0.040692 48 1 Eda2r ENSRNOT00000017429 R 2.12 0.041872 
AABR07030366.1 R 2.50 0.000107 35 1 AABR07041724.1 ENSRNOT00000085536 R -4.36 2.19x10-13 
P WKY 
vs 
SHRSP 
AABR07051787.1 R -4.08 1.47x10-20 79 1 Crb2 ENSRNOT00000037257 F 2.36 0.029324 
AABR07030366.1 R 2.26 0.000846 101 1 Samd14 ENSRNOT00000005519 F 2.44 0.018565 
The proximity of lncRNA to significant DE protein coding (PC) genes used the cut-off of within 5 million base pairs in either direction from the lncRNA. Genes in bold 
signify that the protein coding gene is on the same strand as the lncRNA.
249 
 
 
Table 5-12: Selected lncRNA for PCR validation 
Comparison Group lncRNA 
lncRNA 
No. 
padj 
Fold 
change 
NP WKY vs NP SHRSP 
AABR07051787.1 1 1.05x10-16 -3.91 
AABR07069473.1 2 0.032714 -2.20 
P WKY vs P SHRSP 
AABR07051787.1 1 1.47E-20 -4.08 
AABR07055801.1 3 0.037022 2.10 
WKY NP vs P AABR07069816.1 4 0.020451 -2.23 
SHRSP NP vs P 
AABR07008309.1 5 0.003342 -2.10 
Rn50_X_0663.2 6 0.014578 -2.05 
The lncRNAs with the greatest fold change were chosen to be validated along with one that was 
identified to be proximal to significant DE protein coding genes (lncRNA2). Primers were then 
designed spanning exon-exon boundaries (apart from the primers for lncRNA 6 which only had one 
exon). 
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Figure 5-20: LncRNA PCR products visualised on agarose gels. 
All 6 lncRNA were amplified using PCR and the products visualised on 1.5% agarose gel. Products of approximately the correct size were observed for at least one 
sample from lncRNA1, 2, 3 and 6. Fragment size is indicated in base pairs (bp) for all lncRNA. Lanes 1-3 = NP WKY, lanes 4-6 = NP SHRSP, lanes 7-9 = GD6.5 WKY, 
lanes 10-12 = GD6.5 SHRSP, lanes 13-15 = GD18.5 WKY and lanes 16-18 = GD18.5 for all lncRNA except lncRNA1; where lanes 1-2 and 4 = NP WKY, lanes 3 and 
5-6 = NP SHRSP. The final lane was used as a non-template control, any product visualised here was assumed to be primer dimer formation. 
AABR07051787.1 = lncRNA1 (222bp)
AABR07069473.1 = lncRNA 2 (370bp)
AABR07055801.1 = lncRNA3 (106bp)
AABR07069816.1 = lncRNA4 (255bp)
AABR07008309.1 = lncRNA5 (141bp)
Rn50_X_0663.2 = lncRNA6 (196bp)
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
200bp
300bp
400bp
300bp
200bp
100bp
300bp
200bp
200bp
100bp
200bp
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Figure 5-21: Melt curves of SYBR Green qRT-PCR products for lncRNA1 and lncRNA2 
The expression differences of lncRNA1 and 2 could not be quantified using SYBR Green qRT-PCR 
as the melt curves demonstrated more than one product was being amplified. 
 
 
Figure 5-22: Melt curves of SYBR Green qRT-PCR product for lncRNA3 and lncRNA 6. 
Melt curves produced from the SYBR Green qRT-PCR of lncRNA 3 and 6 demonstrated that only 
one product was amplified.  
  
lncRNA1 lncRNA2
lncRNA3 lncRNA6
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Figure 5-23: Quantification of lncRNA3 and lncRNA6 in non-pregnant and pregnant WKY 
and SHRSP 
The relative quantities (RQ) of lncRNA3 and 6 were determined comparing to non-pregnant (NP) 
WKY. This revealed that lncRNA3 expression was significantly decreased in only one comparison 
group (SHRSP GD6.5 vs NP). No significant changes in expression were found between any of the 
comparison groups for lncRNA6. Numbers above bars represent average cycle threshold (CT) 
values. Data normalised to B2m housekeeper and expressed as relative quantity (RQ) to WKY NP. 
Analysed using one-way ANOVA with Tukey post-hoc test for the four comparison groups 
previously stated; *p<0.05; n=3-4. 
 
 
Figure 5-24: Quantification of lncRNA3 and lncRNA6 at GD18.5 in WKY and SHRSP 
The expression levels of the lncRNA was assessed at GD18.5. LncRNA3 was significantly reduced 
in SHRSP compared to WKY. There were no significant differences between WKY and SHRSP 
lncRNA6 expression. Numbers above bars represent average cycle threshold (CT) values. Data 
normalised to B2m housekeeper and expressed as relative quantity (RQ) to WKY. Analysed using 
student’s t-test **p<0.01, n=3. 
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5.5 Discussion 
This chapter focused on the changes of the transcriptome profile of uterine 
arteries in WKY and SHRSP from NP to GD6.5. This provided information on 
maternal gene expression responses to the 1st week of pregnancy, prior to any 
observed functional vascular changes. This novel study joins only a few studies 
that have focused on maternal gene expression during pregnancy. It is the first 
to have a specific focus of examining the maternal uterine vasculature response 
to early pregnancy.  
The findings from the RNA sequencing study and qRT-PCR validation are at the 
mRNA transcriptional level, with preliminary follow-up of some of these findings 
using protein expression (e.g. Nox2) and functional validation (e.g. measurement 
of calcium signalling). The results provide an insight into the strain differences 
of WKY and SHRSP, as well as evidence that the transcriptome profile changes in 
response to pregnancy. The findings of common gene changes to both SHRSP and 
WKY suggest a necessary vascular response to pregnancy that is conserved in 
both strains. The biological functions associated with these common gene 
changes are functions associated with vascular remodelling in pregnancy, as well 
as other pathological vascular remodelling processes such as hypertension and 
atherosclerosis (Tajsic and Morrell, 2011, Gomez and Owens, 2012, Ballantyne et 
al., 2016, Cipolla and Osol, 1994, van der Heijden et al., 2005b). Yet, the 
pregnancy dependent gene expression changes apparent in WKY and SHRSP 
uterine arteries do differ, suggesting the two strains have different adaptations 
to early pregnancy but both successfully produce similar numbers of offspring 
(see Chapter 3). Interestingly, the number of differential gene changes observed 
are greater in the SHRSP NPvsP group than in the WKY NPvsP group. This is a 
feature that has been observed in the SHRSP transcriptome previously, in 
different tissue. Bailey et al demonstrated that the largest number of gene 
changes in the brain occurred in salt-loaded SHRSP compared to non-salt loaded 
SHRSP as opposed to the salt-loading changes in WKY (Bailey et al., 2018). This 
suggests altered gene expressions in response to stressors (such as salt or 
pregnancy) could be exaggerated in the hypertensive SHRSP rats. 
From the analysis of predicted function using the differentially expressed gene 
profiles in IPA®, four major differences were identified between WKY and SHRSP 
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response to pregnancy. These included changes to NADPH oxidase expression, 
Ca2+ signalling, inflammation and mitochondrial function. These highlighted 
pathways are crucial to vascular function and have been implicated in 
hypertensive disorders of pregnancy as well as in cardiovascular disease (Konior 
et al., 2014, Sitras et al., 2015, McLachlan et al., 2014, Rubattu et al., 2014). A 
study of the placental proteome found that the major signalling pathways 
affected in pre-eclamptic placenta were inflammation and mitochondrial 
organisation (Jin et al., 2017). These pathways are also influenced by each other 
with mitochondria and NADPH oxidase both contributing to the production of 
ROS and this in turn can influence Ca2+ signalling and inflammation (Gorlach et 
al., 2015, Jonckheere et al., 2012). These are important physiological processes 
required for normal vascular function; however common to the dysregulation of 
these processes is an imbalance in reactive oxygen species production and 
metabolism, which can lead to increased oxidative stress and vascular damage. 
NADPH oxidase (Nox) is a major source of reactive oxygen species (ROS) and the 
hyper activation of these enzymes are known to play key roles in vascular 
endothelial dysfunction and remodelling in the development of hypertension 
(Montezano and Touyz, 2014). The production of ROS is key to the correct 
function of many intracellular signalling pathways, including initiating calcium 
signalling, influencing mitochondrial function and mediating inflammatory 
responses (Rubattu et al., 2014, Lee and Griendling, 2008, Montezano and 
Touyz, 2014). There are many isoforms of Nox that have different roles in 
vascular physiology. The differential gene expressions in this study suggested 
dysregulation of Nox2 in SHRSP pregnancy, due to the differential expression of 
the catalytic gp91 subunit (Cybb) and regulatory subunit p40phox (Ncf4) (Konior 
et al., 2014, Rivera et al., 2010). Nox2 is expressed in many tissues and in cell 
types including VSMCs, adventitial fibroblasts, perivascular adipocytes, 
endothelial cells and macrophages (Konior et al., 2014, Montezano and Touyz, 
2014, Datla and Griendling, 2010). It is unclear in this instance which cell type 
has differential Nox2 gene expression in SHRSP as these can all be found within 
the vasculature and localisation was not confirmed in the immunohistochemical 
analysis. An increased ROS production was predicted for the SHRSP vessels due 
to the increased expression of Nox2 subunits. A dysregulation of Nox2 in the 
vasculature (including the aorta, coronary artery, saphenous vein and resistance 
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arteries) has been linked to endothelial dysfunction, inflammation and fibrosis in 
hypertension (Montezano and Touyz, 2014, Wang et al., 2001, Guzik et al., 2004, 
Guzik et al., 2006, Touyz et al., 2005). Animal models have shown that Nox2 
plays a pathological role in induced hypertension models (Rivera et al., 2010). 
Wang, et al, showed that Nox2-/- mice did not demonstrate increased ROS 
production or vascular hypertrophy when exposed to AngII induced hypertension 
(Wang et al., 2001). Due to Nox2’s association with hypertension its expression 
has been previously examined in the SHRSP, as this is a well-established model 
of human essential hypertension (Davidson et al., 1995, Yamori et al., 1981). 
Akasaki et al found Cybb and Cyba to be unchanged between WKY and SHRSP 
(Akasaki et al., 2006). This study also provided no evidence that Cybb and Cyba 
expression differs between WKY and SHRSP, only Cyba increases in the uterine 
artery of SHRSP over the first week of pregnancy, a pattern that is not observed 
in WKY.  
Pregnancy dependent changes to gene expression within mitochondria, in 
complex I, IV and V of the electron transport chain were observed only in WKY. 
Mitochondria provide energy in the form of ATP to all functioning cells and ROS 
by-products are produced from the electron transport chain (Han et al., 2001). 
The maternal energy demand increases during pregnancy due the increase in 
demands on the cardiovascular, respiratory and renal systems (Pitkin, 1999). One 
of the sites within the mitochondria that demonstrated an increased gene 
expression in this study was Complex V. This is also known as ATP synthase and is 
the final stage of the electron transport chain responsible for ATP synthesis 
(Jonckheere et al., 2012). This suggests the WKY have an increased energy 
production in the uterine arteries during the first week of pregnancy, which was 
not observed in SHRSP. The dysregulation of mitochondrial functions has been 
associated with cardiovascular disease and hypertension (Ballinger, 2005, 
Gutierrez et al., 2006, Kokoszka et al., 2001). Changes in mitochondria have also 
been documented in many pregnancy pathologies, such as pre-eclampsia, fetal 
growth restriction and gestational diabetes (Furui et al., 1994, Zhou et al., 2017, 
Mayeur et al., 2013, Holland et al., 2017). However, the changes that have been 
reported vary on whether the mitochondria content increases or decreases 
(Holland et al., 2017).  Pre-eclampsia has been associated with reduced 
mitochondrial expression and activity, and thus a shortage of ATP (Zhou et al., 
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2017). A reduction of movement of electrons through the electron transport 
chain can result in an increase ROS production, which is often observed in pre-
eclampsia (Furui et al., 1994).  
It is interesting that Nox2 and mitochondria both contribute to ROS production 
and yet in SHRSP pregnancy there is an increased Nox2 expression and no change 
in mitochondrial components, where as in WKY there is no change in Nox2 
expression yet a predicted increase in mitochondrial function. This could suggest 
that different processes could be altering ROS status during pregnancy in the 
two different strains. The predicted pregnancy dependent increase in 
mitochondrial function observed in WKY uterine arteries was due to increases in 
gene expression in more than one complex; therefore it is a reasonable 
assumption that the mitochondria are not over producing superoxide (which are 
known to be produced and can leak from complex I) as the increases in 
expression of genes in other complexes will keep the flow of electrons moving 
through the transport chain, thus keeping ROS production at a physiological level 
(Turrens, 2003). The natural increase in ROS which are associated with increased 
mitochondrial activity, is likely to be counteracted by increased antioxidant 
activity. The SHRSP do not show any alterations in mitochondrial gene expression 
in response to early pregnancy. SHRSP rats have previously been associated with 
mitochondrial dysfunction (Tokoro et al., 1996), therefore it is possible that the 
lack of observed pregnancy dependent gene changes is indication of this 
dysfunction. As mentioned in previous chapters, pregnancy places an increased 
stress on the maternal cardiovascular system, therefore it could be speculated 
that pregnancy places an extra demand for energy on the blood vessels, 
particularly the uteroplacental circulation. The increased expression of several 
subunits of the mitochondrial electron transport chain observed in WKY may be a 
pregnancy-induced adaptation to meet the demands for increased energy 
provision. However, these adaptations were not observed in SHRSP uterine 
arteries, which may indicate that mitochondria in the blood vessels of SHRSP 
dams are unable to respond to the increased energy demands placed upon them 
by pregnancy. 
Both WKY and SHRSP were found to have gene expression changes that suggested 
an increased inflammatory response to pregnancy in the uterine artery. This was 
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expected as inflammation plays key roles in implantation, pregnancy and labour 
(Stephen et al., 2015, Bowen et al., 2002, Hauguel-de Mouzon and Guerre-Millo, 
2006). However, there was an increased number of differentially expressed 
genes predicted to influence inflammation in SHRSP, and conditions such as pre-
eclampsia and other gestational hypertensive disorders have been associated 
with an increased inflammatory response (Redman et al., 1999, Trifonova et al., 
2014). Some of the SHRSP specific inflammatory genes that were dysregulated 
were also found in the other specified pathways, such as Cyba and Cybb from 
Nox2 and Mylk from the calcium signalling pathway. This may suggest that the 
altered gene expression profile in pregnant SHRSP uterine arteries have a broad 
effect on many different pathways. This study was able to reveal this interplay 
due to assessing the transcriptome as opposed to the genome. Therefore, the 
total gene network and interactions of the differentially expressed genes was 
visualised as opposed to just acknowledging their presence/absence.  
Alterations to genes involved in intracellular calcium release were observed in 
both WKY and SHRSP pregnancy. This could impact on the molecular 
communications within the uteroplacental vasculature as Ca2+ is a major 
signalling molecule (Gorlach et al., 2015). The observed genes that had altered 
transcript expression were different in each strain, with Ip3R and Calm1 showing 
differential expression only in WKY pregnancy and Mylk expression changes 
observed only in the SHRSP. The WKY gene changes suggest that early pregnancy 
in these dams is associated with a reduced release of Ca2+ in the uterine 
arteries. An increase in Ca2+-calmodulin binding would in turn reduce the 
availability of intracellular Ca2+ and thus diminish constriction responses of 
vascular smooth muscle. Vascular contraction relies heavily on the interactions 
of myosin light chain kinase (Mylk) and calmodulin (Calm) as Mylk is 
Ca2+/calmodulin-dependent (Webb, 2003). Interestingly these two genes show 
strain specific expression, with pregnant WKY demonstrating an increase in 
vascular Calm1 expression with no change in Mylk, and SHRSP demonstrating a 
pregnancy dependent decrease in Mylk, with no change in Calm1. It is unclear 
how these expression changes could alter cellular function as their functions are 
normally interdependent (Webb, 2003). It could be speculated that the ‘normal’ 
WKY response to reduce contractility in pregnant vessels does not occur in 
SHRSP, thus other gene expression changes account for the small reduction in 
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vasomotor tone observed at GD18.5 (Small et al., 2016). WKY appeared to have 
a pregnancy-dependent reduction in Ca2+ release via the reduction in Ip3R 
expression. However, this expression could not be validated using qRT-PCR, 
which identified significantly lower expression of Ip3R transcript Itpr1 in GD6.5 
WKY compared to SHRSP but only a trend towards reduced expression between 
GD6.5 to NP WKY uterine arteries. The Taqman® probe used in this expression 
validation was designed to recognise a conserved area in all transcripts between 
the exon-exon boundaries of the last exons, so this should not have influenced a 
difference in expression quantification methods. However, due to multiple 
transcripts influencing expression levels there may have been more variation in 
the qRT-PCR as this focuses on one transcript of a protein coding gene, where 
RNA-Seq provides expression data on all transcripts.  
Functional calcium signalling was investigated in the VSMC of WKY uterine 
arteries. Calcium release was found to be reduced in VSMC isolated from 
pregnant WKY compared to their non-pregnant counterparts, which is consistent 
with the predictions from the RNA-Seq experiment. However, these cellular 
function studies were preliminary and would benefit greatly from conducting 
experiments with greater numbers as well as a comparison to SHRSP VSMC. 
(Holland et al., 2017) (Haché et al., 2011) It is well recognized that the main 
contributors of ROS (mitochondria and NADPH oxidase) can influence calcium 
signalling (Gorlach et al., 2015). This would be an interesting area to study 
further in the uterine arteries from non-pregnant and pregnant WKY and SHRSP, 
to determine whether the SHRSP environment at GD6.5 is more detrimental than 
that of WKY.  
Focus was given to the non-pregnant vs pregnant comparison groups in this study 
since this allowed us to gain insight into the overall characterisation of the early 
stages of pregnancy dependent uterine artery remodelling. However, the RNA-
Seq also produced data regarding strain differences. It revealed that the number 
of significantly differentially expressed genes was much greater in the non-
pregnant strain comparison than the pregnant comparison. It is unclear why this 
was the case. The relatively short pregnancy of a rat (between 21-23 days) 
creates an issue with specific timings of tissue collection, which could introduce 
variation in the pregnant groups thus increasing confidence intervals and 
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reducing significant detection. An attempt to minimize this variation was made 
by sacrificing dams at the same time of day and immediately dissecting and 
freezing the arteries. However, pregnancy confirmation by the presence of a 
copulation plug meant that there could have been a delay of up to 12 hours after 
mating for pregnancy to be confirmed. This could introduce variation in the 
length of an already short gestation, and therefore variation in the 
transcriptome. Fortunately, this variation would be present and detected in both 
RNA-Seq and qRT-PCR experiments, unfortunately; due to low RNA quantity, the 
same samples could not be used for both gene expression assessments. Another 
factor that could influence the transcriptomic profile of the uterine arteries is 
the oestrous cycle stage of the rat pre-pregnancy. Details of oestrus cycle stage 
were not ascertained in this study. These issues could have also influenced the 
qRT-PCR validation experiments also leading to a lack of significance due to 
variation within the same group. The conclusions stated would be more robust if 
further characterisation of the protein expression was conducted and functional 
studies examining mitochondrial and Nox2 function and calcium release were 
further investigated in the primary VSMCs. 
Previous pregnancy focused transcriptome studies have mainly utilised 
microarray technology (Enquobahrie et al., 2008, Akehurst et al., 2015, De 
Felice et al., 2015, Zhao et al., 2014, Lian et al., 2010, Lian et al., 2013, Sitras 
et al., 2015, Highet et al., 2016). Microarrays produce information about 
expression of a set of pre-determined genes. This allows for information on 
specific gene expressions but does not cover the entire genome (Cox et al., 
2015, Chandran et al., 2016). RNA sequencing is more beneficial in this respect 
as it allows for the profiling of tissue and time point specific expression of 
actively transcribed RNAs. This technique therefore provides information not 
only on typical protein coding genes, but also on the expression of lncRNAs. 
There is an emerging role for lncRNAs in regulating and influencing gene 
expression, which may be dependent on their location and proximity to protein 
coding genes (Wang and Chang, 2011). In this study the RNA-Seq aligned 1966 
lncRNAs with the rat genome. This shows the RNA-Seq accurately detected 
approximately 60% of the known lncRNAs in rat, however this animal strain has 
less known lncRNAs (3,288) compared to both mouse and human (9,443 and 
14,720 respectively; see Table 1-3 in section 1.3.2 for more comparison details) 
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This study revealed 19 lncRNAs were significantly differentially expressed 
between the study groups, with 13 being proximal to a significantly differentially 
expressed protein coding gene. These genes had a range of functions and it 
would be beneficial to examine these protein coding genes and their 
transcriptional regulation in more detail in future. The expression of lncRNA 
AABR07055801.1 was validated using qRT-PCR, providing more robust evidence 
of a true expression change. Understanding the role of these lncRNAs will 
require further study, which is hindered in rat models due to lack of lncRNA 
investigation and discoveries when compared to the mouse. However, the 
genome of both WKY and SHRSP has been sequenced and parallels can be drawn 
between the two animal models as well as new lncRNA discoveries, which would 
eventually lead to the ability to fully classify them and determine their influence 
on gene expression and/or biological function.  
The RNA-Seq performed in this chapter allowed a vast dataset of gene 
expression information to be generated. This could be utilised to identify major 
pathways involved in vascular remodelling. The RNA-Seq analysis provided 
information on hundreds of significantly differentially expressed transcribed 
RNAs; only a small subset were investigated during this study. This has been a 
major drawback, as only a collection of changes observed in RNA-Seq studies are 
published. Therefore, there is wide variation of the publicised genes that have 
been found to be dysregulated in gestational hypertensive disorders. This issue 
has begun to be overcome by full data sets being inputted into repositories (such 
as the ArrayExpress Archive hosted by the European Bioinformatics Institute), 
which could lead to a more in-depth examination of RNA-Seq profiles in future. 
The major limitation to deciphering any underlying molecular changes to uterine 
artery functions in this study was that the validation was limited to just three 
main findings, and furthermore due to time constraints only small sample sizes 
were available. Future studies should also be considered to fully evaluate 
functional changes in the key pathways noted in this chapter. For example, Nox2 
gene expression changes were found in both the RNA-Seq and qPCR validation as 
well as the Nox2 changes being evident at the protein level, however this did not 
provide any information of NADPH production or Nox2 activity which would be 
beneficial to know in the future. 
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This study provided evidence that the transcriptome of uterine arteries of WKY 
and SHRSP respond differently to pregnancy resulting in different gene 
signatures. Pregnancy was found to be the dominant driver of gene expression 
changes, with more changes detected between non-pregnant and pregnant 
uterine arteries, with differences between strains more difficult to detect. It is 
still unknown whether the SHRSP responses are altering gene expression to adapt 
to a hypertensive phenotype or whether the gene expression differences are 
indicating an early dysfunction of the uterine artery’s ability to remodel in 
response to pregnancy. By GD18.5 the SHRSP inability of the uterine artery to 
adapt to pregnancy correctly is obvious; yet the subtle gene expression changes 
detected at this early pregnancy time point (GD6.5) make this an intriguing 
model to study maternal-driven vascular remodelling in hypertensive pregnancy. 
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Chapter 6 SHRSP as a Model of Superimposed 
Pre-Eclampsia 
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6.1 Introduction 
Between 25-30% of the population of premenopausal women are estimated to 
suffer from chronic hypertension (August et al., 2015). These women have a 
significant increased risk of developing pre-eclampsia during pregnancy. Pre-
eclampsia superimposed on chronic hypertension is estimated to effect 15-25% of 
pregnancies worldwide (August et al., 2015). It is a condition that is increasing in 
prevalence in the Western world (Savitz et al., 2014, Kearney et al., 2005); 
possibly due to an increase in childbearing women possessing maternal risk 
factors for hypertension before pregnancy, such as obesity and advanced 
maternal age. Superimposed pre-eclampsia is diagnosed by the observations of 
any of the features used to diagnose pre-eclampsia, detailed in section 1.2, 
where the pregnant women has already had a hypertension diagnosis pre-
pregnancy (or before the 20th week of gestation) (Preeclampsia-Foundation, 
2010). The detection of superimposed pre-eclampsia is crucial as it impacts high-
risk women (i.e. those with pre-existing hypertension) and can worsen rapidly. 
Further complications can arise as many premenopausal women are not routinely 
screened for hypertension, therefore high blood pressure may not be identified 
pre-conception. Furthermore, pre-pregnancy hypertension can be masked in the 
first and second trimester by the physiological pregnancy-associated decrease in 
blood pressure (Hermida and Ayala, 2002). Women with pre-existing 
hypertension have a significant increased risk of morbidity and mortality, mostly 
due to the complications associated with a significant further increase in blood 
pressure (Bramham et al., 2014). This can have a hugely negative impact on the 
developing fetus and can impact the child’s development later in life (Bramham 
et al., 2014).  
The renin-angiotensin system (RAS) plays a crucial role in cardiovascular 
haemostasis during pregnancy (Chapman et al., 1998). There is a stimulation of 
RAS components during pregnancy which is contributes significantly to the 
increased blood volume and cardiac output associated with healthy pregnancy 
(Figure 6-1) (Langer et al., 1998). The placenta is the largest extra-renal 
contributor to the RAS and has a major influence over the local RAS regulation 
and the production of angiotensin II (AngII) (Ihara et al., 1987, Li et al., 2000, 
Herse et al., 2007). Whilst the production of AngII increases in healthy 
pregnancy, it is paradoxically associated with a reduced sensitivity to its pressor 
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response (Gant et al., 1973). Contrary to this, in gestational hypertensive 
disorders, a dysregulation of the RAS has been observed without alterations in 
AngII production (Langer et al., 1998). This has been found to lead to AngII 
vascular hypersensitivity via the AT1 receptor illustrated in Figure 6-2. 
 
 
 
Figure 6-1: The cascade of physiological changes associated with pregnancy 
Outlined are the major physiological changes that occur to increase cardiac output in pregnant 
women. The blue boxes are the changes whilst the text beside is the organ responsible/affected.  
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Figure 6-2: The role of the RAS in healthy and hypertensive pregnancy 
Increases in the RAS are common to both healthy and hypertensive pregnancy. This diagram 
illustrates the main AngII mediated effects or lack thereof on the vasculature of pregnant women 
and the outcomes of improper vasodilation due to the AngII receptor type 1 (AT1R) change in 
sensitivity. 
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Irrespective of its prevalence and impact on the health and wellbeing of both 
mother and child; chronic hypertension during pregnancy is relatively under-
studied in comparison to other gestational hypertensive disorders, such as pre-
eclampsia. A search of the NCBI PubMed database revealed that in 2017 of 1347 
papers published on gestational hypertensive disorders 71% focused on pre-
eclampsia whereas only 1.6% focused specifically in superimposed pre-eclampsia 
(search conducted in January 2018; full details of search terms in Appendix 8.2). 
Having an appropriate animal model on which to study the underlying disease 
mechanisms would help inform future investigations in women and provide a 
platform for clinical trials of novel therapeutics.  
AngII infusion in rodents has been used by several groups to mimic hypertensive 
disorders during pregnancy (Arguelles et al., 2017, Xue et al., 2017, Shirasuna et 
al., 2015, Bohlender et al., 2000, Takimoto et al., 1996, Hering et al., 2010, 
Verlohren et al., 2010). The chief focus has been on hypertension development 
in later life in offspring exposed to AngII in utero with few AngII infusion models 
investigating maternal adaptations. Shirasuna et al have demonstrated that an 
infusion of AngII in pregnant wild type and inflammasome deficient mice causes 
an increase in blood pressure and reduction in fetal weight that is associated 
with increased placental inflammation (Shirasuna et al., 2015). Infusion of AngII 
in pregnant Sprague-Dawley rats had similar maternal effects and found that 
further to the pro-inflammatory cytokines in the brain of the offspring, as adults 
they had an increased pressor response to AngII (Brewer et al., 2013, Xue et al., 
2017). Circulating and local placental AngII have been investigated using a 
refined transgenic cross rodent model which increases placental-specific AngII 
production (Hering et al., 2010, Geusens et al., 2008, Verlohren et al., 2008, 
Bohlender et al., 2000, Takimoto et al., 1996). The consensus from these studies 
revealed that dams exhibited a sudden yet sustained increase in blood pressure 
from mid-gestation which returned to pre-pregnancy levels after delivery. This 
was found alongside an increase in proteinuria, evidence of kidney damage and a 
reduction in fetal weight, all commonly associated with pre-eclampsia in 
humans.  
As mentioned in previous chapters, the pregnant stroke-prone spontaneously 
hypertensive (SHRSP) rat is hypertensive prior to and throughout gestation (Small 
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et al., 2016). The elevated blood pressure associated with this model is 
accompanied with reduced uteroplacental blood flow and impaired uterine 
artery function during pregnancy (Small et al., 2016). This impaired vascular 
response to pregnancy is a key phenotype of human pre-eclampsia and was 
found to occur independently of the chronic hypertension in SHRSP rats. Despite 
these complications, the SHRSP are able to produce viable offspring at birth and 
they lack the more severe characteristics of pre-eclampsia. For this reason, this 
study was designed to impose a greater challenge to the cardiovascular system 
of pregnant SHRSP, using infusion of AngII, to generate a novel model of 
superimposed pre-eclampsia.  
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6.2 Hypothesis and Aims 
6.2.1 Hypothesis 
Angiotensin II infusion will increase the hypertensive insult on the maternal 
cardiovascular system of the pregnant SHRSP and imitate superimposed pre-
eclampsia phenotypes. 
6.2.2 Aims 
 To develop an animal model useful for the study of gestational 
hypertensive conditions that arise on a background of chronic 
hypertension 
 To investigate how AngII infusion impacts the maternal cardiovascular and 
renal system during pregnancy in SHRSP rats 
 To assess if AngII infusion impacts pregnancy dependent vascular 
adaptations 
 To examine any impact AngII infusion during pregnancy has on fetal 
development and placental structure 
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6.3 Materials and Methods 
Animals were housed and mated as described in general materials and methods 
section 2.3). Urines were collected using 24-hour collections in metabolic cages 
at time points; one-week pre-pregnancy, at GD6.5 and at GD14.5. 
Echocardiography and uterine Dopplers were recorded at these time points, 
along with venous blood collected from the tail vein. Maternal blood pressure 
was recorded at the time points specified above via tail cuff plethysmography or 
monitored throughout gestation and parturition using radiotelemetry. Maternal 
tissue and fetoplacental units were obtained at gestational GD18.5, a time point 
at the end of pregnancy yet prior to the dip in blood pressure observed in SHRSP 
dams (Small et al., 2016). Functional and passive mechanical properties of the 
uterine and mesenteric arteries was assessed using myography. Placentas were 
dissected and fixed or frozen for histological or gene expression analysis. Full 
details of these methods can be found in the general materials and methods 
(sections 2.2, 2.3, 2.4 and 2.5). 
6.3.1 Angiotensin II Treatment via Osmotic Minipump 
AngII doses were delivered via osmotic minipumps implanted in pregnant rats. 
The dose was determined with guidance from Dr Ralf Dechend and Dr Florian 
Herse, according to AngII treatment regimes used previously in pregnant rat 
studies (Hering et al., 2010).  Prior to AngII infusion dams were weighed at 
GD9.5 and randomly assigned to either vehicle, 500ng/kg/min AngII or 
1000ng/kg/min AngII treatment groups.   
ALZET® 2002 osmotic minipumps (Charles River, Kent, UK) were used to obtain a 
constant infusion of AngII over the last 8-12 days of pregnancy from GD10.5. 
These minipumps had a constant 0.5µl/hour flow rate for 14 days, after this 
period flow rate was unreliable. Preparation of AngII solutions and the 
minipumps were carried out under sterile conditions and sterile latex, powder-
free gloves were worn at all times when handling the minipump. A stock 50µg/µl 
AngII solution was prepared using sterile H2O. The ALZET® 2002 osmotic 
minipumps have a reservoir volume of 200µl therefore, in order to achieve 
complete filling of the minipump, AngII stock was then diluted in sterile H2O to a 
volume of 300µl. This dilution was calculated as required based on the GD9.5 
weight of the dam and which treatment group she belonged, as well as the flow 
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rate of the osmotic minipump. The minipump and flow moderator were removed 
from packaging and placed in a sterile pre-weighed 5ml Sterilin™ container 
(VWR, Leicestershire, UK). The weight of the empty minipump was recorded. A 
filling tube (sterile blunt tipped needle appropriate for 200µl reservoir volume) 
(Charles River, Kent, UK) was attached to a 1ml syringe containing 300µl of 
appropriately diluted AngII solution. The minipump was carefully filled by 
inserting the filling tube into the reservoir and expelling the solution slowly in an 
upright position. It was of crucial importance that no air bubbles were forced 
into the minipump reservoir by rapid filling or trapped air in the syringe as this 
can interfere with the flow rate. Once filled, the flow moderator was gently 
inserted into the reservoir and any excess solution wiped away. The minipumps 
were then returned to the same 5ml Sterilin™ container and re-weighed. The 
difference between this weight and the original empty weight (mg) gave an 
indication of the volume of solution loaded into the pump (µl); this was always 
greater than 90% of the stated mean fill volume stated on the manufacturers 
product insert. Filled minipumps were then primed overnight by placing in 0.9% 
sterile saline solution at room temperature. This ensured that upon implantation 
the minipump begins delivery of AngII at the correct rate immediately. 
6.3.1.1 Minipump Implantation Surgery 
Surgery was conducted under sterile conditions with the operating table covered 
with sterile surgical drapes and surgical gowns and gloves were worn at all 
times. All instruments were autoclaved prior to use. Dams at GD10.5 were 
anaesthetised as in section 2.3.2 and maintained at 3% isoflurane in 1.5L/min 
oxygen. The procedure was carried out in the prone position, with the animal 
slightly turned on its left side. The right flank of the dam was shaved and 
swabbed with povidone-iodine solution (Betadine®). A superficial incision 
(approximately 3cm in length) was made in the skin parallel to the shoulder 
blade using surgical scissors. The left side of the incision was held with toothed 
forceps and gently lifted. The skin was parted from the muscular layer 
underneath by gently opening and part-closing the scissors within the incision to 
produce a subcutaneous pocket. The pocket was held open and the minipump 
was removed from the saline solution using toothed forceps. The minipump was 
inserted subcutaneously, with the flow moderator distal to the incision site. The 
incision was then sutured using VICRYL® Ethicon sutures (NU-CARE, 
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Bedfordshire, UK). Rats were given 5mg/kg Rymadil analgesic subcutaneously 
and placed in clean cages. The well-being of the dams was checked daily. 
6.3.2 Neonatal Sacrifice 
Dams placed in the radiotelemetry group were allowed to progress to 
parturition. The number of neonates born was recorded as soon as the litter was 
observed (between 1-14 hours after birth) and this was allocated as the day of 
birth. Litter number was recorded and the neonates were weighed together on 
day 1 and day 2. The weights were divided by litter number to give a neonatal 
weight average for each dam. Neonates were sacrificed using decapitation on 
day 2 due to the minipumps implanted in dams at GD10.5 (section6.3.1) only 
having a reliable constant infusion for 14 days. Approximately 1-2ml of blood 
was collected in EDTA BD Vacutainer® tubes with 50µl of 25mM 1,10-
phenanthroline monohydrate (a metalloprotease inhibitor to prevent AngII 
degradation) and placed on ice to prevent clotting (Düsterdieck and McElwee, 
1971). Blood remained at 4°C for no longer than 30 minutes before being 
centrifuged at 1200xg for 20 minutes at 4°C to obtain plasma. The plasma was 
collected and stored at -80°C. The neonatal heads and bodies were weighed and 
recorded. Hearts and kidneys were then dissected and snap frozen in liquid 
nitrogen for RNA extraction and subsequent gene expression analysis (detailed in 
sections 2.2.1, 2.2.2, and 2.2.3) 
6.3.3 Enzyme Immunoassay Detection of Plasma AngII  
The concentration of AngII in plasma samples collected in section 6.3.2 was 
determined using an SPI-bio enzyme immunoassay (EIA) kit assay specific for 
AngII detection (Bertin Bioreagent, Yvelines, France). Samples where defrosted 
and kept on ice. The angiotensin peptides were extracted from the sample by 
passing 1ml of plasma through a washed and prepared phenyl column and eluting 
absorbed peptides with methanol. The methanol was evaporated and the 
peptides resuspended in 500µl of EIA buffer and centrifuged at 3000xg for 10 
minutes at 4°C. Standards, reagents and buffers were prepared as instructed by 
manufacturer’s instructions and all samples and reagents brought to room 
temperature. Standard concentrations ranged from 125pg/ml to 0.98pg/ml. 
Samples, standards and an AngII quality control were diluted 1:1 with EIA buffer 
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and added to the 96-well EIA plate in duplicate. The plate was covered and 
incubated at room temperature for one hour with gentle agitation on a Rotatest 
orbital plate shaker (LUCKHAM R100, at low speed). Equal amounts of 
glutaraldehyde and borane trimethylamine (50µl) were added to each reaction; 
excluding the blank wells, which would act as a negative control. These reagents 
covalently linked the peptides to the immobilised anti-AngII antibody and 
denatured them in order to release the epitope. The plate was washed with the 
supplied wash buffer 5 times and any excess buffer was removed by blotting the 
plate on absorbent paper. This released epitope was detected using 100µl AngII 
tracer that was conjugated to acetylcholinesterase. The plate was covered and 
incubated overnight at 4°C. The plate was washed as previously described, this 
wash process was repeated twice, and 200µl of Ellman’s reagent, containing the 
enzymatic substrate, was added to each well. The plate was covered and 
incubated at room temperature in the dark for 1 hour. The production of the 
chromogen (5-thio-2-nitrobenzoic acid) appeared yellow and the plate was read 
on a SpectraMax M2 microplate reader (Molecular Devices, Berkshire, UK) at 
410nm. Blanks were subtracted from all samples and standards and a standard 
curve constructed to extrapolate the unknown sample concentrations. 
6.3.4 Scoring of Placental Glycogen Staining 
Placental sections were stained with periodic acid Schiff, as in the general 
materials and methods section 2.2.6.2, and imaged, as in section 2.2.8. 
Placental glycogen cell content was determined by the percentage of positive 
magenta staining in the junctional zone, this section was outlined and staining 
intensity measured as a percentage of positive pixels (section 2.2.8). Placenta 
were also scored for junctional zone disorganisation with 1 denoting organised 
and structured cell layers comprising of glycogen cells trophoblast giant cells 
and spongiotrophoblasts, and 5 being the highest score for observing 
disorganisation, associated with almost complete loss of structured, ordered cell 
layers with major gaps between cell types. 
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6.4 Results 
6.4.1 Maternal Pregnancy Profile 
6.4.1.1 Survival Rate  
AngII infusion was conducted in pregnant WKY and SHRSP rats. WKY rats were 
included as normotensive controls; however they were removed from further 
study after a pilot study revealed very low survival rate. Figure 6-3 illustrates 
the proportion of dams that survived (grey) or that were removed from the study 
early due to deterioration of health (red); study length was to GD18.5. WKY had 
100% survival in the vehicle treated group, but only a 25% survival when treated 
with 500ng/kg/min AngII and none survived the 1000ng/kg/min AngII treatment. 
The deterioration of health in the latter group was much more rapid (between 2 
and 4 days after infusion began) than that of the SHRSP dams, thus the WKY rats 
were removed from further study. Dams were removed from the study due to a 
weight loss of >20% of their pre-pregnancy weight and a loss in the condition of 
the animal. Better survival rates were observed in SHRSP dams. The entire group 
of vehicle treated dams survived for the duration of the study; with a 12.5% 
removal from study for 500ng/kg/min AngII treatment and a 33.3% removal from 
study for 1000ng/kg/min AngII treatment.  
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Table 6-1 details the numbers of pregnancies that resulted in a successful 
pregnancy carried until study completion (GD18.5), animals that showed 
deterioration and where removed from study but were still carrying a pregnancy 
and also those animals that had lost the pregnancy post-AngII infusion. 
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Table 6-1: Pregnancy success and failure rates 
  WKY  SHRSP 
 
Vehicle 
AngII 
500ng 
AngII 
1000ng 
Vehicle 
AngII 
500ng 
AngII 
1000ng 
Number of pregnant dams  
Fetal survival to GD18.5 
Pregnant at time of removal from study  
Total litter resorption at time of removal 
6 
6 
- 
- 
4 
1 
1 
- 
2 
0 
0 
2 
8 
8 
- 
- 
8 
7 
1 
- 
15 
10 
3 
2 
The total number of pregnant rats used and whether they carried a pregnancy to term (GD18.5) or 
were removed from the study prior to this time point due to deterioration of maternal health. Also 
indicated is whether the pregnancy was still apparent (by the presence of well-developed fetuses) 
or whether pregnancy had been lost (evident by the appearance of a total resorption of all 
fetoplacental units) at the time of maternal death. 
 
 
 
Figure 6-3: Survival rates as a proportion of total number of dams used in study group 
The proportional survival of dams that completed the study successfully (grey shade) and dams 
that were removed due to deterioration of health (red), with the total of pregnant rats used stated to 
the right of each group. Completion of the study was determined by carrying the pregnancy to 
GD18.5. 
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6.4.1.2 AngII Influence on Maternal Weight Change 
Pregnancy is associated with an increase in weight, due to increases in maternal 
adipose tissue, blood volume and the developing fetuses. The vehicle treated 
SHRSP exhibited a net maternal weight gain over the course of pregnancy, 
independent of the weight of the gravid uterus (147±5.3g GD0.5 versus 186±2.9g 
GD18.5; p<0.001), whilst the dams in the 500ng/kg/min AngII treatment group 
did not demonstrate a significant change in maternal weight (147±9.3g GD0.5 
versus 170.0±9.7g GD18.5) and the 1000ng/kg/min AngII treatment group had a 
net decrease in gravid independent weight over the course of pregnancy 
(154±3.2g GD0.5 versus 133.7.3±g GD18.5; p<0.05) (Figure 6-4A). By GD18.5 the 
gravid maternal weights of dams treated with 1000ng/kg/min AngII were 
significantly less than the 500ng/kg/min AngII treatment group and the vehicle 
group (160.0±10.3g versus 199.8±14.5g and 213.0±4.8g respectively; p<0.01 and 
p<0.0001) (Figure 6-4B). These weight changes were not due to a reduction in 
the number of fetuses per litter as the weight change was corrected for the 
number of fetuses (Figure 6-4C). The weight change per fetus was significantly 
less in the 1000ng/kg/min treatment group compared to all other groups 
(1000ng/kg/min: 0.4±2.5g versus 500ng/kg/min: 5±1.0g; p<0.01 and vehicle: 
7±1.4g; p<0.001), with a negative weight change indicating 3 of the dams in this 
group fell below their pre-pregnancy weight (Figure 6-4C). 
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Figure 6-4: Maternal weight change from the beginning of pregnancy to term 
Maternal weights were recorded throughout pregnancy. (A) The pregnancy independent maternal 
weight change was significantly increased from GD0.5 (when pregnancy was confirmed) to GD18.5 
in the vehicle group (***p<0.001; n=5) but was unchanged in dams treated with 500ng/kg/min AngII 
(n=4) and reduced in 1000ng/kg/min AngII treated dams (*p<0.05; n=6); analysed using one-way 
ANOVA with Tukey post-hoc test. (B) The weight change across pregnancy including the 
fetoplacental unit weights shows all pregnant dams gained weight before minipump implantation 
(GD10.5) and the 1000ng/kg/min AngII treated dams lose this pregnancy weight with AngII infusion 
and by GD18.5 have a significantly lower weight than vehicle and 500ng/kg/min AngII treated dams 
(****p<0.0001 vs vehicle; §§p<0.01 vs 500ng/kg/min AngII, n=4-6; analysed using two-way ANOVA 
with Bonferroni post-hoc test). (C) The total weight gain expressed per fetus reduced any influence 
litter size had on maternal weight change. This showed 1000ng/kg/min AngII treated dams did not 
put on as much weight as the vehicle or 500ng/kg/min AngII treated dams; with some AngII 1000ng 
dams losing weight by GD18.5 (***p<0.001 vs vehicle and **p<0.01 vs 500ng/kg/min AngII treated 
dams). (D) The total uterine weight (including the fetoplacental units) at GD18.5 corrected for the 
number of fetuses per littler was significantly lower in the 1000ng/kg/min AngII treated group 
compared to both other groups (***p<0.001 vs vehicle and **p<0.01 vs 500ng/kg/min AngII treated 
dams). All data are expressed as mean ±SEM; analysed using one-way ANOVA with Tukey post-
hoc test 
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6.4.1.3 Blood Pressure Profile of AngII Infused SHRSP Dams 
Blood pressure monitoring of AngII infused SHRSP dams was conducted using tail 
cuff plethysmography; detailed in the general materials and methods section 
2.3.4, as a pilot study to determine appropriate AngII doses. All the SHRSP dams 
were borderline hypertensive prior to pregnancy compared to non-pregnant WKY 
rats as a reference strain (Vehicle: 141±8.5mmHg, 500ng/kg/min: 
143±13.4mmHg and 1000ng/kg/min: 147±3.3mmHg). Figure 6-5A details the 
blood pressure of the SHRSP dams in each treatment group over the course of 
pregnancy; pre and post AngII infusion (which was implanted via minipump at 
GD10.5). The vehicle treated SHRSP rats remained borderline hypertensive, with 
no significant changes over the course of pregnancy (GD6.5: 139±5.7mmHg, 
GD14.5: 132±1.6mmHg and GD18.5: 141±13.7mmHg). There was a significant 
increase in the blood pressure of dams treated with 500ng/kg/min AngII GD14.5 
(4 days post AngII infusion) compared to both pre-pregnancy and pre-AngII 
infusion (GD6.5) blood pressure measures (NP: 143±13.4mmHg, GD6.5; 
150.1±7.3mmHg versus GD14.5: 180±0.4mmHg; p<0.05). However, by the later 
stages of pregnancy (GD18.5) the blood pressure was no longer significantly 
higher than pre-pregnancy or pre-AngII measurements (171±8.0mmHg). The dams 
in the 1000ng/kg/min AngII treatment group had a significant increase in blood 
pressure compared to pre-pregnancy (NP: 147±3.3mmHg versus GD14.5: 
172±7.7mmHg; p<0.05, and GD18.5: 195±7.2mmHg; p<0.001). This treatment 
group also showed a significant increase in blood pressure from GD6.5, prior to 
AngII minipump implantation in both post-AngII infusion measurements (GD6.5: 
146±6.5mmHg; p<0.001 and p<0.05 respectively). A significant increase between 
GD14.5 and GD18.5 was also determined in the 1000ng/kg/min treatment group 
(p<0.05). The change in blood pressure is represented in Figure 6-5B. Both SHRSP 
AngII treatment groups had a significant increase in blood pressure from a non-
pregnant baseline compared to the vehicle treated group at GD14.5 
(500ng/kg/min AngII: 23±8.0mmHg, 1000ng/kg/min AngII: 24±8.2mmHg versus 
vehicle: -5±8.5mmHg change; p<0.05 and p<0.01 respectively). Only dams in the 
1000ng/kg/min AngII treatment group demonstrated a significantly raised blood 
pressure at GD18.5 (47±6.9mmHg versus 0.6±6.9mmHg change; p<0.001).  
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Figure 6-5: The influence of AngII treatment on maternal blood pressure pre-pregnancy and 
at three specific pregnant time points. 
Blood pressure was measured at a non-pregnant (NP) time point and at pregnant, pre-AngII 
infusion (GD6.5) and pregnant, post AngII infusion (GD14.5 and GD18.5) time points by tail cuff 
plethysmography. (A) The absolute values of systolic blood pressure at the different time points. 
There was no significant change between non-pregnant and pregnant blood pressures in the 
vehicle. The blood pressure of 500ng/kg/min AngII and 1000ng/kg/min AngII treated dams showed 
a significant increases from NP and GD6.5 (pre-AngII infusion). 1000ng/kg/min AngII treatment 
also showed a significant increase at GD18.5 compared to all other time points. Data expressed as 
mean ±SEM; time points compared within each separate group; analysed using repeated measure 
one-way ANOVA with Tukey post-hoc test; *p<0.05, ***p<0.001 n=4-6. (B) The blood pressure 
across pregnancy expressed as a change from NP. Both AngII treatment groups had significantly 
higher blood pressure than vehicle at GD14.5 (AngII 500ng: †p<0.05 and AngII 1000ng: **p<0.01), 
only 1000ng/kg/min AngII demonstrated significant change from vehicle at GD18.5 (***p<0.001); 
analysed using two-way ANOVA with Bonferroni post-hoc test; n=4-6. 
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6.4.1.4 Direct Haemodynamic Measurements of AngII Infused SHRSP Dams  
Radiotelemetry is the gold standard in blood pressure monitoring in 
conscious animals and was used to fully assess haemodynamic changes, 
including systolic and diastolic blood pressures, activity and heart rate. 
These direct measurements were obtained for one week prior to 
pregnancy (during this time the animal was mated) and throughout 
gestation and parturition. Data for untreated WKY rats was obtained from 
previous radiotelemetry experiments conducted in 2013; however data 
was analysed at the same time as the SHRSP rats in this study. All SHRSP 
groups had a significantly higher average blood pressure in the 5 days 
before pregnancy than the untreated WKY group (SHRSP: 156±0.6mmHg, 
153±0.6mmHg, 157±0.5mmHg versus WKY: 118±0.6mmHg; systolic 
pressure; p<0.01). There were no significant differences in any of the 
measured haemodynamic parameters between the pregnant vehicle 
SHRSP group and either pregnant AngII treatment group prior to AngII 
infusion, between GD0.5 and GD10 (Figure 6-6 and Figure 6-7). After AngII 
infusion only the 1000ng/kg/min AngII infusion caused a significant 
increase in systolic blood pressure compared to vehicle after GD10.5 
(192±2.1mmHg versus 144±2.3mmHg; p<0.05) (Figure 6-6A), whereas 
diastolic pressure was significantly increased in both the 500ng/kg/min 
AngII and the 1000ng/kg/min AngII treatment groups (157±2.3mmHg and 
158±2.2mmHg versus 105±1.7mmHg; p<0.01 respectively) compared to 
vehicle after GD10.5 (Figure 6-6B). Mean heart rate was not significantly 
affected by AngII treatment (Figure 6-7A); however a sudden decrease 
was observed in the 1000ng/kg/min AngII treatment group immediately 
after minipump implantation and this group also demonstrated a change 
in the typical diurnal rhythm, with a loss of amplitude after AngII infusion. 
The activity, as measured by count of movement, was measured every 5 
minutes throughout the experiment. Dams treated with AngII were found 
to be more sedentary than the vehicle SHRSP group.  The 1000ng/kg/min 
AngII treatment group was significantly less active than the vehicle group 
during the nocturnal (awake) periods after AngII infusion at GD10.5 
(2.4±0.3 counts/min versus 3.1±0.2 counts/min; p<0.05) (Figure 6-7B).  
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Figure 6-6: Radiotelemetry measurement of systolic and diastolic blood pressure of 
pregnant AngII treated dams 
Radiotelemetry measured conscious blood pressure for 5 days prior to pregnancy and then 
throughout gestation and parturition. Parturition in SHRSP and WKY falls between the greyed area 
(GD21-23) and was not exactly the same day for each animal. Pregnant WKY untreated rats are 
presented as a reference for normotensive values. (A) Systolic and (B) diastolic blood pressures of 
the SHRSP rats are greater than WKY and all SHRSP groups were equal prior to pregnancy and 
prior to AngII infusion (minipump surgery). Systolic and diastolic blood pressure was significantly 
increased in 1000ng/kg/min AngII treated dams (*p<0.05; **p<0.01), and only diastolic blood 
pressure was significantly increased in the 500ng/kg/min AngII treatment group (††p<0.01) 
compared to vehicle SHRSP. Data expressed as day and night  mean values ±SEM; analysed 
using one-way ANOVA comparison of AUC of separate segments (pre-AngII and post-AngII 
infusion) with Tukey post-hoc test; n=3 for all SHRSP groups, n=4 for untreated WKY. 
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Figure 6-7: Radiotelemetry measurement of heart rate and activity during pregnancy  
Conscious heart rate and activity counts were measured for 5 days prior to pregnancy and then 
throughout gestation and parturition. Pregnant WKY untreated rats are presented as a reference 
for normotensive values. (A) The heart rate pre-AngII infusion (minipump implantation) is similar in 
all SHRSP groups and the untreated WKY. Post AngII infusion there is no significant difference in 
the AUC of the AngII treatment groups compared to vehicle, however the 1000ng/kg/min AngII 
treated dams demonstrate a drop in heart rate immediately after minipump implantation and 
decreased amplitude of the nocturnal values, reducing the diurnal rhythm. (B) The activity pre-
pregnancy increased during mating periods (GD-4 to GD0) and was similar between all SHRSP 
groups during pregnancy pre-AngII infusion. SHRSP treated with 1000ng/kg/min AngII had a 
significantly lower activity after minipump implantation than the vehicle SHRSP group (*p<0.05). 
Data expressed as day and night  mean values ±SEM; analysed using one-way ANOVA 
comparison of AUC of separate segments (pre-AngII and post-AngII infusion) with Tukey post-hoc 
test; n=3 for all SHRSP groups, n=4 for untreated WKY. 
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6.4.1.5 Cardiac Profile  
Echocardiography on anaesthetised dams showed that that stroke volume (SV) 
(Figure 6-8A) and cardiac output (CO) (Figure 6-8B) increase with gestation in 
vehicle treated dams (SV: 140±16µl NP versus 214±17µl GD18.5 (p<0.01); CO: 
54±6ml/min NP versus 81±5ml/min; p<0.05). The dams in the 500ng/kg/min 
AngII treatment group did not show this response to pregnancy and furthermore 
the dams in the 1000ng/kg/min AngII treatment group had a significantly 
reduced SV (90±15µl versus 155±12µl; p<0.05) and CO (36±6ml/min versus 
59±5ml/min; p<0.05) compared to non-pregnant measurements. This treatment 
group also showed significant reductions post-AngII infusion (at GD14.5 and 
GD18.5) compared to pregnant pre-AngII infusion (GD6.5) in SV (123±11µl and 
90±15µl versus 192±17µl; p<0.05 and p<0.001 respectively) and CO (47±4ml/min 
and 36±6ml/min versus 73±6ml/min; p<0.05 and p<0.001 respectively). There 
were no differences in calculated fractional shortening (Figure 6-8C) or ejection 
fraction (Figure 6-8D) between the treatment groups and there were no changes 
over the course of pregnancy. The left ventricular mass calculated using 
echocardiography was normalised to tibia length and no changes were observed 
over pregnancy (Figure 6-8E). At sacrifice (GD18.5) the left ventricles were 
dissected and weighed; these weights were normalised to tibia length and are in 
line with the echocardiography data (Figure 6-8F). 
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Figure 6-8: Echocardiography estimations of cardiac function and left ventricle mass 
Echocardiography was conducted at NP (pre-pregnancy) (n=4) and GD 6.5 (n=4-6), 14.5 (n=3-6) 
and 18.5 (n=3-6) pregnancy time points. (A) Stroke volume increased from NP to GD18.5 in vehicle 
treated SHRSP, this change was not apparent in the 500ng/kg/min AngII treated group and was 
reversed, with stroke volume decreasing across pregnancy in the 1000ng/kg/min AngII treatment 
group. (B) Cardiac output calculated from stroke volume and conscious heart rate data. The vehicle 
group was found to have an increased cardiac output at GD18.5, whereas there was no change in 
the 500ng/kg/min AngII group and AngII treatment at 1000ng/kg/min caused a significant decrease 
compared to NP and pre-AngII infusion (GD6.5). No change was determined for (C) fractional 
shortening or (D) ejection fraction. (E) The left ventricular mass was calculated from the 
echocardiography measures and normalised to tibia length. There were no significant differences 
across pregnancy regardless of AngII infusion. This was supported by weights of the left ventricle 
taken at GD18.5 sacrifice (n= 4-6) (F). Data presented as mean ±SEM; *p<0.05; n=4-6, **p<0.01 
vs NP; *p<0.05, ***p<0.001 vs GD6.5; analysed using one-way ANOVA for comparisons across 
pregnancy within each treatment group; or for comparison across treatment groups for left 
ventricular mass at sacrifice. 
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6.4.1.6 Urinary Analysis  
24 hour water intake and urine excretion was measured at a pre-pregnancy time 
point (NP) and pre-AngII infusion (GD6.5) and post-AngII infusion (GD14.5) using 
metabolic cages. There were no differences in water intake (Figure 6-9A) or 
urine excretion (Figure 6-9B) between either treatment groups at the pre-
pregnancy or pre-AngII infusion time points. There were significant increases in 
water intake (56.8±6ml versus 30.8±2ml; p<0.01) and urine excretion (48.2±7ml 
versus 16.8±3ml; p<0.0001) at GD14.5 in the 1000ng/kg/min AngII treatment 
group compared to vehicle. The 1000ng/kg/min AngII treatment group was the 
only treatment group that had a significant change from pre-pregnancy to 
GD14.5 for both water intake (26.0±3ml versus 56.8±6ml; p<0.001) and urine 
excretion (9.9±0.8 versus 48.2±7ml; p<0.0001). This group also had a significantly 
increased urine excretion compared to the 500ng/kg/min treatment group 
(48.2±7ml versus 17.4±2ml; p<0.0001). The proportional urine excretion 
(corrected for volume intake) (Figure 6-9C) was also significantly greater in the 
1000ng/kg/min AngII treatment group compared to vehicle (73.6±3% versus 
53.7±7%; p<0.05) and to the 500ng/kg/min AngII group (73.6±3% versus 41.6±4%; 
p<0.001). The 1000ng/kg/min AngII treatment group was found to have a 
significantly increased albumin:creatinine ratio (Figure 6-9D) at GD14.5 
compared to vehicle (3.0±0.26 versus 0.5±0.19; p<0.0001). This group also had a 
significantly higher albumin:creatinine ratio (ACR) when compared to the 
500ng/kg/min AngII treatment group (3.0±0.26 versus 1.3±0.20; p<0.0001) and 
was the only treatment group to demonstrate an increase in ACR by GD14.5 
compared to pre-pregnancy (GD0) levels (3.0±0.26 versus 0.6±0.06; p<0.0001) 
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Figure 6-9: The effect of AngII infusion on water intake and urine excretion during 
pregnancy 
Metabolic cages were used to collect 24-hour measurements of water intake and urine excretion at 
a week prior to pregnancy (NP)), pregnant pre-AngII (GD6.5-7.5) and pregnant post-AngII 
(GD14.5-15.5) time points. (A) Water intake did not change across pregnancy in the vehicle or 
AngII 500ng/kg/min treatment group. 1000ng/kg/min AngII treatment caused as significant increase 
in volume drank. (B) The urine excretion volume increased after AngII infusion only in the 
1000ng/kg/min AngII treatment group. (C) The proportional excretion of urine to total volume intake 
at GD14.5 was significantly higher in 1000ng/kg/min AngII treated dams (*p<0.05, ***p<0.001; 
analysed by one-way ANOVA). (D) The concentration of albumin and creatinine was measured 
from urine samples at each time point and expressed as a ratio of albumin to creatinine. The 
1000ng/kg/min AngII treated dams were the only group to have a significant increase in the 
albumin:creatinine ratio. Data expressed as mean ±SEM (n=3-6); comparisons across gestation 
and treatment were analysed using a two-way ANOVA with Bonferroni post-hoc tests; ***p<0.001, 
****p<0.0001 AngII 1000ng vs vehicle; §p<0.05, §§§p<0.001 §§§§p<0.0001 AngII 1000ng vs AngII 
500ng; a*p<0.0001 NP vs GD14.5. 
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6.4.1.7 Kidney Morphology  
Kidney morphology was assessed using periodic acid Schiff (PAS) and picrosirius 
red staining (Figure 6-10). The PAS stain was used to critically examine the 
cortex, with specific focus on the glomerular regions. Representative images of 
the cortex show areas of possible glomeruli swelling in the kidneys exposed to 
AngII infusion (Figure 6-10A). The vehicle treated SHRSP shows a typical 
glomeruli structure with clear cell definition within in the glomeruli capillaries 
and visible space between the visceral and parietal layers of the Bowman’s 
capsule. There is evidence of Bowman’s capsule defects in the kidneys of both 
AngII treatment groups, with a reduction in the space observed between the 
visceral and parietal layers.  
AngII treatment did not significantly alter picrosirius red staining in GD18.5 
maternal kidneys (Figure 6-10B-C). The assessment of positive staining was 
restricted to the cortex and medulla regions and expressed as a percentage of 
the total kidney area. All groups examined had a significantly greater proportion 
of staining in the medulla than the cortex (Vehicle: 1.9±0.30% versus 0.5±0.18%; 
p<0.01, 500ng/kg/min AngII: 1.8±0.35% versus 0.4±0.06%; p<0.01, 
1000ng/kg/min AngII: 1.8±0.30% versus 0.5±0.02%; p<0.01).  
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Figure 6-10: Histological examination of GD18.5 kidneys from vehicle and AngII treated 
dams. 
Periodic acid Schiff stain allowed for the morphological examination of maternal kidneys. 
Observationally, the area between parietal and visceral layers surrounding the glomeruli, the 
Bowman’s space, was reduced in the kidneys from AngII treated dams (indicated by arrows), n=4 
kidneys examined for each treatment group.  
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Figure 6-11: Examination of collagen content in GD18.5 kidneys from vehicle and AngII 
treated dams. 
(A) Picrosirius red stain was conducted to identify differences in collagen deposition within the 
kidney, representative images of the medulla and cortex from kidneys from each treatment group 
are shown. (B) The percentage of medulla and cortical staining as a proportion of the whole kidney 
was determined by a blinded observer using Image J to identify positively stained pixels. Statistical 
analysis was conducted using a repeated measure two-way ANOVA with Tukey post-hoc test; 
**p<0.01 medulla vs cortex within same treatment group; n=4. 
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6.4.1.8 In Vivo Uterine Artery Blood Flow 
Uterine artery blood flow was imaged in vivo using Doppler ultrasound; this was 
then assessed by measuring the systolic/diastolic (S/D) peak ratio and the 
resistance index (RI). There was no evidence of significant differences in the S/D 
ratio (Figure 6-12A) or RI (Figure 6-12B) between the three treatment groups at 
each gestational age. All groups showed a trend towards a decrease in S/D ratio 
and RI at GD18 compared to pre-pregnancy, however this did not reach 
significance. A representation of the uterine artery Doppler trace at pre-
pregnancy and GD18.5 are shown in Figure 6-12C. 
  
291 
 
 
 
Figure 6-12: Doppler ultrasound examination of uterine artery blood flow 
Uterine artery blood flow was assessed using waveform measurements from Doppler ultrasound 
taken a week prior to pregnancy (Non-pregnant – NP) and at GD6.5, 14.5 and 18.5. (A) The peak 
systolic and end diastolic volumes were measured and expressed as a ratio. (B) Resistance index 
was calculated from the peak systolic and end diastolic volumes. Neither of these parameters 
changed with gestation or with AngII treatment. (C) Representative images of waveform traces of 
the three SHRSP treatment groups pre-pregnancy and at the end of gestation show no significant 
differences. Data expressed as mean ±SEM; n=3-6; analysed using two-way ANOVA with 
Bonferroni post-hoc test. 
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6.4.1.9 Ex Vivo Uterine Artery Function 
The uterine artery functional responses to a vasoconstrictor (noradrenaline) and 
vasodilators (the synthetic analogue of acetylcholine: carbachol, and nitric oxide 
donor: sodium nitroprusside) were assessed using wire myography at GD18.5. 
Uterine arteries from either AngII treatment groups did not demonstrate any 
significant differences in contractile responses to noradrenaline from vehicle 
treated arteries (Figure 6-13A). AngII treatment also did not significantly alter 
vasodilation responses to carbachol (Figure 6-13B) or sodium nitroprusside 
(Figure 6-13C). Uterine arteries from vehicle, 500ng/kg/min AngII and 
1000ng/kg/min AngII treatment groups all had similar contractile responses to 
exogenously applied AngII (1x10-8M) (Figure 6-13D). 
6.4.1.10 Ex Vivo Uterine Artery Passive Mechanical Properties  
External and internal diameter was measured over a range of physiological 
pressures using arteries at GD18.5 mounted on a pressure myograph, and 
structural parameters were calculated. The uterine arteries from 1000ng/kg/min 
AngII treated dams had a significantly reduced external (Figure 6-14A) and 
internal (Figure 6-14B) diameter compared to vehicle (421±20µm versus 
531±20µm; p<0.05 at 110mmHg and 338±23µm versus 431±31µm; p<0.01 at 
110mmHg, respectively). These arteries also demonstrated a significantly 
reduced cross-sectional area compared to vehicle treated (4.9x104±1963µm2 
versus 8.3x104±2793µm2; p<0.05 at 110mmHg) (Figure 6-14C). The uterine 
arteries from dams in the 500ng/kg/min treatment group also demonstrated a 
significant decrease in internal diameter compared to vehicle, but only at 
pressures greater than 40mmHg (363±26µm versus 531±20µm; p<0.05 at 
110mmHg) (Figure 6-14B). These arteries demonstrated a reduced cross-
sectional area only at a pressure of 40mmHg, compared to vehicle 
(6.3x104±7573µm2 versus 8.7x104±5405µm2; p<0.05) (Figure 6-14C). Neither AngII 
treatment group demonstrated a significant change in uterine artery wall 
thickness (Figure 6-14D). Wall stress increased as pressure within the artery 
increased, however there was no alteration in wall stress response between the 
two treatment groups (Figure 6-14E). AngII treatment did not significantly alter 
the vessels stress/strain relationship (Figure 6-14F). 
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Figure 6-13: Wire myography assessment of GD18.5 uterine artery function from AngII 
treated dams  
Functional responses of GD18.5 uterine arteries were assessed ex vivo using wire myography. (A) 
Contractile response to increasing concentrations of noradrenaline was not affected by in vivo 
AngII infusion.  (B) All uterine arteries responded similarly to a maximum concentration of 1x10-8 M 
AngII and there was no significant difference between the AngII treatment group (500ng/kg/min vs 
1000ng/kg/min; analysed using unpaired students t-test). (C-D) There were no significant 
differences between vehicle and AngII treatment groups when vasodilation was assessed using 
carbachol and sodium nitroprusside. Data expressed as mean ±SEM; n=3-6; dose response 
curves used to calculated AUC or EC50 values of each curve and comparisons made using one-
way ANOVA with Sidak post-hoc test. 
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Figure 6-14: Structural parameters of GD18.5 uterine arteries obtained from pressure 
myography 
Pressure myography was used to directly measure the external and internal vessel diameter over a 
range of physiological pressures (10-120mmHg), these were then used to calculate a range of 
structural parameters. (A) The external diameter was significantly reduced in uterine arteries from 
1000ng/kg/min AngII treated dams. (B) The internal diameter of the arteries from 1000ng/kg/min 
and 500ng/kg/min AngII treated dams were significantly reduced compared to vehicle. (C) The 
cross-sectional area of 1000ng/kg/min AngII treated uterine arteries was significantly smaller, yet 
there was no significant change in the (D) wall thickness, (E)  wall stress or (F) the stress/strain 
relationships of the uterine arteries. Data presented as mean ±SEM (n=3-4); statistical significance 
was determined using AUC compared using one-way ANOVA with Sidak post-test to compare 
overall pressure response trends (*p<0.05, **p<0.01 Vehicle vs 1000ng/kg/min; †p<0.05 Vehicle vs 
500ng/kg/min). A repeated measures two-way ANOVA with Sidak post-hoc test was also 
conducted to compare changes between treatment groups at each pressure; *p<0.05, **p<0.01, 
***p<0.001 Vehicle vs 1000ng/kg/min AngII; ††p<0.01 Vehicle vs 500ng/kg/min; #p<0.05 
500ng/kg/min vs 1000ng/kg/min. 
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6.4.1.11 Systemic vascular characteristics  
Mesenteric arteries were analysed using wire and pressure myography in the 
same manner as uterine arteries. Functional analysis using wire myography did 
not reveal any significant changes in vascular responses to noradrenaline (Figure 
6-15A). However, the half maximal response of the arteries from vehicle treated 
dams demonstrated a significant reduction compared to arteries 500ng/kg/min 
AngII treated dams (1.50±0.78x10-6M versus 4.37±0.79x10-6M; p<0.05) (Figure 
6-15B). No significant changes in responses to carbachol (Figure 6-15B), or SNP 
(Figure 6-15C) were observed, and the half maximal responses were unchanged. 
There was no significant differences determined between the vehicle and 
500ng/kg/min AngII treatment group for any of the passive mechanical 
properties determined from pressure myography (Figure 6-16A-F). Statistical 
significance could not be determined in any measured or calculated structural 
parameter for arteries from 1000ng/kg/min AngII treated dams due to low 
numbers (Figure 6-16).  
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Figure 6-15: Functional responses of the mesenteric arteries of GD18.5 dams 
Wire myography assessed the functional responses of GD18.5 third order mesenteric arteries. The 
contractile response to noradrenaline expressed as (A) an active effective pressure and (B) the half 
maximal responses (EC50) for each curve. (C-D) The vasodilation responses to carbachol and 
sodium nitroprusside expressed as a percentage of 2x10-5M noradrenaline constriction. Data 
expressed as mean ±SEM (n=3-5); statistical significance determined using comparisons of AUC 
or EC50 values of each curve using one-way ANOVA with Sidak post-hoc test; *p<0.05. 
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Figure 6-16: Mesenteric artery structural parameters from pressure myography 
Pressure myography was used to directly measure the external and internal vessel diameter over a 
range of physiological pressures (10-120mmHg), these were then used to calculate a range of 
structural parameters. No changes were observed in (A) external diameter, (B) internal diameter, 
(C) cross-sectional area, (D) wall thickness, (E) wall stress or (F) the stress/strain relationships of 
the mesenteric arteries. Data expressed as mean ±SEM (n=2-4); comparisons only made between 
vehicle (n=4) and 500ng/kg/min AngII (n=3) treatment groups. Statistical significance was 
determined using AUC compared using one-way ANOVA with Sidak post-test to compare overall 
pressure response trends.  
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6.4.2 Offspring Outcome 
6.4.2.1 Fetal weight and size distribution  
AngII treatment had no significant effects on the number of pups in each litter at 
the fetal (GD18.5) or neonatal stage (Figure 6-17). Fetal weights and 
anthropometric measurements were taken at GD18.5. The fetuses exposed to 
1000ng/kg/min AngII treatment had a significantly reduced weight compared to 
both vehicle and the 500ng/kg/min AngII treatment groups (0.71±0.04g versus 
1.08±0.03g; p<0.0001) (Figure 6-18A). Representative images of the fetal size at 
GD18.5 are shown in Figure 6-18B. This reduction in size was symetrical and 
there was no evidence of head sparing as similar significant reductions in 
abdominal circumference (18±0.8mm versus 23±0.2mm; p<0.001), crown-rump 
length (21±0.7mm versus 25±0.1mm; p<0.001) and head circumference (21±0.8 
versus 25±0.2mm; p<0.01) were observed and there were no changes to the 
head:body ratio between the vehicle and AngII treatment groups (Figure 6-18C-
F). Fetuses from the 1000ng/kg/min treatment group also showed a significant 
reduction in weight (0.71±0.04g versus 0.99±0.04g; p<0.0001) and abdominal 
circumference (18±0.8mm versus 22±0.3mm; p<0.01), crown-rump length 
(21±0.7mm versus 24±0.6mm; p<0.05) and head circumference (21±0.8 versus 
24±0.4mm; p<0.05) compared to the 500ng/kg/min AngII treatment group 
(Figure 6-18A-E). To give a more clinical representation of the fetal growth the 
weight data was expressed as a weight distribution curve (Figure 6-19). The 5th 
centile for vehicle treated fetal weights was calculated to be weights that fell 
under 0.94g. Using this centile threshold it was concluded that 47.8% of fetuses 
from 500ng/kg/min treated dams and 95.7% from 1000ng/kg/min treated dams 
were below this threshold, and would be classed as growth restricted clinically.  
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Figure 6-17: Number of offspring per litter at GD18.5 fetal stage and at birth 
The number of offspring per litter was recorded at GD18.5 (fetal) and on the date of birth 
(neonatal). AngII treatment did not significantly alter the number of offspring at either 
developmental stage. There was no difference between fetal and neonatal litter sizes in any of the 
treatment groups. Data presented as individual litter averages ±SEM (n=3-7); analysed using two-
way ANOVA with Bonferroni post-hoc test. 
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Figure 6-18: Weights and anthropometric measurements of GD18.5 fetuses  
At GD18.5 the fetuses were removed from the uterine horn, all amniotic fluid and membranes were 
removed and they were separated from their placenta. (A) Fetal weight was significantly reduced 
with 1000ng/kg/min AngII treatment. (B) Representative images of fetal size show that fetuses from 
1000ng/kg/min AngII treated dams are smaller. The anthropometric measurements of (C) 
abdominal circumference, (D) crown:rump length and (E) head circumference are all significantly 
reduced with 1000ng/kg/min AngII treatment. (F) There was no difference in the head body weight 
ratios. Data presented as individual litter averages with mean ±SEM; n=4-7; analysed using one-
way ANOVA with Tukey post-hoc test; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 6-19: Frequency distribution of all GD18.5 fetal weights 
The proportion of total fetal weights at GD18.5 that fall below the 5th centile (green line) was 
determined by constructing a non-linear fit of frequency distributions of fetal weights for each 
treatment group. The 5th centile was determined from vehicle SHRSP (n=37 fetuses, from 5 
pregnancies) fetal weights (i.e. the lowest 5% of fetal weights). 47.8% of fetuses from 500ng/kg/min 
treated dams (n=42 fetuses from 4 pregnancies) and 95.7% from 1000ng/kg/min treated dams 
(n=54 fetuses from 8 pregnancies) were below this threshold limit. 
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6.4.2.2 Live Birth Differences and Neonatal Size 
A group of dams on each treatment were allowed to progress to parturition in 
order to investigate the neonatal outcome. The number of live births per litter 
was recorded at on day of birth and on neonatal day 2 (Table 6-2). There was no 
change in the number of neonates per litter in the vehicle group or the 
500ng/kg/min AngII treatment group. The 1000ng/kg/min AngII treatment group 
was the only group to have a neonate death in the first two days.  
Neonate weights were recorded on day 1 and day 2 after birth. The neonates 
from vehicle treatment and 500ng/kg/min AngII treatment groups both showed a 
significant weight gain in this time period (Vehicle: 5.1±0.2g to 5.4±0.2g; 
p<0.001, AngII 500ng/kg/min: 4.4±0.3g to 4.6±0.3g; p<0.01) (Figure 6-20A). No 
significance was found between day 1 and day 2 in the neonates from the 
1000ng/kg/min AngII treatment group; however data was only collected for 2 
litters’ therefore statistical analysis could not be conducted (Figure 6-20A). 
There were no significant differences in neonatal weight gain between the 
vehicle and 500ng/kg/min AngII treatment groups (Figure 6-20B). No evidence of 
asymmetrical growth restriction was observed in the 500ng/kg/min AngII (Figure 
6-20C).  
There were no significant differences in the weights of males versus females at 
neonatal day 2 in any of the treatment groups. There were also no significant 
differences in the weight reductions of each gender in response to either AngII 
treatment (Figure 6-20D). 
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Table 6-2: Number of live neonates per litter on the date of birth and two days later 
 
Vehicle  
(n=4 dams) 
AngII 500ng 
(n=3 dams) 
AngII 1000ng 
(n=3 dams) 
Day of birth 9.75±1.6 9.33±0.7 9.00±1.0 
Neonatal day 2 9.75±1.6 9.33±0.7 8.00±1.2 
The number of offspring born was recorded as soon as the litter was found (and this day was noted 
as the date of birth) and then again two days later on neonatal day 2. The vehicle and 
500ng/kg/min AngII treatment groups had the same number of offspring on neonatal day two as 
they had had on the date of birth. The 1000ng/kg/min AngII treatment group was the only group to 
show offspring death over this two day period; however this was not significantly different. Data 
presented as litter average ±SEM; analysis between date of birth and neonatal day 2 differences by 
paired student’s t-test. 
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Figure 6-20: Live neonatal weights recorded in the two days following birth  
Weights of the total litter were recorded on neonatal day one and two, these values were corrected 
for the number of pups on that day. (A) The rate of growth over 24 hours (between day 1 and day 
2) was found to be similar between vehicle (gradient of 0.56±0.07) and 500ng/kg/min AngII 
treatment group (gradient of 0.45±0.06). (B) The increase in weight from day 1 to day 2 was 
calculated as the Δ weight gain. No significant differences were determined between treatment 
groups. (C) The head weights were recorded at sacrifice on day 2 and expressed as a ratio to total 
body weight. There were no significant differences observed with AngII treatment. (D) At sacrifice 
on day 2 the neonates were gendered and there was found to be no gender disparity in weight 
changes. Data is presented as mean litter average ±SEM. All statistical analysis was conducted on 
vehicle (n=4) and 500ng/kg/min AngII treatment (n=3) groups only as data set for 1000ng/kg/min 
AngII treatment was not large enough to determine significance (n=2). The differences in gradients 
and the comparisons between genders within each treatment group was conducted using an 
unpaired student’s t-test. Other statistical tests were one-way ANOVA with Tukey post hoc test. 
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6.4.2.3 Neonatal changes in AngII and RAS gene expression 
The concentration of AngII in neonatal plasma was assessed via an ELISA for 
AngII. In untreated WKY and vehicle treated SHRSP the concentration of AngII 
was below detectable levels (Figure 6-21). The plasma collected from neonates 
from AngII treated dams had detectable concentrations; 500ng/kg/min AngII 
treatment group demonstrated concentrations of 11.2±5pg/ml (n=2) and the 
1000ng/kg/min AngII treatment group had a concentration of 48.2pg/ml (n=1). 
The gene expression of RAS components downstream of AngII were investigated 
in the neonatal kidney using qRT-PCR (Figure 6-22). AngII treatment did not 
change the gene expression levels of either AngII receptor (Agtr1a or Agtr2) in 
the neonatal kidneys, compared to vehicle. There was a significantly increased 
expression of angiotensin converting enzyme 2 (Ace2) in the kidneys of neonates 
that had been exposed to 1000ng/kg/min AngII treatment compared to vehicle 
(11.4±0.15 ΔCT versus 10.9±0.07 ΔCT; p<0.05), this did not reach significance in 
neonates from the 500ng/kg/min treatment group; however this may be due to 
the low statistical power as this group had only 3 biological replicates (Figure 
6-22). 
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Figure 6-21: Neonatal plasma AngII concentration on neonatal day two 
The AngII concentrations in neonatal day 2 plasma were determined using an ELISA. There were 
no detectable levels in plasma from untreated WKY (n=3) or vehicle SHRSP (n=3) neonates. There 
were detectable levels in all samples from AngII treated pregnancies. The increase observed in 
500ng/kg/min AngII treatment group (n=2) was increased further in the 1000ng/kg/min AngII 
treatment group (n=1). Plasma samples collected as pooled litter samples and data presented as 
mean ±SEM.  
 
 
Figure 6-22: Gene expression of AngII receptor type 1 (Agtr1a) and type 2 (Agtr2) and 
angiotensin converting enzyme 2 (Ace2) in the neonatal kidney. 
Gene expressions of components of the RAS were analysed using qRT-PCR and are presented as 
relative quantities (RQ) compared to vehicle. All gene expression was normalised to β actin 
expression. AngII treatment during pregnancy did not significantly change the expression of either 
receptor (Agtr1a and Agtr2). Ace2 expression was significantly higher in the kidneys from neonates 
exposed to 1000ng/kg/min AngII treatment in utero. Data presented as 2-ΔΔCT relative to vehicle 
±SEM relative to the ΔCT. Statistical analysis was conducted using ΔCT values compared using 
one-way ANOVA with Tukey post-hoc test; n=3-8; *p<0.05. 
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6.4.3 Placental Characteristics 
6.4.3.1 Placental Morphology 
Placental weights followed the same pattern of change as fetal weights (section 
6.4.2.1) which identified 1000ng/kg/min AngII treatment caused a significant 
reduction in placental weights compared to vehicle (0.16±0.007g versus 
0.24±0.008g; p<0.0001) and compared to the 500ng/kg/min AngII treatment 
group (0.16±0.007g versus 0.21±0.002g; p<0.01) (Figure 6-23A). No significant 
difference was observed between vehicle and the 500ng/kg/min AngII treatment 
group. Fetal: placental ratios were determined and found that there was no 
significant change between the two AngII and vehicle treatment groups (Figure 
6-23B) 
The placental gross morphology was assessed using PAS staining to identify the 
junctional and labyrinth placental layers. Representative images of the full 
placental cross-sectional area are shown in Figure 6-25. There were no 
differences in the proportional size of the two zones between the three 
treatment groups, with the junctional zone being between 18-21% of total 
placental size (Figure 6-24). The junctional zone appeared to lose its defined 
structure with AngII treatment (Figure 6-26A). The PAS staining intensity in the 
junctional zone was significantly reduced in the 1000ng/kg/min AngII treatment 
group compared to the vehicle group (4±1.6% versus 13±1.5%; p<0.05) (Figure 
6-26B). The cellular organisation of the junctional zone was visually assessed by 
a blinded observer and given a score corresponding to its structural organisation 
(with 1 being organised typical structure, with ordered distribution of cell types 
and five being the highest score with evidence of no structural order and many 
large vacuous regions with sparse and disorganised distribution of cell types). 
Placentas from 1000ng/kg/min AngII treatment groups scored significantly higher 
than the vehicle treated group (3.8±0.40 versus 2.1±0.31; p<0.05) (Figure 
6-26C). No statistically significant differences were observed in the placenta 
from the 500ng/kg/min AngII treatment group.  
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Figure 6-23: Placental weights and fetal:placental weight ratio determined at GD18.5 
The placentas were separated from the fetus after being removed from the uterus. Excess fluid 
was removed by blotting with absorbent swabs. (A) Weights were recorded for each placenta and 
were averaged to give a litter mean. There was a significant reduction in placental weight in to 
1000ng/kg/min AngII treatment group compared to vehicle and 500ng/kg/min AngII groups. (B) The 
ratio of fetal weigh to placental weight was calculated and showed that fetal and placental weight 
reductions followed the same pattern as there was no significant difference in the weight ratios. 
Data presented as litter average with mean ±SEM; n=4-6; statistical significance determined using 
one-way ANOVA with Sidak  post-hoc test; **p<0.01, ***p<0.001. 
 
 
Figure 6-24: Placental layer size expressed as a proportion of the total placenta  
Placental sections stained with periodic acid shciff stain were used to determine total placental size 
and the size of the junctional zone and labyrinth zones. The percentage of placenta that the 
junctional (Jx) and labyrinth (Lab) zones occupy is not altered with AngII treatment. Data presented 
as stacked mean ±SEM; n=3-5. Analysed using repeated measure two-way ANOVA, with SIdak 
post-hoc test comparing change between treatment group for each zone.
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Figure 6-25: Representative cross-sections of the GD18.5 placenta 
Composite images of GD18.5 placenta, showing the structure and layer definition of vehicle, 500ng/kg/min AngII treated and 1000ng/kg/min AngII treated placenta. 
2mm
Vehicle 500ng/kg/min 1000ng/kg/min
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Figure 6-26: Periodic acid Schiff assessment of the junctional zone of the placenta 
The morphology of the placenta was assessed visually using PAS staining at the midpoint (n=3-4). 
The junctional zone was identified by expected location and cellular morphology. (A) 
Representative images of the junctional zone at 10x magnification showing differences in staining 
intensity and structural organisation. (B) The percentage of pink positive staining within the outlined 
junctional zone was significantly reduced in 1000ng/kg/min AngII treatment groups. (C) The 
junctional zone was scored for disorganisation of the expected structure by a blinded operator with 
1 = organised typical structure, with ordered distribution of cell types; 5 = no order and many large 
vacuous regions with sparse and disorganised distribution of cell types. The placenta from 
1000ng/kg/min AngII treatment groups had a significantly greater disorganisation score. Mes = 
mesometrial triangle; Jx = junctional zone; Lab = labyrinth zone. Statistical analysis conducted 
using one-way ANOVA with Sidak post-hoc test; *p<0.05 
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6.4.3.2 Placental gene expression  
The expression of genes involved in the RAS (Figure 6-27), oxidative stress 
(Figure 6-28), extracellular matrix degradation, hypoxia (Figure 6-29) and 
inflammation (Figure 6-30) were compared over the maternal component of the 
placenta (the mesometrial triangle (Mes)) and the two distinct placental layers 
(the junctional (Jx) and labyrinth (Lab) zones). The AT1 (Agtr1a) and AT2 (Agtr2) 
receptors had a 4.4 and 4.6 fold increase in expression, respectively, in the 
mesometrial triangle of the 1000ng/kg/min AngII treatment group compared to 
vehicle (Agtr1a: 11.7±0.3 ΔCT versus 13.8±0.6 ΔCT; p<0.05 and Agtr2: 13.8±0.7 
ΔCT versus 15.4±0.5 ΔCT; p<0.05) (Figure 6-27 A-B). The AT2 receptor also 
demonstrated a 14 fold increase in the junctional zone of placenta from 
1000ng/kg/min AngII treated SHRSP compared to vehicle (12.1±0.9 ΔCT versus 
14.8±0.9 ΔCT; p<0.05) (Figure 6-27B). The labyrinth zone had the highest levels 
of Ace2 gene expression in all treatment groups and the 1000ng/kg/min AngII 
treatment significantly decreased the expression compared to vehicle and the 
500ng/kg/min treatment group (10.7±0.2 ΔCT versus 9.9±0.1 ΔCT; p<0.05 and 
10.1±0.1 ΔCT; p<0.01, respectively) (Figure 6-27C). The expression of Ace was 
undetectable in these experiments (CT values >38). 
The expression of markers of oxidative stress (Sod1) and hypoxia (Vegf1 and 
Hif1α) were not influenced by AngII treatment at either dose (Figure 6-28A-C). 
However, there was variation in the pattern of expression observed between 
layers, with vehicle treated dams having significantly greater Sod1 expression in 
the placental junctional zone compared to the other locations examined. This 
variation between layers was not observed in the two AngII treatment groups. 
Matrix-metalloprotease 2 and 9 gene expressions were found to be reduced in 
the mesometrial triangle of the 1000ng/kg/min AngII treatment group (Figure 
6-29A-B). Mmp2 (2.7±0.1 ΔCT versus 2.1±0.2 ΔCT; p<0.05) and Mmp9 (14.1±0.2 
ΔCT versus 12.6±0.3 ΔCT; p<0.01) both had a reduced expression in the 
1000ng/kg/min AngII treatment group compared to vehicle, with Mmp9 also 
having a significantly reduced expression in the 1000ng/kg/min group compared 
to the 500ng/kg/min AngII treatment group (4.1±0.2 ΔCT versus 13.2±0.2 ΔCT; 
p<0.05). There was no AngII-treatment dependent expression differences in 
Mmp8 or the tissue inhibitor of Mmps (Timp1) (Figure 6-29C-D). 
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The expression of the C-C chemokine ligand 2 (Ccl2); a chemokine responsible 
for recruitment of monocytes and T-cells at sites of inflammation, and its 
receptor, the C-C chemokine receptor 11 (Ccrl1) were not significantly altered 
by AngII treatment in any of the maternal or placental locations (Figure 6-30A-
B).  
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Figure 6-27: RAS component gene expression across the maternal and placental layers 
Gene expressions of components of the RAS were analysed using qRT-PCR and are presented as 
relative quantities (RQ). All gene expression was normalised to β actin expression. (A) AngII 
receptor type 1 (Agtr1a) and (B) type 2 (Agtr2) expression was increased in the maternal 
mesometrial triangle layer (Mes) in placenta from 1000ng/kg/min AngII treated dams. Agtr2 gene 
expression was also significantly increased in the junctional layer (Jx). (C) The expression of Ace2 
was greatest in the labyrinth zone (Lab) and this expression was decreased in the 1000ng/kg/min 
AngII treatment group. Data presented as 2-ΔΔCT relative to vehicle mesometrial triangle (Mes) 
±SEM relative to the ΔCT. Statistical analysis was conducted using ΔCT values compared using 
one-way ANOVA with Tukeys post-hoc test for comparisons over treatment group (*p<0.05, 
**p<0.01), and separately compared expression change over the different layers for each treatment 
group (vs Mes: †p<0.05, ††p<0.01; vs Jx: αp<0.05, ααp<0.01, αααp<0.001) (n=4-5). Values above 
each bar indicate unadjusted cycle threshold values. 
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Figure 6-28: Gene expression of markers of oxidative stress and hypoxia across the 
maternal and placental layers 
Gene expressions of (A) superoxide dismutase 1 (Sod1), (B) vascular endothelial growth factor 
receptor (Vegf1) and (C) hypoxia-inducible factor α (Hif1α) were analysed using qRT-PCR and are 
presented as relative quantities (RQ). All gene expression was normalised to β actin expression. 
There were no significant differences in the expression due to AngII treatment within each layer 
(Mes = mesometrial triangle; Jx = junctional zone; Lab = labyrinth zone). Data presented as 2-ΔΔCT 
relative to vehicle Mes ±SEM relative to the ΔCT. Statistical analysis was conducted using ΔCT 
values compared using one-way ANOVA with Tukeys post-hoc test for comparisons over treatment 
group and separately compared expression change over the different layers for each treatment 
group (vs Mes: †p<0.05, ††p<0.01; †††p<0.001; ††††p<0.0001 vs Jx: ααp<0.01, αααp<0.001) (n=4-5). 
Values above each bar indicate unadjusted cycle threshold values. 
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Figure 6-29: Gene expression of factors influencing extracellular matrix composition and 
degradation 
Gene expressions of (A-C) matrix metalloprotease (Mmp) 2, 9 and 8 and (D) tissue inhibitor of 
metalloproteinase 1 (Timp1) were analysed using qRT-PCR and are presented as relative 
quantities (RQ). All gene expression was normalised to β actin expression. Mmp2 and Mmp9 were 
significantly less expressed in the mesometrial triangle (Mes) of placenta from 1000ng/kg/min AngII 
treated dams. There were no significant differences in response to AngII treatment in the placental 
layers (junctional (Jx) and labyrinth (Lab) zones). There were also no significant differences in 
expression of Mmp8 or Timp1 in any of the investigated locations. Data presented as 2-ΔΔCT relative 
to vehicle mesometrial triangle (Mes) ±SEM relative to the ΔCT. Statistical analysis was conducted 
using ΔCT values compared using one-way ANOVA with Tukeys post-hoc test for comparisons 
over treatment group (*p<0.05, **p<0.01), and separately compared expression change over the 
different layers for each treatment group (vs Mes: †p<0.05, ††p<0.01; †††p<0.001; ††††p<0.0001 vs 
Jx: ααp<0.01, αααp<0.001; ααααp<0.0001) (n=4-5). Values above each bar indicate unadjusted cycle 
threshold values.  
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Figure 6-30: Gene expression of factors influencing placental inflammatory response 
Gene expressions of (A) C-C chemokine ligand 2 (Ccl2) and (B) C-C chemokine receptor type 11 
(CcrL1) were analysed using qRT-PCR and are presented as relative quantities (RQ). All gene 
expression was normalised to β actin expression. There were also no significant differences in 
expression of either gene in any of the investigated maternal (mesometrial triangle: Mes) or 
placental (junctional zone: Jx and labyrinth zone: Lab) layers. Data presented as 2-ΔΔCT relative to 
vehicle mesometrial triangle (Mes) ±SEM relative to the ΔCT. Statistical analysis was conducted 
using ΔCT values compared using one-way ANOVA with Tukeys post-hoc test for comparisons 
over treatment group, and separately compared expression change over the different layers for 
each treatment group (vs Mes: ††p<0.01; †††p<0.001 vs Jx: ααp<0.01, αααp<0.001) (n=4-5). Values 
above each bar indicate unadjusted cycle threshold values. 
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6.5 Discussion 
This chapter has provided evidence that AngII infusion in the pregnant SHRSP can 
mimic phenotypes of superimposed pre-eclampsia. The data presented indicate 
that SHRSP treated with the 1000ng/kg/min dose of AngII had an impairment of 
their haemodynamic and cardiovascular responses to pregnancy. Phenotypes of 
severe pre-eclampsia; such as a further elevation of blood pressure, decreased 
cardiac output, proteinuria, fetal growth restriction (FGR) and placental 
abnormalities were all documented in this study. 
The SHRSP rat has pre-existing chronic hypertension which made it an ideal 
candidate for studying superimposed pre-eclampsia. The current study intended 
to use normotensive rats (WKY) as a control strain for AngII infusion during 
pregnancy in the SHRSP strain. However, this was unsuccessful due to the low 
survival of the WKY dams. The more rapid deterioration observed in maternal 
health in AngII treated WKY rats was unexpected and may suggest that SHRSP 
rats having compensatory mechanisms that allow these dams to cope with a high 
blood pressure during pregnancy. Chronically hypertensive SHRSP males have 
been found to have higher plasma AngII levels than WKY in later adult life (25 
weeks) (Kim et al., 1991). This suggests that SHRSP are exposed to ‘high’ AngII 
concentrations during adult life and thus may be primed to deal with this insult 
on the cardiovascular system (Kim et al., 1991). The same may be true for 
females, although this has not been previously investigated. 
Vehicle treated SHRSP dams demonstrated maternal weight gain and increased 
cardiac output during pregnancy, despite pre-existing hypertension. In human 
pregnancy maternal weight is found to increase by approximately 12.5kg, on 
average (Thornburg et al., 2015). This increase can be attributed to an 
approximate 10% increase in protein, 30% increase in fat and 60% increase in 
water, with the gravid uterus only accounting for 10% of this weight increase 
(Thornburg et al., 2015). The increases in cardiac output are essential to 
maintain adequate organ perfusion in the mother whilst increasing 
uteroplacental blood flow in order to sustain the developing fetus and placenta. 
The AngII treated dams did not show this increase in weight or cardiac output, 
and in fact showed a ‘gradient’ of pathophysiology in which there was no change 
in the CO with the lower AngII dose and negative impact on CO in the higher 
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AngII treatment group as this demonstrated a reduction over pregnancy. The 
weight loss associated with the higher (1000ng/kg/min) AngII treatment group 
could be in part attributed to the increased urine excretion observed, however 
further measurements of body composition would need to be conducted to 
conclude this. Reductions in weight gain have been associated with poor fetal 
outcome and impaired CO is often observed in severe pre-eclampsia in humans 
(Visser and Wallenburg, 1991, Stott et al., 2017).  
Tail cuff plethysmography and radiotelemetry both confirmed AngII 
administration was responsible for an increase in systolic and diastolic blood 
pressure, as anticipated. However, the radiotelemetry revealed a disruption of 
the diurnal heart rate rhythm. The dip observed immediately post-AngII infusion 
in the 1000ng/kg/min treatment group could be accounted for by an activation 
of the baroreflex. The sudden increase in blood pressure activates the stretch 
sensitive baroreceptors which signal to reduce heart rate in order to reduce 
blood pressure. This may also account for the loss of amplitude observed in this 
group as the constant active firing of the receptors can lead to desensitization 
and thus loss of diurnal control. Interestingly, many cardiac events occur early 
morning suggesting circadian rhythm plays an important role in the homeostasis 
of the cardiovascular system and likewise the onset of labour is more common at 
these times. The blood pressure profiles of the vehicle and AngII treated SHRSP 
should be judged with caution, this is due to the limited sample size. Only three 
dams from each group were analysed. This was due to equipment and time 
constraints, but also due to uncertainty over pregnancy outcome, i.e. some 
dams did not give birth and it was unclear whether they had not been pregnant 
to begin with or had lost the pregnancy. These animals were removed as to not 
add variation of the impact of AngII on no-pregnant SHRSP blood pressure. 
Treatment with AngII impacted the kidney function of SHRSP evident by the 
increased urine production with increased proteinuria. ACR in the 
1000ng/kg/min AngII treated group was higher despite increased urine 
production. This increase in urine production is in contrast to the physiological 
role of AngII in the kidney to stimulate water reabsorption. Further kidney 
abnormalities were noted in the reduction of the Bowman’s space in kidneys 
from dams treated with AngII. This morphological assessment provides some 
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evidence that AngII infusion impacts on the structure of the renal corpuscle. 
However, assessment of glomeruli function and filtration rates would be provide 
a more in depth renal evaluation of this model.  
Pre-eclampsia is associated with endothelial dysfunction and  an increased 
vascular resistance (Steegers et al., 2010). Small et al have previously shown 
that pregnant uterine arteries from SHRSP have an impaired blood flow, and 
impaired responses to vasoconstrictors and vasodilators (Small et al., 2016). The 
AngII treatment did not significantly alter the uterine artery blood flow in vivo 
or impact significantly on the ex vivo functional properties. This could be due to 
uterine arteries from SHRSP having a ‘maximum impairment’ regardless of 
treatment; therefore, it is possible that the blood flow and function of the 
uterine arteries are as inefficient as they can be whilst still maintaining a 
pregnancy. The uterine artery sensitivity to exogenous AngII was unchanged 
between treatment groups. Other studies using the transgenic human 
angiotensinogen-renin cross have found that exposing uterine arteries from the 
transgenic dams to AngII ex vivo does increase contractile responses, suggesting 
these animals have increased sensitivity to AngII (Hering et al., 2010, Verlohren 
et al., 2008). It is possible that the lack of responses observed in our SHRSP 
model could be due to a low exposure time during pregnancy (a total of 8 days 
AngII infusion) compared to similar studies, or that the systemic increase in AngII 
has different effects than the more localised AngII exposure in the transgenic 
model; around the uteroplacental area (Hering et al., 2010, Xue et al., 2017). 
Alternatively, SHRSP rats have a different genetic profile to the Sprague Dawley 
rats used as the transgenic background which alters the proportion of AngII 
receptors available. However further pharmacological manipulations would need 
to be conducted to confirm this. 
There was evidence of reduced uterine artery diameter with reduced cross-
sectional area suggesting the period of AngII infusion in pregnancy is having an 
impact on uterine artery structure and may be indicative of a lack of appropriate 
pregnancy associated remodelling (Small et al., 2016). Healthy pregnancy is 
associated with outward hypertrophic remodelling of uterine vasculature (Osol 
and Mandala, 2009). This creates an increased vessel diameter with wider lumen 
due to dedifferentiation of vascular smooth muscle cells and allows the 
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increased blood flow to the placenta (Lash et al., 2010b). Changes observed in 
these AngII treated dams were more akin to inward eutrophic remodelling, a 
reduction in diameter with no change in wall thickness, which is associated with 
small arteries and hypertension. However, it is possible that the vessels are not 
undergoing any remodelling, and are simply remaining at in a pre-pregnancy 
state. In order for this to be fully investigated uterine arteries from untreated 
dams at GD10.5 would need to be studied to determine the remodelling that had 
already taken place before AngII infusion began. Pre-eclampsia in humans has 
been associated with a lack of the outward hypertrophic remodelling observed in 
normal pregnancy (Mandala and Osol, 2012).  
The mesenteric arteries were used as a representation of the systemic 
vasculature. Pressure myography showed that 500ng/kg/min AngII treatment had 
no significant effect on vessel structure over a range of physiological pressures. 
Unfortunately, a major limitation to this study was that only two sets of 
mesenteric arteries were successfully assessed using pressure myography and 
thus no robust conclusion can be drawn from the highest AngII treated group.  
As well as investigating the effects AngII-induced hypertension during pregnancy 
has on maternal health, this study assessed the effect elevated AngII had on 
placental and fetal development. The main finding was that the offspring from 
AngII treated dams had a reduced size both at the fetal stage and neonatal. 
Fetal growth restriction (FGR) is the failure of the fetus to reach its genetically 
predetermined growth potential and commonly occurs alongside pre-eclampsia 
(Bamfo and Odibo, 2011). FGR and pre-eclampsia have similar risk factors and in 
some instances the pre-eclampsia can be the cause of FGR and in others the FGR 
may be occur independently (Odegard et al., 2000). FGR is associated with a 
separate set of risks to the fetus, such as an increased risk of stillbirth (Gardosi 
et al., 2013). Clinically if a fetus is determined to be below the lowest 5th 
percentile of the population of fetal weights it is deemed growth restricted 
(Gardosi et al., 2013). The majority of fetuses from the 1000ng/kg/min AngII 
treatment group had a weight that fell under the 5th centile for normal SHRSP 
fetal weights at GD18.5. Smaller neonatal weights were also observed and the 
growth rate in the first two days was reduced in the offspring exposed to the 
high dose AngII treatment in utero. However, due to the low sample size for 
321 
 
 
neonates (with measurements for only two 1000ng/kg/min AngII treated litters 
being available) the interpretations of neonatal growth are very preliminary. 
Furthermore, the offspring development after parturition was only limitedly 
examined in this study. The in utero environment plays a vital role in fetal 
development and has been linked to the developmental origins of health and 
cardiovascular disease (The Barker Hypothesis) (Barker et al., 1993). 
Dysregulation of the RAS in utero has been associated with pathophysiological 
responses in the offspring in later life and has been linked to the development of 
hypertension (Arguelles et al., 2017, Xue et al., 2017, Sibai, 2002).  Xue et al 
demonstrated offspring exposed to low pressor AngII in utero developed a hyper-
sensitivity to AngII-induced hypertension as adults (Xue et al., 2017). These 
offspring had a higher chance of developing cardiovascular disease due to 
differences in developmental programming in utero compared to untreated 
counterparts (Xue et al., 2017). The cause for the growth restriction in the 
SHRSP-AngII infusion model used in this study is unclear as there were no further 
deficiencies in uteroplacental blood flow of AngII treated SHRSP rats. This 
suggests that there was no restriction of nutrient availability to the placenta and 
thus the fetus via impaired blood flow. However, we did not investigate the 
impact of AngII on the spiral arteries of these dams. It is these vessels which 
undergo the most remodelling and there is general agreement that a failure of 
remodelling is linked to the development of pre-eclampsia and FGR. Another 
factor that could impair fetal growth is placental function and its transport 
capacity, however this was not assessed in this study. In human placenta an 
activation of the AT1R via AngII has been found to reduce the placental transport 
of system-A amino acids (Shibata et al., 2006). 
Placental abnormalities were evident when examining the morphology of the 
placenta as there was a reduction in positive PAS staining in the junctional zone, 
which also appeared disorganised compared to vehicle. PAS staining can identify 
glycogen, glycoproteins and glycolipids (Akison et al., 2017). The stain can be 
used to highlight the glycogen cells of the junctional zone in the placenta. These 
cells are known to disappear before parturition and the functions of the 
glycogen stores are not fully understood (Akison et al., 2017, Furukawa et al., 
2014). The depletion of these stores associated with the AngII treatment may be 
indicative of the placenta struggling to maintain an appropriate function and 
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possibly utilising the glycogen reserves as it is not receiving appropriate 
nutrients from the mother. This is concurrent with growing evidence that 
placental glycogen depletion is associated with complications of pregnancy and 
fetal distress (Akison et al., 2017). However, the glycogen stores in human and 
rodent placenta differ as humans do not have the sub-populations of giant 
trophoblast cells (Furukawa et al., 2014). Any interpretation of placental 
function would require a more rigorous study of function and metabolism before 
any substantial conclusions were drawn. 
The placenta is the main extra renal source of AngII, and has been found to 
process all the components for a working RAS (Nielsen et al., 2000). Vaswani et 
al found there is a gestational dependent increase in the expression of RAS 
components in rodent placenta (Vaswani et al., 2013, Vaswani et al., 2015). This 
study suggests that the placental RAS is dynamic throughout pregnancy and can 
be altered by changes in AngII. Placental gene expression investigated in this 
chapter revealed that AngII infusion influenced the expression of the angiotensin 
receptors (AT1R and AT2R) and Ace2 in different layers of the placenta. The AngII 
receptors have been located within the placenta in humans and rats, amongst 
many other placental mammals (Nielsen et al., 2000). The AT1R has been found 
in rodent placenta and its expression has been found to be altered by AngII 
concentrations in humans (Kalenga et al., Kalenga et al., 1996). The AT2R 
subtype has been found to be the more prominent type found in non-pregnant 
rat uterus and human myometrium (Nielsen et al., 2000, de Gasparo et al.). Both 
receptor subtypes were identified in SHRSP placenta in this study and were 
found to be upregulated in the maternal tissue (the mesometrial triangle) when 
concentrations of AngII treatment were highest. This layer is highly vascularised 
and an increased expression of AT1R could suggest an increased sensitivity to 
AngII and thus an enhanced constriction response and restriction of blood flow to 
the placenta. Pre-eclampsia has been associated with an increased activation of 
the AT1R via the angiotensin II type I receptor agonistic autoantibody (AT1-AA) 
(Wallukat et al., 1999, Herse and LaMarca, 2013). The presence of this 
autoantibody has not been investigated in SHRSP pregnancy. There was also, 
however, an increase in AT2R expression in this maternal layer. AT2R expression 
was also found to increase more than 10-fold in the junctional zone in the 
presence of elevated AngII. A strength of these studies was the placenta 
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dissections performed, which gives a better representation of the gene 
expressions in the placenta and the different functions of the cells within it. 
Previously, studies have identified AngII receptors in the placenta, however they 
have not been localised to a particular layer. Analysing gene expression in this 
manner this will help evaluate the roles these receptors play in physiological and 
pathophysiological pregnancies. A key enzyme involved in removing AngII is 
Ace2. This enzyme removes AngII by cleaving the peptide to form Ang1-7, which 
is proposed to have a vascular protective effect. This study provided evidence 
that increases in AngII cause a decrease in Ace2 expression in the labyrinth zone. 
This could be exacerbating any possible damage AngII is causing in the placenta 
as it is not being broken down and thus prolonging negative effects. Ace2 is 
mainly found in vascular endothelial cells, and the placental labyrinth is highly 
vascularised with many fetal vessels surrounding maternal blood sinuses. It is 
unclear from this study where Ace2 expression is changed within this zone. The 
effects of AngII on the placental RAS gene expression will have occurred in a 
relatively short period of time (8 days) however AngII was administered once the 
rodent placental cell lineages are established, during the formation of the 
chorioallantoic placenta. This suggests that AngII infusion may be causing 
placental dysfunction rather than causing a failure of placental development 
since viable fetuses were able to develop. 
Matrix metalloprotease 2 and 9 are gelatinases that degrade various 
extracellular matrix components. They are largely expressed in maternal 
decidua and play an important role in early vascular remodelling and are then 
also involved in parturition (Naruse et al., 2009, Dias-Junior et al., 2017, 
Raffetto and Khalil, 2008, Geng et al., 2016). These Mmps were found to be 
decreased in the maternal layer of SHRSP rats exposed to high AngII 
concentrations. A reduction of uterine Mmp2 and 9 has been associated with 
increased placental ischaemia in the reduced uterine perfusion model of pre-
eclampsia in rats, which further suggests AngII is having a detrimental effect on 
the placenta (Dias-Junior et al., 2017). 
The placenta analysis was limited in that the main findings were related to gene 
expression changes. Many of these expression changes could have impacted on 
placental function, such as transport, which unfortunately was not examined in 
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this study. Due to this model utilising AngII, a thorough characterisation of the 
functional placental RAS would have been greatly beneficial. 
To summarise, AngII infusion during pregnancy in SHRSP rats impacts on the 
maternal cardiovascular and renal systems as well as causing a growth restriction 
in the offspring, that is possibly mediated by placental dysfunction. The impact 
in adult SHRSP offspring that were exposed to this increased AngII in utero was 
not determined in this study but would be a useful tool in investigating the 
effects a hypertensive pregnancy can have on development. Furthermore, the 
impact on the maternal systems in the SHRSP have mimicked those changes 
observed with severe hypertensive disorders and could be utilised to investigate 
whether maternal health is negatively altered post-pregnancy and if there is a 
generation of an increased cardiovascular risk because of this elevated 
hypertensive insult during pregnancy. This model has the ability to be adapted 
to expose the already hypertensive mother to different degrees of 
cardiovascular stress.  This will be useful in determining underlying mechanisms 
of gestational hypertension and in the assessment of novel therapeutic strategies 
in future and, when used in parallel with other animal models, has the potential 
to aid our understanding of pre-eclamptic conditions. 
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The prevalence of hypertension in modern society is rapidly increasing the 
frequency of pregnancies with hypertensive complications (Roberts et al., 2011). 
The impact this has on the mother is not only relevant during pregnancy but also 
for decades after (Bokslag et al., 2017). Furthermore, the associated risks to the 
fetus have been well established, thus making the need to fully understand 
these disorders all the more pressing (Staley et al., 2015). The maternal 
cardiovascular system is now more accepted as a major influencer of pregnancy-
related hypertensive disorder development than it once was (Kalafat and 
Thilaganathan, 2017). Therefore, there is a more prominent need for 
investigation of pregnancy related hypertension stemming from a maternal 
pathology. In order for this to be achieved it is crucial that appropriate animal 
models are developed to uncover the underlying mechanisms of the disorders in 
order to determine treatments.  
The SHRSP rat is known to have pre-existing hypertension that is maintained 
through pregnancy (Small et al., 2016). This is associated with an impaired 
maternal vascular response, evident by reduced uteroplacental blood flow and 
impaired uterine artery function (Small et al., 2016). The work outlined in this 
thesis focuses on pregnancy in SHRSP rats in order to provide information on an 
impaired vascular response to pregnancy, and allow for the evaluation of 
placental and fetal development in a hypertensive environment. Prior to this 
work, the need for a more thorough characterisation of SHRSP pregnancy was 
identified. Pregnancy in this strain has been investigated by relatively few 
groups (Small et al., 2016, Barrientos et al., 2017, Yamada et al., 1981, Fuchi et 
al., 1995a), and there have been omissions in regards to the pregnancy-driven 
cardiovascular adaptations of the SHRSP dam. The work of this thesis compiles a 
thorough characterisation of the SHRSP maternal adaptations to pregnancy, 
alongside assessment of fetal and placental outcomes. The investigations in 
SHRSP dams were conducted in parallel with investigations of pregnancy 
adaptations in the normotensive reference strain, WKY. Profiling the 
physiological maternal response to pregnancy was crucial for the correct 
assessment of any pathological change observed in SHRSP pregnancy. The 
cardiovascular parameters measured using echocardiography in this study, have 
to our knowledge, never been used to investigate pregnancy in WKY or SHRSP 
before. The cardiovascular adaptations to pregnancy, outlined in Chapter 1.1.1, 
327 
 
 
revealed WKY dams mirrored the pregnancy-associated changes observed in 
healthy humans (Robson et al., 1989). Interestingly, the increase in cardiac 
output observed in WKY pregnancy was also observed in SHRSP dams. 
Pathologies identified by other studies, such as proteinuria, were not observed 
in this cohort of pregnant SHRSP (Small et al., 2016, Barrientos et al., 2017). 
Proteinuria is often associated with more severe hypertensive disorders of 
pregnancy and the findings of this work suggested SHRSP dams have a milder 
gestational hypertensive phenotype. This suggestion was supplemented by the 
findings of similar fetal size and number per litter between WKY and SHRSP, 
which is in contrast to other studies which have demonstrated significant fetal 
growth restriction and implantation issues in the SHRSP (Fuchi et al., 1995a, 
Small et al., 2016, Barrientos et al., 2017). The yearly variation in litter sizes 
revealed in this thesis, from the large numbers of recorded matings over the last 
decade, suggest caution should be applied when interpreting results from a 
single study cohort of animals. A more definitive consensus on the litter size and 
fetal weights will be achieved eventually through conducting more studies and 
thus further reporting on SHRSP pregnancies. Yet, SHRSP pregnancy, investigated 
in this thesis, was not without impairment. Left ventricular hypertrophy, 
inferred from the increased left ventricular mass, was still evident in SHRSP 
dams during pregnancy. Cardiac hypertrophic remodelling has been associated 
with pre-eclampsia in humans (Melchiorre et al., 2013), and would suggest the 
maternal cardiovascular response to pregnancy in SHRSP dams was not as 
efficient as that of the normotensive WKY.  
Previously, Small et al, have shown that SHRSP dams have a reduced uterine 
artery blood flow during pregnancy and that the uterine artery is less responsive 
to vasodilation than the WKY (Small et al., 2016). Healthy pregnancy is 
associated with reduced vascular resistance and an increased blood flow to the 
uterus (Ferrazzi et al., 2018, Osol and Moore, 2014), yet in the SHRSP the 
uterine artery blood flow was reduced and delivery to the uteroplacental unit 
was restricted. Fuchi et al also found evidence that the central spiral artery that 
supplies the placenta had a reduced lumen in SHRSP dams (Fuchi et al., 1995b). 
Further investigations of pregnancy-dependent maternal vascular changes in the 
SHRSP were conducted in this thesis, firstly, by examining the mesenteric artery 
changes through gestation, outlined in Chapter 4. These resistance arteries are 
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often used as proxy for interpreting what is occurring systemically in other 
hypertensive pathologies (Kopf et al., 2018, Klein et al., 2018, Wynne et al., 
2018). There was evidence of pregnancy-dependent increases in vasodilatory 
response in the WKY which were absent in the SHRSP dams. Both strains 
demonstrated an overall gestational-dependent reduction in cross-sectional 
area, however, the SHRSP exhibited a smaller cross-sectional area compared to 
the WKY at term; this was associated with wall thinning of the mesenteric 
arteries. Hypertension is generally associated with a narrowing of the 
vasculature, whilst pregnancy achieves the opposite aiming to reduce total 
peripheral resistance (Poppas et al., 1997). There was evidence of an increased 
lumen size in both strains, yet SHRSP showed significant wall thinning that was 
not observed in WKY. This implies that systemic vascular adaptation to 
pregnancy is different between strains, yet it is possible that these different 
mechanisms occur to allow the same outcome; which is a vascular system that 
can cope with the increased blood volume associated with pregnancy. 
Measurements of blood volume and total peripheral resistance would provide 
further evidence to support or refute these conclusions. 
One of the main aims of this thesis was to determine the underlying mechanisms 
of uterine artery impairment previously observed in late gestation. Work was 
conducted to establish whether the uterine artery impairment was apparent 
between non-pregnant WKY and SHRSP and in the early stages of pregnancy 
(GD6.5). This early gestational time point is post-implantation but prior to the 
establishment and invasion of placental cells, and so allowed for the 
investigation of maternally driven remodelling effectors (Soares et al., 2012). 
There were no differences in the functional response or passive mechanical 
properties of uterine arteries between non-pregnant and early pregnant state in 
either strain. This observation was intriguing as it provided further evidence that 
the eventual impairment was not pre-existing and therefore could not be 
attributed to maternal hypertension alone. In an attempt to reveal the 
influences of maternal pregnancy-dependent plasma factors on uterine artery 
function, non-pregnant uterine artery explants were incubated with plasma from 
non-pregnant and early/late pregnant dams. The results of which concluded that 
circulating factors in early gestation may have a more prominent role in altering 
vascular function. However, as no functional differences were observed between 
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strains at this early gestational time point the logical step was to then 
investigate transcriptional alterations between uterine arteries from non-
pregnant rats and dams in these early stages of pregnancy. 
The work in Chapter 5 was the first to utilise RNA-Seq to profile the 
transcriptional changes of the uterine arteries during pregnancy. The number of 
expression changes revealed were vast, and only a fraction of the potential 
implications were expanded upon in subsequent data analysis and experiments. 
A number of similar uterine artery gene expression changes were identified 
between WKY and SHRSP in response to pregnancy, which suggests that some 
adaptations to pregnancy are essential and conserved between the two strains. 
However, the profile of uterine artery gene expression between non-pregnant 
and pregnant states also demonstrated numerous differences. When taken with 
the fact that there were no observed functional differences this is all the more 
interesting, as it suggests that at a molecular level the two strains are already 
responding to pregnancy differently even after only a relatively short period of 
gestation. Some of the pathways that were identified belonged to an overarching 
theme of increased energy production/demand and increased inflammatory and 
oxidative stress production. SHRSP uterine arteries demonstrated an increased 
expression of Nox2 subunits and a changed expression pattern of genes 
influencing inflammatory response that suggests a more inflammatory 
environment in these pregnant SHRSP vessels than in WKY. An increased Nox2 
expression has been identified to propagate oxidative damage within the 
vascular system in hypertension (Harvey et al., 2017). It is not clear from the 
work in this thesis why SHRSP pregnancy elicits this gene expression change, but 
the hypothesis derived from these findings is that the uterine arteries of SHRSP 
are primed for to respond differently to pregnancy-associated remodelling 
stimuli. Previous studies in older, male SHRSP rats have demonstrated that the 
damage to the vascular system is associated with increased ROS production and 
inflammation compared to WKY (Harvey et al., 2017, Akasaki et al., 2006, 
Nakamura et al., 2008). Whilst no differences between the gene expression of 
non-pregnant strains was revealed in this work, both pregnancy and age can 
increase stress within the cardiovascular system and may be doing so via similar 
mechanisms (Hibbard et al., 2015, Weisfeldt, 1998). Further analysis of 
functional and gene expression changes of the uterine artery as gestation 
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progresses could be conducted to determine when the impairment occurs. In 
order to fully determine the mechanisms of SHRSP uterine artery remodelling (or 
lack thereof) it would also be beneficial to look at the individual cell types 
composing the uterine artery. Nox2, for example, is mainly located in 
endothelial cells, whereas the majority of differentially expressed genes 
identified as involved in Ca2+ regulation reside in the VSMC (Selemidis et al., 
2008, Webb, 2003). Work towards examining the different cell types was 
initiated in this thesis as VSMC were isolated and WKY Ca2+ signalling 
investigated in vitro. With advancements in RNA-Seq capabilities there is the 
potential to examine the gene expression profiles of specific cell populations. 
The sensitivity of RNA-Seq means that low volumes of starting material can now 
be used which could utilise the isolation of the different cell populations or laser 
capture of specific regions (Nelson et al., 2016). 
The changes specific to the uterine vascular transcriptome have not previously 
been investigated during pregnancy in any species or model, furthermore no 
other vascular beds have been examined across gestation. RNA-Seq technologies 
are incredibly beneficial in determining alterations in gene expressions that 
occur over short periods of time and in providing insight into transcriptional 
regulation, and thus are well suited to the relatively short timescale of change 
over the gestational period (Wang et al., 2009). Many pregnancy-related studies 
have focused on the transcriptome profile of the placenta, which is 
understandable as this vital pregnancy-specific organ is central to the success 
and maintenance of pregnancies (Kaartokallio et al., 2015, Cox et al., 2015, 
Nelson et al., 2016, Wakeland et al., 2017). However, the acceptance of the 
theory that hypertensive disorders of pregnancy are solely placental syndromes 
is waning, with the maternal cardiovascular system being at the forefront of 
alternate concepts of disorder development (Kalafat and Thilaganathan, 2017). 
It has been suggested that it is the maladaptation’s of the cardiovascular system 
that result in the symptoms, and thus, the vascular system gene expression 
regulation and alterations that occur in response to pregnancy should be of key 
importance. Of course, in human pregnancy it is only possible to sample 
microvasculature, such as resistance arteries from subcutaneous fat biopsies or 
spiral arteries from decidual/myometrial biopsies taken from the placental bed 
(Corcoran et al., 2012, Cockell and Poston, 1997), and this sampling is often 
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conducted only at term; therefore, the gene expression changes cannot compare 
early gestational changes. These issues can be overcome by the use of 
appropriate animal models, which allow for the precise investigation into 
physiological and pathophysiological pregnancy-dependent changes.  
Another strength of RNA-Seq technologies is that it allows the informative 
assessment on non-coding RNAs. In this thesis the focus was placed upon protein 
coding genes, with only limited investigation of the lncRNAs conducted. LncRNAs 
can modify many cellular processes, most crucially for the context of this work 
are the roles involved with control of RNA expression (Wang and Chang, 2011, 
Wang et al., 2017). There are many proposed actions of this epigenetic 
regulation, from direct promotion/silencing of genes to modifications of the 
methylation status (Wang and Chang, 2011, Wang et al., 2017), and a range of 
diverse and complex mechanisms of action that are specific for individual 
lncRNAs and locations (Wang et al., 2017). In human studies, lncRNAs identified 
in the placenta have been implicated in the development of pre-eclampsia (He 
et al., 2013, Li et al., 2018). The study of lncRNAs is still a rapidly expanding 
field, with the majority of work conducted in humans and mice. This can be seen 
as a drawback in conducting gene expression research in rats, however the 
SHRSP rat is a widely used genetic model of hypertension and has had its genome 
sequenced, so has potential to keep pace with other species. 
A large proportion of the work in this thesis has focused on the determination of 
maternally driven pathologies associated with hypertensive pregnancy in the 
SHRSP. Yet both maternal and placental factors have been shown to play a 
crucial role in the development of hypertensive disorders of pregnancy, and the 
placental involvement should not be ignored. Placental abnormalities have been 
observed in SHRSP pregnancies prior to this study, with this thesis providing 
further evidence towards placental impairment (Fuchi et al., 1995a, Small et al., 
2016, Barrientos et al., 2017). Placental glycogen content was lower in SHRSP 
than WKY at mid-gestation and late gestation. Placental glycogen cells found in 
the junctional zone of the rodent placenta are known for their accumulation of 
glycogen (Coan et al., 2006). Their precise functions have not yet been 
identified, however, one possible function is that they are an energy supply for 
the placenta (Gebbe et al., 1972). This is supported by the findings of depleted 
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glycogen in late gestation, when the exponential growth of the fetus places a 
greater demand on maternal resources thus using the placental glycogen 
reserves to meet those demands (Coan et al., 2006). This makes the reduced 
glycogen content of SHRSP placenta observed in this thesis of key interest in 
evaluating any pathophysiology associated with SHRSP pregnancy. The SHRSP did 
not establish normal levels of placental glycogen reserves and therefore may 
have a limited energy supply in later gestational periods. The SHRSP placenta 
has been found to have reduced Na+/K+ ATPase activity, which would suggest a 
reduced transport of amino acids via Na+ dependent transporters (Fuchi et al., 
1995a). An attempt to clarify the transport capacity of SHRSP placenta was 
made in this study and the methodology optimised to assess transport of neutral 
amino acids across the maternal-placental barrier in WKY and SHRSP. The 
approach was successfully used to measure the rate of the Na+ coupled system A 
transporter. This preliminary data could be built upon to not only characterise 
the transport of these neutral amino acids, but also other amino acids and 
substances such as glucose and calcium transport. Issues with SHRSP 
placentation development were further highlighted by the proportionally 
reduced depth of trophoblast invasion into the maternal mesometrial triangle 
and the reduced gene expression of key Mmps involved in regulating this 
invasion. Further analysis revealed evidence of shallower spiral artery 
remodelling in SHRSP placenta and placental gene expression profiles which 
were suggestive of increased oxidative stress and hypoxia as well as changes in 
the placental RAS components.  
This work has shown that abnormalities of SHRSP pregnancy stem from both 
maternal and placental driven factors. It may be beneficial to directly assess the 
proportional control that these factors have on SHRSP pregnancy development 
by utilising embryo transfer studies in future work. This would allow the 
maternal and placental influences to be studied independently, with SHRSP 
placenta invading into WKY uterine tissues and secreting placentally derived 
factors into a normotensive circulatory system. This would have the potential to 
answer the question of whether the uterine arteries of SHRSP dams are failing to 
respond to pregnancy-dependent signals stimulated by the placenta, whether 
there is a lack of signalling from the SHRSP placenta, or perhaps a combination 
of the two.  
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A final and important focus of this thesis was in establishing a novel model of 
superimposed pre-eclampsia. Utilising the commonly used method of infusing 
AngII to induce hypertension, this work was the first to increase systemic AngII in 
hypertensive pregnant rats. Many of the phenotypes of severe human pre-
eclampsia were found in the AngII-SHRSP model, such as reduced cardiac output, 
kidney damage and associated FGR (Tranquilli et al., 2014). The rationale for 
developing this model was that the maternal cardiovascular system is placed 
under considerable stress during pregnancy and in cases such as pre-eclampsia 
the maternal cardiovascular system fails to adapt normally to an increased load. 
Increasing the blood pressure via artificial increases of circulating AngII created 
an environment of heightened maternal cardiovascular stress (Kalafat and 
Thilaganathan, 2017). Interestingly, this study found that the normotensive WKY 
were highly sensitive to the increases in systemic AngII, more so than the SHRSP 
as indicated by their rapid deterioration of health. It has yet to be determined 
why this is the case and the mechanisms behind this paradox. A possible theory 
as to why WKY dams rapidly deteriorate when exposed to high levels of AngII is 
that they do not spontaneously develop hypertension as the SHRSP do. As SHRSP 
age their blood pressure increases to severely hypertensive levels (>200mmHg). 
Therefore, even though the animals used in this study were relatively young and 
had not reached their maximum blood pressure, they may possess compensatory 
mechanisms that allow them to withstand high blood pressure levels in early life. 
As a normotensive model, WKY rats may not have mechanisms in place to cope 
with a sudden increase in blood pressure. The different mechanical properties 
and functional responses of the mesenteric and uterine arteries to pregnancy in 
WKY and SHRSP rats, along with the different transcriptome of the two models 
at the non-pregnant stage, highlights that the two strains have different vascular 
mechanisms in place to deal with cardiovascular stress. The WKY responds to the 
physiological stress of pregnancy appropriately, whereas the SHRSP does not. 
However, under pathological conditions, such as with AngII infusion, the WKY is 
unable to cope. This finding could possibly have implications in the mechanistic 
studies of hypertension as well as in understanding of pregnancy disorders. 
However, other normotensive rodents have been subject to the same high level 
AngII infusion during pregnancy and survived (Hering et al., 2010), thus more in 
depth analysis of female WKY hypertensive responses are required. 
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Some of the findings in this thesis are in contrast to previous studies which 
conclude that SHRSP do not show evidence of FGR, yet when this strain was 
subject to increased cardiovascular stress, using AngII infusion, the fetal growth 
was negatively impacted. Reduced fetal size is often associated with a reduced 
uteroplacental blood flow (Burton et al., 2009, Intapad et al., 2014). This can be 
observed in (and is a possible cause of) pre-eclampsia, yet can also cause FGR in 
the absence of any hypertensive phenotypes (Bamfo and Odibo, 2011). The 
growth restriction associated with increased systemic AngII was maintained into 
the neonatal period for offspring from AngII treated damns, which indicates a 
developmental handicap of these animals exposed to AngII in utero. Indeed, this 
is an area that has been studied in SHRSP with regards to cardiovascular disease 
development and poor in utero environment (Otani et al., 2012, Otani et al., 
2004). In this study, preliminary investigations were conducted to examine the 
impact of the increased maternal cardiovascular stress on the offspring’s 
physiology. Weights and growth trajectories, AngII plasma concentration and 
gene expression of RAS components in the kidneys identified that offspring which 
developed in a detrimental (high AngII) environment were smaller, had elevated 
AngII in their own systemic circulation and had an increased Ace2 expression. 
Dysregulation of RAS in utero has been found to sensitise the offspring to the 
development of hypertension as adults (Xue et al., 2017). It is well established 
that the development of offspring from hypertensive pregnancies are impacted 
directly from a restricted in utero environment, but an emerging field is 
transgenerational epigenetic modifications that can be passed to subsequent 
generations (Ho, 2014). This is a mechanism that regulates gene expression 
independent of genetic information (Skinner, 2011). Modifications occur globally 
in the fetus and female offspring that develop during exposure to a hypertensive 
insult in utero can transfer these epigenetic modifications to their own offspring 
(Skinner, 2011). This complex mechanism and the role it plays in development of 
cardiovascular disease still requires further investigation, yet it highlights the 
importance of the need to better diagnose, treat and eventually prevent 
pregnancies impacted by hypertension. The cause of the growth restriction was 
not fully determined in this project. However, the impaired uteroplacental 
blood flow in untreated SHRSP was not worsened by AngII infusion. This is 
noteworthy as it suggests other mechanisms must be influencing fetal growth. 
The structural organisation of the placenta, specifically the junctional zone, was 
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negatively affected by AngII infusion. This zone is the main endocrine 
compartment of the rodent placenta and may have wider implications on the 
observed FGR (Coan et al., 2006, Ain et al., 2003). AngII has been found be 
involved in the regulation of trophoblast invasion and can reduce the activity of 
Na+/K+ ATPase and SysA transport in the placenta (Shibata et al., 2006). These 
findings do not answer the question of why AngII infusion creates a model of 
fetal growth restriction, but it does suggest that restricted placental blood flow 
is not the only factor. 
Treatment options for all hypertensive disorders of pregnancy are lacking (Fisk 
and Atun, 2008). However, hypertensive complications in an already 
hypertensive mother are less well studied than other hypertensive conditions. 
Manipulations of the pre-existing hypertension in SHRSP pregnancy will be a 
useful tool in understanding the pathologies and will also provide a robust 
animal model for investigating therapies. A main strength of the infusion model 
utilised in this thesis is that it can be adapted to study variations of severity. We 
showed a gradient of pathologies, with the 1000ng/kg/min ‘high’ AngII 
treatment group showing large, statistically significant changes from vehicle and 
with the 500ng/kg/min ‘low’ AngII group showing similar directionality of 
changes but often to a lesser extent. Furthermore, the RAS involvement appears 
to be interlinked with SHRSP impairments. AngII plays more roles in physiology 
and pathophysiology than simply stimulating vasoconstriction. It has also been 
shown to stimulate vascular production of reactive oxygen species via NADPH 
oxidases, including Nox2 (Nguyen Dinh Cat et al., 2013). Considering the findings 
that SHRSP have increased Nox2 mRNA expression in uterine arteries during 
pregnancy, revealed in Chapter 5, the AngII-SHRSP model is even more 
compelling. Other manipulations of the RAS have been considered to be involved 
in the development of hypertensive disorders of pregnancy, such as propagated 
activation of AngII receptor type 1 via the angiotensin II type I receptor agonistic 
autoantibody (AT1-AA). Circulatory AngII is not found at increased level in pre-
eclamptic women, yet there is evidence of elevated AT1-AA (Herse and LaMarca, 
2013, Wallukat et al., 1999). This works via the same AngII receptor responsible 
for the vascular damage and altered placental function, and is associated with 
reduced uteroplacental perfusion. Investigating its presence in SHRSP physiology 
and subsequent manipulations would greatly increase the understanding of RAS 
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dysregulation in pregnancy associated hypertensive disorders and expand the 
usefulness of SHRSP as a model of superimposed pre-eclampsia.  
This thesis has provided information on the systemic and uterine specific 
vascular responses to pregnancy, the underlying transcriptional differences that 
could potentially be driving the varied responses and the impact that severe 
cardiovascular impairment can have on fetal and placental development in 
hypertensive pregnancies. Whilst much is still unknown about hypertensive 
disorders during pregnancy, there is greater evidence to support that similarly 
presenting disorders stem from different causes. With that in mind, focusing on 
the maternal dysfunction is a promising area that will require an intimate 
knowledge of physiological and pathophysiological response. The work in this 
thesis has provided the means to create an easily reproducible rodent model to 
investigate underlying mechanisms in the development of pre-eclamptic like 
conditions. 
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8.1 Sacrifice Sheet 
8.1.1 GD18.5 Fetal and Placental Data 
Date: 
Strain:  
Maternal ID: 
Maternal weight:  
GD ............      
Heart W                                         LV 
Kidney L                                             R 
Liver  
Tibia  
Uterus  
 
Fetal 
# 
Fetal 
weight 
Placental 
weight 
Fetal Measures 
Head C:R HC AC NOTES 
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
 
  
Fetal Location 
R L 
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8.1.2 GD6.5 Maternal Data 
Six day harvest protocol 
Date: 
Strain:  
Maternal ID: 
Weights 
Maternal: ………………… 
Heart: ……………………… 
Kidney: …………………… 
Liver: ……………………… 
Tibia: ……………………… 
Whole Uterus: ………………… 
 
Collection check list (tick) 
 
 
 
 
  
 Fix S/F Myography 
Mesenteric artery     
Uterine artery     
Uterus units     
Kidney    
Adrenal    
Embedded Location 
R L 
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8.2 PubMed Search Terms 
Search terms ("hypertension, pregnancy-induced"[MeSH Terms] OR 
("hypertension"[All Fields] AND "pregnancy-induced"[All Fields]) OR "pregnancy-
induced hypertension"[All Fields] OR ("gestational"[All Fields] AND 
"hypertension"[All Fields]) OR "gestational hypertension"[All Fields]) where 
limited to the year published 2017. This revealed 1347 studies in the database. 
The search was then filtered to add the following terms: AND ("pre-
eclampsia"[MeSH Terms] OR "pre-eclampsia"[All Fields] OR "preeclampsia"[All 
Fields]), this revealed 962 publications that included pre-eclampsia. This search 
also contained those with specific focus on superimposed preeclampsia so the 
further search amendment was added: AND "superimposed"[All Fields] OR 
"superimpose"[All Fields]. This revealed 22 publications in 2017. Therefore the 
total number of publications was deemed to be 1347, the number containing 
preeclampsia studies without superimposed preeclampsia were recorded as 930 
and with 22 including superimposed. No reviews were excluded from the search. 
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